WorldWideScience

Sample records for analysis yttrium-90 y-90

  1. Hanford isotope project strategic business analysis yttrium-90 (Y-90)

    International Nuclear Information System (INIS)

    1995-10-01

    The purpose of this analysis is to address the short-term direction for the Hanford yttrium-90 (Y-90) project. Hanford is the sole DOE producer of Y-90, and is the largest repository for its source in this country. The production of Y-90 is part of the DOE Isotope Production and Distribution (IP and D) mission. The Y-90 is ''milked'' from strontium-90 (Sr-90), a byproduct of the previous Hanford missions. The use of Sr-90 to produce Y-90 could help reduce the amount of waste material processed and the related costs incurred by the clean-up mission, while providing medical and economic benefits. The cost of producing Y-90 is being subsidized by DOE-IP and D due to its use for research, and resultant low production level. It is possible that the sales of Y-90 could produce full cost recovery within two to three years, at two curies per week. Preliminary projections place the demand at between 20,000 and 50,000 curies per year within the next ten years, assuming FDA approval of one or more of the current therapies now in clinical trials. This level of production would incentivize private firms to commercialize the operation, and allow the government to recover some of its sunk costs. There are a number of potential barriers to the success of the Y-90 project, outside the control of the Hanford Site. The key issues include: efficacy, Food and Drug Administration (FDA) approval and medical community acceptance. There are at least three other sources for Y-90 available to the US users, but they appear to have limited resources to produce the isotope. Several companies have communicated interest in entering into agreements with Hanford for the processing and distribution of Y-90, including some of the major pharmaceutical firms in this country

  2. Hanford isotope project strategic business analysis yttrium-90 (Y-90)

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    1995-10-01

    The purpose of this analysis is to address the short-term direction for the Hanford yttrium-90 (Y-90) project. Hanford is the sole DOE producer of Y-90, and is the largest repository for its source in this country. The production of Y-90 is part of the DOE Isotope Production and Distribution (IP and D) mission. The Y-90 is ``milked`` from strontium-90 (Sr-90), a byproduct of the previous Hanford missions. The use of Sr-90 to produce Y-90 could help reduce the amount of waste material processed and the related costs incurred by the clean-up mission, while providing medical and economic benefits. The cost of producing Y-90 is being subsidized by DOE-IP and D due to its use for research, and resultant low production level. It is possible that the sales of Y-90 could produce full cost recovery within two to three years, at two curies per week. Preliminary projections place the demand at between 20,000 and 50,000 curies per year within the next ten years, assuming FDA approval of one or more of the current therapies now in clinical trials. This level of production would incentivize private firms to commercialize the operation, and allow the government to recover some of its sunk costs. There are a number of potential barriers to the success of the Y-90 project, outside the control of the Hanford Site. The key issues include: efficacy, Food and Drug Administration (FDA) approval and medical community acceptance. There are at least three other sources for Y-90 available to the US users, but they appear to have limited resources to produce the isotope. Several companies have communicated interest in entering into agreements with Hanford for the processing and distribution of Y-90, including some of the major pharmaceutical firms in this country.

  3. Radiolabeling Of Albumin Particles With Yttrium-90

    International Nuclear Information System (INIS)

    Nguyen Thi Thu; Nguyen Thi Khanh Giang; Bui Van Cuong, Vo Thi Cam Hoa

    2011-01-01

    This paper presents the process of the radiolabeling of microaggregated albumin particles with radionuclide Yttrium-90 using the directed method. The albumin microsphere kit was prepared in sodium phosphate buffer. The original solution includes 2 mg albumin particle and 0.5 mg stannous chloride dihydrate. The albumin particles size was ranged from 5 ?m to 30 ?m. The mixture was washed three times with phosphate buffer saline, pH 7.2 by centrifugation and suspended in 0.5 M sodium acetate buffer, pH 6. Yttrium - 90 in 1.0 M acetic acid was collected from 90 Sr/ 90 Y generator. The labeling of the particles with Y-90 (185 MBq) was performed at pH 5.5 in acetate buffer with agitating for 60 min at room temperature. The labeled albumin suspensions were centrifuged at 3000 rpm for 15 min. Labeling yields was calculated using centrifugation, filtration and compared with paper chromatography, which is developed in the Tris Acetic EDTA. In this system, the unbound of Y-90 migrates to an R f of 0.9-1.0 and the radiolabeled albumin particles remains at the point of origin (R f = 0). The size of 90 Y-albumin particles was compared with the albumin particles in the original solution to be sure that they did not change during the labeling treatment. The radiolabeling yields were more than 80%. The labeled compound was dialysis in phosphate buffer. The radiochemical purity was 98%. The 90 Y- albumin is an ideal radiopharmaceutical for potential use in malignant cancer treatment as brachytherapy. (author)

  4. Analysis of Prognostic Factors After Yttrium-90 Radioembolization of Advanced Hepatocellular Carcinoma

    International Nuclear Information System (INIS)

    Inarrairaegui, Mercedes; Martinez-Cuesta, Antonio; Rodriguez, Macarena; Bilbao, J. Ignacio

    2010-01-01

    Purpose: To analyze which patient-, tumor-, and treatment-related factors may influence outcome after 90 Y radioembolization ( 90 Y-RE) for hepatocellular carcinoma (HCC). Patients and Methods: Seventy-two consecutive patients with advanced HCC treated with 90 Y-RE were studied to detect which factors may have influenced response to treatment and survival. Results: Median overall survival was 13 months (95% confidence interval, 9.6-16.3 months). In univariate analysis, survival was significantly better in patients with one to five lesions (19 vs. 8 months, p = 0.001) and in patients with alpha-fetoprotein 52 UI/mL, and their survival in the multivariate analysis was significantly worse (hazard ratio, 4.7; 95% confidence interval, 13-1.73) (p = 0.002). Conclusions: Yttrium-90 radioembolization results in control of target lesions in the majority of patients with HCC but does not prevent the development of new lesions. Survival of patients treated with 90 Y-RE seems to depend largely on factors related to the aggressiveness of the disease (number of nodules, levels of alpha-fetoprotein, and presence of microscopic disease).

  5. 90Sr-90Y radionuclide generator based on ionex chromatography. Part 1 - project

    International Nuclear Information System (INIS)

    Miler, V.; Budsky, F.; Malek, Z.

    2003-09-01

    This part contains a proposal for the generator column design, materials to be used (chemicals, ionexes) and technological procedures. The proposal was inspired by the 90 Sr- 90 Y generator operated by Zfk Rossendorf. The aim was to develop and launch a generator for the preparation of carrier-free 90 Y in the form of [ 90 Y] chloride solution in dilute hydrochloric acid. The separation of Y from Sr is based on ionex chromatography by sorbing the two radionuclides on a catex. While Sr remains sorbed, 90 Y is eluted with lithium citrate. During this process, 90 Y is bonded in a citrate complex which, having a negative charge, is subsequently trapped by an anex. A guard column is inserted before the anex column to trap any traces of 90 Sr. 90 Y is eluted from the anex in the yttrium chloride form by using dilute hydrochloric acid. The product from the generator can be used for the preparation of [ 90 Y] - Fe colloid injection or [ 90 Y] - yttrium citrate injection for intra-articular application or for the development of monoclonal antibodies and peptides

  6. Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates.

    Science.gov (United States)

    Kukis, D L; DeNardo, S J; DeNardo, G L; O'Donnell, R T; Meares, C F

    1998-12-01

    Radioimmunotherapy (RIT) with 90Y-labeled immunoconjugates has shown promise in clinical trials. The macrocyclic chelating agent 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA) binds 90Y with extraordinary stability, minimizing the toxicity of 90Y-DOTA immunoconjugates arising from loss of 90Y to bone. However, reported 90Y-DOTA immunoconjugate product yields have been typically only BAD) was conjugated to the monoclonal antibody Lym-1 via 2-iminothiolane (2IT). The immunoconjugate product, 2IT-BAD-Lym-1, was labeled in excess yttrium in various buffers over a range of concentrations and pH. Kinetic studies were performed in selected buffers to estimate radiolabeling reaction times under prospective radiopharmacy labeling conditions. The effect of temperature on reaction kinetics was examined. Optimal radiolabeling conditions were identified and used in eight radiolabeling experiments with 2IT-BAD-Lym-1 and a second immunoconjugate, DOTA-peptide-chimeric L6, with 248-492 MBq (6.7-13.3 mCi) of 90Y. Ammonium acetate buffer (0.5 M) was associated with the highest uptake of yttrium. On the basis of kinetic data, the time required to chelate 94% of 90Y (four half-times) under prospective radiopharmacy labeling conditions in 0.5 M ammonium acetate was 17-148 min at pH 6.5, but it was only 1-10 min at pH 7.5. Raising the reaction temperature from 25 degrees C to 37 degrees C markedly increased the chelation rate. Optimal radiolabeling conditions were identified as: 30-min reaction time, 0.5 M ammonium acetate buffer, pH 7-7.5 and 37 degrees C. In eight labeling experiments under optimal conditions, a mean product yield (+/- s.d.) of 91%+/-8% was achieved, comparable to iodination yields. The specific activity of final products was 74-130 MBq (2.0-3.5 mCi) of 90Y per mg of monoclonal antibody. The immunoreactivity of 90Y-labeled immunoconjugates was 100%+/-11%. The optimization of 90Y-DOTA chelation conditions represents an important advance in 90Y RIT

  7. Quantitative and Qualitative Assessment of Yttrium-90 PET/CT Imaging

    OpenAIRE

    Attarwala, Ali Asgar; Molina-Duran, Flavia; Büsing, Karen-Anett; Schönberg, Stefan O.; Bailey, Dale L.; Willowson, Kathy; Glatting, Gerhard

    2014-01-01

    Yttrium-90 is known to have a low positron emission decay of 32 ppm that may allow for personalized dosimetry of liver cancer therapy with (90)Y labeled microspheres. The aim of this work was to image and quantify (90)Y so that accurate predictions of the absorbed dose can be made. The measurements were performed within the QUEST study (University of Sydney, and Sirtex Medical, Australia). A NEMA IEC body phantom containing 6 fillable spheres (10-37 mm ∅) was used to measure the 90Y distribut...

  8. Validation of Extraction Paper Chromatography as a Quality Control Technique for Analysis of Sr-90 in Y-90 Product

    International Nuclear Information System (INIS)

    Nipavan, Poramatikul; Jatupol, Sangsuriyan; Wiranee, Sriweing

    2009-07-01

    Full text: Yttrium-90 (Y-90) is a daughter product of strontium-90 (Sr-90). It is specified that there should be less than 2 micro-curie of Sr-90 in Y-90 radiopharmaceuticals. Since both nuclides are beta emitting and there is always a contamination of Y-90 in Sr-90 sample, validation of the analytical method is necessary. In this study, commercial Y-90 and Sr-85 (a gamma emitting isotope of strontium) were used as daughter and mother nuclides, respectively. Extraction paper chromatography technique and its efficient validation method were investigated. Bis-(2-ethylhexyl) diphosphonate was dropped at the origin of chromatography paper and air dried prior to sample drops. Validation of the separation was done by radio-chromatography scanning of the chromatography paper. Their energy spectra were identified in the spectra mode of Packard Cobra II automatic gamma counter, which can differentiate a pure gamma, a pure beta and a mixture of beta and gamma nuclides. Results showed that yttrium acetate remained fixed at the origin of the chromatography paper while strontium acetate moved to the solvent front when developed in saline. In conclusion, the extraction paper chromatography technique can effectively separate Sr-90 from Y-90

  9. Development of methodology for the preparation of 90Sr-90Y generators

    International Nuclear Information System (INIS)

    Barrio, Graciela; Osso, Joao A.

    2008-01-01

    Among the more attractive radionuclides for therapeutic applications is yttrium-90. Its relatively short half-life (64.0h), maximum beta energy (2.28 MeV) make it well suited for a variety of applications, ranging from the radiolabeling of antibodies for tumor therapy to the production of radiolabeled particles for the treatment of liver malignancies. Yttrium-90 results from the decay of strontium-90 (28y) and decays to a stable daughter ( 90 Zr) and has no γ-ray, what makes this nuclide very attractive for therapeutic applications. 90 Y is produced through a generator system, from the decay of 90 Sr. Before it can safely employed in clinical applications, the 90 Y must be made essentially free of 90 Sr, an isotope known to cause bone marrow suppression. The objective of this work is to develop 90 Sr- 90 Y generator using a cation exchange method resin. This method was the most effects for the separation of 90 Y and 90 Sr. 90 Sr is strongly adsorbed in the resin and 90 Y is eluted in 0.003M EDTA. The generator efficiency and radionuclide control results were also evaluated using 85 Sr (γ-ray emitter). The generator was developed, using AG 50WX8 exchange resin converted to the Na+ form and then conditioned with 0.003M EDTA solution (pH=4.8). The quality control showed that 90 Y had no 8 '5Sr impurities, inside the detection limits of the detector. The results presented here are very promising, showing that the methodology is able to separate the two nuclides, with low quantities of 90 Sr impurity and satisfactory elution yields. (author)

  10. Development of 90Sr-90Y generators

    International Nuclear Information System (INIS)

    Barrio, Graciela

    2007-01-01

    Yttrium-90 is a radioisotope of great interest in the field of Nuclear Medicine. It is considered one of the most important and most used radionuclides for radioimmunotherapeutical applications, especially promising for the treatment of certain types of cancer. Another important application of 90 Y is radio synovectomy. This radionuclide has a half-life of 64 hours, emits long range beta particles (maximum energy of 2.3 MeV) and decays, without intermediate nuclides, to a stable daughter. 90 Y may be obtained carrier-free, generated by the decay of its parent 90 Sr (half-life=28 years). 90 Sr is a product from uranium fission, and due to its long half-life, can be indefinitely used, which is certainly advantageous. It is present in great amounts, and needs to be processed and purified in order to be used as raw material for the generators. Generators of 90 Sr- 90 Y may thus be used during various months, due to 90 Sr long half-life. Several methods for the separation of 90 Y from 90 Sr by solvent extraction and ion exchange have been reported in literature. Thanks to its simplicity, ion exchange techniques have been more commonly used for this generator system. The main objective of this work was to develop a methodology for the preparation of 90 Sr- 90 Y generators, using cationic exchange resins. In such method, 90 Sr is strongly adsorbed in the resin and 90 Y is eluted by a 0.003 M EDTA solution. According to the quality control carried out, results showed that elution yields are greater than 65%, thus confirming the efficiency of the separation method used.

  11. Adsorption of 90Sr and 90Y by bottom-set beds in the Atlantic ocean

    International Nuclear Information System (INIS)

    Gromov, V.V.; Shakhova, N.F.; Emel'yanov, E.M.

    1978-01-01

    The behaviour of 90 Sr and 90 Y has been studied in an adsorption system of sea water-bottom-set beds of the Atlantic ocean (red clay; pelitic silt). It has been shown that strontium is present in the sea water in one form, viz, Sr 2+ . Adsorption of 90 Sr with bottom-set beds follows the ion-exchange mechanism. Yttrium is present in the sea water at least three forms (two absorbable and one non-absorbable). Yttrium-90 adsorption is an irreversible process and only about 10% 90 Y is desorbed by the sea water from red clay and silt

  12. Development of {sup 90}Sr-{sup 90}Y generators; Desenvolvimento de geradores de {sup 90}Sr-{sup 90}Y

    Energy Technology Data Exchange (ETDEWEB)

    Barrio, Graciela, E-mail: gracielabarrio@gmail.co [Pontificia Univ. Catolica de Sao Paulo (PUC-SP), SP (Brazil). Dept. de Fisica; Osso Junior, Joao Alberto, E-mail: jaossoj@ipen.b [Instituto de Pesquisas Energeticas e Nucleares (IPEN/CNEN-SP), Sao Paulo, SP (Brazil)

    2007-07-01

    Yttrium-90 is a radioisotope of great interest in the field of Nuclear Medicine. It is considered one of the most important and most used radionuclides for radioimmunotherapeutical applications, especially promising for the treatment of certain types of cancer. Another important application of {sup 90}Y is radio synovectomy. This radionuclide has a half-life of 64 hours, emits long range beta particles (maximum energy of 2.3 MeV) and decays, without intermediate nuclides, to a stable daughter. {sup 90}Y may be obtained carrier-free, generated by the decay of its parent {sup 90}Sr (half-life=28 years). {sup 90}Sr is a product from uranium fission, and due to its long half-life, can be indefinitely used, which is certainly advantageous. It is present in great amounts, and needs to be processed and purified in order to be used as raw material for the generators. Generators of {sup 90}Sr-{sup 90}Y may thus be used during various months, due to {sup 90}Sr long half-life. Several methods for the separation of {sup 90}Y from {sup 90}Sr by solvent extraction and ion exchange have been reported in literature. Thanks to its simplicity, ion exchange techniques have been more commonly used for this generator system. The main objective of this work was to develop a methodology for the preparation of {sup 90}Sr-{sup 90}Y generators, using cationic exchange resins. In such method, {sup 90}Sr is strongly adsorbed in the resin and {sup 90}Y is eluted by a 0.003 M EDTA solution. According to the quality control carried out, results showed that elution yields are greater than 65%, thus confirming the efficiency of the separation method used.

  13. Development of 90Sr/90Y Generator Systems Based on SLM Techniques for Radiolabelling of Therapeutic Biomolecules with 90Y. Chapter 14

    International Nuclear Information System (INIS)

    Thu, N.T.; Van Dong, D.; Van Cuong, B.; Van Khoa, C.; Cam Hoa, V.T.

    2015-01-01

    Yttrium-90 is one of the most useful radionuclides for radioimmunotherapeutic applications, especially for labelling peptides and antibodies. Studies were carried out to develop a 90 Sr/ 90 Y generator system based on the SLM technique. Two stages of 90 Sr/ 90 Y generator systems were developed at different activity levels of 5, 20, 50 and 100 mCi and operated with semiautomation in sequential mode. In the first stage of the system, PC88A based SLM was used, which transported 90 Y from a nitric acid medium containing 0.01–4M HNO 3 . In the second stage, the 90 Y from the first stage was transferred to the first compartment of the second stage using carbamoylmethyl phosphine oxide (CMPO) based SLM where 1M acetic acid was used as the receiving phase for 90 Y. Quality control was carried out for the products of 90 Y using EPC with paper chromatography and Tec control chromatography. Peptides and antibodies were labelled using the 90 Y product obtained from the generator developed in house. (author)

  14. Radiation protection data sheets for the use of Strontium 90-Yttrium 90 in unsealed sources

    International Nuclear Information System (INIS)

    Anon.

    1993-01-01

    This radiation protection data sheet is intended for supervisors and staff in the different medical, hospital, pharmaceutical, university and industrial laboratories and departments where Strontium 90-Yttrium 90 is handled, and also for all those involved in risk prevention in this field. It provides essential data on radiation protection measures during the use of Strontium 90-Yttrium 90 in unsealed sources: physical characteristics, risk assessment, administrative procedures, recommendations, regulations and bibliography

  15. Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver.

    Science.gov (United States)

    Lewandowski, Robert J; Salem, Riad

    2006-03-01

    Yttrium-90 ((90)Y) radioembolization is a catheter-based therapy that delivers internal radiation to hepatic tumors in the form of microspheres. (90)Y can be delivered to the hepatic tumor as either a constituent of a glass microsphere, TheraSphere(®), or as a biocompatible resin-based microsphere, SIR-Spheres(®). Once embedded within the tumor microcirculation, these microspheres emit β-radiation at therapeutic levels. While the technical aspects of radioembolization are quite complex, the collective clinical experience presented in the literature supports the use of (90)Y radioembolization for unresectable hepatic malignancies.

  16. Treatment of persistent knee effusions with Yttrium 90

    International Nuclear Information System (INIS)

    Bouyoucef, S.E.; Drahmoune, R.; Mechken, F.; Amimour, A.; Hanni-Haddam, F.; Abtroun, F.; Sellah, M.; Mansouri, B.

    2002-01-01

    Yttrium 90 intra-articular injection is used in persisting active joint of the knee, where medication has failed to resolve chronic inflammation. The effective dose delivered to the synovia is linked to Y 90 activity and depends on the size of the joint space, the synovial structure and thickness and the inflammatory activity of the synovitis. The amount of the injected activity of Y90 was estimated according the volume effusion in 28 pathologic knee of 18 patients aged 18 years and more (mean age 46 years). All patients have persistent knee effusions and most of them have rheumatoid arthritis but others had ankylosing spondylitis, Behcet disease, psoriatic arthritis. According the radiological classification of Steinbrocker, 19 pathological knees were in stage 1, 5 in stage 2 and 4 in stage 3. The mean value of the monthly removed volume of the synovial liquid from the pathological knee was determined during the last month preceding the radiosynoviorthesis and four groups were identified: V0 no evidence of effusion liquid, 0 ml 100ml. The activity of Y 90 was estimated in order to obtain a total of 100 Gray in the envelope of 3 spherical phantoms with the same range of volume as defined above. The lowest activity of Y90, 111 MBq (3mCi) was determined for V0 according a mean value of standard sizes of knees. An activity of 18 MBq (0.5mCi) was added for each stage of 50 ml, so 129 MBq (3.5 mCi) for G1, 148 MBq (4 mCi) for G2 and 166 MBq (4.5 mCi) for G3. Efficacy of Y90 treatment was clinically assessed in all patients according to three parameters: pain, hydrarthrosis and range of joint movement at 1, 3, 6 and 12 months. The results were excellent in 13 knees and good in 9 and for most of them the efficacy of Y 90 was observed after 6 months. The results were less good in 3 knees but with an initial good evolution for all at 1 month. For 4 knees, the efficacy of Y 90 was bad. Although the small number of patients, these results show a high rate, 75%, of successful

  17. {sup 90}Y Production and Its Biodistribution in Mice; Pembuatan {sup 90}Y dan Biodistribusinya ke Mencit

    Energy Technology Data Exchange (ETDEWEB)

    Tri-Murni,; Cahyana,; Triyanto,; Djoharly,; Abidin,; Dede-K,; Karyadi, [Center for Development of Radioisotope and Radiopharmacentical(Indonesia)

    2001-11-15

    Yttrium - 90 is radioisotope emitting pure {beta} with maximum energy of 2.27 MeV while its average {beta} energy is 0.93 MeV. {sup 90}Y radioisotope was produced utilizing G.A Siwabessy reactor employing thermal neutron capture process. In nuclear medicine this radioisotope is utilized for bone mettastase palliative and curative therapies. Parameters in this research were the weight of natural Y{sub 2}O{sub 3} target, irradiation time in the reactor, radiochemical purity and specific activity. The end product of the process is YCl{sub 3}, in saline solution. Then sterility of the {sup 90}Y radioisotope so produced is tested and its biodistribution analysis results in mice organs show that the percentage of this radioisotope in the liver is much higher than the ones in heart, kidneys, lung and intestine. Therefore it is concluded that {sup 90}Y radioisotope in the form of YCl{sub 3} can be utilized as a radiopharmaceutical in nuclear medicine. (author)

  18. The sequential separation of strontium-90, yttrium-90, promethium-147, and cerium-144 from urine and their subsequent estimation

    International Nuclear Information System (INIS)

    Kramer, G.H.; Davies, J.M.

    1981-04-01

    A method has been developed for separating low-level activities of the beta-emitting isotopes strontium-90, yttrium-90, promethium-147 and cerium-144 from urine and aqueous solutions. They are subsequently estimated by planchet or liquid scintillation counting. The radionuclides are separated from each other and from interfering elements by solvent extraction with HDEHP (di-2-ethylhexyl phosphoric acid) in n-heptane. It is possible to separate the elements with a minimum of cross-contamination by selecting appropriate pH's and solvent concentrations. Percentage recoveries for the radionuclides are: 90 Sr, 100 +- 12; 90 Y, 65 +- 4; 147 Pm, 90 +- 8; 144 Ce, 87 +- 11. The limits of detection are: 90 Sr, 0.6 pCi; 90 Y, 0.7 pCi; 147 Pm, 1.0 pCi; 144 Ce, 0.8 pCi. (author)

  19. Study on stability of labeled yttrium-90 with lipiodol by chemical extraction for liver cancer

    International Nuclear Information System (INIS)

    Mu, P.Y.; Jiang, X.L.; Chen, J.; Zhu, Y.J.

    2005-01-01

    Liver cancer, particularly hepatocellular carcinoma, is one of the most common malignant diseases in many developed and developing countries. It is also one of the most common diseases endangering the people's lives and health heavily. Surgery is very effective in early-stage patients. Unfortunately, there is less than 10% of the patients with hepatocellular carcinoma fitting for surgical therapy. Instead of surgical therapy, other methods are considered for patients in whom surgery may not work well. Systemic administration of chemotherapeutic agents is not often considered in liver cancer patients, due to discouraging result and adverse side effects. Also, hepatocellular carcinoma is not keen on usual radioactive therapy. However, method of inner interventional radioactive nuclide is a potential way to cure liver tumors. Hepatocellular carcinoma would be cured with inner interventional radioactive nuclide, which is a hot topic in experimental research on hepatocellular carcinoma at home and abroad. The purpose of the study is to label Yttrium-90 with lipiodol by means of the chemical extraction method and research the stability of labeled Yttrium-90 ( 90 Y-P204-Lipiodol) in serum of a newly-born cattle and human's blood. We chose to label steady yttrium with lipiodol, because radioactive yttrium has great nuclear character for liver cancer, yttrium-90 can eradiate pure β radial, and it's half time is 64 hours. Average energy of it is 0.93 Mev, the highest energy is 2.27 Mev. Yttrium-90 can be labeled with lipiodol by means of the chemical extraction method, which is mature in chemical techniques, combined with method of radioactive nuclide labeled in. nuclear medicine. At first, yttrium-90 is extracted in certain condition(pH, temperature, whisk time, whisk frequency, etc ) after adding yttrium-90 solution. We use some distilled water to balance the labeled organic phase twice, and test the stability of labeled yttrium-90 in serum of a newly-born cattle and

  20. Yttrium-90 - ED 4310

    International Nuclear Information System (INIS)

    Ammerich, M.; Frot, P.; Gambini, D.; Gauron, C.; Moureaux, P.; Herbelet, G.; Lahaye, T.; Pihet, P.; Rannou, A.; Vidal, E.

    2013-03-01

    This sheet presents the characteristics of yttrium-90, its origin, and its radio-physical and biological properties. It briefly describes its use in nuclear medicine. It indicates its dosimetric parameters for external exposure, cutaneous contamination, and internal exposure due to acute contamination or to chronic contamination. It indicates and comments the various exposure control techniques: ambient dose rate measurement, surface contamination measurement, atmosphere contamination. It addresses the means of protection: premise design, protection against external exposure and against internal exposure. It describes how areas are delimited and controlled within the premises: regulatory areas, controls to be performed. It addresses the personnel classification, training and medical survey. It addresses the issue of solid and liquid wastes and liquid or gaseous effluents. It briefly recalls the administrative procedures related to the authorization and declaration of possession and use of sealed and unsealed sources. It indicates regulatory aspects related to the transport of yttrium-90, describes what is to be done in case of incident or accident (for the different types of contamination or exposure)

  1. Determination of 90Sr in milk by solvent extraction of 90Y

    International Nuclear Information System (INIS)

    Mitsuhashi, Toshihiko; Sakanoue, Masanobu.

    1977-01-01

    In order to replace the conventional method using violent fuming nitric acid, a new method for the determination of 90 Sr in milk has been developed by using the solvent extraction with bis (2-ethylhexyl) phosphoric acid (HDEHP). The daughter nuclide 90 Y in a radiochemical equilibrium with its parent 90 Sr was extracted with 2:1 HDEHP-toluene from the acid solution (1M HCl) of milk ash sample prepared by dry-ashing. After stripping with 8M HCl, 90 Y, together with stable yttrium added as carrier, was precipitated as oxalate to prepare β-counting source. The radiochemical purity was confirmed by decay curve. The decontamination of strontium was checked by applying non-dispersive fluorescence x-ray analysis using 133 Ba as irradiating source. Bone samples of cow were also analyzed by the same method and the results were compared with those obtained by other methods. The duplicate crosschecking analyses of finely ground bone samples were carried out to examine the effectiveness of this method. This simple new method was found to be very effective for the routine analysis of 90 Sr in these samples. (auth.)

  2. Successful treatment of Cushing's disease using yttrium-90 rods

    International Nuclear Information System (INIS)

    White, M.C.; Doyle, F.H.; Mashiter, K.; Joplin, G.F.

    1982-01-01

    Interstitial irradiation using yttrium-90 ( 90 Y) rods implanted by needle into the pituitary gland was used as primary treatment in 16 patients with pituitary dependent Cushing's disease. Clinical and biochemical remission was observed within three to six months in 13 and in the remaining three after a supplementary implant. There was no perioperative morbidity. Follow-up from the time of definitive operation ranged from six to 123 months (mean 39). No recurrence has been observed. The return of a normal diurnal cortisol rhythm has been observed in 10/12 patients studied after remission. Some form of long-term pituitary hormone replacement therapy was required in only the six patients who had received the largest irradiation dose. Implantation of 90 Y is safe and effective treatment for patients with Cushing's disease, comparing favourably with selective trans-sphenoidal pituitary surgery. (author)

  3. Use of Chelex-100 for selectively removing Y-90 from its parent Sr-90

    International Nuclear Information System (INIS)

    Huntley, M.W.

    1996-01-01

    A method for selectively removing yttrium-90 from its parent strontium-90 contained in an environmental sample includes loading the sample onto a column containing a chelating ion-exchange resin capable of retaining yttrium-90; washing the column with a solution capable of removing strontium, calcium, and other contaminants from the yttrium-90 fraction retained on the column; removing excess acetate salts from the column; eluting yttrium-90 solution from the column and adjusting the pH of this solution to about 2.7; filtering the yttrium-90 solution and weighing this solution for gravimetric yield; and, counting the yttrium-90 containing solution with a radiological counter for a time sufficient to achieve the statistical accuracy desired. It is preferred that the chelating ion-exchange resin is a ligand having the chemical name iminodiacetic acid mounted on a divinyl benzene substrate, converted from sodium form to ammonia form

  4. A revised method of labeling mouse IgG with yttrium-90

    International Nuclear Information System (INIS)

    Arbab, A.S.; Koizumi, Kiyoshi; Araki, Tsutomu

    1996-01-01

    We report the successful labeling of mouse IgG with yttrium-90 (Y-90) using isothiocyanatobenzyl-ethylenediaminetetraacetic acid (SCN-Bz-EDTA) as a chelating agent and compared the result with labeling by indium-111 (In-111). After conjugating IgG with SCN-Bz-EDTA, a predetermined volume of conjugated IgG was mixed with different volumes of either Y-90 or In-111 acetate and incubated at 37degC. Labeling efficiency was assessed at specific intervals upto 3 hr. After 3 hr, the mixtures were challenged with Na 2 EDTA to evaluate the transchelation of labeled Y-90 or In-111. All mixtures showed labeling efficiency of around 50% with Y-90 and the leveling was fairly preserved even after Na 2 EDTA challenge. However, labeling with In-111 was unsuccessful when conjugated IgG was not separated from the unconjugated form. When separated, however, In-111 showed more than 80% labeling efficiency though labeling with In-111 could not tolerate Na 2 EDTA challenge. In conclusion IgG was efficiently labeled by Y-90 using SCN-Bz-EDTA though labeling with In-111 showed some problems associated with this method. (author)

  5. Yttrium-90 microsphere induced gastrointestinal tract ulceration

    Directory of Open Access Journals (Sweden)

    Rikabi Ali A

    2008-09-01

    Full Text Available Abstract Background Radiomicrosphere therapy (RT utilizing yttrium-90 (90Y microspheres has been shown to be an effective regional treatment for primary and secondary hepatic malignancies. We sought to determine a large academic institution's experience regarding the extent and frequency of gastrointestinal complications. Methods Between 2004 and 2007, 27 patients underwent RT for primary or secondary hepatic malignancies. Charts were subsequently reviewed to determine the incidence and severity of GI ulceration. Results Three patients presented with gastrointestinal bleeding and underwent upper endoscopy. Review of the pretreatment angiograms showed normal vascular anatomy in one patient, sclerosed hepatic vasculature in a patient who had undergone prior chemoembolization in a second, and an aberrant left hepatic artery in a third. None had undergone prophylactic gastroduodenal artery embolization. Endoscopic findings included erythema, mucosal erosions, and large gastric ulcers. Microspheres were visible on endoscopic biopsy. In two patients, gastric ulcers were persistent at the time of repeat endoscopy 1–4 months later despite proton pump inhibitor therapy. One elderly patient who refused surgical intervention died from recurrent hemorrhage. Conclusion Gastrointestinal ulceration is a known yet rarely reported complication of 90Y microsphere embolization with potentially life-threatening consequences. Once diagnosed, refractory ulcers should be considered for aggressive surgical management.

  6. Determination of /sup 90/Sr in milk by solvent extraction of /sup 90/Y

    Energy Technology Data Exchange (ETDEWEB)

    Mitsuhashi, T [National Inst. of Animal Industry, Chiba (Japan); Sakanoue, M

    1977-10-01

    In order to replace the conventional method using violent fuming nitric acid, a new method for the determination of /sup 90/Sr in milk has been developed by using the solvent extraction with bis (2-ethylhexyl) phosphoric acid (HDEHP). The daughter nuclide /sup 90/Y in a radiochemical equilibrium with its parent /sup 90/Sr was extracted with 2:1 HDEHP-toluene from the acid solution (1M HCl) of milk ash sample prepared by dry-ashing. After stripping with 8M HCl, /sup 90/Y, together with stable yttrium added as carrier, was precipitated as oxalate to prepare ..beta..-counting source. The radiochemical purity was confirmed by decay curve. The decontamination of strontium was checked by applying non-dispersive fluorescence x-ray analysis using /sup 133/Ba as irradiating source. Bone samples of cow were also analyzed by the same method and the results were compared with those obtained by other methods. The duplicate crosschecking analyses of finely ground bone samples were carried out to examine the effectiveness of this method. This simple new method was found to be very effective for the routine analysis of /sup 90/Sr in these samples.

  7. Yttrium-90

    International Nuclear Information System (INIS)

    Ammerich, Marc; Frot, Patricia; Gambini, Denis-Jean; Gauron, Christine; Moureaux, Patrick; Herbelet, Gilbert; Lahaye, Thierry; Pihet, Pascal; Rannou, Alain; Vial, Eric

    2013-03-01

    This sheet belongs to a collection which relates to the use of radionuclides essentially in unsealed sources. Its goal is to gather on a single document the most relevant information as well as the best prevention practices to be implemented. These sheets are made for the persons in charge of radiation protection: users, radioprotection-skill persons, labor physicians. Each sheet treats of: 1 - the radio-physical and biological properties; 2 - the main uses; 3 - the dosimetric parameters; 4 - the measurement; 5 - the protection means; 6 - the areas delimitation and monitoring; 7 - the personnel classification, training and monitoring; 8 - the effluents and wastes; 9 - the authorization and declaration administrative procedures; 10 - the transport; and 11 - the right conduct to adopt in case of incident or accident. This sheet deals specifically with Yttrium-90

  8. Yttrium 90 microspheres for the treatment of hepatocellular carcinoma.

    Science.gov (United States)

    Memon, Khairuddin; Lewandowski, Robert J; Riaz, Ahsun; Salem, Riad

    2013-01-01

    Yttrium-90 microspheres are radioactive particles which are increasingly being employed for treating patients with unresectable hepatocellular carcinoma (HCC). The procedure is called radioembolization. It involves the injection of micron-sized embolic particles loaded with a radioisotope by use of transarterial techniques. Because of the sensitivity of liver parenchyma and relative insensitivity of tumor, external radiation has played a limited role in treating HCC. (90)Y administered via arterial route directs the highly concentrated radiation to the tumor while healthy liver parenchyma is relatively spared due to its preferential blood supply from portal venous blood. This technique has proven useful for the majority of patients with HCC as most of them present in advanced stage, beyond potentially curative options (resection/liver transplantation). (90)Y microspheres can be used in downstaging large tumors to bring within transplantable criteria, in patients with portal venous thrombosis due to tumor invasion and as palliative therapy. There are two available devices for (90)Y administration; TheraSphere® (glass based) and SIR-Spheres® (resin based). The procedure is performed on an outpatient basis. The incidence of complications is comparatively less and may include nausea, fatigue, abdominal pain, hepatic dysfunction, biliary injury, fibrosis, radiation pneumonitis, GI ulcers, and vascular injury; however, these can be avoided by meticulous pretreatment assessment, careful patient selection, and adequate dosimetry. This article explores the technical and clinical aspects of (90)Y radioembolization with keeping emphasis on patient selection, uses, and complications.

  9. Determination of strontium-90 from direct separation of yttrium-90 by solid phase extraction using DGA Resin for seawater monitoring.

    Science.gov (United States)

    Tazoe, Hirofumi; Obata, Hajime; Yamagata, Takeyasu; Karube, Zin'ichi; Nagai, Hisao; Yamada, Masatoshi

    2016-05-15

    It is important for public safety to monitor strontium-90 in aquatic environments in the vicinity of nuclear related facilities. Strontium-90 concentrations in seawater exceeding the background level have been observed in accidents of nuclear facilities. However, the analytical procedure for measuring strontium-90 in seawater is highly demanding. Here we show a simple and high throughput analytical technique for the determination of strontium-90 in seawater samples using a direct yttrium-90 separation. The DGA Resin is used to determine the abundance of strontium-90 by detecting yttrium-90 decay (beta-emission) in secular equilibrium. The DGA Resin can selectively collect yttrium-90 and remove naturally occurring radionuclides such as (40)K, (210)Pb, (214)Bi, (238)U, and (232)Th and anthropogenic radionuclides such as (140)Ba, and (140)La. Through a sample separation procedure, a high chemical yield of yttrium-90 was achieved at 95.5±2.3%. The result of IAEA-443 certified seawater analysis (107.7±3.4 mBq kg(-1)) was in good agreement with the certified value (110±5 mBq kg(-1)). By developed method, we can finish analyzing 8 samples per day after achieving secular equilibrium, which is a reasonably fast throughput in actual seawater monitoring. By processing 3 L of seawater sample and applying a counting time of 20 h, minimum detectable activity can be as low as 1.5 mBq kg(-1), which could be applied to monitoring for the contaminated marine environment. Reproducibility was found to be 3.4% according to 10 independent analyses of natural seawater samples from the vicinity of the Fukushima Daiichi Nuclear Power Plant in September 2013. Copyright © 2016 Elsevier B.V. All rights reserved.

  10. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma.

    Science.gov (United States)

    Geschwind, Jean Francois H; Salem, Riad; Carr, Brian I; Soulen, Michael C; Thurston, Kenneth G; Goin, Kathleen A; Van Buskirk, Mark; Roberts, Carol A; Goin, James E

    2004-11-01

    Unresectable hepatocellular carcinoma is extremely difficult to treat. TheraSphere consists of yttrium-90 (a pure beta emitter) microspheres, which are injected into the hepatic arteries. This article reviews the safety and survival of patients with hepatocellular carcinoma who were treated with yttrium-90 microspheres. Eighty patients were selected from a database of 108 yttrium-90 microsphere-treated patients and were staged by using Child-Pugh, Okuda, and Cancer of the Liver Italian Program scoring systems. Patients were treated with local, regional, and whole-liver approaches. Survival from first treatment was analyzed with Kaplan-Meier and Cox regression methods. Adverse events and complications of treatment were coded by using the Southwest Oncology Group toxicity scoring system. Patients received liver doses ranging from 47 to 270 Gy. Thirty-two patients (40%) received more than 1 treatment. Survival correlated with pretreatment Cancer of the Liver Italian Program scores ( P = .002), as well as with the individual Cancer of the Liver Italian Program components, Child-Pugh class, alpha-fetoprotein levels, and percentage of tumor replacement. Patients classified as Okuda stage I (n = 54) and II (n = 26) had median survival durations and 1-year survival rates of 628 days and 63%, and 384 days and 51%, respectively ( P = .02). One patient died of liver failure judged as possibly related to treatment. Thus, in selected patients with hepatocellular carcinoma, yttrium-90 microsphere treatment is safe and well tolerated. On the basis of these results, a randomized controlled trial is warranted comparing yttrium-90 microsphere treatment with transarterial chemoembolization by using the Cancer of the Liver Italian Program system for prospective stratified randomization.

  11. Effect of intra-articular yttrium-90 on chronic pyrophosphate arthropathy of the knee

    International Nuclear Information System (INIS)

    Doherty, M.; Dieppe, P.A.

    1981-01-01

    Fifteen patients with bilateral, symmetrical chronic pyrophosphate arthropathy of the knee were given intra-articular injections of yttrium-90 (5 mCi) plus steroid (triamcinolone hexacetonide, 20 mg) into one knee, and saline plus steroid into the other (control) knee. Allocation of the 90 Y injection was random and double blind. After 6 months there was significantly less pain, inactivity stiffness, joint-line tenderness, and effusion in the 90 Y-injected knees than in the controls (p 90 Y-injected and control knees in the changes in range of movement (p 90 Y may be of benefit in chronic pyrophosphate arthropathy, a disease for which there is no treatment. The predilection of this condition to affect the knees of the elderly makes such treatment highly suitable because the joint lends itself readily to injection and the procedure carries very few actual or potential risks in this age group. (author)

  12. Yttrium-90 microspheres (TheraSphere and SIR-Spheres) for the treatment of unresectable hepatocellular carcinoma.

    Science.gov (United States)

    Allison, C

    2007-09-01

    (1) Microspheres containing radioactive yttrium-90 (90Y) are infused into the hepatic artery. These deliver high doses of ionizing radiation to inoperable hepatocellular carcinoma, the most common type of primary liver cancer. (2) Limited evidence from several case series indicates that palliative therapy with 90Y microspheres may reduce tumour size and increase survival time. (3) In some patients, 90Y treatment may result in enough tumour reduction to permit liver resection or transplantation. (4) While 90Y microsphere therapy is generally well tolerated, major complications and several treatment-related deaths have occurred. Improved patient selection criteria and technical changes to microsphere delivery have reduced the risks of complications and death. (5) Patient selection and the technical aspects of 90Y microsphere treatment are complex and require the coordinated expertise of a multidisciplinary team.

  13. Effects of yttrium 90 on experimental allergic arthritis in rabbits

    International Nuclear Information System (INIS)

    Meier-Ruge, W.; Mueller, W.; Pavelka, K.

    1976-01-01

    Fifteen weeks after allergic arthritis developed in the knee joint of 17 immunized rabbits, 8 animals were given an injection of 200 μCi yttrium 90( 90 Y) into the left joint cavity and 7 were injected with 400 μCi. The animals were sacrificed at 2, 4, 8, 12, and 16 weeks, and at 6 to 12 months after the injection. Two uninjected animals used as morphological controls were sacrificed 13 weeks after immunization, and showed allergic arthritis had progressed to severe inflammation of the knee joint marked by massive round-cell infiltration, oedema, and proliferation of synovial mesothelium in the synovial villi and joint capsule. Treatment with 90 Y was effective 2 weeks after injection and the disappearance of inflammatory odema and marked regression of round-cell infiltration. This was accompanied by degeneration of the synovial mesothelium and fibrosis of the subsynovial tissue and synovial vessels as a secondary effect of the radiation. In the animals with severe allergic arthritis, the healing effects of 90 Y were more marked than the secondary effects of the radiation which were dose-dependent. Treatment with 90 Y of arthritic knee joints with the lowest effective dose of the isotope - if necessay with repeated application - seems justified. A single large dose does not have a greater therapeutic effect and causes more radiation damage to the joint. In view of the possible secondary effects in the joint, the indication for 90 Y therapy should be restricted, particularly in young patients, to cases of chronic relapsing arthritis unresponsive to other treatment. (U.K.)

  14. Effects of yttrium 90 on experimental allergic arthritis in rabbits

    Energy Technology Data Exchange (ETDEWEB)

    Meier-Ruge, W [Sandoz A.G., Basel (Switzerland); Mueller, W; Pavelka, K

    1976-02-01

    Fifteen weeks after allergic arthritis developed in the knee joint of 17 immunized rabbits, 8 animals were given an injection of 200 ..mu..Ci yttrium 90(/sup 90/Y) into the left joint cavity and 7 were injected with 400 ..mu..Ci. The animals were sacrificed at 2, 4, 8, 12, and 16 weeks, and at 6 to 12 months after the injection. Two uninjected animals used as morphological controls were sacrificed 13 weeks after immunization, and showed allergic arthritis had progressed to severe inflammation of the knee joint marked by massive round-cell infiltration, oedema, and proliferation of synovial mesothelium in the synovial villi and joint capsule. Treatment with /sup 90/Y was effective 2 weeks after injection and the disappearance of inflammatory odema and marked regression of round-cell infiltration. This was accompanied by degeneration of the synovial mesothelium and fibrosis of the subsynovial tissue and synovial vessels as a secondary effect of the radiation. In the animals with severe allergic arthritis, the healing effects of /sup 90/Y were more marked than the secondary effects of the radiation which were dose-dependent. Treatment with /sup 90/Y of arthritic knee joints with the lowest effective dose of the isotope - if necessay with repeated application - seems justified. A single large dose does not have a greater therapeutic effect and causes more radiation damage to the joint. In view of the possible secondary effects in the joint, the indication for /sup 90/Y therapy should be restricted, particularly in young patients, to cases of chronic relapsing arthritis unresponsive to other treatment.

  15. Quantitative and qualitative assessment of Yttrium-90 PET/CT imaging.

    Directory of Open Access Journals (Sweden)

    Ali Asgar Attarwala

    Full Text Available Yttrium-90 is known to have a low positron emission decay of 32 ppm that may allow for personalized dosimetry of liver cancer therapy with (90Y labeled microspheres. The aim of this work was to image and quantify (90Y so that accurate predictions of the absorbed dose can be made. The measurements were performed within the QUEST study (University of Sydney, and Sirtex Medical, Australia. A NEMA IEC body phantom containing 6 fillable spheres (10-37 mm ∅ was used to measure the 90Y distribution with a Biograph mCT PET/CT (Siemens, Erlangen, Germany with time-of-flight (TOF acquisition. A sphere to background ratio of 8:1, with a total (90Y activity of 3 GBq was used. Measurements were performed for one week (0, 3, 5 and 7 d. he acquisition protocol consisted of 30 min-2 bed positions and 120 min-single bed position. Images were reconstructed with 3D ordered subset expectation maximization (OSEM and point spread function (PSF for iteration numbers of 1-12 with 21 (TOF and 24 (non-TOF subsets and CT based attenuation and scatter correction. Convergence of algorithms and activity recovery was assessed based on regions-of-interest (ROI analysis of the background (100 voxels, spheres (4 voxels and the central low density insert (25 voxels. For the largest sphere, the recovery coefficient (RC values for the 30 min -2-bed position, 30 min-single bed and 120 min-single bed were 1.12 ± 0.20, 1.14 ± 0.13, 0.97 ± 0.07 respectively. For the smaller diameter spheres, the PSF algorithm with TOF and single bed acquisition provided a comparatively better activity recovery. Quantification of Y-90 using Biograph mCT PET/CT is possible with a reasonable accuracy, the limitations being the size of the lesion and the activity concentration present. At this stage, based on our study, it seems advantageous to use different protocols depending on the size of the lesion.

  16. Planar gamma camera imaging and quantitation of Yttrium-90 bremsstrahlung

    International Nuclear Information System (INIS)

    Shen, S.; DeNardo, G.L.; Yuan, A.

    1994-01-01

    Yttrium-90 is a promising radionuclide for radioimmunotherapy of cancer because of its energetic beta emissions. Therapeutic management requires quantitative imaging to assess the pharmacokinetics and radiation dosimetry of the 90 Y-labeled antibody. Conventional gamma photon imaging methods cannot be easily applied to imaging of 90 Y-bremsstrahlung because of its continuous energy spectrum. The sensitivity, resolution and source-to-background signal ratio (S/B) of the detector system for 90 Y-bremsstrahlung were investigated for various collimators and energy windows in order to determine optimum conditions for quantitative imaging. After these conditions were determined, the accuracy of quantitation of 90 Y activity in an Alderson abdominal phantom was examined. When the energy-window width was increased, the benefit of increased sensitivity outweighed degradation in resolution and S/B ratio until the manufacturer's energy specifications for the collimator were exceeded. Using the same energy window, the authors improved resolution and S/B for the medium-energy (ME) collimator when compared to the low-energy, all-purpose (LEAP) collimator, and there was little additional improvement using the high-energy (HE) collimator. Camera sensitivity under tissue equivalent conditions was 4.2 times greater for the LEAP and 1.7 times greater for the ME collimators when compared to the HE collimator. Thus, the best, most practical selections were found to be the ME collimator and an energy window of 55-285 keV. When they used these optimal conditions for image acquisition, the estimation of 90 Y activity in organs and tumors was within 15% of the true activities. The results for this study suggest that reasonable accuracy can be achieved in clinical radioimmunotherapy using 90 Y-bremsstrahlung quantitation. 28 refs., 5 figs., 7 tabs

  17. Yttrium-90 Radioembolization for Unresectable Standard-chemorefractory Intrahepatic Cholangiocarcinoma: Survival, Efficacy, and Safety Study

    Energy Technology Data Exchange (ETDEWEB)

    Rafi, Shoaib; Piduru, Sarat M. [Emory University School of Medicine, Division of Interventional Radiology and Image Guided Medicine, Department of Radiology (United States); El-Rayes, Bassel; Kauh, John S. [Emory University School of Medicine, Department of Hematology and Medical Oncology (United States); Kooby, David A.; Sarmiento, Juan M. [Emory University School of Medicine, Department of Surgical Oncology in Surgery (United States); Kim, Hyun S., E-mail: kevin.kim@emory.edu [Emory University School of Medicine, Division of Interventional Radiology and Image Guided Medicine, Department of Radiology (United States)

    2013-04-15

    To assess the overall survival, efficacy, and safety of radioembolization with yttrium-90 (Y90) for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma (ICC). Patients with unresectable standard-chemorefractory ICC treated with Y90 were studied. Survival was calculated from the date of first Y90 procedure. Tumor response was assessed with the Response Evaluation Criteria in Solid Tumors criteria on follow-up computed tomography or magnetic resonance imaging scans. National Cancer Institute Common Terminology Criteria (NCI CTCAE), version 3, were used for complications. Statistical analysis was performed by the Kaplan-Meier estimator by the log rank test. Nineteen patients underwent a total of 24 resin-based Y90 treatments. Median survival from the time of diagnosis and first Y90 procedure was 752 {+-} 193 [95 % confidence interval (CI) 374-1130] and 345 {+-} 128 (95 % CI 95-595) days, respectively. Median survival with Eastern Cooperative Oncology Group (ECOG) performance status 1 (n = 15) and ECOG performance status 2 (n = 4) was 450 {+-} 190 (95 % CI 78-822) and 345 {+-} 227 (95 % CI 0-790) days, respectively (p = .214). Patients with extrahepatic metastasis (n = 11) had a median survival of 404 {+-} 309 (95 % CI 0-1010) days versus 345 {+-} 117 (95 % CI 115-575) days for patients without metastasis (n = 8) (p = .491). No mortality was reported within 30 days from first Y90 radioembolization. One patient developed grade 3 thrombocytopenia as assessed by NCI CTCAE. Fatigue and transient abdominal pain were observed in 4 (21 %) and 6 (32 %) patients, respectively. Y90 radioembolization is effective for unresectable standard-chemorefractory ICC.

  18. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma

    International Nuclear Information System (INIS)

    Wiseman, G.A.; Dunn, W.L.; White, C.A.; Berlfein, J.R.; Ding, E.; Grillo-Lopez, A.J.; Stabin, M.; Erwin, W.; Spies, S.; Dahlbom, M.; Silverman, D.H.S.; Raubitschek, A.; Karvelis, K.; Schultheiss, T.; Witzig, T.E.; Belanger, R.

    2000-01-01

    Dosimetry studies in patients with non-Hodgkin's lymphoma were performed to estimate the radiation absorbed dose to normal organs and bone marrow from 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) treatment in this phase I/II, multicenter trial. The trial was designed to determine the dose of Rituximab (chimeric anti-CD20, Rituxan, IDEC-C2B8, MabThera), the unlabeled antibody given prior to the radioconjugate to clear peripheral blood B cells and optimize distribution, and to determine the maximum tolerated dose of 90 Y-Zevalin [7.4, 11, or 15 MBq/kg (0.2, 0.3, or 0.4 mCi/kg)]. Patients received 111 In-Zevalin (indium-111 ibritumomab tiuxetan, IDEC-In2B8) on day 0 followed by a therapeutic dose of 90 Y-Zevalin on day 7. Both doses were preceded by an infusion of the chimeric, unlabeled antibody Rituximab. Following administration of 111 In-Zevalin, serial anterior/posterior whole-body scans were acquired. Major-organ radioactivity versus time estimates were calculated using regions of interest. Residence times were computed and entered into the MIRDOSE3 computer software program to calculate estimated radiation absorbed dose to each organ. Initial analyses of estimated radiation absorbed dose were completed at the clinical site. An additional, centralized dosimetry analysis was performed subsequently to provide a consistent analysis of data collected from the seven clinical sites. In all patients with dosimetry data (n=56), normal organ and red marrow radiation absorbed doses were estimated to be well under the protocol-defined upper limit of 20 Gy and 3 Gy, respectively. Median estimated radiation absorbed dose was 3.4 Gy to liver (range 1.2-7.8 Gy), 2.6 Gy to lungs (range 0.72-4.4 Gy), and 0.38 Gy to kidneys (range 0.07-0.61 Gy). Median estimated tumor radiation absorbed dose was 17 Gy (range 5.8-67 Gy). No correlation was noted between hematologic toxicity and the following variables: red marrow radiation absorbed dose, blood T 1/2 , blood AUC

  19. 90Sr- 90Y and 89Sr beta radioactivity measurement in milk samples using a proportional counter

    International Nuclear Information System (INIS)

    Mananes, A.; Perez Santos, C.; Martinez Churiaque, F.

    1987-01-01

    A thin window glas flow proportional counter is used to measure the 90 Sr- 90 Y and 89 Sr beta radioactivity in milk samples. A chemical procedure is used to separate strontium-yttrium from the other radionuclides present in milk. A calculation of the total efficiency of the system is performed which includes an empirical estimation of the backscattering factor. The calibration of the whole process allows the determination of the 90 Sr activity within 10% relative error in spite of uncertainties in the recovery yields of strontium and yttrium. No 89 Sr activity has been detected, and the mean value obtained for the 90 Sr activity in nine milk samples of Cantabria is 0.115 Bq/1 with a minimum detectable activity of 0.0105 Bq. (author) 18 refs

  20. Yttrium-90 radioembolization using TheraSphere in the management of primary and secondary liver tumors.

    Science.gov (United States)

    Riaz, A; Lewandowski, R J; Kulik, L; Salem, R

    2009-06-01

    Locoregional therapies, such as transarterial chemoembolization, radioembolization and thermal ablation (e.g., radiofrequency ablation) are establishing their roles in the management of liver malignancies. With yYttrium-90 radioembolization therapy (90Y) radionuclide labeled microspheres are injected into the tumor feeding artery. This allows the delivery of a high radioactive dose to the tumor with minimal toxicity to normal tissues. 90Y has demonstrated to be safe and effective in the management of liver tumors. Authors present a review of the literature available for the use of TheraSphere for radioembolization in the management of liver tumors.

  1. Treatment of persistent knee synovitis with Yttrium 90

    International Nuclear Information System (INIS)

    Bouyoucef, S.E.

    2007-01-01

    Full text: Management of persistent knee synovitis includes both systemic and local articular treatment relevant to specific etiology. Local treatment may involve attempts to control inflammation and pain in knee joints by intra articular application of analgesics or glucocorticoids. However, in many patients these fail to reduce significantly the synovitis phenomenon and moreover they may lead to severe side effects. Radiosynoviorthesis with Y90 has been in use for many years in several joint pathologies. Indications of Radiosynoviorthesis include various inflammatory and degenerative diseases and its use should be envisaged when other conservative methods have failed like intra articular injections of long acting corticosteroids. Persistent knee synovitis is defined by the presence of hydrops in the joint or functional impairment with warmth, pain and local signs and symptoms requiring intra articular injection of glucocorticoids. In this study, 151 knees with persistent knee synovitis have been treated with Y 90 and have had all a minimum of one year follow up. Many parameters have been identified to measure efficiency of the RSO including pain, hydarthrosis, mobility, as well as global perception of the patients. Excellent and good responses have been appreciated through pain at rest, pain at stress, volume of effusion, and articular mobility. Results showed that percentage of excellent and good response is superior to 80% at three and six months. Success of Y 90 appears to be higher for rheumatoid arthritis as well as for oligoarthritis. Whatever the etiology, intensity of the inflammatory process appears one the major parameters which could better predict the outcomes of yttrium 90 in persistent knee synovitis. (author)

  2. Development of techniques for rapid analysis of 90Sr breakthrough and 90Y activity from a 90Sr-90Y generator

    International Nuclear Information System (INIS)

    Chism, S.E.; Goodwin, D.A.; Meares, C.F.

    1986-01-01

    Recently there has been interest in labelling monoclonal antibodies with therapeutic amounts of a pure beta emitting isotope. 90 Y offers many desirable features and may be conveniently and economically obtained from a 90 Sr- 90 Y generator. A potential hazard with this system is breakthrough of the parent 90 Sr which has a half life of 28 years and is an extremely toxic bone seeking isotope. Therefore it is essential that the daughter be completely separated from its parent. We have devised two simple techniques which allow us to monitor rapidly the amount of 90 Sr breakthrough and quantitate the 90 Y activity over a 5 log range. (author)

  3. Radiochemistry, pre-clinical studies and first clinical investigation of 90Y-labeled hydroxyapatite (HA) particles prepared utilizing 90Y produced by (n,γ) route

    International Nuclear Information System (INIS)

    Vimalnath, K.V.; Chakraborty, Sudipta; Rajeswari, A.; Sarma, H.D.; Nuwad, Jitendra; Pandey, Usha; Kamaleshwaran, K.; Shinto, Ajit; Dash, Ashutosh

    2015-01-01

    Introduction: The scope of using no carrier added (NCA) 90 Y [T 1/2 = 64.1 h, E β(max) = 2.28 MeV] obtained from 90 Sr/ 90 Y generator in radiation synovectomy (RSV) is widely accepted. In the present study, the prospect of using 90 Y produced by (n,γ) route in a medium flux research reactor for use in RSV was explored. Methods: Yttrium-90 was produced by thermal neutron irradiation of Y 2 O 3 target at a neutron flux of ~ 1 × 10 14 n/cm 2 .s for 14 d. The influence of various experimental parameters were systematically investigated and optimized to arrive at the most favorable conditions for the formulation of 90 Y labeled hydroxyapatite (HA) using HA particles of 1–10 μm size range. An optimized kit formulation strategy was developed for convenient one-step compounding of 90 Y-HA, which is easily adaptable at hospital radiopharmacy. The pre-clinical biological evaluation of 90 Y-HA particles was studied by carrying out biodistribution and bioluminiscence imaging studies in Wistar rats. The first clinical investigation using the radiolabeled preparation was performed on a patient suffering from chronic arthritis in knee joint by administering 185 MBq 90 Y-HA formulated at the hospital radiopharmacy deploying the proposed strategy. Results: Yttrium-90 was produced with a specific activity of 851 ± 111 MBq/mg and radionuclidic purity of 99.95 ± 0.02%. 90 Y-labeled HA particles (185 ± 10 MBq doses) were formulated in high radiochemical purity (> 99%) and excellent in vitro stability. The preparation showed promising results in pre-clinical studies carried out in Wistar rats. The preliminary results of the first clinical investigation of 90 Y-HA preparation in a patient with rheumatoid arthritis in knee joints demonstrated the effectiveness of the formulation prepared using 90 Y produced via (n,γ) route in the management of the disease. Conclusion: The studies revealed that effective utilization of 90 Y produced via (n,γ) route in a medium flux research

  4. Treatment of rheumatoid arthritis with 90yttrium. Follow up studies

    International Nuclear Information System (INIS)

    Teuber, J.; Baenkler, H.W.; Regler, G.; Erlangen-Nuernberg Univ., Erlangen

    1978-01-01

    90 Yttrium-silicate was injected into 131 knee-joints from patients with rheumatoid arthritis with stadium II-IV according to Steinbrocker. The observation period lasted until two years. After three months about 80% and after 24 months still more than 50% of the patients treated showed complete or partial remission. Side-effects as formerly observed with 198 -goldpreparations did not occur. Therefore the treatment with 90 Yttrium-silicate offers an alternative to surgical synovectomy. (orig.) [de

  5. Complexation studies with 90Y from a novel 90Sr-90Y generator

    International Nuclear Information System (INIS)

    Venkatesh, M.; Pandey, U.; Banerjee, S.; Samuel, G.; Pillai, M.R.A.; Dhami, P.S.; Kannan, R.; Achuthan, P.V.; Chitnis, R.R.; Gopalakrishnan, V.; Ramanujam, A.

    2001-01-01

    Some features of a novel 90 Sr- 90 Y generator which employs supported liquid membrane (SLM) to separate carrier-free 90 Y from 90 Sr present in the high level waste of the spent fuel of reactor are described. After ascertaining the purity of 90 Y particularly with respect to 90 Sr breakthrough, its complexation was studied with a few oxo/aza donor ligands, such as DTPA, EDTMP, DOTA, TETA and a cyclic phosphonate, CTMP. These studies were primarily carried out to adjudge the quality of the 90 Y obtained from a novel 90 Sr- 90 Y generator and ascertain its usability for labelling biomolecules such as antibodies and peptides. The DOTA complexes are most stable at 37 C in human serum; they appear to be ideal bifunctional chelating agent for use in radioimmunotherapy with 90 Y. (orig.)

  6. Country report: Syria. Development of 90Y/90Sr Generator and 90Y Radiopharmaceuticals

    International Nuclear Information System (INIS)

    Yassine, Taufik; Mukhallalati, Ch. Heyam

    2010-01-01

    The aim of this project is to develop a technique for preparation of 90 Sr- 90 Y generator, we have developed a separation technique for isolation of 90 Y from 90 Sr based on using Sr – Spec resin packed in three columns for separation and purification of 90 Sr- 90 Y .The resulting Y90 is used for therapeutic applications. The first part of this project describe a prototype design for the 90 Sr- 90 Y generator in order to get a very accurate method to obtain the minimum possible 90 Sr Breakthrough. 25 mci of 90 Sr was used in the generator 90 Sr- 90 Y and we obtained the elution yield of 90 Y higher than 88%, Also the eluate was used for preparation of several 90 Y radiopharmaceuticals such as 90 YEDTMP and 90 Y-DOTA-HR 3 . And the work is continues to investigate more radiopharmaceuticals applications in the second part of this project such as 90 Y– FHMA. In this part of the co-coordination research programmer, A protocol based on results of this studies was developed to prepare and operate a higher activity generator (50-100mci), the resulting elution yield was approximately 94% of 90 Y . The elute was used in preparation of new 90 Y radiopharmaceuticals. The monoclonal antibodies is still evolving by conjugate Rituximab to The macrocyclic bifunctional chelating agent,(p-SCN-Bn-DOTA)S-2-(4-Isothiocyanatobenzyle)-1,4,7,10- tetraazacyclododecane-tetraaceticacid to obtain the inmunoconjugate DOTA-Rituximub in simple way and then investigating the radio labeling conditions with 90 Y. (author)

  7. Yttrium-90 resin microspheres and their use in the treatment of intrahepatic cholangiocarcinoma.

    Science.gov (United States)

    Filippi, Luca; Schillaci, Orazio; Cianni, Roberto; Bagni, Oreste

    2018-04-01

    Intrahepatic cholangiocarcinoma (ICC) is a severe and rapidly progressive hepatic tumor. Surgery is often impracticable due to locally advanced presentation. On the other hand, chemotherapy has demonstrated only limited effectiveness. For these reasons, liver-directed therapies have been successfully applied for treating ICC. In particular, radioembolization with Yttrium-90 ( 90 Y)-labeled spheres has been reported to be a promising therapeutic approach for this neoplasia. Two commercial forms of 90 Y-labeled spheres are available: glass (TheraSphere ® ) and resin (SIR-Spheres ® ) microspheres. The aim of the present paper is to review the existing literature on the use of the resin microspheres for the treatment of unresectable and chemorefractory ICC, focusing on the methodology, clinical applications and side effects.

  8. Non-target activity detection by post-radioembolization yttrium-90 PET/CT: Image assessment technique and case examples

    Directory of Open Access Journals (Sweden)

    Yung Hsiang eKao

    2014-02-01

    Full Text Available High-resolution yttrium-90 (90Y imaging of post-radioembolization microsphere biodistribution may be achieved by conventional positron emission tomography with integrated computed tomography (PET/CT scanners that have time-of-flight capability. However, reconstructed 90Y PET/CT images have high background noise, making non-target activity detection technically challenging. This educational article describes our image assessment technique for non-target activity detection by 90Y PET/CT which qualitatively overcomes the problem of background noise. We present selected case examples of non-target activity in untargeted liver, stomach, gallbladder, chest wall and kidney, supported by angiography and 90Y bremsstrahlung single photon emission computed tomography with integrated computed tomography (SPECT/CT or technetium-99m macroaggregated albumin SPECT/CT.

  9. Preparation of 90Sr-90Y generator

    International Nuclear Information System (INIS)

    Jin Xiaohai; Yu Haibin; Zhang Jinming; Zhang Peixin; Lin Qiongfang

    1990-01-01

    In recent years, 90 Y has been considered as one of the best radionuclides for tumor radioimmunotherapy when chelated to tumor-associated antibodies. This evaluation is based on the superior properties of this radionuclide (suitable half-life, pure β-ray emitter of intermediate energy, stable daughters, and suitable chemical properties) and because it is available as a radionuclide generator product by decay of its 28a parent 90 Sr. The experimental conditions of 90 Sr- 90 Y generator are described. The elution efficiency of 90 Sr- 90 Y generator reaches 98%. One of the most important problems is the 90 Sr contamination breakthrough from the generator. The level of 90 Sr contamination must be controlled to the clinical standard. The cation exchange resin 732 (100-150 mesh) was successfully used for the separation of 90 Y from 90 Sr. The method used by the authors provides a 90 Y-HAc solution which is very simple and safe for administration to the patients. 90 Y was separated from 90 Sr almost completely, the level of the 90 Sr contamination per 740 MBq 90 Y product was only 0.74 kBq. However the toxicity of 90 Sr is extremely high, the human life-time permissible dose is 74 kBq, then 740 MBq of 90 Y is allowed to be administrated to a patient for 50-100 times

  10. Electrochemical separation of 90-yttrium in the electrochemical 90Sr/90Y generator and its use for radiolabelling of DOTA-conjugated somatostatin analog [DOTA0, Tyr3] octreotate

    Directory of Open Access Journals (Sweden)

    Petrović Đorđe Ž.

    2012-01-01

    Full Text Available Radiopharmaceuticals based on 90Y are widely used in the treatment of malignant deseases. In order to meet the requirements for their future application, a 90Sr/90Y generator was developed and 90Y eluted from this locally produced generator was used for the radiolabelling of the DOTA-conjugated somatostatin analog [DOTA0,Tyr3] octreotate and the preparation of [90Y-DOTA0,Tyr3] octreotate (90Y-DOTATATE for peptide receptore radionuclide therapy. 90Sr/90Y generator was based on the electrochemical separation of 90Y from 90Sr in a two-cycle electrolysis procedure. Three electrode cells were used to perform both electrolyses. In both cycles, working electrodes were kept on constant potential. The pH of the solution was adjusted to 2.7 of the value before the electrolyses. The radionuclidic purity of the 90Y solution was analysed by ITLC and extraction paper chromatography. The labelling of peptide (100 mg DOTATATE with 90YCl3 was performed at 95°C for 30 minutes. Radiochemical purity was determined by HPLC and chromatographic separation, using a solid SepPak C-18 column. Results obtained confirmed the efficiency of our electrochemical separation technique and quality control methods for 90Y. The achieved efficiency of the 90Sr/90Y generator above 96% of the theoretical value represents a good basis for the further development of this generator. The labelling of the DOTATATE with 90Y exhibited a high efficiency, too: there was less than 1% of 90Y3+in the 90Y-DOTATATE.

  11. A retrospective review of Y90 synovectomy in Auckland

    International Nuclear Information System (INIS)

    Stamp, L.

    2000-01-01

    Full text: A retrospective review of Yttrium 90 synovectomies carried out from June 1997 to February 1999 in Auckland Hospital to determine outcome from the procedure. Methods: Patients were sent a questionnaire for each treated knee The principal outcome measures assessed in the month prior and the 6 months after the Y90 were pain, swelling, walking distance and overall disability score. Referring doctors were sent a questionnaire to provide information on duration of synovitis and treatment. Outcomes measured were presence of effusion 6 months after the Y90, requirement for intra-articular steroid in the 12 months prior to and after the yttrium and change of therapy due lo ongoing symptoms in the treated knee. Results: 29 patients and 40 knees had Y90 during the study period 86% patients with 87.5% knees responded. Referring doctors for 86% patients accounting for 87.5% knees responded. The procedure was well tolerated with the majority of patients reporting nil-mild discomfort during and in the 24 hours after Y90. 86% knees treated reported improvement with a reduction in pain and swelling Patient global assessment reduced from 3.8 to 2.0 while physician global assessment reduced from 3.9 to 3.0. There was an improvement in walking distance 6 months after Y90 with the number of knees able to walk >1km increasing from 2 to 17 14 of 25 patients required a change in treatment because of ongoing problems in the treated knee and one patient has undergone knee joint replacement One further patient is waiting knee joint replacement The need for intra-articular steroid was reduced with 83%, knees having an average of 2.4 steroid injections in the 12 months prior to Y90 compared to 38% knees having an average of 0.7 steroid injections in the 12 months after Y90. Of the 30 knees reporting Improvement 24 knees are at least 12 months post Y90. Of these 50% were Improved at 12 months. As a result of this audit we continue to offer this procedure in the Auckland area, and

  12. Lung Shunt Fraction prior to Yttrium-90 Radioembolization Predicts Survival in Patients with Neuroendocrine Liver Metastases: Single-Center Prospective Analysis

    International Nuclear Information System (INIS)

    Ludwig, Johannes M.; Ambinder, Emily McIntosh; Ghodadra, Anish; Xing, Minzhi; Prajapati, Hasmukh J.; Kim, Hyun S.

    2016-01-01

    ObjectiveTo investigate survival outcomes following radioembolization with Yttrium-90 (Y90) for neuroendocrine tumor liver metastases (NETLMs). This study was designed to assess the efficacy of Y90 radioembolization and to evaluate lung shunt fraction (LSF) as a predictor for survival.MethodsA single-center, prospective study of 44 consecutive patients (median age: 58.5 years, 29.5 % male) diagnosed with pancreatic (52.3 %) or carcinoid (47.7 %) NETLMs from 2006 to 2012 who underwent Y90 radioembolization was performed. Patients’ baseline characteristics, including LSF and median overall survival (OS) from first Y90 radioembolization, were recorded and compared between patients with high (≥10 %) and low ( 1.2 mg (p = 0.016), and lack of pretreatment with octreotide (p = 0.01) as independent prognostic factors for poorer survival. Tumor type and total radiation dose did not predict survival.ConclusionsLSF ≥10 %, elevated bilirubin levels, and lack of pretreatment with octreotide were found to be independent prognostic factors for poorer survival in patients with NETLMs.

  13. Retrospective analysis of cystic craniopharyngeomas after intracavital irradiation with yttrium-90 colloid

    International Nuclear Information System (INIS)

    Urbanova, E.; Vizda, J.; Netikova, M.; Kafka, P.; Jakubec, J.

    2002-01-01

    Aim: The authors report about follow up the patients after intracavitary irradiation for cystic craniopharyngeoma. Material and Methods: For retrospective analysis 15 patients were selected. The volume of the cyst was determined by CT or MRI. For dosimetry Backlund's formula was used. The cumulative dose to the inner surface of the cyst wall was about 250Gy. 90 Yttrium silicate colloid was administered directly during stereotactically (CT guided) surgery or through the Ommaya drainage system. Control scintigraphy was performed 2-3 hours after 90 Y injection with gamma camera to detect possible leakage of the radioisotope. None of our patients showed evidence of this. In addition to this, the patients were checked daily to pay attention to visual function, neurological condition and possible meningeal irritation. Results: Cyst shrinkage was monitored by repeated CT examinations. CT cyst volume measurement analysed all patients before and 1,2,3 and 5 years after the treatment. In our study 45% of cysts decreased in volume during 4 month, shrinkage of the initial cyst volume was 75% after 1 year. The cyst disappeared nearly totally in 5 patients. Only 3 cyst remain unchanged and 90 Y treatment was repeated. No patients developed a visual field defect or evidence of hypothalamic dysfunction after the treatment. The neuro-opthalmological state completely recovered in 2 patients and improved in 5 patients. The prognosis was good only when an intact optic discs in time of the treatment was present. In some cases the radioisotope was implanted at a late stage of the disease without the opthalmological and neurological improvement. One patient died due to pulmonary embolism one week after the procedure. One patient died within a one year of the treatment from complications related to a solid cystic recurrence. One of typical signs for recurrence was worsening of neuro-opthalmological state. Conclusion: From our results this intracavitary 90 Y therapy is minimally invasive

  14. 90Sr content in 90Y-labeled SIR-spheres and Zevalin.

    Science.gov (United States)

    Metyko, John; Erwin, William; Poston, John; Jimenez, Sandra

    2014-11-01

    Three different 90Y internally administered radionuclide therapies are currently used in both standard-of-care and clinical trial procedures atMD Anderson Cancer Center. TheraSphere and SIR-Spheres therapies utilize 90Y-labeled microspheres, while Zevalin is an 90Y-labeled radioimmunotherapeutic agent. Several publications have indicated radionuclidic impurities resulting from 90Y production methods. The 90Y in SIR-Spheres and Zevalin are produced from a 90Sr/90Y generator, which leaves measurable quantities of 90Sr in the final product. TheraSphere 90Y is produced in a nuclear reactor which results in a large number of impurities, most notably 88Y and 91Y. Product information sheets reference these impurities with specific limits given. These limits represent a tiny fraction of the total product activity, and in the case of TheraSphere and SIR-Spheres gamma-emitting impurities, this has been verified in the literature. An analysis of 90Sr impurities in SIR-Spheres and Zevalin is presented in this paper. Impurity quantities were found to be within the vendors’ documented limits.

  15. Radiochemical schemes of obtaining 89Sr and 90Y radionuclides

    International Nuclear Information System (INIS)

    Usarov, Z. O.

    2010-03-01

    Key words: strontium-89, yttrium-90, extraction and extraction-chromatographic purification of radionuclides, radiopharmaceuticals. Subjects of research: strontium-89 and yttrium-90 radionuclides and their chloride forms. Purpose of work is developing of radiochemical technologies on obtaining of 89 Sr and 90 Y on the WWR-SM reactor with high radionuclide purity. Methods of research: extraction and extraction-chromatographic methods of radionuclides separation, beta- and gamma-spectrometric methods of activity measuring. The results obtained and their novelty: Were determined the conformity to laws of Y and Sr distribution in two-phase systems TBP-HNO 3 , TBP-NH 4 NO 3 , TBP-HCI, HDEHP-NO 3 , HDEHP-NH 4 NO 3 and HDEHP-HCI. Were determined the conformity to laws of Y and Sr distribution in systems with craun ethers DB-18K-6 and DTBDB-18K-6 from water solutions of HNO 3 . Radiochemical technologies on obtaining of 89 Sr and 90 Y radionuclides including radiochemical process of yttrium target with using the systems TBP-HNO 3 and HDEHP/Teflone were developed. Practical value: the radiochemical technology of obtaining 89 Sr with high radionuclide purity was developed. The method of preparation a chloride compound of 89 SrCl 2 which is used as a drug form for preparation of 89 Sr- 'Metastron' was developed. The relatively simple method of on the way obtaining 90 Y in the reactor with high radionuclidic purity that is useful for follow using in medical practice was offered. Degree of embed and economic effectivity: the developed technologies have approbation in manufacturing conditions in Radiopreparat Enterprise of INP AS RU and were offered for receiving of domestic preparations against of import foreign analogues. The statement about using the invention by obtained patent is attached to dissertation. Field of application: the received results will be introduced in manufacture at Radiopreparat Enterprise of INP AS RU for receiving of domestic preparations

  16. {sup 90}Y microspheres prepared by sol-gel method, promising medical material for radioembolization of liver malignancies

    Energy Technology Data Exchange (ETDEWEB)

    Łada, Wiesława, E-mail: w.lada@ichtj.waw.pl [Institute of Nuclear Chemistry and Technology, 03-195 Warsaw, Dorodna 16 (Poland); Iller, Edward [National Centre for Nuclear Research, Radioisotope Centre POLATOM, 05-400 Otwock, Andrzej Sołtan 7 (Poland); Wawszczak, Danuta [Institute of Nuclear Chemistry and Technology, 03-195 Warsaw, Dorodna 16 (Poland); Konior, Marcin, E-mail: marcin.konior@polatom.pl [National Centre for Nuclear Research, Radioisotope Centre POLATOM, 05-400 Otwock, Andrzej Sołtan 7 (Poland); Dziel, Tomasz [National Centre for Nuclear Research, Radioisotope Centre POLATOM, 05-400 Otwock, Andrzej Sołtan 7 (Poland)

    2016-10-01

    A new technology for the production of radiopharmaceutical {sup 90}Y microspheres in the form of spherical yttrium oxide grains obtained by sol-gel method has been described. The authors present and discuss the results of investigations performed in the development of new production technology of yttrium microspheres and determination of their physic-chemical properties. The final product has the structure of spherical yttrium oxide grains with a diameter 25–100 μm, is stable and free from contaminants. Irradiation of 20 mg samples of grains with diameter of 20–50 μm in the thermal neutron flux of 1.7 × 10{sup 14} cm{sup −2} s{sup −1} at the core of MARIA research nuclear reactor allowed to obtain microspheres labelled with the {sup 90}Y isotope on the way of the nuclear reaction {sup 89}Y(n, γ){sup 90}Y. Specific activity of irradiated microspheres has been determined by application of absolute triple to double coincidence ratio method (TDCR) and has been evaluated at 190 MBq/mg Y. {sup 90}Y microspheres prepared by the proposed technique can be regarded as a promising medical material for radioembolization of liver malignancies. - Highlights: • Sol-gel methods for preparation of spherical yttrium trioxide grains have been proposed. • Determination condition for irradiation {sup 89}Y{sub 2}O{sub 3} grains in nuclear reactor • Evaluation of specific activity of {sup 90}Y microspheres • Estimation of {sup 90}Y microspheres as promising medical material for radioembolization.

  17. Country report: Syria. Development of {sup 90}Y/{sup 90}Sr Generator and {sup 90}Y Radiopharmaceuticals

    Energy Technology Data Exchange (ETDEWEB)

    Yassine, Taufik; Mukhallalati, Ch. Heyam, E-mail: atomic@aec.org.sy [Atomic Energy Commission of Syria, Damascus (Syrian Arab Republic)

    2010-07-01

    The aim of this project is to develop a technique for preparation of {sup 90}Sr-{sup 90}Y generator, we have developed a separation technique for isolation of {sup 90}Y from {sup 90}Sr based on using Sr – Spec resin packed in three columns for separation and purification of {sup 90}Sr-{sup 90}Y .The resulting Y90 is used for therapeutic applications. The first part of this project describe a prototype design for the {sup 90}Sr- {sup 90}Y generator in order to get a very accurate method to obtain the minimum possible {sup 90}Sr Breakthrough. 25 mci of {sup 90}Sr was used in the generator {sup 90}Sr-{sup 90}Y and we obtained the elution yield of {sup 90}Y higher than 88%, Also the eluate was used for preparation of several {sup 90}Y radiopharmaceuticals such as {sup 90}YEDTMP and {sup 90}Y-DOTA-HR{sub 3}. And the work is continues to investigate more radiopharmaceuticals applications in the second part of this project such as {sup 90}Y– FHMA. In this part of the co-coordination research programmer, A protocol based on results of this studies was developed to prepare and operate a higher activity generator (50-100mci), the resulting elution yield was approximately 94% of {sup 90}Y . The elute was used in preparation of new {sup 90}Y radiopharmaceuticals. The monoclonal antibodies is still evolving by conjugate Rituximab to The macrocyclic bifunctional chelating agent,(p-SCN-Bn-DOTA)S-2-(4-Isothiocyanatobenzyle)-1,4,7,10- tetraazacyclododecane-tetraaceticacid to obtain the inmunoconjugate DOTA-Rituximub in simple way and then investigating the radio labeling conditions with {sup 90}Y. (author)

  18. Histological Comparison of Kidney Tissue Following Radioembolization with Yttrium-90 Resin Microspheres and Embolization with Bland Microspheres

    Energy Technology Data Exchange (ETDEWEB)

    Silva, Suresh de, E-mail: suresh.desilva@unsw.edu.au [Southern Radiology Group, Radiology Department Sutherland Hospital (Australia); Mackie, Simon [Western General Hospital, Department of Urology (United Kingdom); Aslan, Peter [St George Hospital, Department of Urology (Australia); Cade, David [Sirtex Technology Pty Ltd (Australia); Delprado, Warick [Douglass Hanly Moir Pathology (Australia)

    2016-12-15

    BackgroundIntra-arterial brachytherapy with yttrium-90 ({sup 90}Y) resin microspheres (radioembolization) is a procedure to selectively deliver high-dose radiation to tumors. The purpose of this research was to compare the radioembolic effect of {sup 90}Y-radioembolization versus the embolic effect of bland microspheres in the porcine kidney model.MethodsIn each of six pigs, ~25–33 % of the kidney volume was embolized with {sup 90}Y resin microspheres and an equivalent number of bland microspheres in the contralateral kidney. Kidney volume was estimated visually from contrast-enhanced fluoroscopy imaging. Morphologic and histologic analysis was performed 8–9 weeks after the procedure to assess the locations of the microspheres and extent of tissue necrosis from {sup 90}Y-radioembolization and bland embolization. A semi-quantified evaluation of the non-acute peri-particle and perivascular tissue reaction was conducted. All guidelines for the care and use of animals were followed.ResultsKidneys embolized with {sup 90}Y-radioembolization decreased in mass by 30–70 % versus the contralateral kidney embolized with bland microspheres. These kidneys showed significant necrosis/fibrosis, avascularization, and glomerular atrophy in the immediate vicinity of the {sup 90}Y resin microspheres. By contrast, glomerular changes were not observed, even with clusters of bland microspheres in afferent arterioles. Evidence of a foreign body reaction was recorded in some kidneys with bland microspheres, and subcapsular scarring/infarction only with the highest load (4.96 × 10{sup 6}) of bland microspheres.ConclusionThis study showed that radioembolization with {sup 90}Y resin microspheres produces localized necrosis/fibrosis and loss of kidney mass in a porcine kidney model. This result supports the study of {sup 90}Y resin microspheres for the localized treatment of kidney tumors.

  19. Histological Comparison of Kidney Tissue Following Radioembolization with Yttrium-90 Resin Microspheres and Embolization with Bland Microspheres

    International Nuclear Information System (INIS)

    Silva, Suresh de; Mackie, Simon; Aslan, Peter; Cade, David; Delprado, Warick

    2016-01-01

    BackgroundIntra-arterial brachytherapy with yttrium-90 ("9"0Y) resin microspheres (radioembolization) is a procedure to selectively deliver high-dose radiation to tumors. The purpose of this research was to compare the radioembolic effect of "9"0Y-radioembolization versus the embolic effect of bland microspheres in the porcine kidney model.MethodsIn each of six pigs, ~25–33 % of the kidney volume was embolized with "9"0Y resin microspheres and an equivalent number of bland microspheres in the contralateral kidney. Kidney volume was estimated visually from contrast-enhanced fluoroscopy imaging. Morphologic and histologic analysis was performed 8–9 weeks after the procedure to assess the locations of the microspheres and extent of tissue necrosis from "9"0Y-radioembolization and bland embolization. A semi-quantified evaluation of the non-acute peri-particle and perivascular tissue reaction was conducted. All guidelines for the care and use of animals were followed.ResultsKidneys embolized with "9"0Y-radioembolization decreased in mass by 30–70 % versus the contralateral kidney embolized with bland microspheres. These kidneys showed significant necrosis/fibrosis, avascularization, and glomerular atrophy in the immediate vicinity of the "9"0Y resin microspheres. By contrast, glomerular changes were not observed, even with clusters of bland microspheres in afferent arterioles. Evidence of a foreign body reaction was recorded in some kidneys with bland microspheres, and subcapsular scarring/infarction only with the highest load (4.96 × 10"6) of bland microspheres.ConclusionThis study showed that radioembolization with "9"0Y resin microspheres produces localized necrosis/fibrosis and loss of kidney mass in a porcine kidney model. This result supports the study of "9"0Y resin microspheres for the localized treatment of kidney tumors.

  20. Abscopal Effects and Yttrium-90 Radioembolization

    Energy Technology Data Exchange (ETDEWEB)

    Ghodadra, Anish; Bhatt, Sumantha [University Pittsburgh School of Medicine, Department of Radiology (United States); Camacho, Juan C. [Emory University School of Medicine, Department of Radiology and Imaging Sciences (United States); Kim, Hyun S., E-mail: kevin.kim@yale.edu [University Pittsburgh School of Medicine, Department of Radiology (United States)

    2016-07-15

    We present the case of an 80-year-old male with squamous cell carcinoma with bilobar hepatic metastases who underwent targeted Yttrium-90 radioembolization of the right hepatic lobe lesion. Subsequently, there was complete regression of the nontargeted, left hepatic lobe lesion. This may represent the first ever reported abscopal effect in radioembolization. The abscopal effect refers to the phenomenon of tumor response in nontargeted sites after targeted radiotherapy. In this article, we briefly review the immune-mediated mechanisms responsible for the abscopal effect.

  1. Progress of 90Y generator preparation

    International Nuclear Information System (INIS)

    Yin Bangshun; Li Mingqi; Deng Qimin; Cheng Zuoyong

    2009-01-01

    90 Y is an important radionuclide in radioimmunotherapy. The medical 90 Y is mainly obtained from 90 Y generator through methods of precipitation,coprecipitation, electrodeposition, solvent extraction, chromatography and so on. The progress of 90 Y generator, the advantages and disadvantages of different types of 90 Y generator, and the tendency of 90 Y generator preparation were described respectively. Comprehensive analysis showed that inorganic ion-exchange chromatography will be the main tendency of future 90 Y generator preparation. (authors)

  2. Treatment of primary liver tumors with Yttrium-90 microspheres (TheraSphere) in high risk patients: analysis of survival and toxicities.

    Science.gov (United States)

    Reardon, Kelli A; McIntosh, Alyson F; Shilling, A Tanner; Hagspiel, Klaus D; Al-Osaimi, Abdullah; Berg, Carl; Caldwell, Stephen H; Northup, Patrick G; Angle, Fritz; Mulder, Robert; Rich, Tyvin A

    2009-02-01

    This retrospective study was undertaken to obtain information regarding the survival and toxicities after Yttrium-90 microspheres treatment in patients with primary liver malignancies. Baseline, treatment, and follow-up data were collected and analyzed for 21 patients treated with Yttrium-90 microspheres. Survival analysis was then performed. The results of this study showed that median survival for all the patients was 120 days. Twenty of 21 patients were categorized as high-risk with a median survival of 114 days. It was also found that one high-risk patient has survived 858 days with no recurrence of disease. Acute grade 3-5 toxicities were recorded for nine patients and consisted of elevations in AST and bilirubin, thrombocytopenia, abdominal pain, ascites, nausea, fatigue, and death. This study concluded that Yttrium-90 is a low-toxicity, outpatient alternative for individuals with liver cancer and without many options. The maximal value, however, may lie in the treatment of low-risk patients.

  3. Effects of hepatic arterial yttrium 90 glass microspheres in dogs.

    Science.gov (United States)

    Wollner, I; Knutsen, C; Smith, P; Prieskorn, D; Chrisp, C; Andrews, J; Juni, J; Warber, S; Klevering, J; Crudup, J

    1988-04-01

    A 22-micron glass microsphere called TheraSphere (Theragenics Corp., Atlanta, GA) has been developed in which yttrium 89 oxide is incorporated into the glass matrix and is activated by neutron bombardment to form the beta-emitting isotope yttrium 90 (Y 90) before using the spheres as radiotherapeutic vehicles. The injection of up to 12 times (on a liver weight basis) the anticipated human dose of nonradioactive TheraSphere into the hepatic arteries of dogs was well tolerated and produced clinically silent alterations within centrolobular areas. The hepatic arterial (HA) injection of radioactive TheraSphere also produced portal changes similar to those observed in humans after external beam therapy. While the extent of damage increased with the delivered dose, radiation exposures in excess of 30,000 cGy did not cause total hepatic necrosis and were compatible with survival. No microspheres distributed to the bone marrow and absolutely no myelosuppression was encountered in any animal. Proposed hepatic exposures to humans of 5000 to 10,000 cGy by means of these microspheres, therefore, would appear to be feasible and tolerable. Radiotherapeutic microsphere administration preceded by regional infusion of a radiosensitizing agent and/or immediately following the redistribution of blood flow toward intrahepatic tumor by vasoactive agents can potentially yield a synergistic, highly selective attack on tumors confined to the liver.

  4. Biodistribution of Yttrium-90-Labeled Anti-CD45 Antibody in a Nonhuman Primate Model

    International Nuclear Information System (INIS)

    Nemecek, Eneida; Hamlin, Donald K.; Fisher, Darrell R.; Krohn, Kenneth A.; Pagel, John M.; Applebaum, F. R.; Press, Oliver W.; Matthews, Dana C.

    2005-01-01

    Radioimmunotherapy may improve the outcome of hematopoietic cell transplantation for hematologic malignancies by delivering targeted radiation to hematopoietic organs while relatively sparing nontarget organs. We evaluated the organ localization of yttrium-90-labeled anti-CD45 (90Y-anti-CD45) antibody in macaques, a model that had previously predicted iodine-131-labeled anti-CD-45 (131I-anti-CD45) antibody biodistribution in humans. Experimental Design: Twelve Macaca nemestrina primates received anti-CD45 antibody labeled with 1 to 2 mCi of 90Y followed by serial blood sampling and marrow and lymph node biopsies, and necropsy. The content of 90Y per gram of tissue was determined by liquid scintillation spectrometry. Time-activity curves were constructed using average isotope concentrations in each tissue at measured time points to yield the fractional residence time and estimate radiation absorbed doses for each organ per unit of administered activity. The biodistribution of 90Y-anti-CD45 antibody was then compared with that previously obtained with 131I-anti-CD45 antibody in macaques. Results: The spleen received 2,120, marrow 1,060, and lymph nodes 315 cGy/mCi of 90Y injected. The liver and lungs were the nontarget organs receiving the highest radiation absorbed doses (440 and 285 cGy/mCi, respectively). Ytrrium-90-labeled anti-CD45 antibody delivered 2.5- and 3.7-fold more radiation to marrow than to liver and lungs, respectively. The ratios previously observed with 131I-antiCD45 antibody were 2.5-and 2.2-fold more radiation to marrow than to liver and lungs, respectively. Conclusions: This study shows that 90Y-anti-CD45 antibody can deliver relatively selective radiation to hematopoietic tissues, with similar ratios of radiation delivered to target versus nontarget organs, as compared with the 131I immunoconjugate in the same animal model

  5. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma: A review

    International Nuclear Information System (INIS)

    Salem, Riad; Hunter, Russell D.

    2006-01-01

    To present a critical review of yttrium-90 (TheraSphere) for the treatment of hepatocellular carcinoma (HCC). Medical literature databases (Medline, Cochrane Library, and CANCERLIT) were searched for available literature concerning the treatment of HCC with TheraSphere. These publications were reviewed for scientific and clinical validity. Studies pertaining to the use of yttrium-90 for HCC date back to the 1960s. The results from the early animal safety studies established a radiation exposure range of 50-100 Gy to be used in human studies. Phase I dose escalation studies followed, which were instrumental in delineating radiation dosimetry and safety parameters in humans. These early studies emphasized the importance of differential arteriolar density between hypervascular HCC and surrounding liver parenchyma. Current trends in research have focused on advancing techniques to safely implement this technology as an alternative to traditional methods of treating unresectable HCC, such as external beam radiotherapy, conformal beam radiotherapy, ethanol ablation, trans-arterial chemoembolization, and radiofrequency ablation. Yttrium-90 (TheraSphere) is an outpatient treatment option for HCC. Current and future research should focus on implementing multicenter phase II and III trials comparing TheraSphere with other therapies for HCC

  6. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma: a review.

    Science.gov (United States)

    Salem, Riad; Hunter, Russell D

    2006-01-01

    To present a critical review of yttrium-90 (TheraSphere) for the treatment of hepatocellular carcinoma (HCC). Medical literature databases (Medline, Cochrane Library, and CANCERLIT) were searched for available literature concerning the treatment of HCC with TheraSphere. These publications were reviewed for scientific and clinical validity. Studies pertaining to the use of yttrium-90 for HCC date back to the 1960s. The results from the early animal safety studies established a radiation exposure range of 50-100 Gy to be used in human studies. Phase I dose escalation studies followed, which were instrumental in delineating radiation dosimetry and safety parameters in humans. These early studies emphasized the importance of differential arteriolar density between hypervascular HCC and surrounding liver parenchyma. Current trends in research have focused on advancing techniques to safely implement this technology as an alternative to traditional methods of treating unresectable HCC, such as external beam radiotherapy, conformal beam radiotherapy, ethanol ablation, trans-arterial chemoembolization, and radiofrequency ablation. Yttrium-90 (TheraSphere) is an outpatient treatment option for HCC. Current and future research should focus on implementing multicenter phase II and III trials comparing TheraSphere with other therapies for HCC.

  7. Country report: Thailand. Development of Sr-90/ Y-90 Generator and Development of Radiopharmaceuticals Using Y-90

    International Nuclear Information System (INIS)

    Nipavan, Poramatikul

    2010-01-01

    The research project has been conducted at Thailand Institute of Nuclear Technology in accordance to the 1st RCM plan during the IAEA meeting in Warsaw. The objectives of the project include the following 5 specific aims: 1. Development of Sr-90/Y-90 ion-exchange chromatography generator 2. Development of Sr-90/Y-90 extraction chromatography generator 3. Development of quality control technique 4. Development of herapeutic radiopharmaceuticals Y-90 particulates/colloids 5. Development of Re-188 DMSA–bis-phosphonates Currently we have achieved specific aims 1 to 3. The specific aims 4 and 5 are during investigation. For specific aim 4, we are during the process to extract high purity 90 Y from 90 Sr/ 90 Y generator that will yield the starting 90 Y for the production of Y-90 particulates and colloids. For the 5 th specific aim, we are on hold to receive the starting agent, bis- Phosphonates, from Dr. Blower group. Therefore, this progress report will cover our work focusing on specific aims 1 to 3

  8. Country report: Thailand. Development of Sr-90/ Y-90 Generator and Development of Radiopharmaceuticals Using Y-90

    Energy Technology Data Exchange (ETDEWEB)

    Nipavan, Poramatikul [Nuclear Research and Development Group, Thailand Institute of Nuclear Technology (Public Organization), Bangkok (Thailand)

    2010-07-01

    The research project has been conducted at Thailand Institute of Nuclear Technology in accordance to the 1st RCM plan during the IAEA meeting in Warsaw. The objectives of the project include the following 5 specific aims: 1. Development of Sr-90/Y-90 ion-exchange chromatography generator 2. Development of Sr-90/Y-90 extraction chromatography generator 3. Development of quality control technique 4. Development of herapeutic radiopharmaceuticals Y-90 particulates/colloids 5. Development of Re-188 DMSA–bis-phosphonates Currently we have achieved specific aims 1 to 3. The specific aims 4 and 5 are during investigation. For specific aim 4, we are during the process to extract high purity {sup 90}Y from {sup 90}Sr/{sup 90}Y generator that will yield the starting {sup 90}Y for the production of Y-90 particulates and colloids. For the 5{sup th} specific aim, we are on hold to receive the starting agent, bis- Phosphonates, from Dr. Blower group. Therefore, this progress report will cover our work focusing on specific aims 1 to 3.

  9. Development of an electrochemical 90Sr-90Y generator for separation of 90Y suitable for targeted therapy

    International Nuclear Information System (INIS)

    Chakravarty, Rubel; Pandey, Usha; Manolkar, Remani B.; Dash, Ashutosh; Venkatesh, Meera; Pillai, M.R. Ambikalmajan

    2008-01-01

    90 Y of high specific activity and very high radionuclidic purity (>99.998%) is essential for targeted therapy. Since the current methods used for the preparation of 90 Y from 90 Sr are not adaptable for use in a central/hospital radiopharmacy, a simple 90 Sr- 90 Y generator system based on electrochemical separation technique was developed. Methods: Two-cycle electrolysis procedure was developed for separation of 90 Y from 90 Sr in nitrate solution. The first electrolysis was performed for 90 min in 90 Sr(NO 3 ) 2 feed solution at pH 2-3 at a potential of -2.5V with 100-200 mA current using platinum electrodes. The second electrolysis was performed for 45 min in 3 mM HNO 3 at a potential of -2.5V with 100 mA current. In this step, the cathode from the first electrolysis containing 90 Y was used as anode along with a fresh circular platinum electrode as cathode. The 90 Y deposited on the circular cathode after the second electrolysis was dissolved in acetate buffer to obtain 90 Y acetate, suitable for radiolabeling. Results: >96% recovery of 90 Y could be achieved in each cycle, with an overall decay corrected yield of >90%. The recovered 90 Y had high radionuclidic purity with barely 30.2±15.2 kBq (817±411 nCi) of 90 Sr per 37 GBq (1 Ci) of 90 Y (0.817±0.411 ppm). Consistent and repeated separation could be demonstrated using up to 1.85 GBq (50 mCi) of 90 Sr. The generator was named 'Kamadhenu,' the eternally milk-yielding Indian mythological cow. Conclusions: A technique suitable for adaptation at central radiopharmacies for obtaining therapeutic quantities of pure 90 Y has been developed

  10. 90Y and 90Sr separation from hydrochloric acid solutions using TODGA as the extractant by solvent extraction and SLM methods

    International Nuclear Information System (INIS)

    Dutta, S.; Raut, D.R.; Mohapatra, P.K.; Manchanda, V.K.

    2010-01-01

    Yttrium-90 is an important radionuclide known for its therapeutic application in nuclear medicine. It is a pure β-emitter with no associated gamma rays and decays to stable daughter 90 Zr. Suitability of this isotope is because of its short half-life (t 1/2 = 64.2 hrs) and high β emissions (E max = 2.28 MeV. An important source of 90 Y is through the decay of 90 Sr, which produces carrier free isotope. 90 Sr (t 1/2 28 yrs) attains secular equilibrium with 90 Y in a short period and can serve as a long term source for the latter isotope because of relatively long half-life of the parent isotope. Solvent extraction studies with N,N,N',N'-tetra-octyldiglycolamide (TODGA) has shown that Y(III) is well extracted in 6 M HCI while at the same time, extraction of Sr(II) is very low leading to a separation factor (D Y /D Sr = 60,000). This property of TODGA can be exploited for the separation of Y from Sr. In the present work, Supported Liquid Membrane (SLM) based separation of Y and Sr has been explored using TODGA as the carrier

  11. Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus 90Y-radioembolization for hepatocellular carcinoma

    International Nuclear Information System (INIS)

    Ludwig, Johannes M.; Xing, Minzhi; Zhang, Di; Kim, Hyun S.

    2017-01-01

    To investigate comparative effectiveness of drug-eluting bead transarterial chemoembolization (DEB-TACE) versus Yttrium-90 ( 90 Y)-radioembolization for hepatocellular carcinoma (HCC). Studies comparing conventional (c)TACE versus 90 Y-radioembolization or DEB-TACE for HCC treatment were identified using PubMed/Medline, Embase, and Cochrane databases. The adjusted indirect meta-analytic method for effectiveness comparison of DEB-TACE versus 90 Y-radioembolization was used. Wilcoxon rank-sum test was used to compare baseline characteristics. A priori defined sensitivity analysis of stratified study subgroups was performed for primary outcome analyses. Publication bias was tested by Egger's and Begg's tests. Fourteen studies comparing DEB-TACE or 90 Y-radioembolization with cTACE were included. Analysis revealed a 1-year overall survival benefit for DEB-TACE over 90 Y-radioembolization (79 % vs. 54.8 %; OR: 0.57; 95 %CI: 0.355-0.915; p = 0.02; I-squared: 0 %; p > 0.5), but not for the 2-year (61 % vs. 34 %; OR: 0.65; 95%CI: 0.294-1.437; p = 0.29) and 3-year survival (56.4 % vs. 20.9 %; OR: 0.713; 95 % CI: 0.21-2.548; p = 0.62). There was significant heterogeneity in the 2- and 3-year survival analyses. The pooled median overall survival was longer for DEB-TACE (22.6 vs. 14.7 months). There was no significant difference in tumour response rate. DEB-TACE and 90 Y-radioembolization are efficacious treatments for patients suffering from HCC; DEB-TACE demonstrated survival benefit at 1-year compared to 90 Y-radioembolization but direct comparison is warranted for further evaluation. (orig.)

  12. 90Y microsphere therapy: does 90Y PET/CT imaging obviate the need for 90Y Bremsstrahlung SPECT/CT imaging?

    Science.gov (United States)

    Zade, Anand A; Rangarajan, Venkatesh; Purandare, Nilendu C; Shah, Sneha A; Agrawal, Archi R; Kulkarni, Suyash S; Shetty, Nitin

    2013-11-01

    Transarterial radioembolization using Y microspheres is a novel therapeutic option for inoperable hepatic malignancies. As these spheres are radiolucent, real-time assessment of their distribution during the infusion process under fluoroscopic guidance is not possible. Bremsstrahlung radiations arising from 90Y have conventionally been used for imaging its biodistribution. Recent studies have proved that sources of 90Y also emit positrons, which can further be used for PET/computed tomography (CT) imaging. This study aimed to assess the feasibility of 90Y PET/CT imaging in evaluating microsphere distributions and to compare its findings with those of Bremsstrahlung imaging. Thirty-five sessions of 90Y microsphere transarterial radioembolization were performed on 30 patients with hepatic malignancies. 90Y PET/CT imaging was performed within 3 h of therapy. Bremsstrahlung imaging was also performed for each patient. The imaging findings were compared for concordance in the distribution of microspheres. Exact one-to-one correspondence between 90Y PET/CT imaging and 90Y Bremsstrahlung imaging was observed in 97.14% of cases (i.e. in 34/35 cases). Discordance was observed only in one case in which 90Y PET/CT imaging resolved the microsphere uptake in the inferior vena cava tumor thrombus, which was, however, not visualized on Bremsstrahlung imaging. There is good concordance in the imaging findings of 90Y PET/CT and 90Y Bremsstrahlung imaging. 90Y PET/CT imaging scores over the conventionally used Bremsstrahlung imaging in terms of better resolution, ease of technique, and comparable image acquisition time. This makes it a preferred imaging modality for assessment of the distribution of 90Y microspheres.

  13. Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers.

    Science.gov (United States)

    Villard, Linda; Romer, Anna; Marincek, Nicolas; Brunner, Philippe; Koller, Michael T; Schindler, Christian; Ng, Quinn K T; Mäcke, Helmut R; Müller-Brand, Jan; Rochlitz, Christoph; Briel, Matthias; Walter, Martin A

    2012-04-01

    Radiopeptide therapy is commonly performed with a single radioisotope. We aimed to compare the effectiveness of somatostatin-based radiopeptide therapy with a single versus a combination of radioisotopes. In a cohort study, patients with metastasized neuroendocrine cancer were treated with repeated cycles of (90)yttrium-labeled tetraazacyclododecane-tetraacetic acid modified Tyr-octreotide ([(90)Y-DOTA]-TOC) or with cycles alternating between [(90)Y-DOTA]-TOC and (177)lutetium-labeled DOTA-TOC ([(177)Lu-DOTA]-TOC) until tumor progression or permanent toxicity. Multivariable Cox regression and competing risk regression were used to study predictors of survival and renal toxicity in patients completing three or more treatment cycles. A total of 486 patients completed three or more treatment cycles; 237 patients received [(90)Y-DOTA]-TOC and 249 patients received [(90)Y-DOTA]-TOC + [(177)Lu-DOTA]-TOC. Patients receiving [(90)Y-DOTA]-TOC + [(177)Lu-DOTA]-TOC had a significantly longer survival than patients receiving [(90)Y-DOTA]-TOC alone (5.51 v 3.96 years; hazard ratio, 0.64; 95% CI, 0.47 to 0.88; P = .006). The rates of severe hematologic toxicities (6.3% v 4.4%; P = .25) and severe renal toxicity (8.9% v 11.2%; P = .47) were comparable in both groups. [(90)Y-DOTA]-TOC + [(177)Lu-DOTA]-TOC was associated with improved overall survival compared with [(90)Y-DOTA]-TOC alone in patients completing three or more cycles of treatment. Contrary to the current practice in radiopeptide therapy, our results suggest an advantage of using a combination of radioisotopes.

  14. Radioembolization with Yttrium-90 microspheres for patients with unresectable hepatocellular carcinoma.

    Science.gov (United States)

    Bhangoo, Munveer Singh; Karnani, Diraj R; Hein, Paul N; Giap, Huan; Knowles, Harry; Issa, Chris; Steuterman, Steve; Pockros, Paul; Frenette, Catherine

    2015-10-01

    Hepatocellular carcinoma (HCC) is aggressive primary malignancy of the liver that most commonly presents late in the disease course. As a result, the majority of patients are not candidates for curative therapies. Locoregional therapies including Yttrium-90 (Y-90) radioembolization play an important role in management of the vast majority of patients with HCC. Patients with unnresectable HCC (n=17) treated with Y-90 radioembolization from 2005 to 2014 were evaluated retrospectively. Data was abstracted from medical records including patient charts, laboratory data, and imaging. Toxicities were recorded using Common Terminology Criteria 3.0. Response was recorded according to modified RECIST (mRECIST) criteria. Seventeen patients received 33 treatments with Y-90 radioembolization. A majority (65%) received TheraSphere with a minority (35%) receiving SIR-Spheres. The median treatment activity delivered was 1.725 gBq (range, 1.4-2.5 gBq). The median treatment dose delivered was 100 Gy (range, 90-120 Gy). The median lung shunt fraction was 2.02% (range, 1.5-4.1%). The most common clinical toxicity among all patients was nausea and vomiting (59%), primarily grade 1 and 2. Other post-treatment findings included abdominal pain (29%), fatigue (53%), and weight loss (18%). One patient developed a grade 5 gastric ulcer after the treatment. A clinical benefit, defined as patients achieving complete response (CR), partial response (PR) or stable disease (SD), was seen in 48% of patients. PR was seen in 24% of cases; progressive disease (PD) was noted in 35%. Patients survived for a median of 8.4 months (range, 1.3 to 21.1 months) after the first radioembolization treatment. Median survival after Y-90 treatment was 8.4 months among patients treated TheraSphere as compared with 7.8 months in patients treated with SIR-Spheres. The mean overall survival from the time of diagnosis was 11.7 months (range, 3.4 to 43.2 months). For patients with unresectable HCC, Y-90

  15. Synovectomy of the knee with 90Y

    International Nuclear Information System (INIS)

    Spooren, P.F.M.J.; Rasker, J.J.; Arens, R.P.J.H.; Ziekenhuis Ziekenzorg, Enschede

    1985-01-01

    In 33 patients with chronic arthritis of the knee, 48 knees were treated with an intra-articular injection of 5 mCi yttrium silicate 90 Y. There were 27 patients with rheumatoid arthritis (RA) and 6 with osteoarthrosis (OA); the mean follow-up period was 33 months. At clinical investigation after 1 year, no signs of pain or swelling were found in 15 knees. In most cases, pain and swelling improved subjectively, with a mean duration of 11 months; in 20 knees, the improvement lasted more than 22 months. When radiographs showed severse destruction, 90 Y treatment was unsuccessful, but an important new finding was that most patients with mild or moderate radiological abormalities appeared to have a long-lasting improvement. The result did not correlate with erythrocyte sedimentation rate (ESR), haemoglobin or Rose titre at the time of injection or at follow up, suggesting that the result of the treatment is more dependent on local factors than on the disease activity. The results of 90 Y treatment in 6 OA knees with persistent swelling were promising regarding swelling, even in patients with moderate radiological abnormalities. The main side-effect was a sometimes painful swelling of the knee, which was always successfully treated with an intra-articular corticosteroid injection. In 90 Y-treated knees, the incidence of unstable joints was not significantly higher than in non-treated knees. In conclusion, 90 Y synovectomy may be a succesful treatment for patients older than 50 years with chronic arthritis of the knee due to RA and probably also OA, even when moderate radiological abnormalities are present. (orig.)

  16. Attempted treatment of meningeosis leucaemica by intrathecal application of 90-silicate and 90Y-citrate colloid in a case of chronic myleoic leukaemia; Behandlungsversuch einer Meningeosis leucaemica durch intrathekale Applikation von {sup 90}Y-Silikat- und {sup 90}Y-Zitrat-Kolloid bei chronisch-myleoischer Leukaemie

    Energy Technology Data Exchange (ETDEWEB)

    Kittner, C.; Schuemichen, C. [Rostock Univ. (Germany). Klinik und Poliklinik fuer Nuklearmedizin; Steiner, B.; Kahl, C.; Wolff, D.; Freund, M. [Rostock Univ. (Germany). Klinik fuer Innere Medizin, Abt. fuer Haematologie; Putzar, H.; Roesler, K.; Hauenstein, K.H. [Rostock Univ. (Germany). Inst. fuer Diagnostische und Interventionalle Radiologie

    2003-12-01

    A 41-year-old man with chronic myeoloic leukaemia was treated for Meningeosis leucaemica by intrathecal application of yttrium-90-citrate colloide as palliative therapy. (orig.) [German] Wir berichten ueber einen 41-jaehrigen Mann mit chronisch-myeloischer Leukaemie bei dem eine Meningeosis leucaemica durch eine intrathekale Applikation von Yttrium-90-Zitrat-Kolloid palliativ therapiert wurde. (orig.)

  17. Accumulation of Sr90-Y90 by the developing spawn and larvae of Coregonus lavaretus L

    International Nuclear Information System (INIS)

    Kulikov, N.V.; Ozhegov, L.N.

    1976-01-01

    The results are given of laboratory experiments aimed at studying accumulation of Sr-90 and its daughter product Y-90 in the spawn and larvae of whitefish, a representative of autumn spawning fish species. The results are of interest for predicting possible consequences of radioactive contamination of water bodies and introduction of limits for permissible concentration of radioactive substances in aqueous medium. The accumulation coefficient of Sr-90 in the spawn reaches its maximum after the first twenty four hours of the experiment. Subsequently throughout the incubation period the accumulation coefficient (AC) of radionuclide does not undergo any changes being about 3. Besides it has been established that the equilibrium distribution of Sr-90 in whitefish spawn and the surrounding solution occurs during the first two hours. Unlike Sr-90 the accumulation of Y-90 occurs during the whole incubation period and results in the AC value of 80 by the end of the spawn incubation. The experiments aimed at determining the strength of radionuclide fixation by whitefish spawn and larvae revealed that both radionuclides in the spawn are rather mobile. Strontium separates fully from it during the first twenty four hours and yttrium marked by higher fixation strength transfers completely from the spawn into surrounding aqueous medium by the end of the experiment. In larvae the radionuclides are fixed stroger than in the spawn. The approximate radiation doses of embryos by the time of their hatching have been estimated. The estimates indicate that the total radiation dose of the spawn developing in aqueous solution of Sr-90 - Y-90 with 1.1 curie/0 -5 concentration is about 500 radl

  18. Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus {sup 90}Y-radioembolization for hepatocellular carcinoma

    Energy Technology Data Exchange (ETDEWEB)

    Ludwig, Johannes M.; Xing, Minzhi [Yale School of Medicine, Division of Interventional Radiology, Department of Radiology and Biomedical Imaging, New Haven, CT (United States); Zhang, Di [University of Pittsburgh Graduate School of Public Health, Department of Biostatistics, Pittsburgh, PA (United States); Kim, Hyun S. [Yale School of Medicine, Division of Interventional Radiology, Department of Radiology and Biomedical Imaging, New Haven, CT (United States); Yale School of Medicine, Yale Cancer Center, New Haven, CT (United States)

    2017-05-15

    To investigate comparative effectiveness of drug-eluting bead transarterial chemoembolization (DEB-TACE) versus Yttrium-90 ({sup 90}Y)-radioembolization for hepatocellular carcinoma (HCC). Studies comparing conventional (c)TACE versus {sup 90}Y-radioembolization or DEB-TACE for HCC treatment were identified using PubMed/Medline, Embase, and Cochrane databases. The adjusted indirect meta-analytic method for effectiveness comparison of DEB-TACE versus {sup 90}Y-radioembolization was used. Wilcoxon rank-sum test was used to compare baseline characteristics. A priori defined sensitivity analysis of stratified study subgroups was performed for primary outcome analyses. Publication bias was tested by Egger's and Begg's tests. Fourteen studies comparing DEB-TACE or {sup 90}Y-radioembolization with cTACE were included. Analysis revealed a 1-year overall survival benefit for DEB-TACE over {sup 90}Y-radioembolization (79 % vs. 54.8 %; OR: 0.57; 95 %CI: 0.355-0.915; p = 0.02; I-squared: 0 %; p > 0.5), but not for the 2-year (61 % vs. 34 %; OR: 0.65; 95%CI: 0.294-1.437; p = 0.29) and 3-year survival (56.4 % vs. 20.9 %; OR: 0.713; 95 % CI: 0.21-2.548; p = 0.62). There was significant heterogeneity in the 2- and 3-year survival analyses. The pooled median overall survival was longer for DEB-TACE (22.6 vs. 14.7 months). There was no significant difference in tumour response rate. DEB-TACE and {sup 90}Y-radioembolization are efficacious treatments for patients suffering from HCC; DEB-TACE demonstrated survival benefit at 1-year compared to {sup 90}Y-radioembolization but direct comparison is warranted for further evaluation. (orig.)

  19. Lack of rise in serum prolactin following yttrium-90 interstitial irradiation for acromegaly

    International Nuclear Information System (INIS)

    Clark, A.J.L.; Chahal, P.; Mashiter, K.; Joplin, G.F.

    1983-01-01

    The authors have investigated the possibility that the increase in serum PRL levels observed in patients with acromegaly treated with external irradiation could be due to damage to the hypothalamus or portal vessels, by comparing the effects of yttrium-90 interstitial irradiation, which is highly localised and does not normally extend to the hypothalamus, in a similar series of patients. These results are consistent with the hypothesis; a less likely explanation is that an overgrowth of radio-resistant PRL-secreting tumour cells is occurring after external irradiation, but not after yttrium-90 implantation. (author)

  20. Lack of rise in serum prolactin following yttrium-90 interstitial irradiation for acromegaly

    Energy Technology Data Exchange (ETDEWEB)

    Clark, A.J.L.; Chahal, P.; Mashiter, K.; Joplin, G.F. (Royal Postgraduate Medical School, London (UK))

    1983-11-01

    The authors have investigated the possibility that the increase in serum PRL levels observed in patients with acromegaly treated with external irradiation could be due to damage to the hypothalamus or portal vessels, by comparing the effects of yttrium-90 interstitial irradiation, which is highly localised and does not normally extend to the hypothalamus, in a similar series of patients. These results are consistent with the hypothesis; a less likely explanation is that an overgrowth of radio-resistant PRL-secreting tumour cells is occurring after external irradiation, but not after yttrium-90 implantation.

  1. Root Cause Analysis of Gastroduodenal Ulceration After Yttrium-90 Radioembolization

    Energy Technology Data Exchange (ETDEWEB)

    Lam, Marnix G. E. H. [Stanford University School of Medicine, Division of Interventional Radiology (United States); Banerjee, Subhas [Stanford University School of Medicine, Division of Gastroenterology and Hepatology (United States); Louie, John D.; Abdelmaksoud, Mohamed H. K. [Stanford University School of Medicine, Division of Interventional Radiology (United States); Iagaru, Andrei H. [Stanford University School of Medicine, Division of Nuclear Medicine and Molecular Imaging (United States); Ennen, Rebecca E.; Sze, Daniel Y., E-mail: dansze@stanford.edu [Stanford University School of Medicine, Division of Interventional Radiology (United States)

    2013-12-15

    IntroductionA root cause analysis was performed on the occurrence of gastroduodenal ulceration after hepatic radioembolization (RE). We aimed to identify the risk factors in the treated population and to determine the specific mechanism of nontarget RE in individual cases. Methods: The records of 247 consecutive patients treated with yttrium-90 RE for primary (n = 90) or metastatic (n = 157) liver cancer using either resin (n = 181) or glass (n = 66) microspheres were reviewed. All patients who developed a biopsy-proven microsphere-induced gastroduodenal ulcer were identified. Univariate and multivariate analyses were performed on baseline parameters and procedural data to determine possible risk factors in the total population. Individual cases were analyzed to ascertain the specific cause, including identification of the culprit vessel(s) leading to extrahepatic deposition of the microspheres. Results: Eight patients (3.2 %) developed a gastroduodenal ulcer. Stasis during injection was the strongest independent risk factor (p = 0.004), followed by distal origin of the gastroduodenal artery (p = 0.004), young age (p = 0.040), and proximal injection of the microspheres (p = 0.043). Prolonged administrations, pain during administration, whole liver treatment, and use of resin microspheres also showed interrelated trends in multivariate analysis. Retrospective review of intraprocedural and postprocedural imaging showed a probable or possible culprit vessel, each a tiny complex collateral vessel, in seven patients. Conclusion: Proximal administrations and those resulting in stasis of flow presented increased risk for gastroduodenal ulceration. Patients who had undergone bevacizumab therapy were at high risk for developing stasis.

  2. Root Cause Analysis of Gastroduodenal Ulceration After Yttrium-90 Radioembolization

    International Nuclear Information System (INIS)

    Lam, Marnix G. E. H.; Banerjee, Subhas; Louie, John D.; Abdelmaksoud, Mohamed H. K.; Iagaru, Andrei H.; Ennen, Rebecca E.; Sze, Daniel Y.

    2013-01-01

    IntroductionA root cause analysis was performed on the occurrence of gastroduodenal ulceration after hepatic radioembolization (RE). We aimed to identify the risk factors in the treated population and to determine the specific mechanism of nontarget RE in individual cases. Methods: The records of 247 consecutive patients treated with yttrium-90 RE for primary (n = 90) or metastatic (n = 157) liver cancer using either resin (n = 181) or glass (n = 66) microspheres were reviewed. All patients who developed a biopsy-proven microsphere-induced gastroduodenal ulcer were identified. Univariate and multivariate analyses were performed on baseline parameters and procedural data to determine possible risk factors in the total population. Individual cases were analyzed to ascertain the specific cause, including identification of the culprit vessel(s) leading to extrahepatic deposition of the microspheres. Results: Eight patients (3.2 %) developed a gastroduodenal ulcer. Stasis during injection was the strongest independent risk factor (p = 0.004), followed by distal origin of the gastroduodenal artery (p = 0.004), young age (p = 0.040), and proximal injection of the microspheres (p = 0.043). Prolonged administrations, pain during administration, whole liver treatment, and use of resin microspheres also showed interrelated trends in multivariate analysis. Retrospective review of intraprocedural and postprocedural imaging showed a probable or possible culprit vessel, each a tiny complex collateral vessel, in seven patients. Conclusion: Proximal administrations and those resulting in stasis of flow presented increased risk for gastroduodenal ulceration. Patients who had undergone bevacizumab therapy were at high risk for developing stasis

  3. Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model

    Energy Technology Data Exchange (ETDEWEB)

    Minh, Duc Do; Gorodetski, Boris; Smolka, Susanne; Savic, Lynn Jeanette; Wainstejn, David [Charite Universitaetsmedizin, Campus Virchow Klinikum, Department of Diagnostic and Interventional Radiology, Berlin (Germany); Yale University School of Medicine, Department of Radiology and Biomedical Imaging, New Haven, CT (United States); Chapiro, Julius; Schlachter, Todd [Yale University School of Medicine, Department of Radiology and Biomedical Imaging, New Haven, CT (United States); Huang, Qiang [Yale University School of Medicine, Department of Radiology and Biomedical Imaging, New Haven, CT (United States); Capital Medical University, Department of Interventional Radiology, Beijing Chaoyang Hospital, Beijing (China); Liu, Cuihong [Yale University School of Medicine, Department of Radiology and Biomedical Imaging, New Haven, CT (United States); Shandong Provincial Hospital Affiliated to Shandong University, The Ultrasound Department, Jinan (China); Lin, MingDe [Yale University School of Medicine, Department of Radiology and Biomedical Imaging, New Haven, CT (United States); Philips Research North America, U/S Imaging and Interventions (UII), Cambridge, MA (United States); Gebauer, Bernhard [Charite Universitaetsmedizin, Campus Virchow Klinikum, Department of Diagnostic and Interventional Radiology, Berlin (Germany); Geschwind, Jean-Francois [Yale University School of Medicine, Department of Radiology and Biomedical Imaging, New Haven, CT (United States)

    2017-12-15

    To compare efficacy, survival outcome and prognostic factors of conventional transarterial chemoembolisation (cTACE), drug-eluting beads TACE (DEB-TACE) and yttrium-90 radioembolisation (Y90) for the treatment of liver metastases from gastroenteropancreatic (GEP) neuroendocrine tumours (NELM). This retrospective analysis included 192 patients (58.6 years mean age, 56% men) with NELM treated with cTACE (N = 122), DEB-TACE (N = 26) or Y90 (N = 44) between 2000 and 2014. Radiologic response to therapy was assessed according to Response Evaluation Criteria in Solid Tumours (RECIST) and World Health Organization (WHO) criteria using periprocedural MR imaging. Survival analysis included propensity score analysis (PSA), median overall survival (MOS), hepatic progression-free survival, Kaplan-Meier using log-rank test and the uni- and multivariate Cox proportional hazards model (MVA). MOS of the entire study population was 28.8 months. As for cTACE, DEB-TACE and Y90, MOS was 33.8 months, 21.7 months and 23.6 months, respectively. According to the MVA, cTACE demonstrated a significantly longer MOS as compared to DEB-TACE (p <.01) or Y90 (p =.02). The 5-year survival rate after initial cTACE, DEB-TACE and Y90 was 28.2%, 10.3% and 18.5%, respectively. Upon PSA, our study suggests significant survival benefits for patients treated with cTACE as compared to DEB-TACE and Y90. This data supports the therapeutic decision for cTACE as the primary intra-arterial therapy option in patients with unresectable NELM until proven otherwise. (orig.)

  4. Development of 90Y-DOTA-nimotuzumab Fab fragment for radioimmunotherapy

    International Nuclear Information System (INIS)

    Alonso Martinez, L.M.; Marylaine Perez-Malo Cruz; Rene Leyva Montana; Calzada Falcon, V.N.; Minely Zamora Barrabi; Alejandro Arbesu Valdivia; Ignacio Hernandez Gonzalez; Mariela Leon Perez

    2014-01-01

    Yttrium-90-( 90 Y) labeled monoclonal antibodies prepared with a chelating agent, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), have been used for radioimmunotherapy of cancer. In the present work, the Fab fragment of anti-EGFR monoclonal antibody nimotuzumab was prepared with high purity, integrity and biological activity. The Fab fragment with high specific recognition of EGFR in NCI-H125 human lung adenocarcinoma cells was derivatized with DOTA-NHS applying a simple procedure. DOTA-nimotuzumab Fab fragment was successfully radiolabeled with 90 Y with high radiochemical yield. The in vitro stability of labeled product was optimal over 24 h in buffered solution at 37 deg C. Biodistribution and pharmacokinetic studies correctly evaluated the in vivo non-tumor uptake, dosage regimen and excretion pathway in normal Wistar rats. (author)

  5. Lung Shunt Fraction prior to Yttrium-90 Radioembolization Predicts Survival in Patients with Neuroendocrine Liver Metastases: Single-Center Prospective Analysis

    Energy Technology Data Exchange (ETDEWEB)

    Ludwig, Johannes M. [Yale University, Division of Interventional Radiology, Department of Radiology and Biomedical Imaging (United States); Ambinder, Emily McIntosh [John Hopkins University School of Medicine, Department of Diagnostic Radiology (United States); Ghodadra, Anish [University of Pittsburgh School of Medicine, Interventional Radiology, Department of Radiology (United States); Xing, Minzhi [Yale University, Division of Interventional Radiology, Department of Radiology and Biomedical Imaging (United States); Prajapati, Hasmukh J. [The University of Tennessee Health Science Center, Division of Interventional Radiology, Department of Radiology (United States); Kim, Hyun S., E-mail: kevin.kim@yale.edu [Yale University, Division of Interventional Radiology, Department of Radiology and Biomedical Imaging (United States)

    2016-07-15

    ObjectiveTo investigate survival outcomes following radioembolization with Yttrium-90 (Y90) for neuroendocrine tumor liver metastases (NETLMs). This study was designed to assess the efficacy of Y90 radioembolization and to evaluate lung shunt fraction (LSF) as a predictor for survival.MethodsA single-center, prospective study of 44 consecutive patients (median age: 58.5 years, 29.5 % male) diagnosed with pancreatic (52.3 %) or carcinoid (47.7 %) NETLMs from 2006 to 2012 who underwent Y90 radioembolization was performed. Patients’ baseline characteristics, including LSF and median overall survival (OS) from first Y90 radioembolization, were recorded and compared between patients with high (≥10 %) and low (<10 %) LSF. Baseline comparisons were performed using Fisher’s exact tests for categorical and Mann–Whitney U test for continuous variables. Survival was calculated using the Kaplan–Meier method. Univariate (Wilcoxon rank-sum test) and multivariate analyses (Cox Proportional Hazard Model) for risk factor analysis were performed.ResultsThere was no statistically significant difference in age, gender, race, tumor properties, or previous treatments between patients with high (n = 15) and low (n = 29) LSF. The median OS was 27.4 months (95 %CI 12.73–55.23), with 4.77 months (95 %CI 2.87–26.73) for high and 42.77 months (95 %CI 18.47–59.73) for low LSF (p = 0.003). Multivariate analysis identified high LSF (p = 0.001), total serum bilirubin >1.2 mg (p = 0.016), and lack of pretreatment with octreotide (p = 0.01) as independent prognostic factors for poorer survival. Tumor type and total radiation dose did not predict survival.ConclusionsLSF ≥10 %, elevated bilirubin levels, and lack of pretreatment with octreotide were found to be independent prognostic factors for poorer survival in patients with NETLMs.

  6. SU-C-204-01: A Dosimetric Investigation Into the Effects of Yttrium-90 Radioembolization On the GI Tract: In-Vivo and Histological Analysis in An Animal Model

    Energy Technology Data Exchange (ETDEWEB)

    Pasciak, A [University of Tennessee Medical Center, Knoxville, TN (United States); The University of Tennessee Graduate School of Medicine, Knoxville, TN (United States); Nodit, L; Bourgeois, A; Bradley, Y [The University of Tennessee Graduate School of Medicine, Knoxville, TN (United States); Paxton, B [Duke university medical center, Durham, NC (United States); Arepally, A [Vanderbilt University Medical Center, Nashville, TN (United States)

    2016-06-15

    Purpose: In Yttrium-90 (90Y) radioembolization, non-target embolization (NTE) to the stomach or small bowel can result in ulceration, a rare but difficult to manage clinical complication. However, dosimetric thresholds for toxicity to these tissues from radioembolization have never been evaluated in a controlled setting. We performed an analysis of the effect of 90Y radioembolization in a porcine model at different absorbed-dose endpoints. Methods: Under approval of the University of Tennessee IACUC, 6 female pigs were included in this study. Animals underwent transfemoral angiography and infusion of calibrated dosages of 90Y resin microspheres into arteries supplying part of the gastric wall. A 99mTc-MAA simulation study was performed first to determine perfused tissue volume for treatment planning along with contrast-enhanced CT. The pigs were monitored for side effects for 9 weeks, after which time they were euthanized and their upper gastrointestinal tracts were harvested for analysis. Results: 90Y radioembolization was infused resulting in average absorbed doses of between 35.5 and 91.9 Gy to the gastric wall. No animal exhibited any signs of pain or gastrointestinal distress through the duration of the study. Excised tissue showed 1–2 small (<3.0 cm2) healed or healing superficial gastric lesions in 5 out of 6 animals. Histologic analysis demonstrated that lesion location was superficial to areas of abnormally high microsphere deposition. An analysis of microsphere deposition patterns within the gastric wall indicated a high preference for submucosal deposition. Dosimetric evaluation at the luminal mucosa performed based on microsphere deposition patterns confirmed that 90Y dosimetry techniques conventionally used in hepatic dosimetry provide a reasonable estimate of absorbed dose. Conclusion: The upper gastrointestinal tract may be less sensitive to 90Y radioembolization than previously thought. Lack of charged-particle equilibrium at the luminal mucosa

  7. Peripheral Blood Lymphocyte Depletion After Hepatic Arterial {sup 90}Yttrium Microsphere Therapy for Hepatocellular Carcinoma

    Energy Technology Data Exchange (ETDEWEB)

    Carr, Brian I., E-mail: brianicarr@hotmail.com [Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA and Department of Nutrition and Exptl Biology, Saverio De Bellis Medical Research Institute, Castellana Grotte, Bari (Italy); Metes, Diana M. [Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA and Department of Nutrition and Exptl Biology, Saverio De Bellis Medical Research Institute, Castellana Grotte, Bari (Italy)

    2012-03-01

    Purpose: The short- and long-term effects of {sup 90}Yttrium microspheres therapy for hepatocellular carcinoma (HCC) on peripheral blood lymphocytes are unknown and were therefore examined. Methods and Materials: Ninety-two HCC patients were enrolled in a {sup 90}Yttrium therapy study and routine blood counts were examined as part of standard clinical monitoring. Results: We found an early, profound, and prolonged lymphopenia. In a subsequent cohort of 25 additional HCC patients, prospective flow cytometric immune-monitoring analysis was performed to identify specific changes on distinct lymphocyte subsets (i.e., CD3, CD4, CD8 T, and CD19 B lymphocytes) and NK cells absolute numbers, in addition to the granulocytes and platelets subsets. We found that the pretreatment lymphocyte subset absolute numbers (with the exception of NK cells) had a tendency to be lower compared with healthy control values, but no significant differences were detected between groups. Posttherapy follow-up revealed that overall, all lymphocyte subsets, except for NK cells, were significantly (>50% from pretherapy values), promptly (as early as 24 h) and persistently (up to 30 months) depleted post-{sup 90}Yttrium microspheres therapy. In contrast, granulocytes increased rapidly (24 h) to compensate for lymphocyte depletion, and remained increased at 1-year after therapy. We further stratified patients into two groups, according to survival at 1 year. We found that lack of recovery of CD19, CD3, CD8, and especially CD4 T cells was linked to poor patient survival. No fungal or bacterial infections were noted during the 30-month follow-up period. Conclusions: The results show that lymphocytes (and not granulocytes, platelets, or NK cells) are sensitive to hepatic arterial {sup 90}Yttrium without associated clinical toxicity, and lack of lymphocyte recovery (possibly leading to dysregulation of adaptive cellular immunity) posttherapy indicates poor survival.

  8. Preclinical evaluation of intravenously administered 111In-and 90Y-labeled B72.3 immunoconjugate (GYK-DTPA) in beagle dogs

    International Nuclear Information System (INIS)

    Quadri, S.M.; Vriesendorp, H.M.; Yi Shao; Blum, J.E.; Leichner, P.K.; Williams, J.R.

    1993-01-01

    B72.3, a monoclonal antibody with reactivity against human adenocarcinomas was obtained from the Cytogen Corporation in the form of an immunoconjugate coupled with linker-chelator GYK-DTPA by using proprietary carbohydrate directed site specific chemistry. The immunoconjugate was radiolabeled with indium-111 or yttrium-90. A preclinical analysis was performed in 10 normal beagle dogs. The pharmacokinetics of intravenously administered indium- and yttrium-labeled immunoconjugates were compared serially in blood, bone marrow and urine samples. Compared to 90 Y less of the 111 In label ended up in urine and more was found in blood and bone marrow. Indium-labeled B72.3 GYK-DTPA had relatively higher uptake in most glandular tissues than 111 In-labeled antiferritin immunoconjugate. Bone marrow toxicity was the dose limiting side effect after intravenous infusion of 90 Y-labeled B72.3 GYK-DTPA. Toxicity was also observed in the liver but not in other organ systems. Recently other investigators obtained similar results with these immunoconjugates in human patients. A preclinical pharmacokinetic analysis of radioimmunoconjugates in beagle dogs provided useful information regarding bone marrow toxicity, liver toxicity and in vivo instability of the immunoconjugate. Data suggest that for future trials in human patients, a more stable chelated immunoconjugate for yttrium is needed to achieve less liver uptake and a better correlation with the 111 In-labeled product than the 90 Y-labeled B72.3 GYK-DTPA used in this investigation. (Author)

  9. Experimental autoabsorption curve 90Sr in SrCO3. Efficiency calculation to detection of 90Sr, 90Y and 90Sr + 90Y in a beta gas proportional counter

    International Nuclear Information System (INIS)

    Gasco, C.; Alvarez, A.

    1987-01-01

    Strontium-90 has been determined by radiochemical separation techniques in environmental samples. These techniques, of course, cannot separate the two strontium radionuclides from each other of from stable strontium. Consequently the end product of the chemical separation contains all strontium isotopes in SrCO 3 . The beta particules emitted by 90 Sr are absorbed by the SrCO 3 precipitate. This is the main source of error in the activity measurement. It has been prepared sources of 90 Sr in SrCO 3 in order to determinate the counting efficiency and autoabsorption curve. Also detection efficiencies have been calibrated using known activities of 90 Y and equilibrium mixture of 90 Sr+ 90 Y in the same geometry than our samples. The activity of 90 Sr by ingrowth of 90 Y has been calculated by our computer program. (author). 2 figs., 3 refs

  10. A Woman with Black Beads in Her Stomach: Severe Gastric Ulceration Caused by Yttrium-90 Radioembolization

    Directory of Open Access Journals (Sweden)

    Indu S. Voruganti

    2018-01-01

    Full Text Available Radioembolization (RE is a selective internal radiation therapy (SIRT delivering targeted, high-dose, intra-arterial radiation directly to the vascular supply of liver tumors. Complications can occur due to aberrant deposition or migration of radiation microspheres into nontarget locations, including normal hepatic parenchyma, lungs, pancreas, and upper gastrointestinal (UGI tract. We report a case of gastric ulcers due to yttrium-90 (90Y seed migration to the stomach to alert clinicians to this rare cause of gastric injury. A 57-year-old woman with stage IV breast cancer with liver and lung metastases presented to the hospital with 2 months of worsening nausea and vomiting. Two months prior, she had received SIRT with 90Y microspheres without complications. Upper GI endoscopy showed diffuse gastritis and extensive antral ulceration. Biopsies revealed black, spherical foreign bodies, consistent with 90Y microspheres, documenting radiation injury. Radiation-induced UGI ulceration is caused by direct radiation injury from beta-radiation. Delay in diagnosis may be due to the nonspecificity of symptoms and temporal delay of symptom onset from SIRT, which was 2 months in our patient. Also, complaints may be attributed erroneously to adjuvant chemotherapy or widespread metastatic disease. Clinicians must consider radiation-associated toxicity in any SIRT-treated patient developing abdominal symptoms.

  11. The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-dPhe1,Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours

    International Nuclear Information System (INIS)

    Stolz, B.; Weckbecker, G.; Smith-Jones, P.M.; Albert, R.; Raulf, F.; Bruns, C.

    1998-01-01

    Somatostatin receptor-expressing tumours are potential targets for therapy with radiolabelled somatostatin analogues. We have synthesized a number of such analogues in the past and identified [DOTA-dPhe 1 , Tyr 3 ]octreotide (SMT 487) as the most promising candidate molecule because of its advantageous properties in cellular and in vivo tumour models. In the current paper we describe the radiotherapeutic effect of yttrium-90 labelled SMT 487 in Lewis rats bearing the somatostatin receptor-positive rat pancreatic tumour CA 20948. SMT 487 binds with nanomolar affinity to both the human and the rat somatostatin receptor subtype 2 (sst 2 ) (human sst 2 IC 50 =0.9 nM, rat sst 2 IC 50 =0.5 nM). In vivo, 90 Y-SMT 487 distributed rapidly to the sst 2 expressing CA 20948 rat pancreatic tumour, with a tumour-to-blood ratio of 49.15 at 24 h post injection. A single intravenous administration of 10 mCi/kg 90 Y-SMT 487 resulted in a complete remission of the tumours in five out of seven CA 20948 tumour-bearing Lewis rats. No regrowth of the tumours occurred 8 months post injection. Control animals that were treated with 30 μg/kg of unlabelled SMT 487 had to be sacrificed 10 days post injection due to excessive growth or necrotic areas on the tumour surface. Upon re-inoculation of tumour cells into those rats that had shown complete remission, the tumours disappeared after 3-4 weeks of moderate growth without any further treatment. The present study shows for the first time the curative potential of 90 Y-SMT 487-based radiotherapy for somatostatin receptor-expressing tumours. Clinical phase I studies with yttrium-labelled SMT 487 have started in September 1997. (orig.)

  12. Validation of an extraction paper chromatography (EPC) technique for estimation of trace levels of 90Sr in 90Y solutions obtained from 90Sr/90Y generator systems

    International Nuclear Information System (INIS)

    Usha Pandey; Yogendra Kumar; Ashutosh Dash

    2014-01-01

    While the extraction paper chromatography (EPC) technique constitutes a novel paradigm for the determination of few Becquerels of 90 Sr in MBq quantities of 90 Y obtained from 90 Sr/ 90 Y generator, validation of the technique is essential to ensure its usefulness as a real time analytical tool. With a view to explore the relevance and applicability of EPC technique as a real time quality control (QC) technique for the routine estimation of 90 Sr content in generator produced 90 Y, a systematic validation study was carried out diligently not only to establish its worthiness but also to broaden its horizon. The ability of the EPC technique to separate trace amounts of Sr 2+ in the presence of large amounts of Y 3+ was verified. The specificity of the technique for Y 3+ was demonstrated with 90 Y obtained by neutron irradiation. The method was validated under real experimental conditions and compared with a QC method described in US Pharmacopeia for detection of 90 Sr levels in 90 Y radiopharmaceuticals. (author)

  13. Clinical outcomes of Y90 radioembolization for recurrent hepatocellular carcinoma following curative resection

    Energy Technology Data Exchange (ETDEWEB)

    Ali, Rehan; Riaz, Ahsun; Gabr, Ahmed; Abouchaleh, Nadine; Mora, Ronald; Al Asadi, Ali [Northwestern University, Department of Radiology, Section of Interventional Radiology, Chicago, IL (United States); Caicedo, Juan Carlos; Abecassis, Michael; Katariya, Nitin [Northwestern University, Department of Surgery, Division of Transplant Surgery, Chicago, IL (United States); Maddur, Haripriya; Kulik, Laura [Northwestern University, Department of Medicine, Division of Hepatology, Chicago, IL (United States); Lewandowski, Robert J. [Northwestern University, Department of Radiology, Section of Interventional Radiology, Chicago, IL (United States); Northwestern University, Department of Medicine, Division of Hematology and Oncology, Chicago, IL (United States); Salem, Riad [Northwestern University, Department of Radiology, Section of Interventional Radiology, Chicago, IL (United States); Northwestern University, Department of Surgery, Division of Transplant Surgery, Chicago, IL (United States); Northwestern University, Department of Medicine, Division of Hematology and Oncology, Chicago, IL (United States)

    2017-12-15

    To assess safety/efficacy of yttrium-90 radioembolization (Y90) in patients with recurrent hepatocellular carcinoma (HCC) following curative surgical resection. With IRB approval, we searched our prospectively acquired database for patients that were treated with Y90 for recurrent disease following resection. Baseline characteristics and bilirubin toxicities following Y90 were evaluated. Intention-to-treat overall survival (OS) and time-to-progression (TTP) from Y90 were assessed. Forty-one patients met study inclusion criteria. Twenty-six (63%) patients had undergone minor (≤3 hepatic segments) resection while 15 (37%) patients underwent major (>3 hepatic segments) resections. Two patients (5%) had biliary-enteric anastomoses created during surgical resection. The median time from HCC resection to the first radioembolization was 17 months (95% CI: 13-37). The median number of Y90 treatment sessions was 1 (range: 1-5). Ten patients received (entire remnant) lobar Y90 treatment while 31 patients received selective (≤2 hepatic segments) treatment. Grades 1/2/3/4 bilirubin toxicity were seen in nine (22%), four (10%), four (10%), and zero (0%) patients following Y90. No differences in bilirubin toxicities were identified when comparing lobar with selective approaches (P = 0.20). No post-Y90 infectious complications were identified. Median TTP and OS were 11.3 (CI: 6.5-15.5) and 22.1 months (CI: 10.3-31.3), respectively. Radioembolization is a safe and effective method for treating recurrent HCC following surgical resection, with prolonged TTP and promising survival outcomes. (orig.)

  14. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin

    International Nuclear Information System (INIS)

    Paganelli, G.; Grana, C.; Chinol, M.; Cremonesi, M.; De Cicco, C.; Zoboli, S.; De Braud, F.; Robertson, C.; Zurrida, S.; Veronesi, U.; Casadio, C.; Siccardi, A.G.

    1999-01-01

    While the incidence of brain tumours seems to be increasing, median survival in patients with glioblastoma remains less than 1 year, despite improved diagnostic imaging and neurosurgical techniques, and innovations in treatment. We have developed an avidin-biotin pre-targeting approach for delivering therapeutic radionuclides to gliomas, using anti-tenascin monoclonal antibodies, which seems potentially effective for treating these tumours. We treated 48 eligible patients with histologically confirmed grade III or IV glioma and documented residual disease or recurrence after conventional treatment. Three-step radionuclide therapy was performed by intravenous administration of 35 mg/m 2 of biotinylated anti-tenascin monoclonal antibody (1st step), followed 36 h later by 30 mg of avidin and 50 mg of streptavidin (2nd step), and 18-24 h later by 1-2 mg of yttrium-90-labelled biotin (3rd step). 90 Y doses of 2.22-2.96 GBq/m 2 were administered; maximum tolerated dose (MTD) was determined at 2.96 GBq/m 2 . Tumour mass reduction (>25%-100%), documented by computed tomography or magnetic resonance imaging, occurred in 12/48 patients (25%), with 8/48 having a duration of response of at least 12 months. At present, 12 patients are still in remission, comprising four with a complete response, two with a parital response, two with a minor response and four with stable disease. Median survival from 90 Y treatment is 11 months for grade IV glioblastoma and 19 months for grade III anaplastic gliomas. Avidin-biotin based three-step radionuclide therapy is well tolerated at the dose of 2.2 GBq/m 2 , allowing the injection of 90 Y-biotin without bone marrow transplantation. This new approach interferes with the progression of high-grade glioma and may produce tumour regression in patients no longer responsive to other therapies. (orig.)

  15. Rapid determination of 90Sr impurities in freshly 'generator eluted'90Y for radiopharmaceutical preparation

    International Nuclear Information System (INIS)

    Bonardi, Mauro L.; Martano, Luigi; Groppi, Flavia; Chinol, Marco

    2009-01-01

    90 Y is one of the most useful radionuclides for radioimmunotherapeutic applications and has a half-life (t 1/2 =64.14 h) suitable for most therapeutic applications, beta particles of high energy and decays to a stable daughter. It is significant that 90 Y is available conveniently and inexpensively from a radionuclide 'generator' by decay of its parent, 90 Sr. Nevertheless, current and planned clinical applications with [ 90 Y] labelled compounds employ activity levels that cannot be readily obtained from an in-house generator, but from commercial sources. We have evaluated Eichrom's Sr-resin, either as an 'in-house' generator or as a fast QC method for analysis of 90 Y solutions. In particular, for the development as a generator, we investigated the percentage of the radio-Sr in the first 8 M HNO 3 eluate: in this fraction the concentration of 90 Sr must be smaller than 10 -5 % (recommendations of the International Commission on Radiological Protection). For evaluation as a rapid QC method, we analyzed the concentration of 90 Y in all the fractions containing 'only' radio-Sr: 90 Y should not be present in these eluates. After the collection of β - and γ spectra and analysis of them, we concluded that commercial Sr-resin minicolumn cannot give us the results expected; we developed an in-house system loaded with 4 mL of Sr-resin which gave better results as a generator and a rapid QC method.

  16. Interstitial pituitary irradiation with 90Y for the treatment of acromomegaly

    International Nuclear Information System (INIS)

    Cassar, J.; Doyle, F.H.; Banks, L.M.; Jadresic, A.; Mashiter, K.; Joplin, G.F.

    1981-01-01

    The management of 54 acromegalics referred to us between 1974 and 1978 has been analysed. Twenty-two patients were treated with pituitary implants of yttrium-90 ( 90 Y). Eleven are in complete remission (mean growth hormone (GH) < 11 mlU/l), 8 had improved (mean GH 11-20 mlU/l or 50% less than preoperatively) and 3 were poor responders. Two patients had temporary 6th nerve paresis. Seven patients are on replacement therapy. Thirty- one patients were not implanted for the following reasons with a number of patients having more than one: extension of the tumour into the spehnoid sinus 10, or above the sella 3, partially empty sella 9, internal carotids too close to midline 2, invisible landmarks 1, mild acromegaly 6, poor general health 3, declined investigations or operation 6. It is concluded that pituitary implant of yttrium is an effective and safe form of treatment on carefully selected patients. (author)

  17. Model-Based Radiation Dose Correction for Yttrium-90 Microsphere Treatment of Liver Tumors With Central Necrosis

    International Nuclear Information System (INIS)

    Liu, Ching-Sheng; Lin, Ko-Han; Lee, Rheun-Chuan; Tseng, Hsiou-Shan; Wang, Ling-Wei; Huang, Pin-I; Chao, Liung-Sheau; Chang, Cheng-Yen; Yen, Sang-Hue; Tung, Chuan-Jong; Wang, Syh-Jen; Oliver Wong, Ching-yee; Liu, Ren-Shyan

    2011-01-01

    Purpose: The objectives of this study were to model and calculate the absorbed fraction φ of energy emitted from yttrium-90 ( 90 Y) microsphere treatment of necrotic liver tumors. Methods and Materials: The tumor necrosis model was proposed for the calculation of φ over the spherical shell region. Two approaches, the semianalytic method and the probabilistic method, were adopted. In the former method, the range--energy relationship and the sampling of electron paths were applied to calculate the energy deposition within the target region, using the straight-ahead and continuous-slowing-down approximation (CSDA) method. In the latter method, the Monte Carlo PENELOPE code was used to verify results from the first method. Results: The fraction of energy, φ, absorbed from 90 Y by 1-cm thickness of tumor shell from microsphere distribution by CSDA with complete beta spectrum was 0.832 ± 0.001 and 0.833 ± 0.001 for smaller (r T = 5 cm) and larger (r T = 10 cm) tumors (where r is the radii of the tumor [T] and necrosis [N]). The fraction absorbed depended mainly on the thickness of the tumor necrosis configuration, rather than on tumor necrosis size. The maximal absorbed fraction φ that occurred in tumors without central necrosis for each size of tumor was different: 0.950 ± 0.000, and 0.975 ± 0.000 for smaller (r T = 5 cm) and larger (r T = 10 cm) tumors, respectively (p 90 Y microsphere treatment of hepatic tumors with central necrosis. With this model, important information is provided regarding the absorbed fraction applicable to clinical 90 Y microsphere treatment.

  18. Yttrium-90 used to treat colon cancer: Awaiting investigational new drug approval

    International Nuclear Information System (INIS)

    Anon.

    1991-01-01

    A new radiation treatment takes just 14 to 21 days to shrink colorectal tumors in laboratory mice, is under review for clinical trials with human cancer patients. The treatment has succeeded in reducing the size of tumors by up to 95%. Colon cancer, the second leading cause of cancer deaths in the US, is extremely difficult to treat unless it is detected early enough for surgical procedures. In laboratory tests over the last 5 years, a team of researchers has developed the treatment using yttrium-90. The yttrium-90 is transported to the tumors by attaching it to monoclonal antibodies that seek out the cancer cells. Once the radioisotope has been targeted to the tumor, the radiation destroys many of the cells, dramatically reducing the size of the tumor. Since this treatment usually does not completely eliminate all the cancer cells, it cannot be called a cure, but it does seem to be an effective method of shrinking colorectal tumors

  19. Spectrographic determination of strontium in yttrium-90 solutions

    International Nuclear Information System (INIS)

    Roca, M.; Capdevila, C.

    1970-01-01

    The copper spark method has been used for determining strontium in the concentration range 1-100 g/ml in yttrium-90 solutions containing 0,5 % or thereabouts of ammonium citrate. The influence of the citric acid as well as the ammonium citrate with regard to 2N HCL solutions has been studied: the citric acid enhances the line intensities of strontium. The employment of either barium or lanthanum as reference element compensates for this enhancement. Because of the increase in sensitivity mentioned above, the study of influence of the citric acid has been extended and several impurities usually determined in radioisotope solutions have been considered. (Author) 4 refs

  20. Acromegaly with sleep disturbances relieved by yttrium-90 pituitary implantation

    International Nuclear Information System (INIS)

    Rosenstock, J.; Doyle, F.H.; Joplin, G.F.; Jung, R.T.; Mashiter, K.

    1982-01-01

    A brief case history is presented of a patient, who, after yttrium-90 implantation, showed a complete clinical and hormonal remission of her acromegaly, maintaining normal pituitary function. The remarkable feature was the rapid disappearance of her attacks of somnolence within 96 hours of pituitary implantation, despite persistence of nocturnal snoring and well before any remodelling of soft tissues could have occurred. This response suggests that her daytime somnolence had a narcoleptic component. (author)

  1. Acromegaly with sleep disturbances relieved by yttrium-90 pituitary implantation

    Energy Technology Data Exchange (ETDEWEB)

    Rosenstock, J.; Doyle, F.H.; Joplin, G.F.; Jung, R.T.; Mashiter, K. (Hammersmith Hospital, London (UK). Postgraduate Medical School)

    1982-03-01

    A brief case history is presented of a patient, who, after yttrium-90 implantation, showed a complete clinical and hormonal remission of her acromegaly, maintaining normal pituitary function. The remarkable feature was the rapid disappearance of her attacks of somnolence within 96 hours of pituitary implantation, despite persistence of nocturnal snoring and well before any remodelling of soft tissues could have occurred. This response suggests that her daytime somnolence had a narcoleptic component.

  2. Recommendations for radioembolisation after liver surgery using yttrium-90 resin microspheres based on a survey of an international expert panel

    International Nuclear Information System (INIS)

    Samim, Morsal; Veenendaal, Linde M. van; Braat, Manon N.G.J.A.; Hoven, Andor F. van den; Bosch, Maurice A.A.J. van den; Lam, Marnix G.E.H.; Hillegersberg, Richard van; Sangro, Bruno; Kao, Yung Hsiang; Liu, Dave; Louie, John D.; Sze, Daniel Y.; Rose, Steven C.; Brown, Daniel B.; Ahmadzadehfar, Hojjat; Kim, Edward

    2017-01-01

    Guidelines on how to adjust activity in patients with a history of liver surgery who are undergoing yttrium-90 radioembolisation ( 90 Y-RE) are lacking. The aim was to study the variability in activity prescription in these patients, between centres with extensive experience using resin microspheres 90 Y-RE, and to draw recommendations on activity prescription based on an expert consensus. The variability in activity prescription between centres was investigated by a survey of international experts in the field of 90 Y-RE. Six representative post-surgical patients (i.e. comparable activity prescription, different outcome) were selected. Information on patients' disease characteristics and data needed for activity calculation was presented to the expert panel. Reported was the used method for activity prescription and whether, how and why activity reduction was found indicated. Ten experts took part in the survey. Recommendations on activity reduction were highly variable between the expert panel. The median intra-patient range was 44 Gy (range 18-55 Gy). Reductions in prescribed activity were recommended in 68% of the cases. In consensus, a maximum D Target of 50 Gy was recommended. With a current lack of guidelines, large variability in activity prescription in post-surgical patients undergoing 90 Y-RE exists. In consensus, D Target ≤50 Gy is recommended. (orig.)

  3. Y-90 PET imaging for radiation theragnosis using bootstrap event re sampling

    International Nuclear Information System (INIS)

    Nam, Taewon; Woo, Sangkeun; Min, Gyungju; Kim, Jimin; Kang, Joohyun; Lim, Sangmoo; Kim, Kyeongmin

    2013-01-01

    Surgical resection is the most effective method to recover the liver function. However, Yttrium-90 (Y-90) has been used as a new treatment due to the fact that it can be delivered to the tumors and results in greater radiation exposure to the tumors than using external radiation nowadays since most treatment is palliative in case of unresectable stage of hepatocellular carcinoma (HCC). Recently, Y-90 has been received much interest and studied by many researchers. Imaging of Y-90 has been conducted using most commonly gamma camera but PET imaging is required due to low sensitivity and resolution. The purpose of this study was to assess statistical characteristics and to improve count rate of image for enhancing image quality by using nonparametric bootstrap method. PET data was able to be improved using non-parametric bootstrap method and it was verified with showing improved uniformity and SNR. Uniformity showed more improvement under the condition of low count rate, i.e. Y-90, in case of phantom and also uniformity and SNR showed improvement of 15.6% and 33.8% in case of mouse, respectively. Bootstrap method performed in this study for PET data increased count rate of PET image and consequentially time for acquisition time can be reduced. It will be expected to improve performance for diagnosis

  4. Separation of 90Sr from Purex high level waste and development of a 90Sr-90Y generator

    International Nuclear Information System (INIS)

    Ramanujam, A.; Dhami, P.S.; Chitnis, R.R.; Achuthan, P.V.; Kannan, R.; Gopalakrishnan, V.; Balu, K.

    2000-04-01

    90 Y (T 1/2 =64.2 h) finds several applications in nuclear medicine. It is formed from the decay of 90 Sr which has a long half-life of 28.8 years. 90 Sr can be used as a long-lasting source for the production of carrier-free 90 Y. 90 Sr itself is abundantly available in high level waste (HLW) of PUREX origin. The present studies deal with the separation of pure 90 Sr from HLW and the subsequent separation of 90 Y from 90 Sr. Actinides and some of the fission products like lanthanides, zirconium, molybdenum and cesium were first removed from the HLW using methods based on solvent extraction and ion-exchange studied earlier in our laboratory. The resulting waste solution was used as a feed for the present process. The separation of 90 Sr from HLW was based on radiochemical method which involved a repeated scavenging with ferric hydroxide followed by strontium carbonate precipitation. The separation of 90 Y from 90 Sr was achieved by membrane separation technique. A compact generator is developed for this separation using a commercially available polytetrafluoroethylene (PTFE) membrane, impregnated with indigenously synthesised 2-ethylhexyl 2-ethylhexyl phosphonic acid (KSM-17). Generator system overcomes the drawbacks associated with conventional solvent extraction and ion-exchange based generators. The product is in chloride form and is suitable for complexation studies. After gaining an operating experience of ∼3 years in generating carrier-free 90 Y at 2 mCi level for initial studies in radiotherapeutic applications, the process was scaled up for the production of about 12 mCi of 90 Y to be used for animal studies before its application to patients. Radiochemical and chemical purity of the product was critically assayed by radiometry, ICP-AES, etc. The process is amenable for further scaling up. (author)

  5. Extractive {sup 90}Y generator

    Energy Technology Data Exchange (ETDEWEB)

    Kodina, G.E. [State Scientific Center, Moscow (Russian Federation). Institute of Giophysics; Korpusov, G.V.; Filyanin, A.T. [Russian Academy of Sciences, Moscow (Russian Federation). Institute of Physical Chemistry

    1997-10-01

    The generator for {sup 90}Y production is made up of two units - an extractive unit and a unit for deep purification. Contrary to the well-known methods of {sup 90}Y separation two mineral acids are used in the developed technology. The solutions of nitric acid are used for preliminary separation of {sup 90}Y and the solutions of hydrochloric acid are used for the deep purification of {sup 90}Y from {sup 90}Sr and stripping. The optimum conditions for carrying out this technology were found. The following results are reported: the carry-over of the stationary phase is excluded in this generator; the separation time is 30-60 minutes; the yield of the final product is not less than 95%; impurity of {sup 90}Sr is not more than 10{sup -9-}-{sup -10}%; the content of the chemical (nonactive) impurities is not more than the allowed one for radiopharmaceuticals 4 refs., 4 tabs., 5 figs.

  6. Use of Yttrium-90 TheraSphere for the treatment of unresectable hepatocellular carcinoma.

    Science.gov (United States)

    Liu, Michael D; Uaje, Michelle B; Al-Ghazi, Muthana S; Fields, Denise; Herman, June; Kuo, Jeffrey V; Milne, Norah; Nguyen, Thong H; Ramsinghani, Nilam S; Tokita, Kenneth M; Tsai, Fong Y; Vajgrt, Duane J; Imagawa, David K

    2004-11-01

    This is a retrospective analysis of a new treatment modality, intra-arterial administration of Yttrium-90 TheraSphere, for unresectable hepatocellular carcinoma (HCC). Patients with HCC not amenable to surgical treatment who had satisfactory physiological function without comorbid disease or significant pulmonary shunting were eligible for treatment. Patients were categorized into complete, partial, or no response based on serum alpha-fetoprotein (AFP) levels and CT or MRI imaging. Fourteen patients were considered candidates for treatment. Three patients were excluded due to significant hepatopulmonary shunting. Eleven patients were treated with TheraSphere. One patient (9%) had a complete response, eight patients (78%) had a partial response, and two patients (18%) showed no response. Partial and complete responders with AFP-associated HCC demonstrated a median decrease in AFP levels of 79 per cent at 73 days. No patients developed liver toxicity nor died due to treatment. Five patients (45%) died of progressive disease at a median of 7 months post-treatment. Six patients (54%) were alive at a median of 11 months (range, 9 to 20 months). Okuda stage 2 and 3 patients showed a median survival of 11 months and 7 months, respectively. Yttrium-90 TheraSphere treatment for unresectable hepatocellular carcinoma is well tolerated and appears to extend survival.

  7. Multi institutional quantitative phantom study of yttrium-90 PET in PET/MRI: the MR-QUEST study.

    Science.gov (United States)

    Maughan, Nichole M; Eldib, Mootaz; Faul, David; Conti, Maurizio; Elschot, Mattijs; Knešaurek, Karin; Leek, Francesca; Townsend, David; DiFilippo, Frank P; Jackson, Kimberly; Nekolla, Stephan G; Lukas, Mathias; Tapner, Michael; Parikh, Parag J; Laforest, Richard

    2018-04-04

    Yttrium-90 ( 90 Y) radioembolization involves the intra-arterial delivery of radioactive microspheres to treat hepatic malignancies. Though this therapy involves careful pre-treatment planning and imaging, little is known about the precise location of the microspheres once they are administered. Recently, there has been growing interest post-radioembolization imaging using positron-emission tomography (PET) for quantitative dosimetry and identifying lesions that may benefit from additional salvage therapy. In this study, we aim to measure the inter-center variability of 90 Y PET measurements as measured on PET/MRI in preparation for a multi-institutional prospective phase I/II clinical trial. Eight institutions participated in this study and followed a standardized phantom filling and imaging protocol. The NEMA NU2-2012 body phantom was filled with 3 GBq of 90 Y chloride solution. The phantom was imaged for 30 min in listmode on a Siemens Biograph mMR non-TOF PET/MRI scanner at five time points across 10 days (0.3-3.0 GBq). Raw PET data were sent to a central site for image reconstruction and data analysis. Images were reconstructed with optimal parameters determined from a previous study. Volumes of interest (VOIs) matching the known sphere diameters were drawn on the vendor-provided attenuation map and propagated to the PET images. Recovery coefficients (RCs) and coefficient of variation of the RCs (COV) were calculated from these VOIs for each sphere size and activity level. Mean RCs ranged from 14.5 to 75.4%, with the lowest mean RC coming from the smallest sphere (10 mm) on the last day of imaging (0.16 MBq/ml) and the highest mean RC coming from the largest sphere (37 mm) on the first day of imaging (2.16 MBq/ml). The smaller spheres tended to exhibit higher COVs. In contrast, the larger spheres tended to exhibit lower COVs. COVs from the 37 mm sphere were  25%. Post-radioembolization dosimetry of lesions or other VOIs ≥ 22 mm in diameter can

  8. The somatostatin receptor-targeted radiotherapeutic [{sup 90}Y-DOTA-dPhe{sup 1},Tyr{sup 3}]octreotide ({sup 90}Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours

    Energy Technology Data Exchange (ETDEWEB)

    Stolz, B.; Weckbecker, G.; Smith-Jones, P.M.; Albert, R.; Raulf, F.; Bruns, C. [Novartis Pharma AG, Basel (Switzerland)

    1998-07-01

    Somatostatin receptor-expressing tumours are potential targets for therapy with radiolabelled somatostatin analogues. We have synthesized a number of such analogues in the past and identified [DOTA-dPhe{sup 1}, Tyr{sup 3}]octreotide (SMT 487) as the most promising candidate molecule because of its advantageous properties in cellular and in vivo tumour models. In the current paper we describe the radiotherapeutic effect of yttrium-90 labelled SMT 487 in Lewis rats bearing the somatostatin receptor-positive rat pancreatic tumour CA 20948. SMT 487 binds with nanomolar affinity to both the human and the rat somatostatin receptor subtype 2 (sst{sub 2}) (human sst{sub 2} IC{sub 50}=0.9 nM, rat sst{sub 2} IC{sub 50}=0.5 nM). In vivo, {sup 90}Y-SMT 487 distributed rapidly to the sst{sub 2} expressing CA 20948 rat pancreatic tumour, with a tumour-to-blood ratio of 49.15 at 24 h post injection. A single intravenous administration of 10 mCi/kg {sup 90}Y-SMT 487 resulted in a complete remission of the tumours in five out of seven CA 20948 tumour-bearing Lewis rats. No regrowth of the tumours occurred 8 months post injection. Control animals that were treated with 30 {mu}g/kg of unlabelled SMT 487 had to be sacrificed 10 days post injection due to excessive growth or necrotic areas on the tumour surface. Upon re-inoculation of tumour cells into those rats that had shown complete remission, the tumours disappeared after 3-4 weeks of moderate growth without any further treatment. The present study shows for the first time the curative potential of {sup 90}Y-SMT 487-based radiotherapy for somatostatin receptor-expressing tumours. Clinical phase I studies with yttrium-labelled SMT 487 have started in September 1997. (orig.) With 4 figs., 2 tabs., 29 refs.

  9. PET/MRI of Hepatic 90Y Microsphere Deposition Determines Individual Tumor Response

    Energy Technology Data Exchange (ETDEWEB)

    Fowler, Kathryn J. [Washington University, Department of Radiology (United States); Maughan, Nichole M. [Washington University, Department of Biomedical Engineering (United States); Laforest, Richard [Washington University, Department of Nuclear Medicine (United States); Saad, Nael E. [Washington University, Department of Radiology (United States); Sharma, Akash [Washington University, Department of Nuclear Medicine (United States); Olsen, Jeffrey; Speirs, Christina K.; Parikh, Parag J., E-mail: parikh@wustl.edu [Washington University, Department of Radiation Oncology (United States)

    2016-06-15

    PurposeThe purpose of our study is to determine if there is a relationship between dose deposition measured by PET/MRI and individual lesion response to yttrium-90 ({sup 90}Y) microsphere radioembolization.Materials and Methods26 patients undergoing lobar treatment with {sup 90}Y microspheres underwent PET/MRI within 66 h of treatment and had follow-up imaging available. Adequate visualization of tumor was available in 24 patients, and contours were drawn on simultaneously acquired PET/MRI data. Dose volume histograms (DVHs) were extracted from dose maps, which were generated using a voxelized dose kernel. Similar contours to capture dimensional and volumetric change of tumors were drawn on follow-up imaging. Response was analyzed using both RECIST and volumetric RECIST (vRECIST) criteria.ResultsA total of 8 hepatocellular carcinoma (HCC), 4 neuroendocrine tumor (NET), 9 colorectal metastases (CRC) patients, and 3 patients with other metastatic disease met inclusion criteria. Average dose was useful in predicting response between responders and non-responders for all lesion types and for CRC lesions alone using both response criteria (p < 0.05). D70 (minimum dose to 70 % of volume) was also useful in predicting response when using vRECIST. No significant trend was seen in the other tumor types. For CRC lesions, an average dose of 29.8 Gy offered 76.9 % sensitivity and 75.9 % specificity for response.ConclusionsPET/MRI of {sup 90}Y microsphere distribution showed significantly higher DVH values for responders than non-responders in patients with CRC. DVH analysis of {sup 90}Y microsphere distribution following treatment may be an important predictor of response and could be used to guide future adaptive therapy trials.

  10. Tomographic bremsstrahlung imaging with yttrium-90 in the context of radioembolisation of liver tumors; Tomografische Bildgebung mit Yttrium-90-Bremsstrahlung im Rahmen der Radioembolisation von Lebertumoren

    Energy Technology Data Exchange (ETDEWEB)

    Grosser, Oliver Stephan

    2013-04-12

    Establish tomographic Bremsstrahlung SPECT imaging (BSPECT) for the clinical validation of Selective Internal Radiotherapy (SIRT) with Yttrium-90 ({sup 90}Y) labelled microspheres. Various energy ranges (75 ± 3.8 keV; 135 ± 6.8 keV; 167 ± 8.4 keV) and the summation window were studied to see if they were suitable for BSPECT. To this end, clinically available reconstruction techniques were analysed for their suitability for BSPECT. The tomographic examinations were performed on a cylindrical phantom filled with spheres of different diameters d = [28; 35; 40; 50; 60] mm in a non-active waterfilled background. The spheres were filled with identical {sup 90}Y activity concentration (AC). Measurements were conducted at AC = [14.58; 5.20; 1.98; 0.66] MBq/cm{sup 3}. The BSPECT were reconstructed with filtered back-projection (FBP), a 2D Ordered-Subset Expectation Maximisation Algorithm (2D-OSEM) and a 3D Geometric Mean Algorithm (3D-GMA). Evaluation was made visually and on the basis of objective performance parameters such as contrast, signal-to-noise ratio (SNR) and image noise. While the 75 keV ± 3.8 keV window was identified as suitable for the BSPECT, limitations were revealed as to use of different implementations of the Point Spread Function (PSF). It was found for all reconstruction techniques that, at a given sphere diameter, there existed a linear relationship between the AC in the spheres and the reconstructed pulse rate per volume element. The recovery effect was verified for small spheres. The iterative techniques were found to be suitable for the BSPECT at all AC. At low AC, the 3D-GMA exhibited the least noise and the highest SNR. The FBP turned out to be entirely inappropriate for the BSPECT. The narrow energy window in which the bremsstrahlung interferes with the characteristic X-radiation of lead can be used for BSPECT. In this approach, the tomographic data reconstructed with different algorithms exhibited a varying image quality, with the iterative

  11. Effects of radiolysis on yttrium-90-labeled Lym-1 antibody preparations.

    Science.gov (United States)

    Salako, Q A; O'Donnell, R T; DeNardo, S J

    1998-04-01

    The physical half-life of 2.6 days and 2.2 MeV beta emissions of 90Y provide excellent properties for radioimmunotherapy applications. However, the clinically useful beta particles may be a source of radiation-induced damage of 90Y-labeled immunoconjugate radiopharmaceuticals during preparation or short-term storage. The stability of 90Y-labeled Lym-1 antibody was studied in standard radiopharmacy conditions to establish a formulation at which radiolysis is not a problem. Lym-1-21T-BAD immunoconjugate intermediate was prepared according to our standard procedure, then labeled with 90Y at 1, 2, 4 and 9.4 mCi/mg Lym-1 using 0.5 M tetramethylammonium acetate, pH 7, labeling buffer. Each mixture was challenged in diethylenetriaminepentaacetic acid to remove nonspecifically bound 90Y. The 90Y-21T-BAD-Lym-1 products were purified by centrifuged molecular sieving column chromatography. The radiochemical purity and immunoreactivity of each preparation was monitored daily by high-performance liquid chromatography (HPLC) and solid-phase radioimmunoassay, respectively, for 3 days. The preparation at 2 mCi/mg was also formulated in 4% (wt/vol) human serum albumin (HSA) overall and at 9.4 mCi/mg in five-fold water, 4 and 10% (wt/vol) HSA overall; all were monitored as above. The monomeric quality and purity profile of products at 1 and 2 mCi/mg were retained (> or = 80%) as was their immunoreactivity (> or = 75%) over 3 days. The radiochemical purity and immunoreactivity of the product at 4 mCi/mg declined to 65% and 28%, respectively, by 3 days after preparation and in just 48 hr, the product at 9.4 mCi/mg had degraded to 21% in radiochemical purity with only 3% immunoreactivity. The current HPLC data and earlier published chromatographic evidence did not support a compromised radiochemical integrity of 90Y-DOTA complexes by loss of 90Y from the DOTA chelate. Radiolysis of 90Y-labeled antibody preparations did not appear to be a problem at 90Y-21T-BAD-Lym-1 products < or = 2 m

  12. Process improvement for the safe delivery of multidisciplinary-executed treatments-A case in Y-90 microspheres therapy.

    Science.gov (United States)

    Cai, Bin; Altman, Michael B; Garcia-Ramirez, Jose; LaBrash, Jason; Goddu, S Murty; Mutic, Sasa; Parikh, Parag J; Olsen, Jeffrey R; Saad, Nael; Zoberi, Jacqueline E

    To develop a safe and robust workflow for yttrium-90 (Y-90) radioembolization procedures in a multidisciplinary team environment. A generalized Define-Measure-Analyze-Improve-Control (DMAIC)-based approach to process improvement was applied to a Y-90 radioembolization workflow. In the first DMAIC cycle, events with the Y-90 workflow were defined and analyzed. To improve the workflow, a web-based interactive electronic white board (EWB) system was adopted as the central communication platform and information processing hub. The EWB-based Y-90 workflow then underwent a second DMAIC cycle. Out of 245 treatments, three misses that went undetected until treatment initiation were recorded over a period of 21 months, and root-cause-analysis was performed to determine causes of each incident and opportunities for improvement. The EWB-based Y-90 process was further improved via new rules to define reliable sources of information as inputs into the planning process, as well as new check points to ensure this information was communicated correctly throughout the process flow. After implementation of the revised EWB-based Y-90 workflow, after two DMAIC-like cycles, there were zero misses out of 153 patient treatments in 1 year. The DMAIC-based approach adopted here allowed the iterative development of a robust workflow to achieve an adaptable, event-minimizing planning process despite a complex setting which requires the participation of multiple teams for Y-90 microspheres therapy. Implementation of such a workflow using the EWB or similar platform with a DMAIC-based process improvement approach could be expanded to other treatment procedures, especially those requiring multidisciplinary management. Copyright © 2016 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

  13. Temporary balloon occlusion of the common hepatic artery for administration of yttrium-90 resin microspheres in a patient with patent hepatoenteric collaterals.

    Science.gov (United States)

    Mahvash, Armeen; Zaer, Navid; Shaw, Colette; Chasen, Beth; Avritscher, Rony; Murthy, Ravi

    2012-02-01

    The most common serious complication of yttrium-90 ((90)Y) therapy is gastrointestinal ulceration caused by extrahepatic microsphere dispersion. The authors describe the use of a balloon catheter for temporary occlusion of the common hepatic artery to reverse hepatoenteric flow for lobar administration of resin microspheres when coil embolization of a retroportal artery was impossible. At 9 months after treatment, the patient had no gastrointestinal side effects and showed a partial response. Copyright © 2012 SIR. Published by Elsevier Inc. All rights reserved.

  14. Recommendations for radioembolisation after liver surgery using yttrium-90 resin microspheres based on a survey of an international expert panel

    Energy Technology Data Exchange (ETDEWEB)

    Samim, Morsal [University Medical Center Utrecht, Department of Surgery, Utrecht (Netherlands); University Medical Center Utrecht, Department of Radiology and Nuclear Medicine, Utrecht (Netherlands); Veenendaal, Linde M. van; Braat, Manon N.G.J.A.; Hoven, Andor F. van den; Bosch, Maurice A.A.J. van den; Lam, Marnix G.E.H. [University Medical Center Utrecht, Department of Radiology and Nuclear Medicine, Utrecht (Netherlands); Hillegersberg, Richard van [University Medical Center Utrecht, Department of Surgery, Utrecht (Netherlands); Sangro, Bruno [Clinica Universidad de Navarra-IDISNA and CIBEREHD, Liver Unit, Pamplona (Spain); Kao, Yung Hsiang [Cabrini Hospital, Department of Nuclear Medicine, Melbourne (Australia); Liu, Dave [Vancouver General Hospital, University of British Columbia, Department of Radiology, Vancouver, British Columbia (Canada); Louie, John D.; Sze, Daniel Y. [Stanford University Medical Center, Division of Interventional Radiology, Stanford (United States); Rose, Steven C. [University of California, Department of Radiology, San Diego (United States); Brown, Daniel B. [Vanderbilt University, Medical Center North, Department of Radiology, Nashville (United States); Ahmadzadehfar, Hojjat [University Hospital Bonn, Department of Nuclear Medicine, Bonn (Germany); Kim, Edward [Icahn School of Medicine at Mount Sinai, Division of Vascular and Interventional Radiology, New York (United States)

    2017-12-15

    Guidelines on how to adjust activity in patients with a history of liver surgery who are undergoing yttrium-90 radioembolisation ({sup 90}Y-RE) are lacking. The aim was to study the variability in activity prescription in these patients, between centres with extensive experience using resin microspheres {sup 90}Y-RE, and to draw recommendations on activity prescription based on an expert consensus. The variability in activity prescription between centres was investigated by a survey of international experts in the field of {sup 90}Y-RE. Six representative post-surgical patients (i.e. comparable activity prescription, different outcome) were selected. Information on patients' disease characteristics and data needed for activity calculation was presented to the expert panel. Reported was the used method for activity prescription and whether, how and why activity reduction was found indicated. Ten experts took part in the survey. Recommendations on activity reduction were highly variable between the expert panel. The median intra-patient range was 44 Gy (range 18-55 Gy). Reductions in prescribed activity were recommended in 68% of the cases. In consensus, a maximum D{sub Target} of 50 Gy was recommended. With a current lack of guidelines, large variability in activity prescription in post-surgical patients undergoing {sup 90}Y-RE exists. In consensus, D{sub Target} ≤50 Gy is recommended. (orig.)

  15. Pathological changes in cystic craniopharyngiomas following intracavital 90Yttrium treatment

    International Nuclear Information System (INIS)

    Szeifert, G.T.; Julow, J.; Slowik, F.; Balint, K.; Lanyi, F.; Pasztor, E.

    1990-01-01

    Radiosurgery, using 90 Y injected directly into the cavity of cystic craniopharyngiomas produces remarkable reduction of tumour size and diminishes cyst fluid production. The authors have studied the histology of biopsy and autopsy material obtained from seven patients presented with cystic craniopharyngiomas. Histological examination was carried out before and after 90 Y silicate implantation. As an effect of 90 Y irradiation, histology of samples taken from the cyst wall revealed that the lining epithelial cell layer became destroyed and the cyst wall shrunk. Large amount of collagen fibres with focal hyaline degeneration was present. Proliferation of intimal cells and subendothelial connective tissue narrowing small vessel lumina also occurred. Considering that fibrotic tissue is more susceptible to shrink, the fibrosis induced by irradiation together with destruction of the squamous epithelium and vascular changes, might explain the reduction of the cyst volume and diminished fluid secretion after 90 Y treatment. (Authors)

  16. Childhood acromegaly successfully treated with interstitial irradiation using Yttrium-90

    International Nuclear Information System (INIS)

    Rosenstock, J.; Doyle, F.H.; Mashiter, K.; Joplin, G.F.

    1982-01-01

    A child with a growth hormone producing tumour presented at the age of 4 1/2 years. The onset of the disease was at 18 months of age. Treatment was given with three doses of interstitial irradiation using yttrium-90 implants. There were no local complications from the procedures. Now, 11 years after diagnosis, she is asymptomatic, of normal appearance, and her height and the size of the pituitary fossa are normal. Growth hormone levels are almost normal, thyroid function is intact, and she is maintained on prednisone and sex hormones. (Authors)

  17. Childhood acromegaly successfully treated with interstitial irradiation using Yttrium-90

    Energy Technology Data Exchange (ETDEWEB)

    Rosenstock, J.; Doyle, F.H.; Mashiter, K.; Joplin, G.F. (Royal Postgraduate Medical School, Hammersmith Hospital, London (UK). Dept. of Medicine and Radiology); Hall, R. (Royal Victoria Infirmary, Newcastle upon Tyne (UK))

    1982-01-01

    A child with a growth hormone producing tumour presented at the age of 4 1/2 years. The onset of the disease was at 18 months of age. Treatment was given with three doses of interstitial irradiation using Yttrium-90 implants. There were no local complications from the procedures. Now, 11 years after diagnosis, she is asymptomatic, of normal appearance, and her height and the size of the pituitary fossa are normal. Growth hormone levels are almost normal, thyroid function is intact, and she is maintained on prednisone and sex hormones.

  18. Comparison by quantitative scanning of the distribution in the body of yttrium-90 and gold-198 after intra-articular injection

    International Nuclear Information System (INIS)

    Williams, E.D.; Caughey, D.E.; John, M.B.; Hurley, P.J.

    1975-01-01

    A new radiopharmaceutical, yttrium-90 ferric hydroxide colloid, has been used to treat knee effusion in patients with rheumatoid arthritis. With a view to assessing absorbed radiation dose, a study was initiated to compare its body distribution with that of gold-198, which has also been used for this purpose. The treated knee was in each case scanned immediately after injection using a dual 5-inch detector scanner, and again two, four and seven days later, when the regional lymph nodes and liver were also scanned. Using calibration factors obtained by scanning water phantoms, data from the scans were used to calculate the percentage of the injected radioactivity in each site. Radioactivity in blood and urine was also measured. Ten knees have been treated, each with five mCi yttrium-90, and twelve with 10 mCi gold-198. The treated knee was immobilized, and the patient rested in bed for four days, to minimize loss of radioactivity from the knee. With this procedure, both radionuclides were found to be equally well retained in the knee. However, the lymph node uptake of yttrium was lower than for gold. Yttrium-90 emits only beta radiation, so the gonadal radiation done in patients treated with yttrium-90 is estimated to be much less than in those treated with gold-198. (author)

  19. Country report: Vietnam. Setting Up of a 90Sr/90Y Generator System Based on Supported Liquid Membrane (SLM) Technique and Radiolabeling of Eluted 90Y with Biomolecules

    International Nuclear Information System (INIS)

    Nguyen Thi Thu; Duong Van Dong; Bui Van Cuong; Chu Van Khoa

    2010-01-01

    In the course of participating in the IAEA-CRP during the last two years, Vietnam has achieved the goal of setting up a 90 Sr/ 90 Y generator system based on Supported Liquid Membrane (SLM) technique and also radiolabeling of the eluted 90 Y with antibody, peptides and albumin. A two stage SLM based 90 Sr- 90 Y generator was set up in-house to generate carrier-free 90 Y at different activity levels viz. 5, 20, 50 mCi. The generator system was operated in sequential mode in which 2-ethylhexyl 2-ethylhexyl phosphonic acid (PC88A) based SLM was used in the first stage for the transport 90 Y in 4.0 M nitric acid from source phase where 90 Sr- 90 Y equilibrium mixture is placed in nitric acid medium at pH to 1-2. In the second stage, octyl (phenyl)-N,N-diisobutylcarbamoylmethyl phosphine oxide (CMPO) based SLM was used for the transport of 90 Y selectively to 1.0 M acetic acid which is the best medium for radiolebeling. The eluted 90 Y from the generator was tested for the presence of any traces of 90 Sr using the Extraction Paper Chromatography (EPC) and was found suitable for radiolabeling. The generator system could be upgraded to 100 mCi level successfully due to an expert mission from India through IAEA. The 90 Y product obtained from the generator system was used for radiolabeling of antibody and peptides viz. Rituximab, DOTATATE and albumin particles under different experimental conditions. A new chromatography system could be developed for analyzing 90 Y labeled albumin using the TAE buffer as mobile phase in PC and ITLC

  20. Verification dosimetry of intravascular 90Sr/90Y source trains

    International Nuclear Information System (INIS)

    Sharma, S.D.; Shanta, A.; Tripathi, U.B.; Bhatt, B.C.

    2001-01-01

    90 Sr/ 90 Y source trains (Novoste Beta-Cath System) are currently under clinical trials in India and abroad for intracoronary brachytherapy for prevention of restenosis. Each source train of the Beta-Cath system is supplied with a source certificate giving dose rate at the reference distance of 2 mm from the centerline of the source train. It is essential that the user should check dose rates of brachytherapy sources before its application on the patients. Dose rates and depth dose measurements for 90 Sr/ 90 Y source trains of active length 40 mm using radiochromic films in a tissue equivalent phantom have been carried out. The objectives of these measurements were (1) to verify the dose rates stated in the source certificate, and (2) to obtain relative depth dose data for treatment planning. This paper presents the results of these measurements

  1. Y-90 microshperes in the treatment of unresectable hepatocellular carcinoma.

    Science.gov (United States)

    Al-Kalbani, Abdullah; Kamel, Yasser

    2008-04-01

    A small percentage of patients with hepatocellular carcinoma (HCC) are candidates for curative treatment in form of resection or transplantation. There are different treatment options for unresectable HCC-like local ablative therapies and recently systemic therapy with Sorafenib. All of these have variable response rate and had been proven to improve survival. In the last few years, there is a growing interest in TheraSphere radioembolization. It consists of yttrium90 (Y-90) embedded into nonbiodegradable glass microspheres. It is selectively administered by intraarterial hepatic injection giving high doses of radiation to the tumor and sparing the liver parenchyma. It has been shown to improve survival and used as a bridge to transplantation and to downstage tumors for resection. Therasphere seems to have favorable safety profile and has been used in patients with portal vein thrombosis with successful outcome.

  2. Dose-response evaluation after Yttrium-90 resin microsphere radio-embolization of breast cancer liver metastases

    International Nuclear Information System (INIS)

    Gnesin, S.; Verdun, F.R.; Baechler, S.; Boubacker, A.; Adib, S.; Cherbuin, N.; Prior, J.O.; Bize, P.; Denys, A.

    2015-01-01

    Full text of publication follows. Aim: Yttrium-90 resin microsphere radio-embolization is a valuable therapeutic option in metastatic breast cancer patients with progressive disease refractory to chemotherapy. The goal of this study was to evaluate the dose-response relationship of liver metastasis based on a 3D voxelized 90 Y PET dosimetry. Materials and methods: we studied the dose-response relationship of twelve hepatic lesions in four selected patients with metastatic breast cancer who underwent 90 Y radio-embolization (Sirtex SIR-Spheres Pty Ltd.). The administered activity ranged from 1 to 1.3 GBq. Ten days before treatment, patients underwent a baseline 18 F-FDG PET/CT. The determination of the 90 Y-microsphere activity to administer for treatment was based on the BSA method refined with the partition model derived from a 99m Tc-MAA SPECT/CT performed a week prior to radio-embolization. Within 24 hours after treatment, 90 Y TOF PET/CT imaging was performed. A follow-up 18 F-FDG PET/CT was performed 1 month after the treatment to evaluate the response to radio-embolization. For each patient, 3D voxelized dose-maps were obtained from the post-treatment 90 Y TOF PET/CT. A volume of interest (VOI) was drawn for each selected hepatic lesion using the baseline 18 F-FDG PET/CT. To obtain dose-volume histogram (DVH) for each lesion, image co-registration and VOI masks were generated using the PMOD 3.4 software and then exported in Matlab for dose calculation. Furthermore, the average absorbed dose in lesions was corrected for PVE effects by multiplication for appropriate (phantom-based) recovery coefficients according to the lesion size. Early metabolic lesion response was assessed in terms of variation in the maximum standard uptake value (ΔSUVmax) between baseline and follow-up 18 F-FDG PET/CT. The average absorbed dose for each lesion was associated with the respective metabolic response. Results: for the 12 selected lesions, the average volume was 35 cm 3

  3. Using Cherenkov Counting For Fast Determination of 90Sr/90Y Activity in Milk

    International Nuclear Information System (INIS)

    Tsroya, S.; Dolgin, B.; German, U.; Pelled, O.; Alfassi, Z. B.

    2014-01-01

    90Sr is one of the main long-lived fission products, and it is transferred into human body primarily by food, with milk being a substantial contributor. Due to its biochemical similarity to calcium, most strontium is efficiently incorporated into bone tissues. 90Sr is characterized by a long physical half life (28.8 y) and decays by beta particles with an Emax of 0.546 MeV to 90Y. This daughter isotope has a half life of 64 h and decays into 90Zr by beta particles with an Emax of 2.284 MeV. The milk components produce a high turbidity and light attenuation, causing a significant decrease of the counting efficiency in liquid scintillation counting (LSC) systems, mostly used for beta emitters detection. Most methods proposed in the past are time-consuming, as they are based on several stages of chemical and physical treatments, including precipitation, ashing, ion exchange and extraction (Wikins et al., 1984, Porter et al, 1961, Kimura et al., 1979). When measuring 90Sr/90Y activity by Cherenkov counting, most of the Cherenkov radiation is produced by 90Y (about 98.6%), due to the much higher energy of its beta particles relative to these from 90Sr. The counting efficiency varies strongly with color quenching, at a greater extent than in standard liquid scintillation counting (L'Annunziata, 2012), and therefore the quench correction is critical. The ‘‘external source area ratio’’ (ESAR) quench correction method was applied to measure 90Sr/90Y activities in aqueous samples with a wide range of quenching levels (Tsroya et al., 2009). This method was proved to be superior to all other quench correction methods (Tsroya et al., 2012) and is applicable also for determination of 90Sr/90Y in human urine (Tsroya et al., 2013). In the present work the applicability of the ESAR method to measurement of 90Sr/90Y activities in milk and some of its products was investigated

  4. Separation and Species Characterization of Complex Compound of Yttrium-90 and Strontium-90 by Paper Electrophoresis

    International Nuclear Information System (INIS)

    Sulaiman; Adang Hardi G; Noor Anis Kundari

    2007-01-01

    The research for species characterization of 90 Y and 90 Sr complex compound have been conducted using variation of buffer, concentration of HCl, electrophoresis operation voltage, time of electrophoresis, and electrophoresis migration media. From many trials, the conclusions are the applicable buffer are tartrate buffer and citrate buffer. These buffers can make a complex compound of 90 Y and there is migration to the anode. But, 90 Sr can’t make any complex compound and migration to the cathode. The optimum concentration of hydrochloride acid is 8 M with tartrate buffer but for citrate buffer, the concentration HCl is 2 M. The hydrochloric acid is used to dissolved the both elements as the mentioned above, but also for making complex ligand. The optimum electrophoresis operation voltage is 200 Volt for the both buffer solution and the duration of electrophoresis operation is 2.5 hours with using tartrate buffer but for citrate buffer the duration is 2 hours. The media of migration which can be used for replacing paper is silica. (author)

  5. Comparative analysis of hepatopulmonary shunt obtained from pretherapy 99mTc MAA scintigraphy and post-therapy 90Y Bremsstrahlung imaging in 90Y microsphere therapy.

    Science.gov (United States)

    Jha, Ashish Kumar A; Zade, Anand A; Rangarajan, Venkatesh; Purandare, Nilendu; Shah, Sneha A; Agrawal, Archi; Kulkarni, Suyash S; Shetty, Nitin

    2012-05-01

    (99m)Tc macroaggregate albumin (MAA) scintigraphy is routinely used to estimate the hepatopulmonary shunt (HPS) of (90)Y microspheres because of their comparable average particle sizes (20-30 µm). However, the MAA particle size can vary from 10 to 90 µm. Therefore, HPS computed from (99m)Tc MAA scintigraphy may not accurately represent the HPS of (90)Y microspheres. In view of this, the present study was undertaken to investigate the accuracy of (99m)Tc MAA scintigraphy in estimating the HPS of (90)Y microspheres. Nineteen sessions of transarterial radioembolization using (90)Y therasphere were carried out in 17 patients for hepatic malignancies (both primary and secondary). For each session of therapy, a pretherapeutic (99m)Tc MAA scintigraphy and post-therapeutic (90)Y Bremsstrahlung scintigraphy were performed. The HPSs obtained from these images were compared. The mean HPS fractions calculated from the pretherapeutic (99m)Tc MAA study and the post-therapeutic (90)Y Bremsstrahlung images were 4.77 ± 2.81 and 4.52 ± 2.5%, respectively. The coefficient of correlation (r) was 0.96. (99m)Tc MAA scintigraphy accurately predicts the HPS of (90)Y microspheres.

  6. 90Y of high purity for medical applications

    International Nuclear Information System (INIS)

    Castillo, A.X.; Alvarez, E.O.; Olive, K.I.

    2001-01-01

    Several 90 Sr/ 90 Y-generator systems have been developed and used to produce 90 Y. The most important parameter of the 90 Y to be assayed is 90 Sr content. In addition, when labelling monoclonal antibodies for therapy trace metal quantities accompanying 90 Y (Fe 3+ , Zn 2+ , Cu 2+ , ZrO 2+ , etc.) are to be kept as low as possible in order to obtain high labelling efficiencies. Generally generators' lifetime is limited due to the 90 Sr breakthrough which increases in eluates as a result of the radiolytic degradation of the resin used as support. In the study a described procedure for 90 Y purification from metal contamination is modified in order to lower the amount of 90 Sr present in eluates from generators. As a result a very low 90 Sr content is always assured ( 90 Sr/ 90 Y -6 ). (author)

  7. A special mini-extrapolation chamber for calibration of 90Sr+90Y sources

    International Nuclear Information System (INIS)

    Oliveira, Mercia L; Caldas, Linda V E

    2005-01-01

    90 Sr+ 90 Y applicators are commonly utilized in brachytherapy, including ophthalmic procedures. The recommended instruments for the calibration of these applicators are extrapolation chambers, which are ionization chambers that allow the variation of their sensitive volume. Using the extrapolation method, the absorbed dose rate at the applicator surface can be determined. The aim of the present work was to develop a mini-extrapolation chamber for the calibration of 90 Sr+ 90 Y beta ray applicators. The developed mini-chamber has a 3.0 cm outer diameter and is 11.3 cm in length. An aluminized polyester foil is used as the entrance window while the collecting electrode is made of graphited polymethylmethacrylate. This mini-chamber was tested in 90 Sr+ 90 Y radiation beams from a beta particle check source and with a plane ophthalmic applicator, showing adequate results

  8. Spectrographic determination of strontium in yttrium-90 solutions; Determinacion espectrografica de estroncio en soluciones de itrio-90

    Energy Technology Data Exchange (ETDEWEB)

    Roca, M; Capdevila, C

    1970-07-01

    The copper spark method has been used for determining strontium in the concentration range 1-100 g/ml in yttrium-90 solutions containing 0,5 % or thereabouts of ammonium citrate. The influence of the citric acid as well as the ammonium citrate with regard to 2N HCL solutions has been studied: the citric acid enhances the line intensities of strontium. The employment of either barium or lanthanum as reference element compensates for this enhancement. Because of the increase in sensitivity mentioned above, the study of influence of the citric acid has been extended and several impurities usually determined in radioisotope solutions have been considered. (Author) 4 refs.

  9. Pharmacokinetics of chimeric L6 conjugated to indium-111- and yttrium-90-DOTA-peptide in tumor-bearing mice

    International Nuclear Information System (INIS)

    DeNardo, S.J.; Zhong, G.R.; Salako, Q.

    1995-01-01

    A bifunctional chelating agent, DOTA-Gly 3 -L-(p-isothiocyanato)-phenylalanine amide (DOTA-peptide-NCS), was studied in nude mice bearing human breast cancer xenografts (HBT 3477) to determine its potential for radioimmunoconjugate therapy. Indium-111 and yttrium-90 were attached to an anti-adenocarcinoma chimeric L6 (ChL6) monoclonal antibody (MAb) after pre-chelation to the DOTA-peptide-NCS and the desired neutral radiochelates were obtained by purification. The unique characteristic of the DOTA-peptide-NCS to form neutral complexes with trivalent metals was utilized to separate the resulting 111 In and 90 Y radiochelates from excess chelating agent and other anionic by-products resulting from metal impurities. The purified radiochelates were then conjugated to ChL6. The paramacokinetics of 111 In- and 90 Y-DOTA-peptide-ChL6 were obtained for 5 days after injection in nude mice bearing HBT 3477 xenographs. The results were compared with the pharmacokinetics of 125 I-ChL6 obtained in the same mouse model. The whole-body clearance of 125 I-ChL6, 90 Y-and 111 In-DOTA-peptide-ChL6 was monoexponential with biologic half-times of 92, 104 and 160 hr, respectively. Blood clearances of the three radiopharmaceuticals were biphasic. The radiometal immunoconjugates had greater tumor uptake and slower clearances. Indium-111- and 90 Y-DOTA-peptide-ChL6 can be produced at high specific activity with fewer than one chelate per MAb by using a pre-labeling method that permits radiochelate purification by charge selection. Studies in mouse xenografts indicate that tumor uptake in enhanced and a favorable therapeutic index is achieved using these agents. 29 refs., 7 figs., 2 tabs

  10. Dosage of strontium 90 in human bone ashes; Dosage du strontium 90 sans les cendres d'os humain

    Energy Technology Data Exchange (ETDEWEB)

    Patti, F; Jeanmaire, L [Commissariat a l' Energie Atomique, Fontenay-aux-Roses (France). Centre d' Etudes Nucleaires

    1964-07-01

    The determination of {sup 90}Sr in bones by dosage of its daughter product {sup 90}Y is a 4-step process: 1) elimination of the phosphate ions by precipitation of the Ca and Sr as oxalate in the presence of acid; 2) reduction in the calcium concentration to a suitable level by the addition of a known volume of nitric acid (a single precipitation is sufficient), the precipitation yield of the strontium nitrate is checked by the measurement of the amount of {sup 85}Sr added as tracer; 3) purification by a yttrium hydroxide precipitation; 4) extraction at equilibrium of the {sup 90}Y which is counted to give the concentration. By using 50 gm of ash it is possible to detect about 0.1 pCi of {sup 90}Sr per gram of calcium. The advantages of this technique: -) treatment of a large quantity of bone ash -) the use of a small volume of nitric acid (less than 2 ml/g of ash, and -) the various operations present no difficulty. (authors) [French] Determination du Sr dans les os par dosage de son produit de filiation {sup 90}Y. Principe du dosage: 1 - Eliminer les ions phosphates par precipitation du calcium et du strontium sous forme d'oxalate en milieu acide. 2 - Reduire la concentration en calcium a un niveau convenable par addition d'un volume determine d'acide nitrique (une seule precipitation est necessaire). Le rendement de precipitation du nitrate de strontium est controle par la mesure de {sup 85}Sr ajoute comme traceur. 3 - Purifier par une precipitation d'hydroxyde d'yttrium. 4 - Extraire a l'equilibre l'{sup 90}Y qui eat compte pour determiner le {sup 90}Sr. En traitant 50 g de cendre, il est possible de deceler de l'ordre de 0,1 pCi de {sup 90}Sr par gramme de calcium. Les 3 avantages de cette technique: 1 - traitement d'une quantite importante de cendres d'os, 2 - emploi d'un faible volume d'acide nitrique (moins de 2 ml/g de cendres), et 3 - les diverses operations ne presentent aucune difficulte.

  11. Optimization of the personnel radiation protection during the treatment by antibodies labelled by yttrium 90

    International Nuclear Information System (INIS)

    Legrand, J.; Prangere, T.; Cougnenc, O.; Leleu, C.; Huglo, D.; Morschhauser, F.

    2007-01-01

    Beyond the acquired experience limiting the exposure time, measures of adequate radiation protection allow to reduce the doses of surface received to extremities by the personnel participating to the preparation of treatments by antibodies labelled by yttrium 90. (N.C.)

  12. radio embolization of yttrium 90 glass microspheres in treatment of hepatocellular carcinoma

    International Nuclear Information System (INIS)

    El Fouly, A.H.A.

    2010-01-01

    Hepatocellular carcinoma (HCC) is a common cancer that typically occurs in the setting of cirrhosis and chronic hepatitis virus infections. HCC is considered currently as global problem; its incidence is expected to increase dramatically by the next few decades. More than 90 % of the accidentally diagnosed patients have non resectable tumor. Portal vein thrombosis, diffuse multifocal liver infiltration and large tumor burden are considered to be a great obstacle in front of the modern lines of treatment, even with Child A liver cirrhosis. Transarterial intrahepatic application of Yttrium-90 glass microspheres may allow effective local ablative treatment of patients with intrahepatic advanced hepatocellular carcinoma (HCC) with or without portal vein thrombosis. The aim of this open-label phase II study was to validate evidence on the safety and efficacy of this treatment in an European cohort of patients with locally advanced HCC such as (large tumor burden, multifocal distribution, portal vein thrombosis). And to assess the response rate according to different approved response assessment guidelines (WHO, RECIST and EASL). Patients and Methods Starting from November 2006 till March 2009, one hundred and eight advanced unresectable HCC patients with and without portal vein thrombosis were included in this prospective study. Yttrium-90 microspheres radiotherapy was performed in a lobar fashion through the right or left hepatic artery. In bilobar disease, right and left liver lobe were treated with 4-6 weeks intervals in between. Response rate was assessed according to different international response assessment criteria (WHO, RECIST and EASL) with sequential computed tomography scans till the last clinical visit or death. The safety of this technique was assessed according to the Common Toxicity Criteria version 3

  13. Dose distribution to spinal structures from intrathecally administered yttrium-90

    Science.gov (United States)

    Mardirossian, George; Hall, Michael; Montebello, Joseph; Stevens, Patrick

    2006-01-01

    Previous treatment of cerebrospinal fluid (CSF) malignancies by intrathecal administration of 131I-radiolabelled monoclonal antibodies has led to the assumption that more healthy tissue will be spared when a pure beta-emitter such as 90Y replaces 131I. The purpose of this study is to compare and quantitatively evaluate the dose distribution from 90Y to the CSF space and its surrounding spinal structures to 131I. A 3D digital phantom of a section of the T-spine was constructed from the visible human project series of images which included the spinal cord, central canal, subarachnoid space, pia mater, arachnoid, dura mater, vertebral bone marrow and intervertebral disc. Monte Carlo N-particle (MCNP4C) was used to model the 90Y and 131I radiation distribution. Images of the CSF compartment were convolved with the radiation distribution to determine the dose within the subarachnoid space and surrounding tissues. 90Y appears to be a suitable radionuclide in the treatment of central nervous system (CNS) malignancies when attached to mAb's and the dose distribution would be confined largely within the vertebral foramen. This choice may offer favourable dose improvement to the subarachnoid and surface of spinal cord over 131I in such an application.

  14. Embolisation of the Gastroduodenal Artery is Not Necessary in the Presence of Reversed Flow Before Yttrium-90 Radioembolisation

    Energy Technology Data Exchange (ETDEWEB)

    Daghir, Ahmed A., E-mail: ahmeddaghir@doctors.net.uk [Imperial College Healthcare NHS Trust, Department of Radiology (United Kingdom); Gungor, Hatice [Imperial College Healthcare NHS Trust, Department of Oncology (United Kingdom); Haydar, Ali A. [Barts and the London NHS Trust, Department of Radiology (United Kingdom); Wasan, Harpreet S. [Imperial College Healthcare NHS Trust, Department of Oncology (United Kingdom); Tait, Nicholas P. [Imperial College Healthcare NHS Trust, Department of Radiology (United Kingdom)

    2012-08-15

    Introduction: The gastroduodenal artery (GDA) is usually embolised to avoid nontarget dispersal before yttrium-90 (Y{sup 90}) radioembolisation to treat liver metastases. In a minority of patients, there is retrograde flow in the GDA. The purpose of this study was to determine if there is any increased risk from maintaining a patent GDA in patients with reversed flow. Materials and Methods: A retrospective review was performed of all patients undergoing Y{sup 90} radioembolisation at our institution. The incidence of toxicities arising from nontarget radioembolisation by way of the GDA (gastric/duodenal ulceration, gastric/duodenal bleeding, and pancreatitis) and death occurring within 2 months of treatment were compared between the reversed and the antegrade GDA groups. Results: Ninety-two patients underwent preliminary angiography. Reversed GDA flow was found on angiography in 14.1% of cases; the GDA was not embolised in these patients. The GDA was coiled in 55.7% of patients with antegrade GDA flow to prevent inadvertent dispersal of radioembolic material. There was no increased toxicity related to nontarget dispersal by way of the GDA, or increased early mortality, in patients with reversed GDA flow (P > 0.05). Conclusion: In patients with reversed GDA flow, maintenance of a patent GDA before administration of Y{sup 90} radioembolisation does not increase the risk of toxicity from nontarget dispersal. Therapeutic injection, with careful monitoring to identify early vascular stasis, may be safely performed beyond the origin of the patent GDA. A patent GDA with reversed flow provides forward drive for infused particles and may allow alternative access to the hepatic circulation.

  15. Study of radionuclide 90Sr-90Y on cell proliferation and apoptosis in benign prostatic hyperplasia

    International Nuclear Information System (INIS)

    Zhang Tong; Wei Wei; Zou Benjie; Liu Fang; Xu Zhishun

    2003-01-01

    Objective: To investigate the effect of 90 Sr- 90 Yon cell proliferation and apoptosis in benign prostatic hyperplasia. Methods: The apoptosis and expression of Ki-67 in benign prostatic hyperplasia (BPH) before and after irradiation 90 Sr- 90 Y were detected by transferase-mediated dUTP-biotin nick end labeling (TUNEL) method and immunohistochemical technique, respectively. Results: The proliferation index (PI) of BPH after 90 Sr- 90 Y irradiation was much lower than that before irradiation, but there was no significant change in apoptosis index (AI). Conclusion: Irradiation with 90 Sr- 90 Y could restrain cell proliferation of BPH, but could not induce apoptosis

  16. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer.

    Science.gov (United States)

    Milowsky, Matthew I; Nanus, David M; Kostakoglu, Lale; Vallabhajosula, Shankar; Goldsmith, Stanley J; Bander, Neil H

    2004-07-01

    To determine the maximum-tolerated dose (MTD), toxicity, human antihuman antibody (HAHA) response, pharmacokinetics, organ dosimetry, targeting, and preliminary efficacy of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 ((90)Y-J591) in patients with androgen-independent prostate cancer (PC). Patients with androgen-independent PC and evidence of disease progression received indium-111-J591 for pharmacokinetic and biodistribution determinations followed 1 week later by (90)Y-J591 at five dose levels: 5, 10, 15, 17.5, and 20 mCi/m(2). Patients were eligible for up to three re-treatments if platelet and neutrophil recovery was satisfactory. Twenty-nine patients with androgen-independent PC received (90)Y-J591, four of whom were re-treated. Dose limiting toxicity (DLT) was seen at 20 mCi/m(2), with two patients experiencing thrombocytopenia with non-life-threatening bleeding episodes requiring platelet transfusions. The 17.5-mCi/m(2) dose level was determined to be the MTD. No re-treated patients experienced DLT. Nonhematologic toxicity was not dose limiting. Targeting of known sites of bone and soft tissue metastases was seen in the majority of patients. No HAHA response was seen. Antitumor activity was seen, with two patients experiencing 85% and 70% declines in prostate-specific antigen (PSA) levels lasting 8 and 8.6 months, respectively, before returning to baseline. Both patients had objective measurable disease responses. An additional six patients (21%) experienced PSA stabilization. The recommended dose for (90)Y-J591 is 17.5 mCi/m(2). Acceptable toxicity, excellent targeting of known sites of PC metastases, and biologic activity in patients with androgen-independent PC warrant further investigation of (90)Y-J591 in the treatment of patients with PC.

  17. Utilization of a novel electrochemical {sup 90}Sr/{sup 90}Y generator for the preparation of {sup 90}Y-labeled RGD peptide dimer in clinically relevant dose

    Energy Technology Data Exchange (ETDEWEB)

    Chakraborty, Sudipta; Chakravarty, Rubel; Pillai, Maroor Raghavan Ambikalmajan; Dash, Ashutosh [Bhabha Atomic Research Centre, Mumbai (India). Radiopharmaceuticals Div.; Sarma, Haladhar Dev [Bhabha Atomic Research Centre, Mumbai (India). Radiation Biology and Health Sciences Div.

    2014-09-01

    The work reported in this paper provides a systematic study towards the development of an optimized strategy for preparation of a clinically relevant dose of {sup 90}Y-labeled dimeric RGD peptide derivative, DOTA-E[c(RGDfK)]{sub 2} [DOTA-(RGD){sub 2}] for in vivo targeted therapy utilizing {sup 90}Y obtained from a novel electrochemical {sup 90}Sr/{sup 90}Y generator. The performance of the generator was evaluated to ensure its suitability for providing {sup 90}Y in adequate quantity and purity required for formulation of clinically relevant dose for PRRT. {sup 90}Y-DOTA-(RGD){sub 2} was synthesized in high yield (86.2 ± 2.5%) and radiochemical purity (98.4 ± 0.5%) using clinically relevant dose (∝ 3.8 GBq) of {sup 90}Y. In vitro stability studies revealed that the radiolabeled conjugate retained its radiochemical purity in normal saline and human serum. Preliminary biodistribution studies carried out in C57/BL6 mice bearing melanoma tumors showed that the preparation exhibited significant tumor uptake (5.30 ± 0.78% of injected activity at 30 min post-injection) with good tumor to background ratio. The optimized radiolabeling protocol seems to be an attractive strategy which is largely viewed as a springboard to realize scope of developing {sup 90}Y labeled cyclic RGD peptides for targeted therapy of tumors over-expressing integrin-α{sub ν}β{sub 3} receptors. (orig.)

  18. Simplified method of analysis of Strontium-90 in milk

    International Nuclear Information System (INIS)

    Suomela, J.

    1987-06-01

    The milk sample is freeze-dried and the milk powder ignited. The ash is dissolved in hydrochloric acid and yttrium is extracted from the solution by 5% HDEHP (dioctyl phosforic acid). After re-extraction in nitric acid the Cherenkov radiation of yttrium 90 is measured in a low beta liquid scintillation counter. (O.S.)

  19. A method for determination of Sr-90 Y-90 by using EDTA and ion-exchangers-Applications to the determination of those radioisotopes in milk

    International Nuclear Information System (INIS)

    Silva, C.M.; Lima, F.W. de.

    1987-05-01

    Amethod in which the complex of ethylenediaminetetraacetic acid (EDTA) with yttrium, used in conjunction with ion-exchangers for determination of Sr-90 is described. The method was to the determination of concentration of Sr-90 in milk, avoiding, in this way, protein elimination by acid precipitation or by evaporation of milk and ashing the residue. Analysis of samples of milk from various places in the state of Sao Pa ulo, Brazil, were carried out and the results are reported. Values found are much lower than maximum permissible concentration. (Author) [pt

  20. Labeling of monoclonal antibody conjugates with 90Y

    International Nuclear Information System (INIS)

    Motta-Hennessy, Cecilia; Sharkey, R.M.; Goldenberg, D.M.

    1991-01-01

    An anti-carcinoembryonic antigen (CEA) antibody, NP-4, was labeled with 90 Y using p-isothiocyanatobenzyl DTPA (SCN-Bz-DTPA) and its derivatives 1-(p-isothiocyanatobenzyl)-3-methyl-DTPA (1B3M), 2-(p-isothiocyanatobenzyl)-4-methyl-DTPA (1M3B), 1-(2)-methyl-4-isothiocyanatobenzyl-DTPA (MX-DTPA) as the chelating agents. The 90 Y conjugates were purified from unbound 90 Y by two different methods, HPLC or acrylamide size exclusion gel chromatography, in order to evaluate the best purification method. Labeling efficiency, reaction kinetics and immunoreactivity were compared to the same antibodies labeled with [ 111 In]citrate. Labeling efficiency, as determined by either HPLC or ITLC (instant thin layer chromatography), was consistently higher by ITLC than HPLC for 90 Y-labeled MAb, but equal for 111 In-labeled MAbs. Discrepancies between the 2 methods were linked to impurities in the 90 Y that remained at the origin of ITLC plates. After purification by acrylamide gel filtration, recovery was 50-60% of loaded 90 Y activity, but was more than 87% for the 111 In compounds. Using HPLC, the recovery measured 85% for 90 Y-labeled MAb and more than 93% for 111 In-labeled conjugates. Immunoreactivity of the [ 90 Y]MAb was comparable to the 111 In-labeled conjugates. These studies indicate that HPLC purification of the [ 90 Y] MAbs improves recovery of activity, and suggests that impurities found in the 90 Y and metal-binding properties of acrylamide may have contributed to the poor recoveries from acrylamide gels. (author)

  1. WE-AB-204-02: Molecular-Imaging Based Assessment of Liver Complications for Yttrium-90 Microsphere Treatments: Can Existing NTCP Models Explain Clinical Outcomes?

    Energy Technology Data Exchange (ETDEWEB)

    Lin, M; Choi, E; Chuong, M; Saboury, B; Moeslein, F; D’Souza, W; Guerrero, M [University of Maryland School of Medicine, Baltimore, MD (United States)

    2015-06-15

    Purpose: To evaluate weather the current radiobiological models can predict the normal liver complications of radioactive Yttrium-90 ({sup 90}Y) selective-internal-radiation-treatment (SIRT) for metastatic liver lesions based on the post-infusion {sup 90}Y PET images. Methods: A total of 20 patients with metastatic liver tumors treated with SIRT that received a post-infusion {sup 90}Y-PET/CT scan were analyzed in this work. The 3D activity distribution of the PET images was converted into a 3D dose distribution via a kernel convolution process. The physical dose distribution was converted into the equivalent dose (EQ2) delivered at 2 Gy based on the linear-quadratic (LQ) model considering the dose rate effect. The biological endpoint of this work was radiation-induce liver disease (RILD). The NTCPs were calculated with four different repair-times (T1/2-Liver-Repair= 0,0.5,1.0,2.0 hr) and three published NTCP models (Lyman-external-RT, Lyman 90Y-HCC-SIRT, parallel model) were compared to the incidence of RILD of the recruited patients to evaluate their ability of outcome prediction. Results: The mean normal liver physical dose (avg. 51.9 Gy, range 31.9–69.8 Gy) is higher than the suggested liver dose constraint for external beam treatment (∼30 Gy). However, none of the patients in our study developed RILD after the SIRT. The estimated probability of ‘no patient developing RILD’ obtained from the two Lyman models are 46.3% to 48.3% (T1/2-Liver-Repair= 0hr) and <1% for all other repair times. For the parallel model, the estimated probability is 97.3% (0hr), 51.7% (0.5hr), 2.0% (1.0hr) and <1% (2.0hr). Conclusion: Molecular-images providing the distribution of {sup 90}Y enable the dose-volume based dose/outcome analysis for SIRT. Current NTCP models fail to predict RILD complications in our patient population, unless a very short repair-time for the liver is assumed. The discrepancy between the Lyman {sup 90}Y-HCC-SIRT model predicted and the clinically

  2. Collimator and energy window optimization for 90Y bremsstrahlung SPECT imaging: A SIMIND Monte Carlo study

    International Nuclear Information System (INIS)

    Roshan, Hoda Rezaei; Mahmoudian, Babak; Gharepapagh, Esmaeil; Azarm, Ahmadreza; Pirayesh Islamian, Jalil

    2016-01-01

    Treatment efficacy of radioembolization using Yttrium-90 ( 90 Y) microspheres is assessed by the 90 Y bremsstrahlung single photon emission computed tomography (SPECT) imaging following radioembolization. The radioisotopic image has the potential of providing reliable activity map of 90 Y microspheres distribution. One of the main reasons of the poor image quality in 90 Y bremsstrahlung SPECT imaging is the continuous and broad energy spectrum of the related bremsstrahlung photons. Furthermore, collimator geometry plays an impressive role in the spatial resolution, sensitivity and image contrast. Due to the relatively poor quality of the 90 Y bremsstrahlung SPECT images, we intend to optimize the medium-energy (ME) parallel-hole collimator and energy window. The Siemens e.cam gamma camera equipped with a ME collimator and a voxelized phantom was simulated by the SImulating Medical Imaging Nuclear Detectors (SIMIND) program. We used the SIMIND Monte Carlo program to generate the 90 Y bremsstrahlung SPECT projection of the digital Jaszczak phantom. The phantom consist of the six hot spheres ranging from 9.5 to 31.8 mm in diameter, which are used to evaluate the image contrast. In order to assess the effect of the energy window on the image contrast, three energy windows ranging from 60 to 160 KeV, 160 to 400 KeV, and 60 to 400 KeV were set on a 90 Y bremsstrahlung spectrum. As well, the effect of the hole diameter of a ME collimator on the image contrast and bremsstrahlung spectrum were investigated. For the fixed collimator and septa thickness values (3.28 cm and 1.14 mm, respectively), a hole diameter range (2.35–3.3 mm) was chosen based on the appropriate balance between the spatial resolution and sensitivity. The optimal energy window for 90 Y bremsstrahlung SPECT imaging was extended energy window from 60 to 400 KeV. Besides, The optimal value of the hole diameter of ME collimator was obtained 3.3 mm. Geometry of the ME parallel-hole collimator and energy

  3. Country report: Vietnam. Setting Up of a {sup 90}Sr/{sup 90}Y Generator System Based on Supported Liquid Membrane (SLM) Technique and Radiolabeling of Eluted {sup 90}Y with Biomolecules

    Energy Technology Data Exchange (ETDEWEB)

    Thu, Nguyen Thi; Dong, Duong Van; Cuong, Bui Van; Khoa, Chu Van [Vietnam Atomic Energy Commission (VAEC), Nuclear Research Institute, Dalat (Viet Nam)

    2010-07-01

    In the course of participating in the IAEA-CRP during the last two years, Vietnam has achieved the goal of setting up a {sup 90}Sr/{sup 90}Y generator system based on Supported Liquid Membrane (SLM) technique and also radiolabeling of the eluted {sup 90}Y with antibody, peptides and albumin. A two stage SLM based {sup 90}Sr-{sup 90}Y generator was set up in-house to generate carrier-free {sup 90}Y at different activity levels viz. 5, 20, 50 mCi. The generator system was operated in sequential mode in which 2-ethylhexyl 2-ethylhexyl phosphonic acid (PC88A) based SLM was used in the first stage for the transport {sup 90}Y in 4.0 M nitric acid from source phase where {sup 90}Sr-{sup 90}Y equilibrium mixture is placed in nitric acid medium at pH to 1-2. In the second stage, octyl (phenyl)-N,N-diisobutylcarbamoylmethyl phosphine oxide (CMPO) based SLM was used for the transport of {sup 90}Y selectively to 1.0 M acetic acid which is the best medium for radiolebeling. The eluted {sup 90}Y from the generator was tested for the presence of any traces of {sup 90}Sr using the Extraction Paper Chromatography (EPC) and was found suitable for radiolabeling. The generator system could be upgraded to 100 mCi level successfully due to an expert mission from India through IAEA. The {sup 90}Y product obtained from the generator system was used for radiolabeling of antibody and peptides viz. Rituximab, DOTATATE and albumin particles under different experimental conditions. A new chromatography system could be developed for analyzing {sup 90}Y labeled albumin using the TAE buffer as mobile phase in PC and ITLC.

  4. Long-Term Palliative Effect of Stenting in Gastric Outlet Obstruction Due to Transarterial Chemoembolization with Yttrium-90 in a Patient with Metastatic Neuroendocrine Tumor

    Directory of Open Access Journals (Sweden)

    Erkan Caglar

    2016-09-01

    Full Text Available Internal radioembolization with yttrium-90 is a promising treatment method, predominantly for liver tumors. However, the shifting of yttrium-90-loaded spherules into the arteries and veins that supply the duodenum and stomach, leading to ulceration, hemorrhage, perforation, and outlet obstruction of these organs, is one of the major undesirable consequences of this technique. We report a case of gastric outlet obstruction (GOO due to antropyloric stenosis with ulceration, edema, and inflammation following transarterial yttrium-90 treatment for a metastatic neuroendocrine tumor in a 58-year-old man. Stenting was used for palliation in this case. GOO improved after stenting and recovery of oral intake was permanent after stent removal.

  5. Patent hepatic falciform artery detected after Tc-99m-macroaggregated albumin injection on SPECT/CT prior to Yttrium-90 microsphere radioembolization: a case report

    International Nuclear Information System (INIS)

    Karaman, B.; Aslan, A.; Hamcan, S.; Ugurel, M.

    2012-01-01

    Full text: Introduction: Yttrium-90 (Y-90) microsphere radioembolization is increasingly used for the treatment of unresectable hepatocellular carcinoma and liver metastasis. Objectives and tasks: We aim to present the upper abdominal wall skin involvement detected during routine pre-therapy Technetium-99m-macroaggregated albumin (Tc-99m-MAA) on SPECT/CT due to patent hepatic falciform artery and the precautions to avoid this potential complication. Material and methods: 38-year-old male with colon cancer and multiple liver metastasis was evaluated prior to radioembolization and Tc-99 MAA was slowly hand injected at the bifurcation of the proper hepatic artery. Then, the SPECT/CT scan was performed in order to investigate the systemic shunt or gastric involvement. Results: On SPECT/CT scan, involvement of the upper abdominal wall through falciform ligament was seen. Re-evaluation of the hepatic angiogram identified a patent hepatic falciform artery arising from the left hepatic artery. Y-90 microspheres were slowly hand injected to the left hepatic artery superselectively and no extra-hepatic activity was seen on SPECT/CT scan. Conclusion: Upper abdominal pain and dermatitis are uncommon findings after radioembolization and may occur due to inadvertent delivery of Y-90 microspheres into patent hepatic falciform artery. To prevent these complications, either patent hepatic falciform artery must be embolized by coil or Y-90 injection must be performed superselectively

  6. Dosimetric comparison of electron beam and 90Sr+90Y applicator for keloids treatment

    International Nuclear Information System (INIS)

    Coelho, Talita S.; Tada, Ariane; Antonio, Patricia L.; Yoriyaz, Helio; Fernandes, Marco A.R.

    2009-01-01

    Studies have been shown that among several methods that have been used for the treatment of keloids the surgical excision followed by the adjuvant radiotherapy presents the lowest relapsed rate of the injury. In this work a comparative dosimetric study has been performed using a 4 MeV electron beam from a Varian Clinac 2100C linear accelerator at the radiotherapy service of the Hospital das Clinicas of UNESP-HC, Botucatu-SP and an Amershan 90 Sr+ 90 Y brachytherapy applicator with 1491 MBq of activity. Percentage depth dose curves from ionization chamber measurements and through Monte Carlo simulation have been obtained and compared. Dose measurements have been obtained using parallel plates ionization chamber (Esradin A12) and extrapolation mini-chamber developed at IPEN. The dose calculations have been obtained using the well-known Monte Carlo radiation transport code MCNP-4C. Maximum dose differences obtained between measured/calculated values for 90 Sr+ 90 Y applicator and for the electron beam were, respectively: 7.8 % and 8.0%. The profiles of the depth and superficial tissue dose distribution produced by the electron beam revealed themselves flatter and more homogeneous than those produced by the 90 Sr+ 90 Y applicator, especially to wider fields, which cannot be obtained with beta therapy applicators because of their geometric limitations. In conclusion this present work has shown that 90 Sr+ 90 Y applicators could be efficient for small and very superficial lesions but in most cases electron beam sources are more adequate especially for large and deeper lesions. (author)

  7. Radio-synoviorthesis with yttrium 90 in the knee-joint in rheumatoid arthritis

    International Nuclear Information System (INIS)

    Hagena, F.W.; Muenchen Univ.

    1982-01-01

    The radio-synoviorthesis with yttrium 90 in the knee-joint in rheumatoid arthritis was performed and controlled in 106 knees of patients with rheumatoid arthritis over a span of time between 6 and 49 months. The results are similar to those of other authors. As compared to synovectomy radio-synoviorthesis seems less successful as far as long-term results are concerned. As local treatment radio-synoviorthesis seems a good supplementory element in the therapeutic plan of rheumatoid arthritis. The indication to alternative procedures has been considered carefully for each individual case and joint. (orig.) [de

  8. Quantitative analysis of strontium 90 in the radioactive wastes by means of thenoyltrifluoroacetone; Dosage du strontium 90 dans les effluents radioactifs par le thenoyltrifluoroacetone

    Energy Technology Data Exchange (ETDEWEB)

    Testemale, G; Leredde, J L [Commissariat a l' Energie Atomique, Fontenay-aux-Roses (France). Centre d' Etudes Nucleaires

    1970-07-01

    A simple method of analysing the quantity of {sup 90}Sr has been perfected. It consists in a double extraction of it by means of thenoyltrifluoroacetone and tributylphosphate in tetrachloride of carbon followed by eliminating yttrium 90 by means of thenoyltrifluoroacetone in the benzene. Numberings on aliquot parts of wastes make the determination of that element possible. The yield is about 97 per cent. (authors) [French] Une technique simple du dosage du {sup 90}Sr a ete mise au point. Elle consiste en une double extraction par le thenoyltrifluoroacetone et le tributylphosphate dans le tetrachlorure de carbone, suivie de l'elimination de l'yttrium 90 par le thenoyltrifluoroacetone dans le benzene, Des comptages sur des parties aliquotes d'effluents permettent la dermination de cet element. Rendement environ 97 pour cent. (auteurs)

  9. Calibration of the 90Sr+90Y ophthalmic and dermatological applicators with an extrapolation ionization minichamber

    International Nuclear Information System (INIS)

    Antonio, Patrícia L.; Oliveira, Mércia L.; Caldas, Linda V.E.

    2014-01-01

    90 Sr+ 90 Y clinical applicators are used for brachytherapy in Brazilian clinics even though they are not manufactured anymore. Such sources must be calibrated periodically, and one of the calibration methods in use is ionometry with extrapolation ionization chambers. 90 Sr+ 90 Y clinical applicators were calibrated using an extrapolation minichamber developed at the Calibration Laboratory at IPEN. The obtained results agree satisfactorily with the data provided in calibration certificates of the sources. - Highlights: • 90 Sr+ 90 Y clinical applicators were calibrated using a mini-extrapolation chamber. • An extrapolation curve was obtained for each applicator during its calibration. • The results were compared with those provided by the calibration certificates. • All results of the dermatological applicators presented lower differences than 5%

  10. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers.

    Science.gov (United States)

    Imhof, Anna; Brunner, Philippe; Marincek, Nicolas; Briel, Matthias; Schindler, Christian; Rasch, Helmut; Mäcke, Helmut R; Rochlitz, Christoph; Müller-Brand, Jan; Walter, Martin A

    2011-06-10

    To investigate response, survival, and safety profile of the somatostatin-based radiopeptide (90)yttrium-labeled tetraazacyclododecane-tetraacetic acid modified Tyr-octreotide ([(90)Y-DOTA]-TOC) in neuroendocrine cancers. In a clinical phase II single-center open-label trial, patients with neuroendocrine cancers were treated with repeated cycles of [(90)Y-DOTA]-TOC. Each cycle consisted of a single intravenous injection of 3.7GBq/m(2) body-surface [(90)Y-DOTA]-TOC. Additional cycles were withheld in case of tumor progression and/or permanent toxicity. Overall, 1,109 patients received 2,472 cycles of [(90)Y-DOTA]-TOC (median, two; range, one to 10 cycles per patient). Of the 1,109 patients, 378 (34.1%) experienced morphologic response; 172 (15.5%), biochemical response; and 329 (29.7%), clinical response. During a median follow-up of 23 months, 491 patients (44.3%) died. Longer survival was correlated with each: morphologic (hazard ratio [HR], 0.46; 95% CI, 0.38 to 0.56; median survival, 44.7 v 18.3 months; P TOC treatment in a large cohort. Response to [(90)Y-DOTA]-TOC is associated with longer survival. Somatostatin receptor imaging is predictive for both survival after [(90)Y-DOTA]-TOC treatment and occurrence of renal toxicity.

  11. Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis.

    Science.gov (United States)

    Salem, Riad; Lewandowski, Robert; Roberts, Carol; Goin, James; Thurston, Kenneth; Abouljoud, Marwan; Courtney, Angi

    2004-04-01

    Intra-arterial injection of Yttrium-90 glass microspheres ((90)Y- microS; TheraSphere, MDS Nordion, Ottawa, Canada) is indicated for treatment of unresectable hepatocellular carcinoma (HCC) in the presence of acceptable liver function. This study presents hepatic toxicity results after unilobar and bilobar intra-arterial administration of (90)Y- microS in patients with unresectable HCC who had known portal vein thrombosis (PVT) without evidence of cavernous transformation. Fifteen patients with unresectable HCC and PVT of one or both first order and related segmental portal venous branches received a total of 29 infusions of (90)Y- microS for treatment of HCC. All patients had pretreatment evaluation including: computed tomography (CT) imaging, alpha-fetoprotein (AFP) levels, liver function tests, technetium-99m macroaggregated albumin ((99)Tc-MAA) scan for evaluation of lung and visceral shunting, and angiography with visualization into the portal venous phase. (90)Y- micro S dose was based on lobar hepatic volume with adjustment for lung shunt activity. Liver toxicity was assessed by serum total bilirubin graded for severity according to the NIH NCI Clinical Toxicity Criteria (CTC version 2.0). Other adverse events were reported according to the standards established by the Society of Interventional Radiology. There were no procedural complications with delivery of (90)Y- microS, and treatment was well tolerated by all patients. Increased post-treatment bilirubin levels were observed across all treatments in five patients, four of whom had CT or AFP evidence of intrahepatic disease progression. After initial treatment, two patients developed bilirubin toxicity (grades 1 and 2); one patient demonstrated an increment in bilirubin toxicity grade (grade 1 to grade 3) and one patient had an improvement in grade after initial treatment. There were no new treatment-related toxicities in nine patients after a second treatment. (90)Y- microS treatment was well tolerated

  12. Enrichment and determination of small amounts of 90Sr/90Y in water samples

    International Nuclear Information System (INIS)

    Mundschenk, H.

    1979-01-01

    Small amounts of 90 Sr/ 90 Y can be concentrated from large volumes of surface water (100 l) by precipitation of the phosphates, using bentonite as adsorber matrix. In the case of samples containing no or nearly no suspended matter (tap water, ground water, sea water), the daughter 90 Y can be extracted directly by using filter beds impregnated with HDEHP. The applicability of both techniques is demonstrated under realistic conditions. (orig.) 891 HP/orig. 892 MKO [de

  13. Y-90 microspheres in the treatment of unresectable hepatocellularcarcinoma

    International Nuclear Information System (INIS)

    Al-Kalbani, A.; Kamel, Y.

    2008-01-01

    A small percentage of patients with hepatocellular carcinoma (HCC) arecandidates for curative treatment in form of resection or transplantation.There are different treatment options for unresectable HCC-like localablative therapies and recently systemic therapy with Sorafenib. All of thesehave variable response rate and had been proven to improve survival. In thelast few years, there is a growing interest in TheraSphere radioembolization.It consists of yttrium (Y-90) embedded into nonbiodegradeable glassmicrospheres. It is selectively administered by intraarterial hepaticinjection giving high doses of radiation to the tumor and sparing the liverparenchyma. It has been shown to improve survival and used as a bridge totransplantation and to downstage tumors for resection. Therasphere seems tohave favorable safety profile and has been used in patients with portal veinthrombosis with successful outcome. (author)

  14. Thermoluminescent dosimetry of beta radiations of 90 Sr/ 90 Y using ZrO2: Eu

    International Nuclear Information System (INIS)

    Olvera T, L.; Azorin N, J.; Barrera S, M.; Soto E, A.M.; Rivera M, T.

    2005-01-01

    In this work the results of studying the thermoluminescent properties (TL) of the doped zirconium oxide with europium (ZrO 2 : Eu 3+ ) before beta radiations of 90 Sr/ 90 Y are presented. The powders of ZrO 2 : Eu 3+ were obtained by means of the sol-gel technique and they were characterized by means of thermal analysis and by X-ray diffraction. The powders of ZrO 2 : Eu 3+ , previously irradiated with beta particles of 90 Sr/ 90 Y, presented a thermoluminescent curve with two peaks at 204 and 292 C respectively. The TL response of the ZrO 2 : Eu 3+ as function of the absorbed dose was lineal from 2 Gy up to 90 Gy. The fading of the information of the ZrO 2 : Eu 3+ was of 10% the first 2 hours remaining almost constant the information by the following 30 days. The ZrO 2 doped with the (Eu 3+ ) ion it was found more sensitive to the beta radiation that the one of zirconium oxide without doping (ZrO 2 ) obtained by the same method. Those studied characteristics allow to propose to the doped zirconium oxide with europium like thermoluminescent dosemeter for the detection of the beta radiation. (Author)

  15. Solvent extraction method for rapid separation of strontium-90 in milk and food samples

    International Nuclear Information System (INIS)

    Hingorani, S.B.; Sathe, A.P.

    1991-01-01

    A solvent extraction method, using tributyl phosphate, for rapid separation of strontium-90 in milk and other food samples has been presented in this report in view of large number of samples recieved after Chernobyl accident for checking radioactive contamination. The earlier nitration method in use for the determination of 90 Sr through its daughter 90 Y takes over two weeks for analysis of a sample. While by this extraction method it takes only 4 to 5 hours for sample analysis. Complete estimation including initial counting can be done in a single day. The chemical recovery varies between 80-90% compared to nitration method which is 65-80%. The purity of the method has been established by following the decay of yttrium-90 separated. Some of the results obtained by adopting this chemical method for food analysis are included. The method is, thus, found to be rapid and convenient for accurate estimation of strontium-90 in milk and food samples. (author). 2 tabs., 1 fig

  16. Yttrium-90 Resin Microsphere Radioembolization Using an Antireflux Catheter: An Alternative to Traditional Coil Embolization for Nontarget Protection

    International Nuclear Information System (INIS)

    Morshedi, Maud M.; Bauman, Michael; Rose, Steven C.; Kikolski, Steven G.

    2015-01-01

    PurposeSerious complications can result from nontarget embolization during yttrium-90 (Y-90) transarterial radioembolization. Hepatoenteric artery coil embolization has been traditionally performed to prevent nontarget radioembolization. The U.S. Food and Drug Administration–approved Surefire Infusion System (SIS) catheter, designed to prevent reflux, is an alternative to coils. The hypothesis that quantifiable SIS procedural parameters are comparable to coil embolization was tested.MethodsFourteen patients aged 36–79 years with colorectal, neuroendocrine, hepatocellular, and other predominantly bilobar hepatic tumors who underwent resin microsphere Y-90 radioembolization using only the SIS catheter (n = 7) versus only detachable coils (n = 7) for nontarget protection were reviewed retrospectively. Procedure time, fluoroscopy time, contrast dose, radiation dose, and cost were evaluated.ResultsMultivariate analysis identified significant cohort differences in the procedural parameters evaluated (F(10, 3) = 10.39, p = 0.04). Between-group comparisons of the pretreatment planning procedure in the SIS catheter group compared to the coil embolization group demonstrated a significant reduction in procedure time (102.6 vs. 192.1 min, respectively, p = 0.0004), fluoroscopy time (14.3 vs. 49.7 min, respectively, p = 0.0016), and contrast material dose (mean dose of 174.3 vs. 265.0 mL, respectively, p = 0.0098). Procedural parameters were not significantly different between the two groups during subsequent dose delivery procedures. Overall cost of combined first-time radioembolization procedures was significantly less in the SIS group ($4252) compared to retrievable coil embolization ($11,123; p = 0.001).ConclusionThe SIS catheter results in a reduction in procedure time, fluoroscopy time, and contrast material dose and may be an attractive cost-effective alternative to detachable coil embolization for prevention of nontarget radioembolization

  17. Yttrium-90 Resin Microsphere Radioembolization Using an Antireflux Catheter: An Alternative to Traditional Coil Embolization for Nontarget Protection

    Energy Technology Data Exchange (ETDEWEB)

    Morshedi, Maud M., E-mail: maud.morshedi@my.rfums.org; Bauman, Michael, E-mail: mbauman@ucsd.edu; Rose, Steven C., E-mail: scrose@ucsd.edu; Kikolski, Steven G., E-mail: skikolski@gmail.com [University of California San Diego Health Sciences, Radiology Department, University of California San Diego Medical Center (United States)

    2015-04-15

    PurposeSerious complications can result from nontarget embolization during yttrium-90 (Y-90) transarterial radioembolization. Hepatoenteric artery coil embolization has been traditionally performed to prevent nontarget radioembolization. The U.S. Food and Drug Administration–approved Surefire Infusion System (SIS) catheter, designed to prevent reflux, is an alternative to coils. The hypothesis that quantifiable SIS procedural parameters are comparable to coil embolization was tested.MethodsFourteen patients aged 36–79 years with colorectal, neuroendocrine, hepatocellular, and other predominantly bilobar hepatic tumors who underwent resin microsphere Y-90 radioembolization using only the SIS catheter (n = 7) versus only detachable coils (n = 7) for nontarget protection were reviewed retrospectively. Procedure time, fluoroscopy time, contrast dose, radiation dose, and cost were evaluated.ResultsMultivariate analysis identified significant cohort differences in the procedural parameters evaluated (F(10, 3) = 10.39, p = 0.04). Between-group comparisons of the pretreatment planning procedure in the SIS catheter group compared to the coil embolization group demonstrated a significant reduction in procedure time (102.6 vs. 192.1 min, respectively, p = 0.0004), fluoroscopy time (14.3 vs. 49.7 min, respectively, p = 0.0016), and contrast material dose (mean dose of 174.3 vs. 265.0 mL, respectively, p = 0.0098). Procedural parameters were not significantly different between the two groups during subsequent dose delivery procedures. Overall cost of combined first-time radioembolization procedures was significantly less in the SIS group ($4252) compared to retrievable coil embolization ($11,123; p = 0.001).ConclusionThe SIS catheter results in a reduction in procedure time, fluoroscopy time, and contrast material dose and may be an attractive cost-effective alternative to detachable coil embolization for prevention of nontarget radioembolization.

  18. The effect of 90Sr/90Y β-rays on benign prostatic hyperplasia

    International Nuclear Information System (INIS)

    Kong Xiangbo; Ma Qingjie; Gu Xinquan

    2004-01-01

    Objective: To investigate the effect of 90Sr/90Y β-rays on Benign prostatic hyperplasia (BPH). Methods: In order to carry out β intracavitary irradiation, the active area of the applicator was located into prostate gland section of urethra in 37 patients. The dose was controlled 30∼50Gy in each patient and the patients were observed for 3 months. Results: After two weeks 26 cases were remarkably improved, 7 cases were improved and 4 cases were ineffective. There was significant difference on MFR, PVR, I-PSS and volume of prostate gland before and after treatment (P<0.01=. Conclusion: Clinical tests indicate that the 90Sr/90Y prostatic hyperplasia applicators provide a safe, effective ,non-invasive and economical therapeutic method for BPH. It is especially applicable for old and high-risk patients. (authors)

  19. Embolization of Hepatic Arterial Branches to Simplify Hepatic Blood Flow Before Yttrium 90 Radioembolization: A Useful Technique in the Presence of Challenging Anatomy

    International Nuclear Information System (INIS)

    Karunanithy, Narayan; Gordon, Fabiana; Hodolic, Marina; Al-Nahhas, Adil; Wasan, Harpreet S.; Habib, Nagy; Tait, Nicholas P.

    2011-01-01

    Purpose: In the presence of variant hepatic arterial anatomy, obtaining whole-liver coverage with yttrium 90 (Y90) radioembolization may be challenging. The purpose of this study was to determine whether a technique whereby variant hepatic arterial branches are embolized and then Y90 is administered selectively into one remaining hepatic arterial branch results in whole-liver coverage and effective therapy. A retrospective comparison of treatment response was made between a group of patients who underwent this technique before Y90 administration and a group of patients who received standard Y90 administration as a single dose into the proper hepatic artery or in divided doses into the immediate hepatic artery branches. The rest of the workup and treatment were identical in both groups, including routine embolization of potential nonhepatic, nontarget vessels (e.g., the gastroduodenal artery). Methods: A total of 32 patients (mean age 56.9 years, range 39–77 years) treated with Y90 between June 2004 and March 2008 were analyzed. The primary malignancy was colorectal in 29, breast in 2, and cholangiocarcinoma in 1. Group 1 comprised 20 patients who had no alterations to their hepatic arterial supply. Group 2 comprised 12 cases who had undergone prior embolization of hepatic arterial branches before administration of Y90. The response to treatment was assessed by comparing standardized uptake value (SUV) on the pre- and postprocedure fludeoxyglucose positron emission tomographic studies of representative lesions within the right and left lobes of the liver. Results: In group 1, significant response (P < 0.001) was seen among right lobe lesions but not among left lobe lesions (P = 0.549). In group 2, there was a significant response among both right (P = 0.028) and left (P = 0.014) lobe lesions. No difference was found in the response of right lobe lesions (P = 0.726) between groups 1 and 2; a significantly greater response was found in group 2 compared to group 1 (P

  20. Half-life evaluations for 3H, 90Sr, and 90Y

    International Nuclear Information System (INIS)

    MacMahon, Desmond

    2006-01-01

    A recent paper has reviewed methods for the evaluation of discrepant sets of data and demonstrated the results of applying these methods to the published half-life data of 90 Sr and 137 Cs [MacMahon, T.D., Pearce, A., Harris, P., 2004. Convergence of techniques for the evaluation of discrepant data. Appl. Radiat. Isot. 60, 275-281]. The half-life data for 3 H has been subject to a comprehensive review and critical evaluation by Lucas and Unterweger [2000. Comprehensive review and critical evaluation of the half-life of tritium. J. Res. Natl. Inst. Stand. Technol. 105, 541-549]. The current paper reports the results of applying the various evaluation procedures of MacMahon et al. Convergence of techniques for the evaluation of discrepant data. Appl. Radiat. Isot. 60, 275-281] to the data of Lucas and Unterweger [Comprehensive review and critical evaluation of the half-life of tritium. J. Res. Natl. Inst. Stand. Technol. 105, 541-549], resulting in a recommended half-life of 4497(4) days. MacMahon et al. [Convergence of techniques for the evaluation of discrepant data. Appl. Radiat. Isot. 60, 275-281] highlighted problems in the evaluation of the discrepant half-life data of 90 Sr, in particular the worrying upward trend in the data, where the weighted mean of all the measurements increases, on average, by 35 days each time a new measurement result is added. The current paper reports on further analyses of these data. New measurements of the half-life of 90 Y have been reported by Kossert and Schrader [2004. Standardization by liquid scintillation counting and half-life measurements of 90 Y. Appl. Radiat. Isot. 60, 741]. This has prompted a new evaluation of all available published 90 Y half-life data. The data are fairly consistent, and a value of 64.063(16) h is recommended

  1. Labeling of monoclonal antibody conjugates with sup 90 Y

    Energy Technology Data Exchange (ETDEWEB)

    Motta-Hennessy, Cecilia; Sharkey, R.M.; Goldenberg, D.M. (Center for Molecular Medicine and Immunology, Newark, NJ (USA))

    1991-01-01

    An anti-carcinoembryonic antigen (CEA) antibody, NP-4, was labeled with {sup 90}Y using p-isothiocyanatobenzyl DTPA (SCN-Bz-DTPA) and its derivatives 1-(p-isothiocyanatobenzyl)-3-methyl-DTPA (1B3M), 2-(p-isothiocyanatobenzyl)-4-methyl-DTPA (1M3B), 1-(2)-methyl-4-isothiocyanatobenzyl-DTPA (MX-DTPA) as the chelating agents. The {sup 90}Y conjugates were purified from unbound {sup 90}Y by two different methods, HPLC or acrylamide size exclusion gel chromatography, in order to evaluate the best purification method. Labeling efficiency, reaction kinetics and immunoreactivity were compared to the same antibodies labeled with ({sup 111}In)citrate. Labeling efficiency, as determined by either HPLC or ITLC (instant thin layer chromatography), was consistently higher by ITLC than HPLC for {sup 90}Y-labeled MAb, but equal for {sup 111}In-labeled MAbs. Discrepancies between the 2 methods were linked to impurities in the {sup 90}Y that remained at the origin of ITLC plates. After purification by acrylamide gel filtration, recovery was 50-60% of loaded {sup 90}Y activity, but was more than 87% for the {sup 111}In compounds. Using HPLC, the recovery measured 85% for {sup 90}Y-labeled MAb and more than 93% for {sup 111}In-labeled conjugates. Immunoreactivity of the ({sup 90}Y)MAb was comparable to the {sup 111}In-labeled conjugates. These studies indicate that HPLC purification of the ({sup 90}Y) MAbs improves recovery of activity, and suggests that impurities found in the {sup 90}Y and metal-binding properties of acrylamide may have contributed to the poor recoveries from acrylamide gels. (author).

  2. Therapeutic result of radioactive nuclide 90Sr/90Y treatment in patients with benign prostatic hypertrophy (BPH)

    International Nuclear Information System (INIS)

    Chen Hanchao; Li Yuying

    2008-01-01

    Objective: To study the effect of radioactive nuclide 90 Sr/ 90 Y treatment in patients with benign prostatic hypertrophy (BPH). Methods: Sixty patients with BPH were treated with a course of transurethral radioactive nuclide 90 Sr/ 90 Y therapy. Results: The severity of BPH was assessed with four parameters: maximal flow rate (MFR), volume of residual urine (VRU), international prostatic symptom score (IPSS) and volume (size) of prostate. In this series, the total effective rate was 93.33% with no treatment- related mortality. Favorable changes of the parameters after a course of radioactive nuclide therapy were significant. Conclusion: Radioactive nuclide 90 Sr/ 90 Y therapy for patients with BPH was safe, easily performed and quite effective. This procedure is worth popularizing in appropriate patients. (authors)

  3. Development of a dosimetric system for 90Sr + 90Y betatherapy applicators

    International Nuclear Information System (INIS)

    Coelho, Talita Salles

    2010-01-01

    The 90 Sr+ 90 Y applicators, used in betatherapy for prevention of keloids and pterigium, are imported and many times their dosimetric features are shown only in an illustrated form by the manufacturers. The exhaustive routine of the medical physicists in the clinic do not make possible the accomplishment of procedures for the confirmation of these parameters. This work presents the development of a methodology for the dosimetry of 90 Sr+ 90 Y betatherapy applicators. The Monte Carlo code MCNP5 was used for the simulation of the percentage depth dose curves and dose distribution profiles produced by these applicators. The experimental measurements of the radial and axial radiation attenuation, have been done with a mini-extrapolation chamber, thermoluminescent dosimeters and radiographic films. The experimental results have been compared with the simulated values. Both percentage depth dose curves and the radial dose profiles, the theoretical and the experimental ones, have presented good agreement, which may validate the use of the MCNP5 for these simulations, confirming the viability of the usage of this method in procedures of beta emitter sources dosimetry. (author)

  4. Development of Technology for the Preparation of 90Sr/90Y Generators at the Radiopharmacy Directory of IPEN/CNEN-SP

    International Nuclear Information System (INIS)

    Barrio, Graciela

    2010-01-01

    90 Y (T /2 = 2,67 d; Eβmax = 2,28 MeV) is a radionuclide with efficacy established for various cancer therapies, labeling biomolecules and treating of radiosinovectomy. Due to its nuclear properties, is obtained through the decay of 90 Sr T /2 = 28 y in the form of a generator. Several types of 90 Sr/ 90 Y generators were developed, and the most employed are the cation exchange resins, where Sr and Y are adsorbed and 90 Y is selectively eluted with acetate or EDTA. The disadvantage of this type of generator is the radiolysis, which degrades its use. The electrochemical generator is a proposed solution because there is no significant effect of radiation. In this concept, the difference between the electrochemical potentials of the elements Sr and Y is used to obtain a rapid separation of 90 Y from 90 Sr. The production of 90 Y via colloid formation is the simplest method for the separation, based on the colloid formation of Y in high alkaline pH, which can be filtered and separated from Sr, and subsequently dissolved in HCl. The objective of this work was the development of technologies for the preparation of 90 Sr/ 90 Y generators, and three technologies were developed: generators using cation resins columns, generators through colloid formation and electrochemical generators. Radionuclidic quality control of 90 Y was also evaluated by liquid scintillation, radionuclide identity, extraction paper chromatography (EPC) using complexing agents for 90 Y and by Optical Emission Spectrometry with Inductively Coupled Plasma (ICP-OES). The results showed that generators using cation resins have the best results related to the elution efficiency (∼83%), the reproducibility and radionuclidic purity. The electrochemical generator showed a potential for development, having the advantage of not suffering the effects of radiolysis of the pair 90 Sr/ 90 Y as the resin. A comparison and evaluation of the methods of the radionuclidic quality control showed that the EPC is very

  5. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.

    Science.gov (United States)

    Virgolini, I; Traub, T; Novotny, C; Leimer, M; Füger, B; Li, S R; Patri, P; Pangerl, T; Angelberger, P; Raderer, M; Burggasser, G; Andreae, F; Kurtaran, A; Dudczak, R

    2002-01-01

    lung cancer ((99m)Tc-depreotide), indicating high diagnostic cabability of this type of receptor tracers. Consequently to their use as receptor imaging agents, hSSTR recognizing radioligands have also been implemented for experimental receptor-targeted radionuclide therapy. Beneficial results were reported for high-dose treatment with (111)In-DTPA-DPhe(1)-octreotide, based on the emission of Auger electrons. The Phase IIa study "MAURITIUS" (Multicenter Analysis of a Universal Receptor Imaging and Treatment Initiative, a eUropean Study) showed in progressive cancer patients (therapy entry criteria) with a calculated tumor dose > 10 Gy / GBq (90)Y-DOTA-lanreotide, the proof-of-principle for treating tumor patients with peptide receptor imaging agents. In the "MAURITIUS" study, cummulative treatment doses up to 200 mCi (90)Y-DOTA-lanreotide were given as short-term infusion. Overall treatment results in 70 patients indicated stable tumor disease in 35% of patients and regressive tumor disease in 10% of tumor patients with different tumor entities expressing hSSTR. No acute or chronic severe hematological toxicity, change in renal or liver function parameters due to (90)Y-DOTA-lanreotide treatment, were reported. (90)Y-DOTA-DPhe(1)-Tyr(3)-octreotide may show a higher tumor uptake in neuroendocrine tumor lesions and may therefore be superior for treatment in patients with neuroendocrine tumors. However, there is only limited excess to long-term and survival data at present. Potential indications for (90Y-DOTA-lanreotide are radioiodine-negative thyroid cancer, hepatocellular cancer and lung cancer. Besides newer approaches and recent developments of 188)Re-labeled radioligands, no clinical results on the treatment response are yet available. In conclusion, several radioligands have been implemented on the basis of peptide receptor recognition throughout the last decade. A plentitude of preclinical data and clinical studies confirm their potential use in diagnosis as well as

  6. [(90)Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: long-term results of a phase 2 clinical trial.

    Science.gov (United States)

    Iten, Fabienne; Muller, Beat; Schindler, Christian; Rasch, Helmut; Rochlitz, Christoph; Oertli, Daniel; Maecke, Helmut R; Muller-Brand, Jan; Walter, Martin A

    2009-05-15

    The authors aimed to explore the efficacy of (90)Yttrium-1,4,7,10-tetra-azacyclododecane N,N',N'',N'''-tetraacetic acid [(90)Y-DOTA]-Tyr(3)-octreotide (TOC) in advanced iodine-refractory thyroid cancer. In a phase 2 trial, the authors investigated biochemical response (assessed by serum thyroglobulin levels), survival, and the long-term safety profile of systemic [(90)Y-DOTA]-TOC treatment in metastasized iodine-refractory thyroid cancer. Adverse events were assessed according to the National Cancer Institute criteria. Survival analyses were performed by using multiple regression models. A total of 24 patients were enrolled. A median cumulative activity of 13.0 GBq (range, 1.7-30.3 GBq) was administered. Response was found in 7 (29.2%) patients. Eight (33.3%) patients developed hematologic toxicity grade 1-3, and 4 (16.7%) patients developed renal toxicity grade 1-4. The median survival was 33.4 months (range, 3.6-126.8 months) from time of diagnosis and 16.8 months (range, 1.8-99.1 months) from time of first [(90)Y-DOTA]-TOC treatment. Response to treatment was associated with longer survival from time of diagnosis (hazard ratio [HR], 0.17; 95% confidence interval [CI], 0.03-0.92; P = .04) and from time of first [(90)Y-DOTA]-TOC therapy (HR, 0.20; 95% CI, 0.04-0.94; P = .04). The visual grade of scintigraphic tumor uptake was not associated with treatment response (odds ratio [OR], 0.98; 95% CI, 0.26-3.14; P = 1.00). Response to [(90)Y-DOTA]-TOC in metastasized iodine-refractory thyroid cancer was associated with longer survival. Upcoming trials should aim to increase the number of treatment cycles.

  7. Studying on process for labeling of EDTMP with 90Y using for bone pain palliation

    International Nuclear Information System (INIS)

    Pham Ngoc Dien; Duong Van Dong; Dang Ho Hong Quang; Nguyen Thanh Binh; Bui Van Cuong; Nguyen Dang Khoa; Nguyen Thi Thu; Mai Phuoc Tho; Vo Cam Hoa

    2013-01-01

    This Study describes the method for preparation of labelling compound Ethylene diamine tetramethylene phosphonic acid (EDTMP) with 90 Y. Malignant cancer is one of the most important resulting in human death. Bone metastases in nearly 25% of all cancer patients; so it is useful to develop radiopharmaceuticals for the treatment of bone cancer. Yttrium-90 is high energy (2.3 MeV) beta emitter required with a physical haft life of 2.7 days which has limited bone-seeking properties. Its physical properties make it ideal for therapeutic application, the most energetic beta emission being able to penetrate to 1 cm from the site of deposition in soft tissue with an average range of approximately 4 mm. Theoretically, therefore, it can penetrate all marrow spaces in normal trabecular bone and conceivably even to the centre of large tumours where bone destruction may be extensive. Specific deposition of 90 Y into the skeleton demands its delivery in a chemical form with affinity for bone mineral alone. Compounds with these properties are the phosphonate analogues of polyaminocarboxylic acids, and one in particular EDTMP (ethylen diamine tetra methylene phosphonate) has already been used to target 153 Sm to bone mineral with success. Because of chemical similarities between 90 Y and the rare earths, EDTMP should form stable complexes with 90 Y and carry it specifically to the bone with comparable efficiency. Skeletal uptake of β - emitting radionuclides may be used for bone pain palliation or myeloablation. The physical characteristics of the β - particles required for the two conditions are, however, different, that is, higher energies are favorable for destruction of bone marrow. (author)

  8. Internal Dosimetry in therapy with 90Y

    International Nuclear Information System (INIS)

    Torres, Leonel; Vergara, Alex; García, Leonardo

    2016-01-01

    Introduction: 90 Y has shown satisfactory results in the therapy of multiple oncological diseases. This radionuclide has been widely used in therapy of diseases such as NHL (Zevalin), TNE ( 90 Y-DOTATOC), liver cancer, etc. Its safe and effective use presupposes the availability of accurate dosimetry methods and reproducible.El objective of this work is to standardize and optimize images use procedures that allow for dosimetric estimates braking during therapy of malignant diseases 90 Y. Materials and Methods: To quantify the activity in absolute units from scans correction methods that consider the peculiarities of the bremsstrahlung of 90 Y were proposed. acquisition parameters such as the selection of the collimator and the definition of energy windows as well as methods of scatter correction, attenuation, interactions of radiation with the collimator (septal penetration and degradation of information with distance) were considered and sensitivity or calibration factor was estimated. They were evaluated and calibrated parameters for dosimetry at the level of organ and estimates of distributions 3D dose, using experimental measurements with SPECT Mediso Nucline ™ Spirit DH-V system and simulations were performed using the Monte Carlo method, using the SIMIND v5 software .0. Results: The optimum position-energy window width and collimator to be used is determined from the relationship between total photons and primary photons (T / P), calculated with SIMIND. The results were favorable to employ HEGP collimator and energy window between 90-170kev. the sensitivity of the system for the selected collimator (HEGP for 90 Y) was estimated. He was evaluated and determined the MTF order to correct dispersive plane images, the source-detector and interactions of radiation with the collimator distance, using filtering methods (Wiener filter), including empirical estimates of the SNR component. Similarly the procedure for the use of transmission maps obtained from

  9. Pyclen Tri-n-butylphosphonate Ester as Potential Chelator for Targeted Radiotherapy: From Yttrium(III) Complexation to (90)Y Radiolabeling.

    Science.gov (United States)

    Le Fur, Mariane; Beyler, Maryline; Lepareur, Nicolas; Fougère, Olivier; Platas-Iglesias, Carlos; Rousseaux, Olivier; Tripier, Raphaël

    2016-08-15

    The Y(3+) complex of PCTMB, the tri-n-butyl phosphonate ester of pyclen (3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene), was synthesized as well as its Ho(3+) and Lu(3+) analogues. X-ray diffraction analyses revealed isomorphous dimeric M2(PCTMB)2·9H2O (M = Y, Ho, Lu) structures that crystallize in the centrosymmetric P1̅ triclinic space group. (1)H NMR and UV studies in aqueous solutions indicated that Y(3+) complexation is fast, being quantitative in 167 min at pH 3.8 and in 13 min at pH 5.5 (25 °C, acetate buffer, I = 0.150 M, [Y(3+)] = [PCTMB] = 0.2 mM). (1)H NMR DOSY and photon correlation spectroscopy experiments evidenced the formation of aggregates in chloroform with a bimodal distribution that changes slightly with concentration (11-24 and 240-258 nm). The behavior of the acid-assisted dissociation of the complex of Y(3+) with PCTMB was studied under pseudo-first-order conditions, and the half-life of the [Y(PCTMB)] complex in 0.5 M HCl at 25 °C was found to be 37 min, a value that decreases to 2.6 min in 5 M HCl. The Y(3+) complex of PCTMB is thermodynamically very stable, with a stability constant of log KY-PCTMB = 19.49 and pY = 16.7 measured by potentiometry. (90)Y complexation studies revealed fast radiolabeling kinetics; optimal radiolabeling conditions were obtained for (90)Y in acetate medium, PCTMB at 10(-4) to 10(-2) M in acetate buffer pH = 4.75, 15 min at 45-60 °C. In vitro stability studies in human serum showed that [(90)Y(PCTMB)] is quite stable, with about 90% of the activity still in the form of the radiotracer at 24 h and 80% from 48 h to 72 h. A comparison with other ligands such as PCTA, DOTA, and DTPA already used for in vivo application shows that [(90)Y(PCTMB)] is an interesting lipophilic and neutral analogue of these reference chelates for therapeutic applications in aqueous and nonaqueous media.

  10. Toxicity of inhaled 90Y in fused clay particles in beagle dogs. VI

    International Nuclear Information System (INIS)

    Hobbs, C.H.; Chiffelle, T.L.; Hahn, F.F.; Jones, R.K.; Mauderly, J.L.; McClellan, R.O.; Pickrell, J.A.

    1974-01-01

    Studies on the metabolism, dosimetry, and effects of inhaled 90 Y in fused clay in the Beagle dog are being continued to assess the consequences of inhalation of an energetic beta emitter that has a short effective half-life in the lung. A radiation dose pattern study in which 12 dogs were sacrificed in pairs at 0, 2, 4, 6, 8, and 12 days post-inhalation exposure has been completed. A longevity study in which 89 dogs have been exposed to 90 Y fused clay with initial lung burdens ranging from 80 to 5200 μCi/kg body weight and 12 control dogs were exposed to stable yttrium in fused clay is in progress. The 90 Y was retained in lung with a half-life similar to its physical half-life (64 hours) and with only small quantities translocated to tracheobronchial lymph nodes, skeleton, and liver. The infinite radiation doses to lung, tracheobronchial lymph nodes, skeleton, and liver for an initial lung burden of 100 μCi 90 Y/kg of body weight were estimated to be 1600, 170, 0.54, and 0.38 rads, respectively. Thirty-eight of 39 dogs with doses to lung from 9300 to 70,000 rads have died at 7.5 to 903 days post-exposure. The one surviving dog in this dose range has radiographic evidence of pulmonary fibrosis at 1316 days post-exposure. All the dogs that died had radiation pneumonitis. The dog that died at 903 days post-exposure with a dose to lung of 11,000 rads also had 2 small pulmonary adenomas. Fifty exposed dogs with doses to lung of 1300 to 7900 rads are surviving with no significant abnormalities at 1278 to 1834 days post-exposure and will be studied for the remainder of their lifespan. (U.S.)

  11. Developing of Ytrium-90 Generator Based on Extraction Chromatography with Crown Ether

    International Nuclear Information System (INIS)

    Yassine, T.; Mukhallalati, Ch.H.

    2009-01-01

    Although the use of radionuclides for therapeutic purposed goes back to about 60 years ago, but interest in this therapy is rapidly increasing in the field of nuclear medicine. The introduction and acceleration of such techniques require the continuous availability and acceptable cost of therapeutic radionuclides and radiopharmaceuticals. Most of therapeutic radionuclides, are reactor (Ho-166, Lu-177 Sm-153, I-131...). Produced ones which makes the generator produced radionuclides such Y-90, is more convenient to start with for developing therapeutic radiopharmaceutical in countries where there are no reactor. Ytrium-90 is an important radionuclide for radioimmunotherapeutic and for radiosynviorethesis. It is pure single high energy beta emitter (Ep=2.3 Mev), decaying to stable Zirconium-90 with half-life of about 64 hrs. It is availability, as generator products resulting from the decay of the long lived strontium-90 (T1/2 = 28y) has increased its importance in nuclear medicine and accelerated its applications. The AECS has initiated wide Programme for development and production of radiopharmaceuticals for covering local and regional demands of nuclear medicine. Existed facility including Cyclotron (cyclon 30 IBA), technetium-99m generator and kits production lines and iodine-131 dispensing and labeling plant, needs to be enhanced by more therapeutic products. The absence of nuclear reactor for radionuclide production makes the generator technology to be a convenient choice. Therefore, Ytrium-90 radiopharmaceuticals were targeted and 90Sr/90Y generator was developed for these purposes. Several designs of Ytrium-90 generator were developed according to different separation techniques, such as solvent extraction, ion exchange, supported liquid membrane and electrodeposition, and each has deferent characterizations and Performances. We found that extraction Chromatography by 18C6 Crown ether loaded on Teflon resins (Sr-Spec) is very convenient for Production of ultra

  12. Occupational exposure following Yttrium-90 microspheres SIR therapy

    International Nuclear Information System (INIS)

    Fontaine, P.; Boirie, G.; Dieudonne, A.; Leguludec, D.; Lebtahi, R.; Ben Reguiga, M.

    2015-01-01

    Full text of publication follows. Introduction: Selective Internal Radiation Therapy (SIRT) is a promising technique for solid hepatic neoplasms treatment. SIRT consists in implanting radioactive microspheres (RMS) in targeted hepatic lesions via femoral artery. Two RMS-Therapsheres [glass-microspheres/TSR] and Sir-Spheres [resin-spheres/SSR]- are marketed in the European market, both radiolabeled with Yttrium-90. The objective of this study is to assess occupational exposure for nuclear medicine, radiology and clinical staff involved in Y 90 -RMS preparation and implantation. Materials and methods: The study was conducted on 20 patients treated for Hepato-Cellular Carcinoma: 10 treated with TSR and 10 with SSR. Dose rate (DR, mSv/h) or absorbed doses (mSv) measurements were made during all steps of TSR and SSR handling: sources receipt and unpacking, preparation, transport to radiology, implantation, and patient care. Measurements were made with portable ionization chamber(Babyline/Nardeux), spectrometer(FieldSpect/Aries), digital dosimeter (NED/Unfors) and operational dosimeter (Mk2/Siemens). Values were expressed as mean±SD. Results: patients received of 1.8 GBq to 3.1 GBq of TSR and 0.55 GBq to 2.4 GBq of SSR. TSR were delivered ready-to-use with the prescribed activity. For SSR only one activity was commercially available and shipped (3 GBq at calibration-time)requiring a preparation step to adjust needed activity. DR measured during RMS was 1723 ± 157 μSv/h SSR and 1189 ± 92 μSv/h for TSR. When preparing spheres in radiopharmacy, fingers and whole body doses were respectively 8326 ± 2360 μSv and 12.3 ± 5,2 μSv for Sir-Spheres vs. 33.5 ± 7.8 μSv and 1.1 ± 0.3 μSv for TSR. DR in contact with carrying case during RMS transfer to radiology were 299 ± 102 μSv/h for SSR and 5.3 ± 1.2 μSv/h for TSR. During RMS infusion, radiologist's finger doses were limited to 3.6 ± 1 μSv for SSR and 0.7± 0.3 μSv for TSR. Finally, following RMS

  13. Treating and Downstaging Hepatocellular Carcinoma in the Caudate Lobe with Yttrium-90 Radioembolization

    Energy Technology Data Exchange (ETDEWEB)

    Ibrahim, Saad M. [Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Department of Radiology, Section of Interventional Radiology (United States); Kulik, Laura [Northwestern University Feinberg School of Medicine, Department of Medicine, Division of Hepatology (United States); Baker, Talia [Northwestern University Feinberg School of Medicine, Division of Transplant Surgery (United States); Ryu, Robert K. [Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Department of Radiology, Section of Interventional Radiology (United States); Mulcahy, Mary F. [Northwestern University Feinberg School of Medicine, Department of Medicine, Division of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center (United States); Abecassis, Michael [Northwestern University Feinberg School of Medicine, Division of Transplant Surgery (United States); Salem, Riad; Lewandowski, Robert J., E-mail: r-lewandowski@northwestern.edu [Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Department of Radiology, Section of Interventional Radiology (United States)

    2012-10-15

    Purpose: This study was designed to determine the technical feasibility, safety, efficacy, and potential to downstage patients to within transplantation criteria when treating patients with hepatocellular carcinoma (HCC) of the caudate lobe using Y90 radioembolization. Methods: During a 4-year period, 8 of 291 patients treated with radioembolization for unresectable HCC had disease involving the caudate lobe. All patients were followed for treatment-related clinical/biochemical toxicities, serum tumor marker response, and treatment response. Imaging response was assessed with the World Health Organization (WHO) and European Association for the Study of the Liver (EASL) classification schemes. Pathologic response was reported as percent necrosis at explantation. Results: Caudate lobe radioembolization was successfully performed in all eight patients. All patients presented with both cirrhosis and portal hypertension. Half were United Network for Organ Sharing (UNOS) stage T3 (n = 4, 50%). Fatigue was reported in half of the patients (n = 4, 50%). One (13%) grade 3/4 bilirubin toxicity was reported. One patient (13%) showed complete tumor response by WHO criteria, and three patients (38%) showed complete response using EASL guidelines. Serum AFP decreased by more than 50% in most patients (n = 6, 75%). Four patients (50%) were UNOS downstaged from T3 to T2, three of who underwent transplantation. One specimen showed histopathologic evidence of 100% complete necrosis, and two specimens demonstrated greater than 50% necrosis. Conclusions: Radioembolization with yttrium-90 appears to be a feasible, safe, and effective treatment option for patients with unresectable caudate lobe HCC. It has the potential to downstage patients to transplantation.

  14. Study On The Preparation Of 90Y-DTPA-Rituximab For Non-Hodgkin Lymphoma Treatment

    International Nuclear Information System (INIS)

    Nguyen Thi Thu; Duong Van Dong; Bui Van Cuong; Vo Thi Cam Hoa; Chu Van Khoa; Phan Quoc Thong

    2011-01-01

    Yttrium is one of the most useful radionuclides for radioimmunotherapeutic applications, especially labelling with monoclonal antibodies. Rituximab was bound to the DTPA chelating agent using Hnatowich methods. Cyclic anhydride DTPA (cDTPAa, 0.1 mg/ml) was dissolved in chloroform and was degassed under a stream of nitrogen for 30 minutes. Rituximab solution in 0.05 M bicarbonate buffer was immediately added and mixed for one minute at room temperature. The antibody Rituximab at different concentration (5 mg/ml and 10 mg/ml) was coupled with the cDTPAa, at molar ratios (cDTPAa : Rituximab) of 1:1, 3:1, 5:1, 10:1 and 20:1. The conjugation of DTPA-Rituximab mixture was labelled with Y-90, then using Sephadex G25 in order to determine coupling efficiency. Coupling efficiency at a 3:1 mole ratio was 70%. After purification, the conjugation DTPA-Rituximab was labeled with Y-90 in 0.5 M acetate buffer, pH 5, at room temperature. The labeling yield was about 99%. The radiochemical purity of 90 Y-DTPA-Rituximab was more than 98 % which determined by ITLC in 0.1 M acetate at pH 6 as mobile phase. The radiopharmaceuticals have been test for sterility, apyrogenicity and biodistribution. This is a potential radiopharmaceutical for clinical application in therapeutic Non Hodgkin Lymphoma treatments. (author)

  15. Thermoluminescent dosimetry of beta radiations of 90 Sr/ 90 Y using amorphous ZrO2

    International Nuclear Information System (INIS)

    Rivera M, T.; Olvera T, L.; Azorin N, J.; Barrera R, M.; Soto E, A.M.

    2005-01-01

    In this work the results of studying the thermoluminescent properties (Tl) of the zirconium oxide in its amorphous state (ZrO 2 -a) before beta radiations of 90 Sr/ 90 Y are presented. The amorphous powders of the zirconium oxide were synthesized by means of the sol-gel technique. The sol-gel process using alkoxides like precursors, is an efficient method to prepare a matrix of zirconium oxide by hydrolysis - condensation of the precursor to form chains of Zr-H 3 and Zr-O 2 . One of the advantages of this technique is the obtention of gels at low temperatures with very high purity and homogeneity. The powders were characterized by means of thermal analysis and by X-ray diffraction. The powders of ZrO 2 -a, previously irradiated with beta particles of 90 Sr/ 90 Y, presented a thermoluminescent curve with two peaks at 150 and 257 C. The dissipation of the information of the one ZrO 2 -a was of 40% the first 2 hours remaining constant the information for the following 30 days. The reproducibility of the information was of ± 2.5% in standard deviation. The studied characteristics allow to propose to the amorphous zirconium oxide as thermoluminescent dosemeter for the detection of beta radiation. (Author)

  16. Thermoluminescent dosimetry of beta radiations of {sup 90} Sr/ {sup 90} Y using ZrO{sub 2}: Eu; Dosimetria termoluminiscente de radiaciones beta de {sup 90} Sr/ {sup 90} Y usando ZrO{sub 2}: Eu

    Energy Technology Data Exchange (ETDEWEB)

    Olvera T, L.; Azorin N, J.; Barrera S, M.; Soto E, A.M. [UAM-I, 09340 Mexico D.F. (Mexico); Rivera M, T. [CICATA-IPN, Legaria 694, 11500 Mexico D.F. (Mexico)

    2005-07-01

    In this work the results of studying the thermoluminescent properties (TL) of the doped zirconium oxide with europium (ZrO{sub 2}: Eu{sup 3+}) before beta radiations of {sup 90}Sr/ {sup 90}Y are presented. The powders of ZrO{sub 2}: Eu{sup 3+} were obtained by means of the sol-gel technique and they were characterized by means of thermal analysis and by X-ray diffraction. The powders of ZrO{sub 2}: Eu{sup 3+}, previously irradiated with beta particles of {sup 90}Sr/ {sup 90}Y, presented a thermoluminescent curve with two peaks at 204 and 292 C respectively. The TL response of the ZrO{sub 2}: Eu{sup 3+} as function of the absorbed dose was lineal from 2 Gy up to 90 Gy. The fading of the information of the ZrO{sub 2}: Eu{sup 3+} was of 10% the first 2 hours remaining almost constant the information by the following 30 days. The ZrO{sub 2} doped with the (Eu{sup 3+}) ion it was found more sensitive to the beta radiation that the one of zirconium oxide without doping (ZrO{sub 2}) obtained by the same method. Those studied characteristics allow to propose to the doped zirconium oxide with europium like thermoluminescent dosemeter for the detection of the beta radiation. (Author)

  17. The Technique and Dosimetry of Pituitary Implantation Using Sources of Y{sup 90}; Technique et Dosimetrie de l'Implantation de Sources d'Yttrium-90 dans l'Hypophyse; ДОЗИМЕТРИЯ ИМПЛАНТИРОВАННЫХ В ГИПОФИЗ ИГЛ ИТТРИЯ-90; Dosimetria de la Implantacion de Fuentes de {sup 90}Y en la Hipofisis

    Energy Technology Data Exchange (ETDEWEB)

    Duggan, Mary H.; Jones, E.; Mallard, J. R. [Department of Physics, Hammersmith Hospital, London (United Kingdom); Joplin, G. F. [Department of Medicine, Postgraduate Medical School, London (United Kingdom)

    1963-03-15

    Pituitary ablation by needle implantation of Y{sup 90} is finding increasing use in the treatment of breast and prostatic cancer, as well as diabetic retinopathy, Cushing's disease, acromegaly, and perhaps exophthalmos in Graves' disease. Yttrium-90 is the most suitable radioisotope when complete ablation of the gland is sought. This is because only {beta}-particles are emitted, the maximum range (7mm) of which is comparable with the dimensions of the gland. The implantation of rods of standard activity into the gland, irrespective of its size, does not permit a standard dose level to be delivered to the gland and the method of implantation is to select the size and activity of the source to fit the dimensions of the gland in question. Thus consistency in procedure may be attempted from one implant to another. The shape of the gland and the mode of access to it is such that complete destruction may conveniently be obtained by implanting two.sources. Each source is a rod of sintered Y{sub 2}O{sub 3}, (2-mm diam., and of length cut to suit the individual gland length). The rod activity is also selected to suit the gland dimensions: typically, it is from 2 to 3 me. Radiation dose has been experimentally related to geometry and activity. Mix D wax is used as the tissue- equivalent absorber, film as the detector and a calibrated Sr{sup 90} source (which decays into Y{sup 90}) as the standard. One outcome of this work is that the pituitary gland requires a radiation dose of between 100 000 and 200 000 rad for necrosis and ablation. (author) [French] L'ablation de l'hypophyse par implantation d'aiguilles a l'yttrium-90 est de plus en plus utilisee dans le traitement du cancer du sein et de la prostate, comme dans celui de la retinite diabetique, de la maladie de Cushing, de l'acromegalie, et peut-etre de l'exophthalmie associee a la maladie de Graves. Lorsqu'on recherche l'ablation totale de la glande, l'yttrium- 90 est le radioisotope qui donne les meilleurs resultats

  18. Development of activity standard for 90Y microspheres

    CSIR Research Space (South Africa)

    Mo, L

    2005-08-01

    Full Text Available 90Y is a therapeutic radiopharmaceuticals used in the treatment of liver cancer following implantation via a catheter in the hepatic artery, 90Y microspheres are embolised in the microvasculature of liver cancer where they irradiate the tumour by a...

  19. Treatment of pains from bone metastases with 90Y

    International Nuclear Information System (INIS)

    Kutzner, J.; Daehnert, W.; Schreyer, T.; Grimm, W.; Brod, K.H.; Becker, M.

    1981-01-01

    For palliation of pain caused by bone metastases beta radiation isotope therapy was successful. As shown in experimental work on animals bone uptake of 90 Y with its shorter half-life is high when it is administered as a citrate complex. 90 Y can be eluted with high purity from a 90 Sr cow. The retention in man was found by whole-body counting to be higher than 80%. In preliminary trials on 16 patients the analgetic effect was the same as that of 89 Sr. The properties of 90 Y therapy are discussed. (orig.) [de

  20. Rapid determination of 90Sr in seawater

    International Nuclear Information System (INIS)

    Pavlotskaya, F.I.; Moskin, A.I.

    1994-01-01

    A method for determining 90 Sr in seawater that is based on direct isolation and radiochemical purification of daughter 90 Y is proposed. The analysis time is 6-8 h. The chemical yield of the Y-carrier during the 90 Sr determination from 35 liters of seawater varies in the range 37-69%. The analysis uncertainty is 90 Sr from seawater and subsequent isolation of 90 Y

  1. Aspects of radiation protection during the treatment of liver cancer using yttrium-90 labelled microspheres

    International Nuclear Information System (INIS)

    Klemp, P.F.B.; Perry, A.M.; Fox, R.A.; Gray, B.N.; Burton, M.A.

    1989-01-01

    Twenty eight patients have received treatment for liver cancer by the intra-hepatic arterial injection of between 1 and 4 GBq of yttrium-90 labelled microspheres. The injection was performed at laparotomy. If 11.1 MBq of yttrium-90 are distributed evenly over 1 sq cm of tissue, the tissue surface will suffer an initial beta dose rate of 16.2 Gy h -1 . Special precautions are therefore essential during the injection procedure, subsequently in nursing the patient and if further intervention becomes necessary. A specially designed apparatus is used for the injection, glass spectacles are worn and if the active liver is to be handled, lead rubber gloves are used. The theatre is prepared so that contaminated items can be easily isolated and a 'spill pack' is readily available. At completion of the operation, the bremsstrahlung dose rate at 15 cm from the liver is initially 15 μSv h -1 GBq -1 . Contamination of urine is typically 20 to 50 kBq L -1 while the contamination of other body fluids is negligible. Finger doses to the surgeons has varied from 2 to 5 mSv GBq -1 injected while personnel film badges used to monitor the dose equivalent to the surgeons and ward staff have recorded maximum doses of 1.5 mSv and 300 μSv respectively. 11 refs., 1 fig., 3 tabs

  2. Development of a dosimetric system for {sup 90}Sr + {sup 90}Y betatherapy applicators; Desenvolvimento de um sistema de dosimetria para aplicadores de betaterapia de {sup 90}Sr + {sup 90}Y

    Energy Technology Data Exchange (ETDEWEB)

    Coelho, Talita Salles

    2010-07-01

    The {sup 90}Sr+{sup 90}Y applicators, used in betatherapy for prevention of keloids and pterigium, are imported and many times their dosimetric features are shown only in an illustrated form by the manufacturers. The exhaustive routine of the medical physicists in the clinic do not make possible the accomplishment of procedures for the confirmation of these parameters. This work presents the development of a methodology for the dosimetry of {sup 90}Sr+{sup 90}Y betatherapy applicators. The Monte Carlo code MCNP5 was used for the simulation of the percentage depth dose curves and dose distribution profiles produced by these applicators. The experimental measurements of the radial and axial radiation attenuation, have been done with a mini-extrapolation chamber, thermoluminescent dosimeters and radiographic films. The experimental results have been compared with the simulated values. Both percentage depth dose curves and the radial dose profiles, the theoretical and the experimental ones, have presented good agreement, which may validate the use of the MCNP5 for these simulations, confirming the viability of the usage of this method in procedures of beta emitter sources dosimetry. (author)

  3. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer

    International Nuclear Information System (INIS)

    Knox, S J.; Goris, M L.; Tempero, M.; Weiden, P L.; Gentner, L.; Breitz, H.; Adams, G. P.; Axworthy, D.; Gaffigan, S.; Bryan, K.; Fisher, Darrell R.; Colcher, D; Horak, I D.; Weiner, L M.

    1999-01-01

    A Phase II study of yttrium-90-tetra-azacyclododecanetetra-acetic acid-biotin (Y-90-DOTA-biotin) pretargeted by NR-LU-10 antibody/streptavidin (SA) was performed. The primary objectives of the study were to evaluate the efficacy and safety of this therapy in patients with metastatic colon cancer. Twenty-five patients were treated with a single dose of 110 mCi/m 2 (mean administered dose, 106.5-10.3 mCi/m 2 ) of Y-90-DOTA-biotin. There were three components of the therapy. Patients first received NR-LU-10/SA on day 1. A clearing agent (biotin-galactose-human serum albumin) was administered 48 h after the NR-LU-10/SA to remove residual circulating unbound NR-LU-10/SA. Lastly, 24 h after administration of clearing agent, patients received biotin-DOTA-labeled with 110 mCi/m 2 Y-90. All three components of the therapy were administered i.v. Both hematological and nonhematological toxicities were observed. Diarrhea was the most frequent grade 4 nonhematological toxicity (16%; with 16% grade 3 diarrhea). Hematological toxicity was less severe with 8% grade 3 and 8% grade 4 neutropenia and 8% grade 3 and 16% grade 4 thrombocytopenia. The overall response rate was 8%. Two partial responders had freedom from progression of 16 weeks. Four patients (16%) had stable disease with freedom from progression of 10-20 weeks. Despite the relatively disappointing results of this study in terms of therapeutic efficacy and toxicity, proof of principle was obtained for the pretargeting approach. In addition, valuable new information was obtained about normal tissue tolerance to low-dose-rate irradiation that will help to provide useful guidelines for future study designs

  4. Thermoluminescent dosimetry of beta radiations of {sup 90} Sr/ {sup 90} Y using amorphous ZrO{sub 2}; Dosimetria termoluminiscente de radiaciones beta de {sup 90} Sr/ {sup 90} Y usando ZrO{sub 2} amorfo

    Energy Technology Data Exchange (ETDEWEB)

    Rivera M, T. [CICATA-Legaria, IPN, Legaria Num. 694, 11500 Mexico D.F. (Mexico); Olvera T, L.; Azorin N, J.; Barrera R, M.; Soto E, A.M. [UAM-I, 09340 Mexico D.F. (Mexico)

    2005-07-01

    In this work the results of studying the thermoluminescent properties (Tl) of the zirconium oxide in its amorphous state (ZrO{sub 2}-a) before beta radiations of {sup 90} Sr/ {sup 90} Y are presented. The amorphous powders of the zirconium oxide were synthesized by means of the sol-gel technique. The sol-gel process using alkoxides like precursors, is an efficient method to prepare a matrix of zirconium oxide by hydrolysis - condensation of the precursor to form chains of Zr-H{sub 3} and Zr-O{sub 2}. One of the advantages of this technique is the obtention of gels at low temperatures with very high purity and homogeneity. The powders were characterized by means of thermal analysis and by X-ray diffraction. The powders of ZrO{sub 2}-a, previously irradiated with beta particles of {sup 90} Sr/{sup 90} Y, presented a thermoluminescent curve with two peaks at 150 and 257 C. The dissipation of the information of the one ZrO{sub 2}-a was of 40% the first 2 hours remaining constant the information for the following 30 days. The reproducibility of the information was of {+-} 2.5% in standard deviation. The studied characteristics allow to propose to the amorphous zirconium oxide as thermoluminescent dosemeter for the detection of beta radiation. (Author)

  5. Preparation & in vitro evaluation of 90Y-DOTA-rituximab

    Science.gov (United States)

    Kameswaran, Mythili; Pandey, Usha; Dash, Ashutosh; Samuel, Grace; Venkatesh, Meera

    2016-01-01

    Background & objectives: Radioimmunotherapy is extensively being used for the treatment of non-Hodgkin's lymphoma (NHL). Use of rituximab, a chimeric anti-CD20 antibody directed against the CD20 antigen in combination with suitable beta emitters is expected to result in good treatment response by its cross-fire and bystander effects. The present work involves the conjugation of p-isothiocyanatobenzyl DOTA (p-SCN-Bn-DOTA) to rituximab, its radiolabelling with 90Y and in vitro and in vivo evaluation to determine its potential as a radioimmunotherapeutic agent. Methods: Rituximab was conjugated with p-SCN-Bn-DOTA at 1:1 antibody: DOTA molar ratio. The number of DOTA molecules linked to one molecule of rituximab was determined by radioassay and spectroscopic assay. Radiolabelling of rituximab with 90Y was carried out and its in vitro stability was evaluated. In vitro cell binding studies were carried out in Raji cells expressing CD20 antigen. Biodistribution studies were carried out in normal Swiss mice. Results: Using both radioassay and spectroscopic method, it was determined that about five molecules of DOTA were linked to rituximab. Radiolabelling of the rituximab conjugate with 90Y and subsequent purification on PD-10 column gave a product with radiochemical purity (RCP) > 98 per cent which was retained at > 90 per cent up to 72 h when stored at 37°C. In vitro cell binding experiments of 90Y-DOTA-rituximab with Raji cells exhibited specific binding of 20.7 ± 0.1 per cent with 90Y-DOTA-rituximab which reduced to 15.5 ± 0.2 per cent when incubated with cold rituximab. The equilibrium constant Kd for 90Y-DOTA-Rituximab was determined to be 3.38 nM. Radiolabelled antibody showed clearance via hepatobiliary and renal routes and activity in tibia was found to be quite low indicating in vivo stability of 90Y-DOTA-rituximab. Interpretation & conclusions: p-SCN-Bn-DOTA was conjugated with rituximab and radiolabelling with 90Y was carried out. In vitro studies carried

  6. Determination of Radiation Absorbed Dose to Primary Liver Tumors and Normal Liver Tissue Using Post Radioembolization 90Y PET

    Directory of Open Access Journals (Sweden)

    Shyam Mohan Srinivas

    2014-10-01

    Full Text Available Background: Radioembolization with Yttrium-90 (90Y microspheres is becoming a more widely used transcatheter treatment for unresectable hepatocellular carcinoma (HCC. Using post-treatment 90Y PET/CT scans,the distribution of microspheres within the liver can be determined and quantitatively assessesed . We studied the radiation dose of 90Y delivered to liver and treated tumors.Methods: This retrospective study of 56 patients with HCC, including analysis of 98 liver tumors, measured and correlated the dose of radiation delivered to liver tumors and normal liver tissue using glass microspheres (TheraSpheres® to the frequency of complications with mRECIST. 90Y PET/CT and triphasic liver CT scans were used to contour treated tumor and normal liver regions and determine their respective activity concentrations. An absorbed dose factor was used to convert the measured activity concentration (Bq/mL to an absorbed dose (Gy.Results: The 98 studied tumors received a mean dose of 169 Gy (mode 90-120 Gy;range 0-570 Gy. Tumor response by mRECIST criteria was performed for 48 tumors that had follow up scans. There were 21 responders (mean dose 215 Gy and 27 nonresponders (mean dose 167 Gy. The association between mean tumor absorbed dose and response suggests a trend but did not reach statistical significance (p=0.099. Normal liver tissue received a mean dose of 67 Gy (mode 60-70 Gy; range 10-120 Gy. There was a statistically significant association between absorbed dose to normal liver and the presence of two or more severe complications (p=0.036.Conclusion: Our cohort of patients showed a possible dose response trend for the tumors. Collateral dose to normal liver is nontrivial and can have clinical implications. These methods help us understand whether patient adverse events, treatment success, or treatment failure can be attributed to the dose which the tumor or normal liver received.

  7. Radioembolization and the dynamic role of 90Y PET/CT

    Directory of Open Access Journals (Sweden)

    Alexander S Pasciak

    2014-02-01

    Full Text Available Before the advent of tomographic imaging, it was postulated that decay of 90Y to the 0+ excited state of 90Zr may result in emission of a positron-electron pair. While the branching ratio for pair production is small (~32x10-6, PET has been successfully used to image 90Y in numerous recent patient and phantom studies. 90Y PET imaging has been performed on a variety of PET/CT systems, with and without time-of-flight (TOF and/or resolution recovery capabilities as well as on both BGO and L(YSO based scanners. On all systems, resolution and contrast superior to bremsstrahlung SPECT has been reported. The intrinsic radioactivity present in L(YSO-based PET scanners is a potential limitation associated with accurate quantification of 90Y. However, intrinsic radioactivity has been shown to have a negligible effect at the high activity concentrations common in 90Y radioembolization. Accurate quantification is possible on a variety of PET scanner models, with or without TOF, although TOF improves accuracy at lower activity concentrations. Quantitative 90Y PET images can be transformed into 3D maps of absorbed dose based on the premise that the 90Y activity distribution does not change after infusion. This transformation has been accomplished primarily with the use of 3D dose point-kernel convolution. From a clinical standpoint, 90Y PET provides a superior post-infusion evaluation of treatment technical success owing to its improved resolution. Absorbed dose maps generated from quantitative PET data can be used to predict treatment efficacy and manage patient follow-up. For patients who receive multiple treatments, this information can also be used to provide patient-specific treatment planning for successive therapies, potentially improving response. The broad utilization of 90Y PET has the potential to provide a wealth of dose-response information, which may lead to development of improved radioembolization treatment-planning models in the future.

  8. Y-90 microsphere therapy: prevention of adverse events.

    Science.gov (United States)

    Schultz, Cheryl C; Campbell, Janice; Bakalyar, Donovan; Beauvais, Michele; Feng, Wenzheng; Savin, Michael

    2009-08-01

    Thirty-three (33) events that were inconsistent with intended treatment for 471 Y-90 microsphere deliveries were analyzed from 2001 to 2007. Each occurrence was categorized, based on root-cause analysis, as a device/product defect and/or operator error event. Events were further categorized, if there was an adverse outcome, as spill/leak, termination, recatheterization, dose deviation, and/or a regulatory medical event. Of 264 Y-90 Therasphere (MDS Nordion, Ottawa, Ontario, Canada) treatments, 15 events were reported (5.7%). Of 207 Y-90 SIR-Spheres (Sirtex, Wilmington, MA) treatments, 18 events were reported (8.7%). Twenty-five (25) of 33 events (76%) were device/product defects: 73% for Therasphere (11 of 15) and 78% for SIR-Spheres (14 of 18). There were 31 adverse outcomes associated with 33 events: 15 were leaks and/or spills, 9 resulted in termination of the dose administration, 3 resulted in recatheterization for dose compensation, 2 were dose deviations (doses differing from the prescribed between 10% and 20%), and 2 were reported as regulatory medical events. Fifty-five (55) corrective actions were taken: 39 (71%) were related to the manufacturer and 16 (29%) were hospital based. This process of analyzing each event and measuring our outcomes has been effective at minimizing adverse events and improving patient safety.

  9. Radiolabeling oligo nuclieotide with 90Y and its radiolysis

    International Nuclear Information System (INIS)

    Liu Changbin; Tian Jiahe; Zhang Jinming; Yin Dayi; Guo Zhe

    2005-01-01

    Objective: To evaluate labeling Morpholinos (MORF), a DNA analogue, with 90 Y using p-isothiocyanatobenzyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) as chelater and assess its stability and hybridization in vitro. Methods: A 25 mer MORF with a primary amine on the 3' equivalent end attached via a 10 member linker was conjugated with an isothiocyanate backbone derivative of DOTA. The conjugated product was labeled in various buffers over a different range of concentrations (0.5-2 mol/L) and pH(3-8.5). The labeled MORF was investigated for stability and hybridization in vitro. Results: By size exclusion high performance liquid chromatogram (HPLC) and instant thin layer chromatography (ITLC) analysis, the DOTA conjugated MORF was successfully radiolabeled, the labeling efficiency was (50 ± 12)%, the specific radioactivity was 5.05 x 10 6 MBq/mmol, radiochemistry purity >95%. The labeled MORF showed one sharp peak by HPLC that shifted completely to earlier retention times following addition of a polymer conjugated with the complementary MORF. In saline at room temperature and in serum at 37 degree C, the radioactivity profile of 90 Y showed a pronounced lower molecular weight peak which did not shifted and was shown due to 90 Y-DOTA resulting from radiolysis. Conclusion: MORF can be successfully labeled with 90 Y via DOTA as chelater, but care it must be taken to avoid the effect of radiolysis. (authors)

  10. Cellular and molecular properties of 90Y-labeled cetuximab in combination with radiotherapy on human tumor cells in vitro

    International Nuclear Information System (INIS)

    Saki, M.; Toulany, M.; Rodemann, H.P.; Sihver, W.; Zenker, M.; Heldt, J.M.; Mosch, B.; Pietzsch, H.J.; Steinbach, J.; Baumann, M.

    2012-01-01

    Purpose: Anti-EGFR antibody cetuximab (C225) is used in combination with radiotherapy of head and neck squamous cell carcinoma (HNSCC) patients. We investigated whether conjugation of cetuximab with trans-cyclohexyl-diethylene-triamine-pentaacetic acid (CHX-A''-DTPA) and radiolabeling with 90 Yttrium affect the molecular and cellular function of cetuximab and improve its combined effect with external-beam irradiation (EBI). Methods: The following cell lines were used: HNSCC UT5, SAS, FaDu, as well as A43, Chinese hamster ovary cells (CHO), and human skin fibroblast HSF7. Binding affinity and kinetics, specificity, retention, and the combination of 90 Y-cetuximab with EBI were evaluated. Results: Control cetuximab and CHX-A''-DTPA-cetuximab blocked the proliferation activity of UT5 cells. In combination with EBI, CHX-A''-DTPA-cetuximab increased the radiosensitivity of UT5 to a similar degree as control cetuximab did. In contrast, in SAS and HSF7 cells neither proliferation nor radiosensitivity was affected by either of the antibodies. Binding [ 90 Y]Y-CHX-A''-DTPA-cetuximab ( 90 Y-cetuximab) to EGFR in HNSCC cells occurred time dependently with a maximum binding at 24 h. Retention of 90 Y-cetuximab was similar in both HNSCC cell lines; 24 h after treatment, approximately 90% of bound activity remained in the cell layer. Competition assays, using cell membranes in the absence of an internalized fraction of cetuximab, showed that the cetuximab affinity is not lost as a result of conjugation with CHX-A''-DTPA. Cetuximab and CHX-A''-DTPA-cetuximab blocked EGF-induced Y1068 phosphorylation of EGFR. The lack of an effect of cetuximab on EGF-induced Akt and ERK1/2 phosphorylation and the inhibition of irradiation (IR)-induced Akt and ERK1/2 phosphorylation by cetuximab were not affected by DTPA conjugation. 90 Y-cetuximab in combination with EBI resulted in a pronounced inhibition of colony formation of HNSCC cells. Conclusions: Conjugation of CHX-A''-DTPA to cetuximab

  11. Treatment of diffuse large B-cell lymphoma of the liver with yttrium-90 microsphere embolization.

    Science.gov (United States)

    Fenske, Timothy S; Benjamin, Heather; Kroft, Steven H; Hohenwalter, Eric J; Rilling, William S

    2008-11-01

    A 41-year-old male with a 4-year history of chronic hepatitis C presented with a 1-month history of abdominal pain, fatigue, weight loss, and night sweats. Laboratory examinations, chest, abdomen, and pelvic CT scans, PET-CT scans, ultrasound-guided needle biopsies of liver lesions, bone-marrow biopsy, flow cytometry, and immunohistochemical staining for B-cell markers including CD20. Chemoresistant diffuse large B-cell lymphoma, with gradual loss of CD20 antigen expression. Embolization of hepatic tumors using yttrium-90 microspheres (Therasphere, Theragenics Corporation, Buford, GA).

  12. Dosimetry analysis of distributions radials dose profiles of {sup 90}Sr + {sup 90}Y beta therapy applicators using the MCNP-4C code and radio chromium films; Analise dosimetrica de perfis de distribuicoes radias de doses relativas de um aplicador de betaterapia de {sup 90}Sr + {sup 90}Y utilizando o codigo MCNP-4C e filmes radiocromicos

    Energy Technology Data Exchange (ETDEWEB)

    Coelho, Talita S.; Yoriyaz, Helio [Instituto de Pesquisas Energeticas e Nucleares (IPEN/CNEN-SP), Sao Paulo, SP (Brazil); Fernandes, Marco A.R., E-mail: tasallesc@gmail.co [UNESP, Botucatu, SP (Brazil). Faculdade de Medicina. Servico de Radioterapia; Louzada, Mario J.Q. [UNESP, Aracatuba, SP (Brazil). Curso de Medicina Veterinaria

    2011-07-01

    Although they are no longer manufactured, the applicators of {sup 90}Sr + {sup 90}Y acquired in the decades of 1990 are still in use, by having half-life of 28.5 years. These applicators have calibration certificate given by their manufacturers, where few have been re calibrated. Thus it becomes necessary to accomplish thorough dosimetry of these applicators. This paper presents a dosimetric analysis distribution radial dose profiles for emitted by an {sup 90}Sr + {sup 90}Y beta therapy applicator, using the MCNP-4C code to simulate the distribution radial dose profiles and radio chromium films to get them experimentally . The results with the simulated values were compared with the results of experimental measurements, where both curves show similar behavior, which may validate the use of MCNP-4C and radio chromium films for this type of dosimetry. (author)

  13. Dosimetry analysis of distribution radial dose profiles of {sup 90}Sr + {sup 90}Y beta therapy applicators using the MCNP-4C code and radio chromium films; Analise dosimetrica de perfis de distribuicoes radiais de doses relativas de um aplicador de betaterapia de {sup 90}Sr + {sup 90}Y utilizando o codigo MCNP-4C e filmes radiocromicos

    Energy Technology Data Exchange (ETDEWEB)

    Coelho, T.S.; Yoriyaz, H. [Instituto de Pesquisas Energeticas e Nucleares (IPEN/CNEN-SP), Sao Paulo, SP (Brazil); Fernandes, M.A.R. [Universidade Estadual Paulista Julio de Mesquita Filho (UNESP), Botucatu, SP (Brazil). Fac. de Medicina. Servico de Radioterapia; Louzada, M.J.Q. [Universidade Estadual Paulista Julio de Mesquita Filho (UNESP), Aracatuba, SP (Brazil). Curso de Medicina Veterinaria

    2010-07-01

    Although they are no longer manufactured, the applicators of {sup 90}Sr +{sup 90}Y acquired in the decades of 1990 are still in use, by having half-life of 28.5 years. These applicators have calibration certificate given by their manufacturers, where few have been recalibrated. Thus it becomes necessary to accomplish thorough dosimetry of these applicators. This paper presents a dosimetric analysis distribution radial dose profiles for emitted by an {sup 90}Sr+{sup 90}Y beta therapy applicator, using the MCNP-4C code to simulate the distribution radial dose profiles and radiochromium films to get them experimentally . The results with the simulated values were compared with the results of experimental measurements, where both curves show similar behavior, which may validate the use of MCNP-4C and radiochromium films for this type of dosimetry. (author)

  14. WE-AB-BRA-05: PET-Guided Delivery Quality Evaluation of Yttrium-90 Microsphere Radioembolizaton for Hepatocellular Carcinoma Patients: The Optimal Sequence of Radioembolizaton and Chemoembolization Treatments

    Energy Technology Data Exchange (ETDEWEB)

    Lin, M [The University of Texas Southwestern Medical Ctr, Dallas, TX (United States); Saboury, B [University of Maryland School of Medicine, Baltimore, MD (United States)

    2016-06-15

    Purpose: Selective-internal-radiation-therapy (SIRT) and transarterial-chemoembolization (TACE) are commonly used for treatment of liver tumors. The use of TACE, which is macroembolic, prior to SIRT may cause hemodynamic changes in tumor vasculature that impair yttrium-90 (90Y) microsphere delivery to the targeted lesions. This work aims to quantify dosimetric tumor coverage using 90Y positron emission tomography (PET) dosimetry after SIRT alone compared to TACE followed by SIRT. Methods: A total of 40 consecutive hepatocellular carcinoma (HCC) SIRT patients who had a post-SIRT 90Y PET/CT scan were evaluated. The patient-specific-3D-dose was reconstructed from the PET images. Patients were categorized into two groups: patients received TACE prior SIRT procedure (n=18) and patient received SIRT alone (n=22). The lesions and liver were delineated by a senior radiologist. We evaluated both the lesion-specific dose-volume-histogram (DVH) and the selectivity index (SI) defined as the ratio of the average dose inside the total lesion(s) and the average dose of the normal liver. The SI values of patients were compared based on whether TACE was previously used. Results: A wide spectrum was observed in the lesion-specific DVH-evaluation and SI appeared to be suitable of evaluating the quality of each SIRT infusion. The average SI of the entire patient group was 3.0, i.e. targeted lesion receiving three times higher dose than normal liver. The average SI was 1.8 for patients who had prior TACE and 3.9 for patients who did not have prior TACE (p=0.008). 85% of the patients with prior TACE demonstrated poor 90Y-microsphere delivery (SI <2) while none demonstrated excellent delivery (SI >4). On the other hand, the incidence SI >4 among patients with no prior TACE was 37%. Conclusion: 3D dose evaluation using post-SIRT PET suggests that 90Y microsphere delivery to liver tumors is impaired among patients who received prior TACE compared to those who receive SIRT alone.

  15. Depth dose curves from 90Sr+90Y clinical applicators using the thermoluminescent technique

    International Nuclear Information System (INIS)

    Antonio, Patricia L.; Caldas, Linda V.E.; Oliveira, Mercia L.

    2009-01-01

    The 90 Sr+ 90 Y beta-ray sources widely used in brachytherapy applications were developed in the 1950's. Many of these sources, called clinical applicators, are still routinely used in several Brazilian radiotherapy clinics for the treatment of superficial lesions in the skin and eyes, although they are not commercialized anymore. These applicators have to be periodically calibrated, according to international recommendations, because these sources have to be very well specified in order to reach the traceability of calibration standards. In the case of beta-ray sources, the recommended quantity is the absorbed dose rate in water at a reference distance from the source. Moreover, there are other important quantities, as the depth dose curves and the source uniformity for beta-ray plaque sources. In this work, depth dose curves were obtained and studied of five dermatological applicators, using thin thermoluminescent dosimeters of CaSO 4 :Dy and phantoms of PMMA with different thicknesses (between 1.0 mm and 5.0 mm) positioned between each applicator and the TL pellets. The depth dose curves obtained presented the expected attenuation response in PMMA, and the results were compared with data obtained for a 90 Sr+ 90 Y standard source reported by the IAEA, and they were considered satisfactory. (author)

  16. Dosimetry characterization of the commercial CaF2 for beta radiation of 90Sr + 90Y

    International Nuclear Information System (INIS)

    Oliveira, Mercia L.; Caldas, Linda V.E.

    2003-01-01

    This work studies the dosimetric characteristics of the CaF 2 commercial dosimetry for detection of 90 Sr + 90 Y beta radiation for using in the calibration of flat and concave appliers. Were determined the repetitiousness and linearity of answers of the samples, and their calibration curves

  17. Time optimization of 90Sr measurements: Sequential measurement of multiple samples during ingrowth of 90Y

    International Nuclear Information System (INIS)

    Holmgren, Stina; Tovedal, Annika; Björnham, Oscar; Ramebäck, Henrik

    2016-01-01

    The aim of this paper is to contribute to a more rapid determination of a series of samples containing 90 Sr by making the Cherenkov measurement of the daughter nuclide 90 Y more time efficient. There are many instances when an optimization of the measurement method might be favorable, such as; situations requiring rapid results in order to make urgent decisions or, on the other hand, to maximize the throughput of samples in a limited available time span. In order to minimize the total analysis time, a mathematical model was developed which calculates the time of ingrowth as well as individual measurement times for n samples in a series. This work is focused on the measurement of 90 Y during ingrowth, after an initial chemical separation of strontium, in which it is assumed that no other radioactive strontium isotopes are present. By using a fixed minimum detectable activity (MDA) and iterating the measurement time for each consecutive sample the total analysis time will be less, compared to using the same measurement time for all samples. It was found that by optimization, the total analysis time for 10 samples can be decreased greatly, from 21 h to 6.5 h, when assuming a MDA of 1 Bq/L and at a background count rate of approximately 0.8 cpm. - Highlights: • An approach roughly a factor of three more efficient than an un-optimized method. • The optimization gives a more efficient use of instrument time. • The efficiency increase ranges from a factor of three to 10, for 10 to 40 samples.

  18. Cellular and molecular properties of {sup 90}Y-labeled cetuximab in combination with radiotherapy on human tumor cells in vitro

    Energy Technology Data Exchange (ETDEWEB)

    Saki, M.; Toulany, M.; Rodemann, H.P. [Tuebingen Univ. (Germany). Div. of Radiobiology and Molecular Environmental Research; Sihver, W.; Zenker, M.; Heldt, J.M.; Mosch, B.; Pietzsch, H.J.; Steinbach, J. [Helmholtz-Zentrum Dresden-Rossendorf (HZDR) e.V., Dresden (Germany). Inst. of Radiopharmacy; Baumann, M. [Technische Univ. Dresden (Germany). Dept. of Radiation Oncology

    2012-09-15

    Purpose: Anti-EGFR antibody cetuximab (C225) is used in combination with radiotherapy of head and neck squamous cell carcinoma (HNSCC) patients. We investigated whether conjugation of cetuximab with trans-cyclohexyl-diethylene-triamine-pentaacetic acid (CHX-A''-DTPA) and radiolabeling with {sup 90}Yttrium affect the molecular and cellular function of cetuximab and improve its combined effect with external-beam irradiation (EBI). Methods: The following cell lines were used: HNSCC UT5, SAS, FaDu, as well as A43, Chinese hamster ovary cells (CHO), and human skin fibroblast HSF7. Binding affinity and kinetics, specificity, retention, and the combination of {sup 90}Y-cetuximab with EBI were evaluated. Results: Control cetuximab and CHX-A''-DTPA-cetuximab blocked the proliferation activity of UT5 cells. In combination with EBI, CHX-A''-DTPA-cetuximab increased the radiosensitivity of UT5 to a similar degree as control cetuximab did. In contrast, in SAS and HSF7 cells neither proliferation nor radiosensitivity was affected by either of the antibodies. Binding [{sup 90}Y]Y-CHX-A''-DTPA-cetuximab ({sup 90}Y-cetuximab) to EGFR in HNSCC cells occurred time dependently with a maximum binding at 24 h. Retention of {sup 90}Y-cetuximab was similar in both HNSCC cell lines; 24 h after treatment, approximately 90% of bound activity remained in the cell layer. Competition assays, using cell membranes in the absence of an internalized fraction of cetuximab, showed that the cetuximab affinity is not lost as a result of conjugation with CHX-A''-DTPA. Cetuximab and CHX-A''-DTPA-cetuximab blocked EGF-induced Y1068 phosphorylation of EGFR. The lack of an effect of cetuximab on EGF-induced Akt and ERK1/2 phosphorylation and the inhibition of irradiation (IR)-induced Akt and ERK1/2 phosphorylation by cetuximab were not affected by DTPA conjugation. {sup 90}Y-cetuximab in combination with EBI resulted in a pronounced inhibition of

  19. Separation of 90Y from 90Sr by solvent extraction with ionizable crown ethers

    International Nuclear Information System (INIS)

    Wood, D.J.; Elshani, S.; Du, H.S.; Natale, N.R.; Wai, C.M.

    1993-01-01

    Sym-Dibenzo-16-crown-5-oxyacetic acid and its analogues are selective for the extraction of Y 3+ over Sr 2+ from aqueous solutions into chloroform. The selectivity and the pH range of extraction are influenced by the structure of the ligand. The size of the macrocyclic cavity, the tether length of the lariat, the attachment of alkyl functional groups to the lariat, and the identity of the ionizable group can affect selectivity and extraction efficiency. When the carboxylic acid at the terminal end of the lariat is replaced by a hydroxamic acid, the selectivity for Y 3+ over Sr 2+ is significantly increased. Using these ionizable crown ethers as extractants, 90 Y fractions of greater than 99.9% purity can be obtained in a single solvent extraction step from solutions of 90 Sr. 11 refs., 5 figs., 2 tabs

  20. The exploration of nursing care for patients with benign prostatic hyperplasia treated using 90Sr-90Y

    International Nuclear Information System (INIS)

    Xiao Lizhen; Bai Xuemei; Zhang Bihui; Yang Xiaoling

    2004-01-01

    An exploration of nursing care for patients with benign prostatic hyperplasia (BPH) treated using 90 Sr- 90 Y through the rectum was carried out . The treatment result and nursing experience in 90 cases were reported in this paper. Before the therapy nurses explained the method and principle of this treatment to the patients for the sake of increasing their confidence and to help them complete the treatment course successfully. During the radiotherapy, nurses practiced strictly radiation protection principles and operating instructions. They assisted the patients to have a healthy life style and good diet . The result of treatment indicated that the total effectiveness rate was 96.7%. The symptoms of lower urinary obstruction were improved evidently and the life quality of the patients elevated. Observation of clinical system confirmed that 90 Sr- 90 Y may be a new treatment method of BPH with benefits of safe irradiation dos, easy operation, non-traumatization, painlessness, and remarkable curative effects. However, it should be stressed that nursing care plays a pivotal role in the treatment result. (authors)

  1. Dosimetry characterization of the commercial CaF{sub 2} for beta radiation of {sup 90}Sr + {sup 90}Y; Caracterizacao dosimetrica de CaF{sub 2} comercial para radiacao beta de {sup 90}Sr + {sup 90}Y

    Energy Technology Data Exchange (ETDEWEB)

    Oliveira, Mercia L.; Caldas, Linda V.E. [Instituto de Pesquisas Energeticas e Nucleares (IPEN/CNEN-SP), Sao Paulo, SP (Brazil)], e-mail: mlolivei@ipen.br, e-mail: lcaldas@ipen.br

    2003-07-01

    This work studies the dosimetric characteristics of the CaF{sub 2} commercial dosimetry for detection of {sup 90}Sr + {sup 90}Y beta radiation for using in the calibration of flat and concave appliers. Were determined the repetitiousness and linearity of answers of the samples, and their calibration curves.

  2. Use of Magic polymer gels for dosimetry of unsealed source of yttrium 90

    International Nuclear Information System (INIS)

    Meynard, K.; Bordage, M.C.; Cassol, E.; Courbon, F.; Ravel, P.

    2007-01-01

    Polymer gels are relative chemical dosimeters. They allow to access to three-dimensional dose distribution. The aim of this study has been to investigate the preparation and the use of a polymer gel with a tissue equivalent density known as MAGIC gel from magnetic resonance imaging and x-ray computed tomography for non-sealed source dosimetry. This kind of gel is 'normoxic' because it can be manufactured and used in normal room atmosphere. In the first part of this study, its accuracy and sensibility were studied using external beam irradiation by photons. Spin-spin relaxation rate (R 2 ) and Computed Tomography (CT) number had been used to record gel responses. Using the same manufacture process. radiolabelled gels composed of 95% MAGIC gel and 5% of 90 Y termed 90 Y-MAGIC 95 with varying activity ranged from 0 to 30 MBq were made. In case of photon external beam irradiation, a linear response is observed whatever the calibration method and the imaging system used (the correlation coefficient r 2 > 0.98 in all cases). 90 Y-MAGIC 95 radiolabelled gel responses were recorded after 28. 76 and 124 h. The R 2 /dose curves are not linear: three phases can be described. the first being linear with a slow slope (0.14 s -1 Gy -1 instead of 0.41 s -1 Gy -1 for external beam irradiation of the same gel batch). This study shows safety of radiolabelled MAGIC gels manufacturing process and their large dosimetric feasibility. 90 Y-MAGIC 95 gel response appears to be reproducible and related to the absorbed dose, thus this gel is a promising tool for non-sealed source dosimetry. (authors)

  3. Yttrium synovectomy: a meta-analysis of the literature

    International Nuclear Information System (INIS)

    Jones, G.

    1993-01-01

    Yttrium synovectomy for chronic synovitis of the knee enjoys widespread usage in Australia with approximately 400 patients receiving yttrium-90 in 1991. Despite abundant anecdotal evidence of its efficacy there is a paucity of controlled trials and those that have been done have produced conflicting results and have been of insufficient sample size. To critically and quantitatively evaluate the published English literature on comparative trials of yttrium-90 therapy for chronic synovitis of the knee, the technique of meta-analysis was utilised. The literature search was carried out using the MeSH terms of synovectomy and knee; and yttrium. This was augmented by referring to reviews, current textbooks and back-references. Outcome measures varied between trials but could be grouped as treatment success. The Peto modification of Mantel and Haenszl was used for statistical pooling of data yielding a pooled odds ratio (OR). The literature search revealed ten controlled trials of which two were excluded from further analysis. It was found that yttrium was superior to placebo (OR 2.42, 95% CI 1.02-5.73) but it is recommended that this result should be interpreted with caution due to possible publication bias. It is concluded that there is insufficient evidence from comparative trials of yttrium in the English literature to show that yttrium synovectomy is convincingly superior to triamcinolone (OR 1.89, 95% CI 0.81-10.55) or other active modalities (OR 1.04, 95% CI 0.72-1.52). 25 refs., 4 tabs

  4. Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review

    Energy Technology Data Exchange (ETDEWEB)

    Lee, Edward Wolfgang; Alanis, Lourdes [Division of Interventional Radiology, Department of Radiology, UCLA Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 (United States); Cho, Sung-Ki [Division of Interventional Radiology, Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351 (Korea, Republic of); Saab, Sammy [Division of Hepatology, Department of Medicine, Pfleger Liver Institute, University of California at Los Angeles, Los Angeles, CA 90024 (United States)

    2016-11-01

    Hepatocellular carcinoma is the most common primary liver cancer and it represents the majority of cancer-related deaths in the world. More than 70% of patients present at an advanced stage, beyond potentially curative options. Ytrrium-90 selective internal radiation therapy (Y90-SIRT) with glass microspheres is rapidly gaining acceptance as a potential therapy for intermediate and advanced stage primary hepatocellular carcinoma and liver metastases. The technique involves delivery of Y90 infused glass microspheres via the hepatic arterial blood flow to the appropriate tumor. The liver tumor receives a highly concentrated radiation dose while sparing the healthy liver parenchyma due to its preferential blood supply from portal venous blood. There are two commercially available devices: TheraSphere® and SIR-Spheres®. Although, Y90-SIRT with glass microspheres improves median survival in patients with intermediate and advanced hepatocellular carcinoma and has the potential to downstage hepatocellular carcinoma so that the selected candidates meet the transplantable criteria, it has not gained widespread acceptance due to the lack of large randomized controlled trials. Currently, there are various clinical trials investigating the use of Y90-SIRT with glass microspheres for treatment of hepatocellular carcinoma and the outcomes of these trials may result in the incorporation of Y90-SIRT with glass microspheres into the treatment guidelines as a standard therapy option for patients with intermediate and advanced stage hepatocellular carcinoma.

  5. Yttrium-90 selective internal radiation therapy with glass microspheres for hepatocellular carcinoma: Current and updated literature review

    International Nuclear Information System (INIS)

    Lee, Edward Wolfgang; Alanic, Lourdes; Cho, Sung Ki; Saab, Sammy

    2016-01-01

    Hepatocellular carcinoma is the most common primary liver cancer and it represents the majority of cancer-related deaths in the world. More than 70% of patients present at an advanced stage, beyond potentially curative options. Ytrrium-90 selective internal radiation therapy (Y90-SIRT) with glass microspheres is rapidly gaining acceptance as a potential therapy for intermediate and advanced stage primary hepatocellular carcinoma and liver metastases. The technique involves delivery of Y90 infused glass microspheres via the hepatic arterial blood flow to the appropriate tumor. The liver tumor receives a highly concentrated radiation dose while sparing the healthy liver parenchyma due to its preferential blood supply from portal venous blood. There are two commercially available devices: TheraSphere® and SIR-Spheres®. Although, Y90-SIRT with glass microspheres improves median survival in patients with intermediate and advanced hepatocellular carcinoma and has the potential to downstage hepatocellular carcinoma so that the selected candidates meet the transplantable criteria, it has not gained widespread acceptance due to the lack of large randomized controlled trials. Currently, there are various clinical trials investigating the use of Y90-SIRT with glass microspheres for treatment of hepatocellular carcinoma and the outcomes of these trials may result in the incorporation of Y90-SIRT with glass microspheres into the treatment guidelines as a standard therapy option for patients with intermediate and advanced stage hepatocellular carcinoma

  6. Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review

    International Nuclear Information System (INIS)

    Lee, Edward Wolfgang; Alanis, Lourdes; Cho, Sung-Ki; Saab, Sammy

    2016-01-01

    Hepatocellular carcinoma is the most common primary liver cancer and it represents the majority of cancer-related deaths in the world. More than 70% of patients present at an advanced stage, beyond potentially curative options. Ytrrium-90 selective internal radiation therapy (Y90-SIRT) with glass microspheres is rapidly gaining acceptance as a potential therapy for intermediate and advanced stage primary hepatocellular carcinoma and liver metastases. The technique involves delivery of Y90 infused glass microspheres via the hepatic arterial blood flow to the appropriate tumor. The liver tumor receives a highly concentrated radiation dose while sparing the healthy liver parenchyma due to its preferential blood supply from portal venous blood. There are two commercially available devices: TheraSphere® and SIR-Spheres®. Although, Y90-SIRT with glass microspheres improves median survival in patients with intermediate and advanced hepatocellular carcinoma and has the potential to downstage hepatocellular carcinoma so that the selected candidates meet the transplantable criteria, it has not gained widespread acceptance due to the lack of large randomized controlled trials. Currently, there are various clinical trials investigating the use of Y90-SIRT with glass microspheres for treatment of hepatocellular carcinoma and the outcomes of these trials may result in the incorporation of Y90-SIRT with glass microspheres into the treatment guidelines as a standard therapy option for patients with intermediate and advanced stage hepatocellular carcinoma

  7. Yttrium-90 selective internal radiation therapy with glass microspheres for hepatocellular carcinoma: Current and updated literature review

    Energy Technology Data Exchange (ETDEWEB)

    Lee, Edward Wolfgang; Alanic, Lourdes [Div. of Interventional Radiology, Dept. of Radiology, UCLA Medical Center, David Geffen School of Medicine at UCLA, Los Angeles (United States); Cho, Sung Ki [Div. of Interventional Radiology, Dept. of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (Korea, Republic of); Saab, Sammy [Div. of Hepatology, Dept. of Medicine, Pfleger Liver Institute, University of California at Los Angeles, Los Angeles (United States)

    2016-07-15

    Hepatocellular carcinoma is the most common primary liver cancer and it represents the majority of cancer-related deaths in the world. More than 70% of patients present at an advanced stage, beyond potentially curative options. Ytrrium-90 selective internal radiation therapy (Y90-SIRT) with glass microspheres is rapidly gaining acceptance as a potential therapy for intermediate and advanced stage primary hepatocellular carcinoma and liver metastases. The technique involves delivery of Y90 infused glass microspheres via the hepatic arterial blood flow to the appropriate tumor. The liver tumor receives a highly concentrated radiation dose while sparing the healthy liver parenchyma due to its preferential blood supply from portal venous blood. There are two commercially available devices: TheraSphere® and SIR-Spheres®. Although, Y90-SIRT with glass microspheres improves median survival in patients with intermediate and advanced hepatocellular carcinoma and has the potential to downstage hepatocellular carcinoma so that the selected candidates meet the transplantable criteria, it has not gained widespread acceptance due to the lack of large randomized controlled trials. Currently, there are various clinical trials investigating the use of Y90-SIRT with glass microspheres for treatment of hepatocellular carcinoma and the outcomes of these trials may result in the incorporation of Y90-SIRT with glass microspheres into the treatment guidelines as a standard therapy option for patients with intermediate and advanced stage hepatocellular carcinoma.

  8. Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review.

    Science.gov (United States)

    Lee, Edward Wolfgang; Alanis, Lourdes; Cho, Sung-Ki; Saab, Sammy

    2016-01-01

    Hepatocellular carcinoma is the most common primary liver cancer and it represents the majority of cancer-related deaths in the world. More than 70% of patients present at an advanced stage, beyond potentially curative options. Ytrrium-90 selective internal radiation therapy (Y90-SIRT) with glass microspheres is rapidly gaining acceptance as a potential therapy for intermediate and advanced stage primary hepatocellular carcinoma and liver metastases. The technique involves delivery of Y90 infused glass microspheres via the hepatic arterial blood flow to the appropriate tumor. The liver tumor receives a highly concentrated radiation dose while sparing the healthy liver parenchyma due to its preferential blood supply from portal venous blood. There are two commercially available devices: TheraSphere® and SIR-Spheres®. Although, Y90-SIRT with glass microspheres improves median survival in patients with intermediate and advanced hepatocellular carcinoma and has the potential to downstage hepatocellular carcinoma so that the selected candidates meet the transplantable criteria, it has not gained widespread acceptance due to the lack of large randomized controlled trials. Currently, there are various clinical trials investigating the use of Y90-SIRT with glass microspheres for treatment of hepatocellular carcinoma and the outcomes of these trials may result in the incorporation of Y90-SIRT with glass microspheres into the treatment guidelines as a standard therapy option for patients with intermediate and advanced stage hepatocellular carcinoma.

  9. SU-G-201-12: Investigation of Beta-Emitter 90Sr-90Y Dose Distribution Using Gafchromic EBT3 Film for Application On Conformal Skin Brachytherapy Device

    International Nuclear Information System (INIS)

    Ferreira, C; Johnson, D; Ahmad, S; Rasmussen, K; Jung, J

    2016-01-01

    Purpose: To investigate 90 Sr- 90 Y as a high dose rate (HDR) source for application in a conformal skin brachytherapy (CSBT) device. The CSBT device has been previously developed to provide patient specific treatment for small inoperable lesions and irregular surfaces. Methods: A popular beta emitter, 90 Sr- 90 Y was tested for feasibility in a CSBT device. A 1 cm diameter plaque was used to deliver dose to a solid water phantom containing EBT3 Gafchromic films arranged at the surface and perpendicular to it. Additionally, a 1 cm diameter 6 MeV electron beam was used to irradiate EBT3 film at 100 cm SSD with a 0.5 cm bolus. Films were digitized with an Epson Expression 10000 XL scanner and calibrated with a 6 MeV electron specific dose curve. Normalized percent depth doses (PDD) and dose profiles for both techniques were analyzed using ImageJ. Results: Dose distributions achieved with the 90 Sr- 90 Y sources were compared with those of external electron beam radiation therapy (EBRT). Penumbra (20%- 80%) for EBRT and 90Sr-90Y were 4.3 mm and 1.6 mm, respectively. PDD values of 50% (normalized to 2 mm) were 10.1 mm and 2.8 mm for electron and 90 Sr- 90 Y, respectively. Flatness (80% of the central beam profile) was 14.1% at a 5 mm depth for EBRT and 4.0% at surface for the 90 Sr- 90 Y. Conclusion: As expected, the PDDs of 90 Sr- 90 Y in water are shallower than that of external electron beams for the same field size. 90 Sr- 90 Y can be used in CSBT to provide patient specific treatment where shallower depth doses than that provided by electron external beams may be required: e.g. eyelids, nose, lips, ears, etc. The customizability of EBRT could be replicated by using multiple adjacent 90 Sr- 90 Y plaque placements.

  10. SU-G-201-12: Investigation of Beta-Emitter 90Sr-90Y Dose Distribution Using Gafchromic EBT3 Film for Application On Conformal Skin Brachytherapy Device

    Energy Technology Data Exchange (ETDEWEB)

    Ferreira, C; Johnson, D; Ahmad, S [University of Oklahoma Health Sciences Center, Oklahoma City, OK (United States); Rasmussen, K [University of Texas HSC SA, San Antonio, TX (United States); Jung, J [East Carolina University Greenville, NC (United States)

    2016-06-15

    Purpose: To investigate {sup 90}Sr-{sup 90}Y as a high dose rate (HDR) source for application in a conformal skin brachytherapy (CSBT) device. The CSBT device has been previously developed to provide patient specific treatment for small inoperable lesions and irregular surfaces. Methods: A popular beta emitter, {sup 90}Sr-{sup 90}Y was tested for feasibility in a CSBT device. A 1 cm diameter plaque was used to deliver dose to a solid water phantom containing EBT3 Gafchromic films arranged at the surface and perpendicular to it. Additionally, a 1 cm diameter 6 MeV electron beam was used to irradiate EBT3 film at 100 cm SSD with a 0.5 cm bolus. Films were digitized with an Epson Expression 10000 XL scanner and calibrated with a 6 MeV electron specific dose curve. Normalized percent depth doses (PDD) and dose profiles for both techniques were analyzed using ImageJ. Results: Dose distributions achieved with the {sup 90}Sr-{sup 90}Y sources were compared with those of external electron beam radiation therapy (EBRT). Penumbra (20%- 80%) for EBRT and 90Sr-90Y were 4.3 mm and 1.6 mm, respectively. PDD values of 50% (normalized to 2 mm) were 10.1 mm and 2.8 mm for electron and {sup 90}Sr-{sup 90}Y, respectively. Flatness (80% of the central beam profile) was 14.1% at a 5 mm depth for EBRT and 4.0% at surface for the {sup 90}Sr-{sup 90}Y. Conclusion: As expected, the PDDs of {sup 90}Sr-{sup 90}Y in water are shallower than that of external electron beams for the same field size. {sup 90}Sr-{sup 90}Y can be used in CSBT to provide patient specific treatment where shallower depth doses than that provided by electron external beams may be required: e.g. eyelids, nose, lips, ears, etc. The customizability of EBRT could be replicated by using multiple adjacent {sup 90}Sr-{sup 90}Y plaque placements.

  11. Evaluation of quantitative planar 90Y bremsstrahlung whole-body imaging

    International Nuclear Information System (INIS)

    Minarik, D; Ljungberg, M; Gleisner, K Sjoegreen; Segars, P

    2009-01-01

    With high-dose administration of 90 Y labeled antibodies, it is possible to image 90 Y without an admixture of 111 In. We have earlier shown that it is possible to perform quantitative 90 Y bremsstrahlung SPECT for dosimetry purposes with reasonable accuracy. However, whole-body (WB) activity quantification with the conjugate view method is not as time consuming as SPECT and has been the method of choice for dosimetry. We have investigated the possibility of using a conjugate view method where scatter-, backscatter- and septal-penetration compensations are performed by inverse filtering and attenuation correction is performed with a WB x-ray image, for total-body and organ activity quantification of 90 Y. The method was evaluated using both Monte Carlo simulated scintillation camera images using realistic source distributions, and by an experimental phantom study. The method was evaluated in terms of image quality and accuracy of the activity quantification. The experimental phantom study was performed using the RSD torso phantom with 90 Y activity uniformly distributed in the liver insert. A GE Discovery VH/Hawkeye system was used to acquire the image. The simulation study was performed for a realistic activity distribution in the NCAT anthropomorphic phantom where 90 Y bremsstrahlung images were generated using the SIMIND MC program. Two different phantom configurations and two activity distributions were simulated. To mimic the RSD phantom experiment one simulation study was also made with 90 Y activity located only in the liver. The SIMIND program was configured to resemble a GE Discovery VH/Hawkeye system. An x-ray projector program was used to generate whole-body x-ray images from the NCAT phantom for attenuation correction in the conjugate view method. Organ activities were calculated from ROIs that exactly covered the organs. Corrections for background activity, overlapping activity and source extension in the depth direction were applied on the ROI data

  12. Comparative effects of inhaled relatively insoluble forms of 90Y, 144Ce, and 90Sr on canine peripheral lymphocyte function

    International Nuclear Information System (INIS)

    Benjamin, S.A.; Jones, R.K.; Snipes, M.B.; Lustgarten, C.S.

    1976-01-01

    Dogs that have inhaled relatively insoluble forms of either alpha- or beta-emitting radionuclides manifest a peripheral lymphopenia, the development and course of which depends on both total dose and dose rate. The remaining peripheral lymphocytes in dogs exposed to longer lived beta-emitting radionuclides showed a depressed function as measured by the ability to respond to plant mitogens in vitro. This experiment was designed to evaluate the effect of dose rate on peripheral lymphocyte function by exposing dogs to aerosols of radionuclides with varied effective half-lives in the lung: 90 Y (2.6 days), 144 Ce (170 days), and 90 Sr (650 days). Three groups of four adult beagle dogs each were exposed by inhalation to 90 Y, 144 Ce, or 90 Sr in fused-clay particles. Two controls were matched with each group. Initial lung burdens and initial dose rates to the lung were 520 to 610 μCi/kg of body weight and 2200 to 2600 rads/day in the 90 Y group, 33 to 60 μCi/kg and 200 to 350 rads/day in the 144 Ce group, and 25 to 32 μCi/kg and 130 to 170 rads/day in the 90 Sr group. Hematologic parameters and lymphocyte function as measured by the ability of lymphocytes to respond to plant mitogen stimulation were evaluated on a weekly or biweekly basis for 8 weeks after exposure and on a monthly basis thereafter. The 90 Y-exposed dogs showed a marked lymphopenia within 1 week with a return to control levels by 20 weeks after exposure. The remaining peripheral lymphocytes, however, showed no functional changes in these dogs. Animals exposed to 144 Ce or 90 Sr developed a progressive and persisent lymphopenia and showed functional depression of the remaining lymphocytes as well. The relationships among dose pattern, lymphopenia, and lymphocyte-function depression are discussed

  13. Practical reconstruction protocol for quantitative 90Y bremsstrahlung SPECT/CT

    International Nuclear Information System (INIS)

    Siman, W.; Mikell, J. K.; Kappadath, S. C.

    2016-01-01

    Purpose: To develop a practical background compensation (BC) technique to improve quantitative 90 Y-bremsstrahlung single-photon emission computed tomography (SPECT)/computed tomography (CT) using a commercially available imaging system. Methods: All images were acquired using medium-energy collimation in six energy windows (EWs), ranging from 70 to 410 keV. The EWs were determined based on the signal-to-background ratio in planar images of an acrylic phantom of different thicknesses (2–16 cm) positioned below a 90 Y source and set at different distances (15–35 cm) from a gamma camera. The authors adapted the widely used EW-based scatter-correction technique by modeling the BC as scaled images. The BC EW was determined empirically in SPECT/CT studies using an IEC phantom based on the sphere activity recovery and residual activity in the cold lung insert. The scaling factor was calculated from 20 clinical planar 90 Y images. Reconstruction parameters were optimized in the same SPECT images for improved image quantification and contrast. A count-to-activity calibration factor was calculated from 30 clinical 90 Y images. Results: The authors found that the most appropriate imaging EW range was 90–125 keV. BC was modeled as 0.53× images in the EW of 310–410 keV. The background-compensated clinical images had higher image contrast than uncompensated images. The maximum deviation of their SPECT calibration in clinical studies was lowest (<10%) for SPECT with attenuation correction (AC) and SPECT with AC + BC. Using the proposed SPECT-with-AC + BC reconstruction protocol, the authors found that the recovery coefficient of a 37-mm sphere (in a 10-mm volume of interest) increased from 39% to 90% and that the residual activity in the lung insert decreased from 44% to 14% over that of SPECT images with AC alone. Conclusions: The proposed EW-based BC model was developed for 90 Y bremsstrahlung imaging. SPECT with AC + BC gave improved lesion detectability and activity

  14. Labelling of 90Y- and 177Lu-DOTA-Bioconjugates for Targeted Radionuclide Therapy: A Comparison among Manual, Semiautomated, and Fully Automated Synthesis

    Directory of Open Access Journals (Sweden)

    Michele Iori

    2017-01-01

    Full Text Available In spite of the hazard due to the radiation exposure, preparation of 90Y- and 177Lu-labelled radiopharmaceuticals is still mainly performed using manual procedures. In the present study the performance of a commercial automatic synthesizer based on disposable cassettes for the labelling of 177Lu- and 90Y-DOTA-conjugated biomolecules (namely, DOTATOC and PSMA-617 was evaluated and compared to a manual and a semiautomated approach. The dose exposure of the operators was evaluated as well. More than 300 clinical preparations of both 90Y- and 177Lu-labelled radiopharmaceuticals have been performed using the three different methods. The mean radiochemical yields for 90Y-DOTATOC were 96.2±4.9%, 90.3±5.6%, and 82.0±8.4%, while for 177Lu-DOTATOC they were 98.3%  ± 0.6, 90.8%  ± 8.3, and 83.1±5.7% when manual, semiautomated, and automated approaches were used, respectively. The mean doses on the whole hands for yttrium-90 preparations were 0.15±0.4 mSv/GBq, 0.04±0.1 mSv/GBq, and 0.11±0.3 mSv/GBq for manual, semiautomated, and automated synthesis, respectively, and for lutetium-177 preparations, they were 0.02±0.008 mSv/GBq, 0.01±0.03 mSv/GBq, and 0.01±0.02 mSv/GBq, respectively. In conclusion, the automated approach guaranteed reliable and reproducible preparations of pharmaceutical grade therapeutic radiopharmaceuticals in a decent RCY. The radiation exposure of the operators remained comparable to the manual approach mainly due to the fact that a dedicated shielding was still not available for the system.

  15. The solvent extraction of carrier-free 90Y from 90Sr with crown ethers

    International Nuclear Information System (INIS)

    Chuang, J.T.; Lo, J.G.

    1995-01-01

    A simple solvent extraction method has been developed for the separation of 90 Y from 90 Sr. Crown ether dissolved in chloroform was used as a selective reagent and organic picrate anion was chosen as a counter ion. The effect of various factors on the extraction equilibrium constant of strontium log K ex = 9.15 was obtained from the study of the distribution coefficient versus to crown ether concentration. The separation method was simple, resulted high purity (>99.9%) and quantitative yield, and took less than half an hour. (author) 27 refs.; 4 figs.; 4 tabs

  16. Standardization of Procedures for the Preparation of (177)Lu- and (90)Y-labeled DOTA-Rituximab Based on the Freeze-dried Kit Formulation.

    Science.gov (United States)

    Wojdowska, Wioletta; Karczmarczyk, Urszula; Maurin, Michal; Garnuszek, Piotr; Mikołajczak, Renata

    2015-01-01

    Rituximab when radiolabelled with (177)Lu or (90)Y has been investigated for the treatment of patients with Non-Hodgkin's Lymphoma. In this study, we optimized the preparation of antibody conjugates with chelating agent in the freeze-dried kit. It shortens procedures needed for the successful radiolabeling with lutetium-177 and yttrium-90 and assures reproducible labelling yields. Various molar ratios of Rituximab:DOTA (from 1:5 to 1:100) were used at the conjugation step and different purification method to remove unbound DOTA were investigated (size-exclusion chromatography, dialysis, ultrafiltration). The final monoclonal antibody concentration was quantified by Bradford method, and the number of DOTA molecules was determined by radiolabeling assay using (64)Cu. The specific activity of (177)Lu-DOTA-Rituximab and (90)Y-DOTA-Rituximab were optimized using various amounts of radiometal. Quality control (SE-HPLC, ITLC) and stability study were performed. An average of 4.2 ± 0.8 p-SCN-Bz-DOTA molecules could be randomly conjugated to a single molecule of Rituximab. The ultrafiltration system was the most efficient for purification and resulted in the highest recovery efficiency (77.2%). At optimized conditions the (177)Lu-DOTARituximab and (90)Y-DOTA-Rituximab were obtained with radiochemical purity >99% and specific activity ca. 600 MBq/mg. The radioimmunoconjugates were stable in human serum and 0.9% NaCl. After 72 h of incubation the radiochemical purity of (177)Lu-DOTA-Rituximab decreased to 94% but it was still more than 88% for (90)Y-DOTA-Rituximab. The radioimmunoconjugate showed stability after six months storage at 2 - 8(0)C, as a lyophilized formulation. Our study shows that Rituximab-DOTA can be efficiently radiolabeled with (177)Lu and (90)Y via p-SCN-Bn-DOTA using a freezedried kit.

  17. Study and industrial applications of the external slowing-down {beta}{sup -} radiation of the yttrium - 90; Etude et applications industrielles du rayonnement de freinage externe des {beta}{sup -} de l'yttrium - 90

    Energy Technology Data Exchange (ETDEWEB)

    Leveque, P; Martinelli, P; Chauvin, R [Commissariat a l' Energie Atomique, Saclay (France). Centre d' Etudes Nucleaires

    1955-07-01

    Inelastic scattering of the {beta}{sup -} particles on the nucleus gives place to the emission of a X-ray Bremsstrahlung radiation. In view of possible industrial applications, we studied the slowing-down radiation of {sup 90}(Sr + Y) sources in various materials. This pure {beta}{sup -} emitter of long period is in the fission products of uranium. Among of the industrial applications, these sources of weak X-rays energy can be used for the radiography of thin pieces, for measuring the thickness, or for the analysis by fluorescence. (M.B.) [French] La diffusion inelastique des particules {beta}{sup -} sur les noyaux donne lieu a l'emission d'un rayonnement X de freinage. En vue de possibles applications industrielles, nous avons etudie le rayonnement de freinage des sources {sup 90}(Sr + Y) dans divers materiaux. Cet emetteur {beta}{sup -} pur a longue periode se trouve dans les produits de fission de l'uranium. Parmi les applications industrielles a l'etude, ces sources de rayons X de faible energie peuvent etre utilisees pour la radiographie de pieces minces, la mesure d'epaisseurs, ou encore pour l'analyse par fluorescence. (M.B.)

  18. Evaluation of the parameters of SPECT images for yttrium-90 in radiosinoviorthesis; Avaliação dos parâmetros de aquisição de imagens SPECT para ítrio-90 em radiosinoviortese

    Energy Technology Data Exchange (ETDEWEB)

    Toledo, B.C. de; Sáa, L.V. de, E-mail: bruce.de.toledo@gmail.com [Instituto de Radioproteção e Dosimetria (IRD/CNEN-RJ), Rio de Janeiro, RJ (Brazil). Física Médica; Ramos, S.M.; Coelho, F.A.; Thomas, S.; Souza, S.A. de; Pinheiro, M.A. [Universidade Federal do Rio de Janeiro (UFRJ), RJ (Brazil). Hospital Universitário Clementino Fraga Filho

    2017-07-01

    Introduction: the evaluation of the distribution of radioactive material in the articulation by SPECT images after radiosinoviorthesis (RSO) can guarantee the efficacy of this therapy. However, Bremsstrahlung image quality has major limitations, necessitating studies on SPECT image acquisition parameters and yttrium-90 image reconstruction methods. Methods: SPECT images were obtained from an acrylic simulator containing four cylindrical inserts to simulate capturing lesions. The images were obtained with collimators of high, medium and low (HEGP, MEGP and LEHR) energy; 130 keV power window, 70% width and 64 x 64 matrix. The reconstruction methods used were: FBP and OSEM with different filters. Results: 45 results found. The images obtained with the MEGP and HEGP collimators presented better results than those obtained with the LEHR collimator. The OSEM reconstructions were superior when the MEGP and HEGP collimators were used. Conclusions: The acquisition of yttrium-90 SPECT images with MEGP collimators showed higher sensitivity, whereas those obtained with HEPG collimators presented lower noise. The image reconstruction methods have relevant importance in the image quality, showing a significant difference between the FBP and OSEM reconstructions and between the filters used.

  19. Temporary Arterial Balloon Occlusion as an Adjunct to Yttrium-90 Radioembolization

    Energy Technology Data Exchange (ETDEWEB)

    Hagspiel, Klaus D., E-mail: kdh2n@virginia.edu [University of Virginia Health System, Department of Radiology and Medical Imaging (United States); Nambiar, Ashwin, E-mail: uvashwin@gmail.com [SUNY Downstate Medical Center, Department of Radiology (United States); Hagspiel, Lauren M., E-mail: lmh4gg@virginia.edu [University of Virginia, College of Arts and Sciences (United States); Ahmad, Ehab Ali, E-mail: ehabradiodiagnosis@yahoo.com [Minia University, Department of Radiology (Egypt); Bozlar, Ugur, E-mail: ubozlar@yahoo.com [Gulhane Military Medical Academy, Department of Radiology (Turkey)

    2013-06-15

    Purpose. This study was designed to describe the technique of arterial occlusion using a temporary occlusion balloon system as an alternative to coil occlusion during Yttrium-90 radioembolization of hepatic tumors. Methods. Review of charts, angiography, and follow-up imaging studies of consecutive patients undergoing oncological embolization procedures in which a HyperForm system (ev3 Neurovascular, Irvine, CA) was used. Intraprocedural target vessel occlusion and patency of the target vessel on follow-up were recorded. Clinical data and Bremsstrahlung scans were reviewed for evidence of nontarget embolization. Results. Four radioembolization procedures were performed in three patients (all female, age 48-54 (mean 52) years). Five arteries were temporarily occluded (three gastroduodenal arteries, one right gastric artery, and one cystic artery). All radioembolization procedures were successfully completed. Follow-up imaging (either digital subtraction angiography (DSA) or computed tomography angiography (CTA)) was available for all patients between 28-454 (mean 183) days following the procedure, demonstrating all five vessels to be patent. No clinical or imaging evidence for nontarget embolization was found. Conclusions. Temporary balloon occlusion of small and medium-sized arteries during radioembolization allows safe therapy with preserved postprocedural vessel patency on early and midterm follow-up.

  20. Use of yttrium-90 hydroxyapatite radiosynovectomy as a primary modality of treatment in diffuse pigmented villonodular synovitis of the knee joint: A first case report

    International Nuclear Information System (INIS)

    Kamaleshwaran, Koramadai Karuppusamy; Rajan, David; Krishnan, Boopathi; Gounder, Thirumalaisamy Subbaih; Chakraborty, Sudipta; Kalarickal, Radhakrishnan; Mohanan, Vyshakh; Shinto, Ajit Sugunan

    2015-01-01

    Pigmented villonodular synovitis (PVNS) is a rare, relatively benign, intra-articular lesion characterized by a slowly progressive proliferation of synovial tissue. Knee is the most frequently involved joint. Localized and diffuse forms of synovial involvement were reported. In extensive diffuse cases, total synovectomy is needed, almost impossible to achieve. Hence, other treatment modalities such as intra-articular injection of yttrium-90 have been tried and shown to be effective in reducing the rate of local recurrence with “acceptable” joint damage. Radiosynovectomy is based on the irradiation of the joint synovium by the intra-articular administration of various β-emitting radiopharmaceuticals. We describe the first case report of use of yttrium-90 hydroxyapatite particulates in a 33-year-old male who presented with diffuse PVNS of knee joint as a primary modality of treatment

  1. Results of radiosynoviorthesis with yttrium 90 in cases of chronic synovitis

    International Nuclear Information System (INIS)

    Schuette, H.

    1982-01-01

    The goal of this study was to answer the following questions: Is the outcome of radiosynoviorthesis with 90 Y in patients who suffer from a chronic polyarthritis dependent on the stage according to Steinbrocker and does this dependency change when the results are measured 1/2 to 3 years later? Is there a difference between the effect of 90 Y on the joints of seropositive and seronegative patients? How are the results of radiosynoviorthesis in patients who suffer under other chronic joint diseases? What is the success distribution of re-synoviorthesis in evaluated patients? Is there a difference in the effectiveness of radiosynoviorthesis between joints in stage I and stage II and is the outcome dependent on whether or not degenerative changes are already present? Is the effect of radiosynoviorthesis, measured after one year, dependent on the duration of the disease in the treated joint or on the process activity of the disease? Is there a connection between the outcome of radiosynoviorthesis and the laboratory parameters of blood sedimentation and hemoglobin content? Does radiosynoviorthesis influence the number of medically induced, intra-articular injections and punctures in the treated joint? Is there a connection between radiosynoviorthesis outcomes and common therapy outcomes? What side effects of radiosynoviorthesis therapy were observed? (orig./MG) [de

  2. Depth dose distribution in the water for clinical applicators of 90Sr + 90Y, with a extrapolation mini chamber

    International Nuclear Information System (INIS)

    Antonio, Patricia de Lara; Caldas, Linda V.E.; Oliveira, Mercia L.

    2009-01-01

    This work determines the depth dose in the water for clinical applicators of 90 Sr + 90 Y, using a extrapolation mini chamber developed at the IPEN, Sao Paulo, Brazil, and different thickness acrylic plates. The obtained results were compared with the international recommendations and were considered satisfactory

  3. Large-scale purification of 90Sr from nuclear waste materials for production of 90Y, a therapeutic medical radioisotope.

    Science.gov (United States)

    Wester, Dennis W; Steele, Richard T; Rinehart, Donald E; DesChane, Jaquetta R; Carson, Katharine J; Rapko, Brian M; Tenforde, Thomas S

    2003-07-01

    A major limitation on the supply of the short-lived medical isotope 90Y (t1/2 = 64 h) is the available quantity of highly purified 90Sr generator material. A radiochemical production campaign was therefore undertaken to purify 1,500 Ci of 90Sr that had been isolated from fission waste materials. A series of alkaline precipitation steps removed all detectable traces of 137Cs, alpha emitters, and uranium and transuranic elements. Technical obstacles such as the buildup of gas pressure generated upon mixing large quantities of acid with solid 90Sr carbonate were overcome through safety features incorporated into the custom-built equipment used for 90Sr purification. Methods are described for analyzing the chemical and radiochemical purity of the final product and for accurately determining by gravimetry the quantities of 90Sr immobilized on stainless steel filters for future use.

  4. Large-scale purification of 90Sr from nuclear waste materials for production of 90Y, a therapeutic medical radioisotope

    International Nuclear Information System (INIS)

    Wester, D.W.; Steele, R.T.; Rinehart, D.E.; DesChane, J.R.; Carson, K.J.; Rapko, B.M.; Tenforde, T.S.

    2003-01-01

    A major limitation on the supply of the short-lived medical isotope 90 Y (t 1/2 =64 h) is the available quantity of highly purified 90 Sr generator material. A radiochemical production campaign was therefore undertaken to purify 1500 Ci of 90 Sr that had been isolated from fission waste materials. A series of alkaline precipitation steps removed all detectable traces of 137 Cs, alpha emitters, and uranium and transuranic elements. Technical obstacles such as the buildup of gas pressure generated upon mixing large quantities of acid with solid 90 Sr carbonate were overcome through safety features incorporated into the custom-built equipment used for 90 Sr purification. Methods are described for analyzing the chemical and radiochemical purity of the final product and for accurately determining by gravimetry the quantities of 90 Sr immobilized on stainless steel filters for future use

  5. {sup 18}F-FDG PET/CT predicts survival after {sup 90}Y transarterial radioembolization in unresectable hepatocellular carcinoma

    Energy Technology Data Exchange (ETDEWEB)

    Jreige, Mario; Mitsakis, Periklis; Gucht, Axel van der; Pomoni, Anastasia; Silva-Monteiro, Marina; Boubaker, Ariane; Nicod-Lalonde, Marie; Prior, John O.; Schaefer, Niklaus [Lausanne University Hospital, Department of Nuclear Medicine and Molecular Imaging, Lausanne (Switzerland); Gnesin, Silvano [Lausanne University Hospital, Institute of Radiation Physics, Lausanne (Switzerland); Duran, Rafael; Denys, Alban [Lausanne University Hospital, Department of Radiodiagnostic and Interventional Radiology, Lausanne (Switzerland)

    2017-07-15

    To compare the value of pretreatment functional and morphological imaging parameters for predicting survival in patients undergoing transarterial radioembolization using yttrium-90 ({sup 90}Y-TARE) for unresectable hepatocellular carcinoma (uHCC). We analysed data from 48 patients in our prospective database undergoing {sup 90}Y-TARE treatment for uHCC (31 resin, 17 glass). All patients underwent {sup 18}F-FDG PET/CT and morphological imaging (CT and MRI scans) as part of a pretherapeutic work-up. Patients did not receive any treatment between these imaging procedures and {sup 90}Y-TARE. Kaplan-Meier estimates of progression-free survival (PFS) and overall survival (OS) were used to assess the prognostic value of {sup 18}F-FDG PET/CT metabolic parameters, including SUV{sub max}, tumour-to-liver (T/L) uptake ratio and SUV{sub mean} of healthy liver, and morphological data, including number and size of lesions, portal-venous infiltration (PVI). Relevant prognostic factors for HCC including Child-Pugh class, Barcelona Clinic Liver Cancer (BCLC) stage, tumour size, PVI and serum AFP level were compared with metabolic parameters in univariate and multivariate analyses. The median follow-up in living patients was 16.2 months (range 11.4-50.1 months). Relapse occurred in 34 patients (70.8%) at a median of 7.4 months (range 1.4-27.9 months) after {sup 90}Y-TARE, and relapse occurred in 24 of 34 patients (70.8%) who died from their disease at a median of 8.1 months (range 2.2-35.2 months). Significant prognostic markers for PFS were the mean and median lesion SUV{sub max} (both P = 0.01; median PFS 10.2 vs. 7.4 months), and significant prognostic markers for OS were the first quarter (Q1) cut-off values for lesion SUV{sub max} and T/L uptake ratio (both P = 0.02; median OS 30.9 vs. 9 months). The multivariate analysis confirmed that lesion SUV{sub max} and T/L uptake ratio were independent negative predictors of PFS (hazard ratio, HR, 2.7, 95% CI 1.2-6.1, P = 0.02, for mean

  6. Radiolabeling, characterization and preliminary studies of 90Y-octreotate

    International Nuclear Information System (INIS)

    Klementyeva, O.E.; Bruskin, A.B.; Larenkov, A.A.; Kodina, G.E.; Korsunsky, V.N.

    2015-01-01

    Full text of publication follows. Introduction: Overexpression of the somatostatin receptors in neuroendocrine tumors has become the molecular basis for the use of somatostatin analogues in diagnosis and therapy for these neoplasms. The high energy (maximum 2.2 MeV) and penetration range (R 95 5.7 mm) of β-particles from 90 Y are advantageous, with a direct killing of somatostatin receptor positive cells and a crossfire effect which hits nearby receptor-negative tumour cells [Ref. 1]. Aim: the investigation of the reaction conditions for the preparation of 90 Y-Octreotate and its in vitro characterization. Materials and methods: DOTA-Octreotate (Farm-Syntez Ltd.) and 88 YCl 3 (V/O Isotop) were used without purification. 88 Y-Octreotate was prepared in acetate buffer solution and its radiochemical purity was controlled by ITLC. In-vitro experiments were carried out with melanoma B16. Studies of internalization were performed as described in [Ref. 2]. Results: the maximal accumulation in the cells was observed after 90 min from the beginning of incubation and was about 3.9%. In our experiments, we found high level of internalization of the surface-bound 88 Y-Octreotate into B16 cells. Maximal internalization level was 80% after 60 min of incubation. Conclusion: the optimal conditions for effective labeling (> 95%) of DOTA-Octreotate were found. The results obtained using the gamma-emitting 88 Y, provide a basis for in vivo research 90 Y octreotate as radiotherapeutic agent. References: [Ref. 1] Bodei, L.; Pepe, G.; Paganelli, G.; Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues. Eur. Rev. Med. Pharmacol. Sci., 2010; v. 14: 347-351. [Ref. 2] Garcia Garayoa E., Allemann-Tannahill L., et al. In vitro and in vivo evaluation of new radiolabeled neurotensin (8-13) analogs with high affinity for NT1 receptors. Nucl. Med. Biol. 2001; 28: 75-84. (authors)

  7. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities.

    Science.gov (United States)

    Goin, James E; Salem, Riad; Carr, Brian I; Dancey, Janet E; Soulen, Michael C; Geschwind, Jean Francois H; Goin, Kathleen; Van Buskirk, Mark; Thurston, Kenneth

    2005-02-01

    Intraarterial injection of yttrium 90 microspheres (TheraSpheres) is used in the treatment of hepatocellular carcinoma (HCC). This article presents an analysis of the incidence of liver toxicities (liver-related events) and pretreatment factors associated with liver toxicities after TheraSphere treatment. Eighty-eight TheraSphere-treated patients with low 90-day mortality risk were selected for analysis, with liver toxicities coded with use of standard oncology criteria. Descriptive and inferential statistical methods were applied to estimate the incidence of liver toxicities and to evaluate the influence of liver radiation dose and various pretreatment factors on the risk of their occurrence. Sixty-eight liver toxicities occurred in 37 of the 88 patients (42%). Thirty-two patients (36%) experienced 50 liver toxicities after the first treatment and nine of 23 patients (39%) who received a second treatment experienced 18 liver toxicities. Pretreatment total bilirubin and liver radiation dose were found to be associated with the risk of at least one liver toxicity and with the time to first occurrence of a liver toxicity after first treatment. Pretreatment total bilirubin also was associated with liver toxicities after the second treatment. Most of the toxicities resolved; however, those that did not resolve were attributed to tumor progression or advancing cirrhosis. The risk of liver toxicities in patients with unresectable HCC treated with TheraSpheres increases with increasing pretreatment total bilirubin level and liver radiation dose to a maximum of 150 Gy for a single administration. The toxicities attributed to treatment resolved over time, and none of the patients studied had confirmed radiation-induced liver disease. Consequently, doses as high as 150 Gy on a single administration and as high as 268 Gy on repeated administrations were well tolerated.

  8. Radiation Safety in Production of Y-90 from an electrochemical generator. CENTIS experience

    International Nuclear Information System (INIS)

    Ayra Pardo, Fernando Enrique

    2016-01-01

    From a project with the International Atomic Energy Agency, Isotope Center installation and commissioning began operating an electrochemical generator of Sr-90 / Y-90 inside a glove box shielded. The aim was to ensure the production of Y-90 needed in the research carried out in Cuba with this radionuclide for the medical industry. Associate at the beginning of this practice, compliance with all regulatory requirements approved in the country from the radiological point of view that demonstrated the safety of this for both operators and the general public became necessary. Using the MCNPX code generator installation was simulated and the equivalent dose Hp (10) were obtained for the operator: 6.27 mSv / y Hp (0.07): 17 mSv / a for a source of 10 Ci of 90 Sr- 90 Y . Also the use of TLD dosimeters similar to those used for gamma emitting radionuclides for controlling beta exposures was evaluated. high sensitivity lithium fluoride tablets couple energy beta particles of Y-90 which ensures its use for measuring the magnitude Hp (007) was demonstrated. two possible solutions for the recovery of liquid waste 90 Sr one another by distillation and ion exchange are evaluated. To transport the Y-90 may be used the package currently used in marketing the rest of the CENTIS radiopharmaceuticals. As a final result, the practice was approved and included in the Operating License Center Isotopes. (author)

  9. Practical reconstruction protocol for quantitative {sup 90}Y bremsstrahlung SPECT/CT

    Energy Technology Data Exchange (ETDEWEB)

    Siman, W.; Mikell, J. K.; Kappadath, S. C., E-mail: skappadath@mdanderson.org [Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 and The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas 77030 (United States)

    2016-09-15

    Purpose: To develop a practical background compensation (BC) technique to improve quantitative {sup 90}Y-bremsstrahlung single-photon emission computed tomography (SPECT)/computed tomography (CT) using a commercially available imaging system. Methods: All images were acquired using medium-energy collimation in six energy windows (EWs), ranging from 70 to 410 keV. The EWs were determined based on the signal-to-background ratio in planar images of an acrylic phantom of different thicknesses (2–16 cm) positioned below a {sup 90}Y source and set at different distances (15–35 cm) from a gamma camera. The authors adapted the widely used EW-based scatter-correction technique by modeling the BC as scaled images. The BC EW was determined empirically in SPECT/CT studies using an IEC phantom based on the sphere activity recovery and residual activity in the cold lung insert. The scaling factor was calculated from 20 clinical planar {sup 90}Y images. Reconstruction parameters were optimized in the same SPECT images for improved image quantification and contrast. A count-to-activity calibration factor was calculated from 30 clinical {sup 90}Y images. Results: The authors found that the most appropriate imaging EW range was 90–125 keV. BC was modeled as 0.53× images in the EW of 310–410 keV. The background-compensated clinical images had higher image contrast than uncompensated images. The maximum deviation of their SPECT calibration in clinical studies was lowest (<10%) for SPECT with attenuation correction (AC) and SPECT with AC + BC. Using the proposed SPECT-with-AC + BC reconstruction protocol, the authors found that the recovery coefficient of a 37-mm sphere (in a 10-mm volume of interest) increased from 39% to 90% and that the residual activity in the lung insert decreased from 44% to 14% over that of SPECT images with AC alone. Conclusions: The proposed EW-based BC model was developed for {sup 90}Y bremsstrahlung imaging. SPECT with AC + BC gave improved lesion

  10. 90Y production of high purity by electrochemical separation

    International Nuclear Information System (INIS)

    Alberti Ramírez, Alejandro; Serra Águila, Rolando; Morín Zorrilla, José Antonio; Pino Peraza, Madián; Soler Iglesias, Joel; Cruz Morales, Amed

    2016-01-01

    In this paper 90 Y is obtained without added carrier, by electrolytic separation from a solution in secular equilibrium Sr-Y and further purification in three cycles electrolytic automated, at constant current. The process productivity was 60-80 mCi (2220-2960 MBq). The long half-life of 90 Sr to be used by virtually indefinitely ensuring the stability of the raw material for generator operation, which helps sustainability and production stability. In 18 productions to date could be found to both content of 90 Sr equal to 0.110 ± 0.004 (k = 2) kBq / g by various methods, for their ability combination with DTPA, bifunctional chelate appropriate range of concentrations and even in the presence of trace metals, resulting in excellent characteristics for use as precursor in the preparation of therapeutic radiopharmaceuticals including radioimmunotherapy. The latter being a pure beta emitter with physical half-life, comparable to the time of capture and residence of many antibodies in tumors. The influence of Fe (III) was studied by the method of addition and concluded that only affects the performance of DTPA 90 Y marking if their presence is above a concentration of 0.018 mol / L. We show that the presence of other metals such as Pb (II), Zn (II) and Cu (II) also affects performance complexation

  11. Right Gastric Artery Embolization Prior to Treatment with Yttrium-90 Microspheres

    International Nuclear Information System (INIS)

    Cosin, Octavio; Bilbao, Jose Ignacio; Alvarez, Sergio; Luis, Esther de; Alonso, Alberto; Martinez-Cuesta, Antonio

    2007-01-01

    Purpose. Intra-arterial infusion of yttrium-90 microspheres is a form of radiation treatment for unresectable hepatic neoplasms. Misdeposition of particles in the gastroduodenal area such as the right gastric artery (RGA) may occur with serious consequences. We present a series of patients who underwent a detailed vascular study followed by RGA embolization. Special emphasis is placed on anatomic variations and technical considerations .Methods. In a 1 year period, 27 patients were treated. Initial vascular evaluation was performed, with careful attention to anatomic variants or extrahepatic arterial supply, especially to the gastroduodenal area. Embolization of such arteries was planned if needed. RGA embolization was performed antegradely from the hepatic artery or retrogradely via the left gastric artery (LGA). Postprocedural follow-up included clinical interview and gastroscopy if necessary. Results. RGA embolization was performed in 9 patients presenting with primary (n = 3) or metastatic liver tumors (n 6). Six patients underwent antegrade RGA embolization and 3 had embolization done retrogradely via the LGA. Retrograde access was chosen for anatomic reasons. None of the patients complained of gastroduodenal symptoms. Conclusion. RGA embolization can help minimize the gastroduodenal deposition of radioactive particles. RGA embolization should routinely be carried out. The procedure can be performed, with similar technical success, by both anterograde and retrograde approaches

  12. Hepatobiliary effects of 90yttrium microsphere therapy for unresectable hepatocellular carcinoma.

    Science.gov (United States)

    Nalesnik, Michael A; Federle, Michael; Buck, David; Fontes, Paulo; Carr, Brian I

    2009-01-01

    (90)Yttrium (Therasphere) microspheres administered via hepatic artery are a valuable option for treatment of hepatocellular carcinoma. This therapy targets tumor nodules while largely sparing hepatic parenchyma. This retrospective study examines liver explants from 13 adult patients with hepatocellular carcinoma who received intrahepatic Theraspheres and subsequently underwent liver transplantation. Histopathologic and laboratory reviews are performed. Theraspheres preferentially migrated to the lobe(s) supplied by the injected artery branches and frequently localized to tumors. Tumors showed a chronology of changes beginning with confluent necrosis typically accompanied by hemorrhage and later by fibrinoid change. This was followed by fibrosis with regenerative activity at tumor peripheries. Adjacent hepatic parenchyma went through a similar sequence of injury and repair that could lead to markedly fibrotic cirrhotic nodules in the vicinity of treated tumors. No consistent pattern of thrombomodulin loss was seen in endothelial cells of the tumors or adjacent parenchyma, suggesting that direct endothelial cell injury was likely not a major contributor to the necrotic process. However, the pattern of injury and repair is suggestive of a localized and subclinical form of radiation-induced liver disease. The pathologist should be aware of these changes to distinguish them from the diffuse "radiation hepatitis" associated with older forms of radiotherapy.

  13. Monte Carlo simulation of PET and SPECT imaging of {sup 90}Y

    Energy Technology Data Exchange (ETDEWEB)

    Takahashi, Akihiko, E-mail: takahsr@hs.med.kyushu-u.ac.jp; Sasaki, Masayuki [Department of Health Sciences, Faculty of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582 (Japan); Himuro, Kazuhiko; Yamashita, Yasuo; Komiya, Isao [Division of Radiology, Department of Medical Technology, Kyushu University Hospital, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582 (Japan); Baba, Shingo [Department of Clinical Radiology, Kyushu University Hospital, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582 (Japan)

    2015-04-15

    Purpose: Yittrium-90 ({sup 90}Y) is traditionally thought of as a pure beta emitter, and is used in targeted radionuclide therapy, with imaging performed using bremsstrahlung single-photon emission computed tomography (SPECT). However, because {sup 90}Y also emits positrons through internal pair production with a very small branching ratio, positron emission tomography (PET) imaging is also available. Because of the insufficient image quality of {sup 90}Y bremsstrahlung SPECT, PET imaging has been suggested as an alternative. In this paper, the authors present the Monte Carlo-based simulation–reconstruction framework for {sup 90}Y to comprehensively analyze the PET and SPECT imaging techniques and to quantitatively consider the disadvantages associated with them. Methods: Our PET and SPECT simulation modules were developed using Monte Carlo simulation of Electrons and Photons (MCEP), developed by Dr. S. Uehara. PET code (MCEP-PET) generates a sinogram, and reconstructs the tomography image using a time-of-flight ordered subset expectation maximization (TOF-OSEM) algorithm with attenuation compensation. To evaluate MCEP-PET, simulated results of {sup 18}F PET imaging were compared with the experimental results. The results confirmed that MCEP-PET can simulate the experimental results very well. The SPECT code (MCEP-SPECT) models the collimator and NaI detector system, and generates the projection images and projection data. To save the computational time, the authors adopt the prerecorded {sup 90}Y bremsstrahlung photon data calculated by MCEP. The projection data are also reconstructed using the OSEM algorithm. The authors simulated PET and SPECT images of a water phantom containing six hot spheres filled with different concentrations of {sup 90}Y without background activity. The amount of activity was 163 MBq, with an acquisition time of 40 min. Results: The simulated {sup 90}Y-PET image accurately simulated the experimental results. PET image is visually

  14. A gate evaluation of the sources of error in quantitative90 Y PET.

    Science.gov (United States)

    Strydhorst, Jared; Carlier, Thomas; Dieudonné, Arnaud; Conti, Maurizio; Buvat, Irène

    2016-10-01

    Accurate reconstruction of the dose delivered by 90 Y microspheres using a postembolization PET scan would permit the establishment of more accurate dose-response relationships for treatment of hepatocellular carcinoma with 90 Y. However, the quality of the PET data obtained is compromised by several factors, including poor count statistics and a very high random fraction. This work uses Monte Carlo simulations to investigate what impact factors other than low count statistics have on the quantification of 90 Y PET. PET acquisitions of two phantoms-a NEMA PET phantom and the NEMA IEC PET body phantom-containing either 90 Y or 18 F were simulated using gate. Simulated projections were created with subsets of the simulation data allowing the contributions of random, scatter, and LSO background to be independently evaluated. The simulated projections were reconstructed using the commercial software for the simulated scanner, and the quantitative accuracy of the reconstruction and the contrast recovery of the reconstructed images were evaluated. The quantitative accuracy of the 90 Y reconstructions were not strongly influenced by the high random fraction present in the projection data, and the activity concentration was recovered to within 5% of the known value. The contrast recovery measured for simulated 90 Y data was slightly poorer than that for simulated 18 F data with similar count statistics. However, the degradation was not strongly linked to any particular factor. Using a more restricted energy range to reduce the random fraction in the projections had no significant effect. Simulations of 90 Y PET confirm that quantitative 90 Y is achievable with the same approach as that used for 18 F, and that there is likely very little margin for improvement by attempting to model aspects unique to 90 Y, such as the much higher random fraction or the presence of bremsstrahlung in the singles data. © 2016 American Association of Physicists in Medicine.

  15. Country report: India. Development of Radiopharmaceuticals Based on 188Re and 90Y for Radionuclide Therapy

    International Nuclear Information System (INIS)

    Venkatesh, M.; Pandey, U.; Dhami, P.S.; Chakravarty, R.; Kameswaran, M.; Subramanian, S.; Dash, A.; Samuel, G.

    2010-01-01

    During the past decade, our group has focused attention on the development of therapeutic radiopharmaceuticals incorporating radioisotopes such as 90 Y, 188 Re etc. As the primary source of the radioisotopes 90 Y and 188 Re are the 90 Sr/ 90 Y generators and 188 W/ 188 Re generators respectively, the local availability of these generator systems is very important for the successful development of radiopharmaceuticals incorporating these radioisotopes. In this context, 90 Sr/ 90 Y generators based on Supported Liquid Membrane (SLM) [1-3] and electrochemical techniques [4] could be designed and deployed in our laboratories for the elution of 90 Y to be used for preparation of 90 Y labeled products. This work formed a part of the IAEA co-ordinated CRP on “Development of Generator Technologies for Therapeutic Radionuclides: 90 Y and 188 Re”. In this report, work on the development of 90 Y radiopharmaceuticals for treatment of liver cancer and non-Hodgkin’s lymphoma (NHL) is reported. In addition, comparison of the Extraction Paper Chromatography technique (EPC) developed for determination of 90 Sr contamination in 90 Y samples with the US Pharmacopeia recommended method as well as the validation of the EPC technique is presented

  16. Clinical results of radionuclide therapy of neuroendocrine tumours with {sup 90}Y-DOTATATE and tandem {sup 90}Y/{sup 177}Lu-DOTATATE: which is a better therapy option?

    Energy Technology Data Exchange (ETDEWEB)

    Kunikowska, Jolanta; Krolicki, Leszek [Medical University of Warsaw, Nuclear Medicine Department, Warsaw (Poland); Hubalewska-Dydejczyk, Alicja; Sowa-Staszczak, Anna [Collegium Medicum Cracow, Cracow (Poland); Mikolajczak, Renata; Pawlak, Dariusz [Institute of Atomic Energy POLATOM, Swierk-Otwock (Poland)

    2011-10-15

    Peptide receptor radionuclide therapy (PRRT) using radiolabelled somatostatin analogues is a treatment option for patients with disseminated neuroendocrine tumours (NET). A combination treatment using the high-energy {sup 90}Y beta emitter for larger lesions and the lower energy {sup 177}Lu for smaller lesions has been postulated in the literature.The aim of the study was to evaluate combined {sup 90}Y/{sup 177}Lu-DOTATATE therapy in comparison to {sup 90}Y-DOTATATE alone. Fifty patients with disseminated NET were included in the study prospectively and divided into two groups: group A (n = 25) was treated with {sup 90}Y-DOTATATE, whereas group B (n = 25) received the 1:1 {sup 90}Y/{sup 177}Lu-DOTATATE. The administered activity was based on 3.7 GBq/m{sup 2} body surface area in three to five cycles, with amino acid infusion for nephroprotection. The median overall survival time in group A was 26.2 months while in group B median survival was not reached. Overall survival was significantly higher in group B (p = 0.027). Median event-free survival time in group A was 21.4 months and in group B 29.4 months (p > 0.1). At the 12-month follow-up, comparison of group A vs group B showed stable disease (SD) in 13 vs 16 patients, disease regression (RD) in 5 vs 3 patients and disease progression (PD) in 3 vs 4 patients; 4 and 2 patients died, respectively. The 24-month follow-up results were SD in nine vs ten patients, RD in one patient vs none and PD in four patients in both groups; three and four patients died, respectively. Side effects were rare and mild. The results indicate that therapy with tandem radioisotopes ({sup 90}Y/{sup 177}Lu-DOTATATE) provides longer overall survival than with a single radioisotope ({sup 90}Y-DOTATATE) and the safety of both methods is comparable. (orig.)

  17. Evaluation of Effective Parameters on Labeling of Hydroxyapatite Compound with 90Y and Introducing the Best Method to Produce 90Y-HAp Radiopharmaceutical for Radio synovectomy

    International Nuclear Information System (INIS)

    Davarpanah, M. R.; Khoshhosn, H. A.; Attar Nosrati, S.; Harati, S. M.; Aghamiri, S. M.; Ghannadi Maragheh, M.

    2012-01-01

    Radio synovectomy is a local intra-articular injection of radionuclides in colloidal form for treatment of articular inflammatory in rheumatoid arthritis, hemophilia or orthopedic troubles. β-emitting radionuclides can be used for various joints based on radiation energy. 90 Y is a pure β-emitter with a half-life of 64.1 hours that is used for treatment of the knee joint. β-radiation of this radionuclide possesses maximum energy of 2.281 MeV (99.98%), mean pathway of 3.6 mm in the soft tissue and maximum 11 mm. In this project, hydroxyapatite (HAp) is applied as a colloid maker agent that interacts with 90 Y 3+ ions via ion-dipole bonds and produces 90 Y-HAp. The colloidal pharmaceutical is produced by adding an acidic solution of 90 YCl 3 to an HAp suspension in saline. Effective parameters within which the colloid is applied, such as the volume of diluent, HAp particle size and sonication effect were evaluated and tested. First, these determinative parameters were optimized in the simulated conditions and then examined in the active phase. Finally, the best procedure was determined for the production of the radiopharmaceutical. Radionuclide purity of the radiopharmaceutical according to the primary 90 YCl 3 solution was over 99.9%. Labeling yield and radiochemical purity were obtained over 99% using TLC method in saline solvent up to three days after production of radiopharmaceutical. Radiochemical purity of 90 Y-HAp colloid was also evaluated in human serum albumin solution for three days at room temperature. The amount of released activity was between 0.3 to 2%.

  18. Total Lesion Glycolysis and Sequential (90)Y-Selective Internal Radiation Therapy in Breast Cancer Liver Metastases: Preliminary Results.

    Science.gov (United States)

    Bagni, Oreste; Filippi, Luca; Pelle, Giuseppe; Cianni, Roberto; Schillaci, Orazio

    2015-12-01

    To assess the prognostic role of total lesion glycolysis (TLG) in patients with breast cancer liver metastases (BCLM) after sequential lobar (90)Y-radioembolization ((90)Y-RE). Seventeen patients with bilobar BCLM underwent FDG PET/CT and TLG calculation before (90)Y-RE. The hepatic lobe with the highest TLG was treated in the first session. PET was performed 6 weeks postprocedure and decrease in TLG (ΔTLG) in the treated lobe was calculated before the second (90)Y administration. Subjects were divided in two groups (group 1: ΔTLG >50%, group 2: ΔTLG 50% and seven had a ΔTLG value 50% and ΔTLG <50% had a mean OS of 16.4 ± 0.6 and 10.3 ± 0.4 months, respectively (p < 0.001). Cox regression analysis demonstrated hepatic tumor load (p = 0.048) and ΔTLG as the only significant (p = 0.005) predictors of survival. ΔTLG after the first (90)Y administration agrees with final outcome in BCLM patients after separate sequential lobar (90)Y-RE.

  19. An Overview of the Production, Quality Control and Feasibility of Using 90Y as a Therapeutic Radionuclide

    International Nuclear Information System (INIS)

    Venkatesh, M.

    2009-01-01

    90 Y is increasingly accepted world wide as a radionuclide for in-vivo therapy owing to attractive decay features (T1/2 2.67 d; Eβ max 2.28 MeV) and viable production feasibility in high specific activities. 90 Y is most often recommended for treatment of large tumour lesions as the hard β rays are effective in delivering therapeutic dose to large volume. However, possibility of high radiation dose to the critical organs such as bone marrow and kidneys is an important concern that is given due weightage while designing therapy using 90 Y. The best route to avail 90 Y for therapy applications is from 90 Sr, though neutron actiation of natural 89 Y(100% abundance) is feasible. The absorption cross section σ is barely 1.38 b, resulting in low specific activity 90 Y which is useful for limited applications. The possibility of obtaining 90Y through a radionuclide generator as the daughter of a long lived parent 90 Sr (T1/2 28.9 y) is a major advantage that enables access to high specific activity 90 Y. Transporting the 90Y activity to a user institution from a centralized production facility is reasonably feasible and this facilitates its wide spread use. Several generator designs have been developed and reported to access 90 Y. Solvent extraction using a chelating molecule in an organic solvent (0.3M HDEHP/n-dodecane), column chromatography using ion exchange resins (cationic as well as anionic; Dowex-50x8; AG 50x16; Aminex-A5) or inorganic exchanger, membrane based separation using chelating ligand impregnated membranes (CMPO in electrochemical separation are some of the methods reported. Limitations such as elution of 90 Y after initial elution of 90 Sr, availability of 90 Y as a chelated complex which then has to be treated to enable labeling the molecule of interest, possibility of obtaining small quantities of 90 Y owing to radiolytic damages to the separation system components, paucity of special automation gadgets for handling the high activities remotely

  20. Radiation protection in radionuclide therapies with (90)Y-conjugates: risks and safety.

    Science.gov (United States)

    Cremonesi, Marta; Ferrari, Mahila; Paganelli, Giovanni; Rossi, Annalisa; Chinol, Marco; Bartolomei, Mirco; Prisco, Gennaro; Tosi, Giampiero

    2006-11-01

    The widespread interest in (90)Y internal radionuclide treatments has drawn attention to the issue of radiation protection for staff. Our aim in this study was to identify personnel at risk and to validate the protection devices used. (90)Y-MoAb (Zevalin, 15 cases, 1.1 GBq/patient) and (90)Y-peptide ((90)Y-DOTATOC) systemic (i.v., 50 cases, 3.0 GBq/patient) and locoregional (l.r., 50 cases, 0.4 GBq/patient) treatments were considered. Radiolabelling was carried out in a dedicated hot cell. Tele-tongs, shielded (PMMA: polymethylmethacrylate) syringes/vials and an automatic dose fractionating system were used. Operators wore anti-X-ray and anti-contamination gloves, with TLD dosimeters placed over the fingertips. For i.v. administration, activity was administered by a dedicated system; for l.r. administration, during activity infusion in the brain cavity, tongs were used and TLDs were placed over the fingertips. The air kerma-rate was measured around the patients. The use of devices provided a 75% dose reduction, with mean fingertip doses of 2.9 mGy (i.v. MoAbs), 0.6 mGy (i.v. peptides)/radiolabelling procedure and 0.5 mGy/l.r. administration. The mean effective dose to personnel was 5 microSv/patient. The air kerma-rate around the patients administered i.v. (90)Y-peptides were 3.5 (1 h) and 1.0 (48 h) microGy/h at 1 m. Patient hospitalisation of 6 h (l.r.)/48 h (i.v.) guaranteed that the recommended limits of 3 mSv/year to family members and 0.3 mSv/year to the general population (Council Directive 97/43/Euratom) were respected. When specific procedures are adopted, a substantial improvement in (90)Y manipulation is attainable, reducing doses and increasing safety. For the widespread clinical use of (90)Y-conjugates, a completely automatic labelling procedure is desirable.

  1. Same-day {sup 90}Y radioembolization: implementing a new treatment paradigm

    Energy Technology Data Exchange (ETDEWEB)

    Gabr, Ahmed; Kallini, Joseph Ralph; Gates, Vanessa L.; Hickey, Ryan; Desai, Kush; Thornburg, Bartley; Marshall, Karen; Salzig, Krystina; Williams, Melissa; Del Castillo, Carlene; Hohlastos, Elias; Lewandowski, Robert J. [Northwestern Memorial Hospital, Robert H. Lurie Comprehensive Cancer Center, Department of Radiology, Section of Interventional Radiology, Chicago, IL (United States); Kulik, Laura; Ganger, Daniel [Northwestern University, Department of Medicine, Division of Hepatology, Chicago, IL (United States); Baker, Talia [Northwestern University, Department of Surgery, Division of Transplantation, Comprehensive Transplant Center, Chicago, IL (United States); Salem, Riad [Northwestern Memorial Hospital, Robert H. Lurie Comprehensive Cancer Center, Department of Radiology, Section of Interventional Radiology, Chicago, IL (United States); Northwestern University, Department of Surgery, Division of Transplantation, Comprehensive Transplant Center, Chicago, IL (United States); Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Department of Medicine, Division of Hematology and Oncology, Chicago, IL (United States)

    2016-12-15

    To assess the feasibility of conducting pretreatment mesenteric angiography, coil embolization, {sup 99m}Tc macroaggregated albumin ({sup 99m}Tc-MAA) scintigraphy, and {sup 90}Y radioembolization treatment in a single, same-day, combined outpatient encounter. This was a retrospective study of 78 patients treated during the period 2008 - 2015 who were managed in a single outpatient encounter under the guidance of the Interventional Radiology Department and The Nuclear Medicine Department. Pretreatment planning was performed by reviewing baseline imaging and estimated perfused liver volume bearing the tumor. The region of interest was estimated using 3-D software; this value was used for dosimetry planning. Maximum lung shunting fractions of 10 % for hepatocellular carcinoma and 5 % for liver metastases were assumed. Subsequently, hepatic angiography and {sup 99m}Tc-MAA scintigraphy were performed followed by {sup 90}Y treatment in one outpatient encounter. Total in-room procedure time was recorded. All patients underwent same-day angiography, {sup 99m}Tc-MAA scintigraphy and {sup 90}Y radioembolization. Of the 78 patients, 16 received multiple segmental treatments to both lobes, 44 received treatment to the right lobe, and 18 received treatment to the left lobe. The median dose was 106 Gy. The median number of {sup 90}Y vials needed was two (range one to six). The median in-room time was 160 min (75 - 250 min). The residential status of the patients was as follows, 18 % (14/78) were local residents, 55 % (43/78) traveled from outside the city limits, 18 % (14/78) were from out-of-state, and 9 % (7/78) were resident abroad. Of the 78 patients, 61 (77 %) had hepatocellular carcinoma, and 17 (22 %) had liver metastases. The median lung dose was 3.5 Gy. This study demonstrated the feasibility of same-day {sup 90}Y evaluation and treatment while maintaining the principles of safe and effective {sup 90}Y infusion including tumoricidal dosimetry (lobar, segmentectomy

  2. 111In and 90Y labelled peptide radiopharmaceuticals for diagnosis and therapy

    International Nuclear Information System (INIS)

    Obenaus, E.; Crudo, J.L.; Castiglia, S.G. de

    2004-01-01

    injected I.V. with 0.37 MBq of 111In labeled peptide. Animals were sacrificed after 4hrs. and samples of different organs obtained and counted and results were expressed as % ID/gm. The radiochemical purity of 111In labeled peptide was higher than 98% when using peptide amounts higher than 10μg/mCi (DOTATOC) or 20μg/mCi(DOTALAN). HPLC analysis after 4h incubation in human serum showed no degradation of the radiolabeled peptide after precipitation with acetonitrile. After 24h incubation the chromatogram showed 95% of labeled peptide. The labeled peptide showed a tendency towards renal excretion and lower levels of activity in liver and intestine. A radiochemical purity of 100% was obtained when using higher amounts than 2μg of DOTA-TOC per mCi of 90 Y and 7μg of DOTALAN. (author)

  3. Clinical feasibility of {sup 90}Y digital PET/CT for imaging microsphere biodistribution following radioembolization

    Energy Technology Data Exchange (ETDEWEB)

    Wright, Chadwick L.; Binzel, Katherine; Zhang, Jun; Knopp, Michael V. [The Ohio State University Wexner Medical Center, Wright Center of Innovation in Biomedical Imaging, Department of Radiology, Columbus, OH (United States); Wuthrick, Evan J. [The Ohio State University Wexner Medical Center, Department of Radiation Oncology, Columbus, OH (United States)

    2017-07-15

    The purpose of this study was to evaluate the clinical feasibility of next generation solid-state digital photon counting PET/CT (dPET/CT) technology and imaging findings in patients following {sup 90}Y microsphere radioembolization in comparison with standard of care (SOC) bremsstrahlung SPECT/CT (bSPECT/CT). Five patients underwent SOC {sup 90}Y bremsstrahlung imaging immediately following routine radioembolization with 3.5 ± 1.7 GBq of {sup 90}Y-labeled glass microspheres. All patients also underwent dPET/CT imaging at 29 ± 11 h following radioembolization. Matched pairs comparison was used to compare image quality, image contrast and {sup 90}Y biodistribution between dPET/CT and bSPECT/CT images. Volumetric assessments of {sup 90}Y activity using different isocontour thresholds on dPET/CT and bSPECT/CT images were also compared. Digital PET/CT consistently provided better visual image quality and {sup 90}Y-to-background image contrast while depicting {sup 90}Y biodistribution than bSPECT/CT. Isocontour volumetric assessment using a 1% threshold precisely outlined {sup 90}Y activity and the treatment volume on dPET/CT images, whereas a more restrictive 20% threshold on bSPECT/CT images was needed to obtain comparable treatment volumes. The use of a less restrictive 10% threshold isocontour on bSPECT/CT images grossly overestimated the treatment volume when compared with the 1% threshold on dPET/CT images. Digital PET/CT is clinically feasible for the assessment of {sup 90}Y microsphere biodistribution following radioembolization, and provides better visual image quality and image contrast than routine bSPECT/CT with comparable acquisition times. With further optimization and clinical validation, dPET technology may allow faster and more accurate imaging-based assessment of {sup 90}Y microsphere biodistribution. (orig.)

  4. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer

    International Nuclear Information System (INIS)

    Ho, S.; Lau, W.Y.; Leung, T.W.T.; Chan, M.; Johnson, P.J.; Li, A.K.C.

    1997-01-01

    Radiation doses to the tumour and non-tumorous liver compartments from yttrium-90 microspheres in the treatment of hepatic cancer, as estimated by a partition model, have been verified by correlation with the actual doses measured with a beta probe at open surgery. The validity of the doses to the lungs, the tumour and non-tumours liver compartment as estimated by the partition model was further evaluated in clinical settings. On the basis of the observation that one of three patients who received more than 30 Gy from a single treatment and one of two patients who received more than 50 Gy from multiple treatments developed radiation pneumonitis, it was deduced that an estimated lung dose 30 Gy as estimated by the partition model and were predicted to develop radiation pneumonitis, did so despite the use of partial hepatic embolization to reduce the degree of lung shunting. Furthermore, a higher radiological response rate and prolonged survival were found in the group of patients who received higher tumour doses, as estimated by the partition model, than in the group with lower estimated tumour doses. Thus the radiation doses estimated by the partition model can be used to predict (a) complication rate, (b) response rate and (c) duration of survival in the same manner as the actual radiation doses measured with a beta probe at open surgery. The partition model has made selective internal radiation therapy using 90 Y microspheres safe and repeatable without laparotomy. (orig.)

  5. 90Y/90 Sr electron induced damages in an essential eucalyptus oil related to the absorbed dose

    International Nuclear Information System (INIS)

    Heredia Cardona, J.A.; Diaz Rizo, O.; Martinez Luzardo, F.; Quert, R.

    2007-01-01

    A good irradiation geometry was achieved in order to carry out the irradiation of an essential eucalyptus oil with a 90 Y/ 90 Sr electron source. The Monte Carlo simulation code MCNP-4C was employed to determine the absorbed doses in this particular experimental configuration. It also helped us to understand which electrons (from an energetic point of view) were responsible for the damages. In order to identify the induced damages, the irradiated samples were studied by mass spectrometry. The obtained results were related to the absorbed doses determined by the computational simulation

  6. Absorbed doses to the main parts of eyeball due to use 90Sr + 90Y ophthalmic applicator

    International Nuclear Information System (INIS)

    Chen Lishu

    1993-05-01

    The ophthalmic radiotherapy dosimetry and some affecting factors are introduced. The distributions of absorbed doses to the main parts of a fresh eyeball such as the cornea, sclera, lens and anterior chamber, during the radiotherapy by using a 90 Sr + 90 Y ophthalmic applicator are presented. An tissue-equivalent extrapolation ionization chamber was used in the dose measurement. The reasonable doses during ophthalmic radiotherapy for different depths have been obtained. Therefore, the absorbed dose to the lens, the most sensitive organ, can be given. These data are useful for radiation protection in ophthalmic radiotherapy

  7. Comparison of positron emission tomography/CT and bremsstrahlung imaging following Y-90 radiation synovectomy

    International Nuclear Information System (INIS)

    Barber, Thomas W.; Yap, Kenneth S.K.; Cherk, Martin H.; Kalff, Victor; Powell, Anne

    2013-01-01

    The aim of this study is to compare the results of positron emission tomography (PET)/CT with bremsstrahlung imaging following Y-90 radiation synovectomy. All patients referred to our institution for Y-90 radiation synovectomy between July 2011 and February 2012 underwent both PET/CT and bremsstrahlung planar (±single photon emission computed tomography (SPECT) or SPECT/CT) imaging at 4 or 24 h following administration of Y-90 silicate colloid. PET image acquisition was performed for between 15 and 20min. In patients who underwent SPECT, side-by-side comparison with PET was performed and image quality/resolution scored using a five-point scale. The distribution pattern of Y-90 on PET and bremsstrahlung imaging was compared with the intra- or extra-articular location of Y-90 activity on fused PET/CT. Thirteen joints (11 knees and two ankles) were imaged with both PET/CT and planar bremsstrahlung imaging with 12 joints also imaged with bremsstrahlung SPECT. Of the 12 joints imaged with SPECT, PET image quality/resolution was superior in 11 and inferior in one. PET demonstrated a concordant distribution pattern compared with bremsstrahlung imaging in all scans, with the pattern classified as diffuse in 12 and predominantly focal in one. In all 12 diffuse scans, PET/CT confirmed the Y-90 activity to be located intra-articularly. In the one predominantly focal scan, the fused PET/CT images localised the Y-90 activity to mostly lie in the extra-articular space of the knee. PET/CT can provide superior image quality compared with bremsstrahlung imaging and may enable reliable detection of extra-articular Y-90 activity when there are focal patterns on planar bremsstrahlung imaging.

  8. Therapy with {sup 90}Y microspheres: radiation protection in new medical therapies; Terapia con microesferas de {sup 90}Y: proteccion radiologica en nuevas terapias medicas

    Energy Technology Data Exchange (ETDEWEB)

    Rojo, Ana; Puerta, Nancy, E-mail: arojo@arn.gob.ar [Autoridad Regulatoria Nuclear (ARN), Buenos Aires (Argentina)

    2013-07-01

    Primary liver cancer is one of the most frequent in the world and with a low cure rate. Radioembolization using 90y spheres is a promising treatment of this pathology and involves the percutaneous vascular application of radioisotope-labeled the order of Micron size particles. The advantages of this technique include the permit administered high doses of radiation to small volumes with low relative toxicity, offer the possibility of treating all the liver including microscopic tumors, and finally, the feasibility of combined with other therapies. Radiation protection in new medical therapies requires justification and optimization, as requirements for their implementation. The application of the principle of optimization in the context of the protection of the patient must be the minimum that it can be reasonably reached compatible with the required doses of treatment dose to healthy tissue. With {sup 90}Y microspheres therapy this optimization applies to the activity of 90y which is administered to the patient, and estimation methods are postulated. in this work are analyzed comparatively these methods, described the early physicists, equations and the limitations of each. Finally, it is concluded that the optimal method to be implemented for the evaluation of the activity of {sup 90}Y manage must be based in a voxel dosimetric model specific for each patient, however, the partitional method may be a good alternative if you don't have the tools to apply the method.

  9. A GATE evaluation of the sources of error in quantitative {sup 90}Y PET

    Energy Technology Data Exchange (ETDEWEB)

    Strydhorst, Jared, E-mail: jared.strydhorst@gmail.com; Buvat, Irène [IMIV, U1023 Inserm/CEA/Université Paris-Sud and ERL 9218 CNRS, Université Paris-Saclay, CEA/SHFJ, Orsay 91401 (France); Carlier, Thomas [Department of Nuclear Medicine, Centre Hospitalier Universitaire de Nantes and CRCNA, Inserm U892, Nantes 44000 (France); Dieudonné, Arnaud [Department of Nuclear Medicine, Hôpital Beaujon, HUPNVS, APHP and Inserm U1149, Clichy 92110 (France); Conti, Maurizio [Siemens Healthcare Molecular Imaging, Knoxville, Tennessee, 37932 (United States)

    2016-10-15

    Purpose: Accurate reconstruction of the dose delivered by {sup 90}Y microspheres using a postembolization PET scan would permit the establishment of more accurate dose–response relationships for treatment of hepatocellular carcinoma with {sup 90}Y. However, the quality of the PET data obtained is compromised by several factors, including poor count statistics and a very high random fraction. This work uses Monte Carlo simulations to investigate what impact factors other than low count statistics have on the quantification of {sup 90}Y PET. Methods: PET acquisitions of two phantoms—a NEMA PET phantom and the NEMA IEC PET body phantom-containing either {sup 90}Y or {sup 18}F were simulated using GATE. Simulated projections were created with subsets of the simulation data allowing the contributions of random, scatter, and LSO background to be independently evaluated. The simulated projections were reconstructed using the commercial software for the simulated scanner, and the quantitative accuracy of the reconstruction and the contrast recovery of the reconstructed images were evaluated. Results: The quantitative accuracy of the {sup 90}Y reconstructions were not strongly influenced by the high random fraction present in the projection data, and the activity concentration was recovered to within 5% of the known value. The contrast recovery measured for simulated {sup 90}Y data was slightly poorer than that for simulated {sup 18}F data with similar count statistics. However, the degradation was not strongly linked to any particular factor. Using a more restricted energy range to reduce the random fraction in the projections had no significant effect. Conclusions: Simulations of {sup 90}Y PET confirm that quantitative {sup 90}Y is achievable with the same approach as that used for {sup 18}F, and that there is likely very little margin for improvement by attempting to model aspects unique to {sup 90}Y, such as the much higher random fraction or the presence of

  10. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation.

    Science.gov (United States)

    Kulik, Laura M; Atassi, Bassel; van Holsbeeck, Lodewijk; Souman, Tameem; Lewandowski, Robert J; Mulcahy, Mary F; Hunter, Russell D; Nemcek, Albert A; Abecassis, Michael M; Haines, Kenneth G; Salem, Riad

    2006-12-01

    To present the clinical data of 35 patients with T3 unresectable hepatocellular carcinoma (HCC) that were treated with (90)Y with the specific intent of downstaging to resection, radiofrequency ablation (RFA) candidate, United Network for Organ Sharing (UNOS) stage T2 or liver transplantation. One hundred fifty patients with unresectable HCC were treated with (90)Y microspheres. Of these, 35 patients were UNOS stage T3 at the time of treatment. Patients were followed for clinical toxicities, alterations in model for end-stage-liver disease (MELD) score, tumor response, downstaging to RFA, resection, transplantation, and survival. Nineteen of 34 patients (56%) were successfully downstaged from T3 to T2 following treatment. 11 of 34 (32%) patients treated were downstaged to target lesions measuring 3.0 cm or less. Twenty-three of 35 (66%) were downstaged to either T2 status, lesion < 3.0 cm (RFA candidate), or resection. Seventeen of 34 (50%) had an objective tumor response by WHO criteria. Eight patients (23%) were successfully downstaged and underwent OLT following treatment. 1, 2, and 3-year survival was 84%, 54%, and 27%, respectively. Median survival by Kaplan-Meier analysis for the entire cohort was 800 days. These data suggest that intra-arterial (90)Y microspheres can be used as a bridge to transplantation, surgical resection, or RFA. (c) 2006 Wiley-Liss, Inc.

  11. Pregnancies in women with hyperprolactinaemia: clinical course and obstetric complications of 41 pregnancies in 27 women. [Yttrium 90

    Energy Technology Data Exchange (ETDEWEB)

    Kelly, W.F.; Doyle, F.H.; Mashiter, K.; Banks, L.M.; Gordon, H.; Joplin, G.F.

    1979-09-01

    Observations are reported on 41 pregnancies in 27 patients who initially had infertility and raised serum prolactin concentrations. Associated symptoms were secondary amenorrhoea and galactorrhoea. All patients were at risk of pituitary expansion during pregnancy, especially these 19 (70 per cent) with radiological evidence of pituitary tumors. Fifteen patients had 21 pregnancies after pituitary implantation with 90 yttrium; 14 patients had 20 pegnancies without prior pituitary implantation or any other attempt to prevent tumor expansion. The induction and Cesarean section rates were about 30 per cent in 32 term pregnancies in 25 patients. Details of how pregnancy was achieved and the associated obstetric problems are given.

  12. Large-scale purification of {sup 90}Sr from nuclear waste materials for production of {sup 90}Y, a therapeutic medical radioisotope

    Energy Technology Data Exchange (ETDEWEB)

    Wester, D.W.; Steele, R.T.; Rinehart, D.E.; DesChane, J.R.; Carson, K.J.; Rapko, B.M.; Tenforde, T.S. E-mail: tenforde@ncrp.com

    2003-07-01

    A major limitation on the supply of the short-lived medical isotope {sup 90}Y (t{sub 1/2}=64 h) is the available quantity of highly purified {sup 90}Sr generator material. A radiochemical production campaign was therefore undertaken to purify 1500 Ci of {sup 90}Sr that had been isolated from fission waste materials. A series of alkaline precipitation steps removed all detectable traces of {sup 137}Cs, alpha emitters, and uranium and transuranic elements. Technical obstacles such as the buildup of gas pressure generated upon mixing large quantities of acid with solid {sup 90}Sr carbonate were overcome through safety features incorporated into the custom-built equipment used for {sup 90}Sr purification. Methods are described for analyzing the chemical and radiochemical purity of the final product and for accurately determining by gravimetry the quantities of {sup 90}Sr immobilized on stainless steel filters for future use.

  13. Investigation of Cerenkov counting of environmental strontium-90

    International Nuclear Information System (INIS)

    Reynolds, S.A.; Eldridge, J.S.

    1979-01-01

    A typical liquid scintillation counter was evaluated for detection of low levels of 90 Sr-Y. A blank of about 5 cpm and 90 Y efficiency of 42% were obtained for 20-ml samples. The corresponding minimum detectable concentration for a 100-minute count is 0.03 pCi/ml, so that measurement of water samples can readily be made at the maximum permissible concentration for 90 Sr, 0.3 pCi/ml. The efficiency for 90 Sr is less than 0.4%, 1.4% for 137 Cs, and less than 0.04% for gamma-emitting 85 Sr, a useful tracer. Some data for 90 Y efficiencies and blanks are given for other liquid scintillation counters. Chemical treatments are necessary in some cases to concentrate 90 Sr-Y, to remove colored substances which cause quenching, or to eliminate interfering radionuclides. However, the manipulations need not be as elaborate as in conventional radiochemical analysis methods for 90 Sr. Ferric ion (yellow) quenches at the 5 ppM level, but the interference can be eliminated by adding a reducing agent. The Rn daughter 214 Bi, an interfering radionuclide, disappears by decay in 2-3 hours after removal of Rn by sweeping with air or gas. Concentration-separation methods studied have included precipitation and ion exchange

  14. Resin 90Y microsphere activity measurements for liver brachytherapy

    International Nuclear Information System (INIS)

    Dezarn, William A.; Kennedy, Andrew S.

    2007-01-01

    The measurement of the radioactivity administered to the patient is one of the major components of 90 Y microsphere liver brachytherapy. The activity of 90 Y microspheres in a glass delivery vial was measured in a dose calibrator. The calibration value to use for 90 Y in the dose calibrator was verified using an activity calibration standard provided by the microsphere manufacturer. This method allowed for the determination of a consistent, reproducible local activity standard. Additional measurements were made to determine some of the factors that could affect activity measurement. The axial response of the dose calibrator was determined by the ratio of activity measurements at the bottom and center of the dose calibrator. The axial response was 0.964 for a glass shipping vial, 1.001 for a glass V-vial, and 0.988 for a polycarbonate V-vial. Comparisons between activity measurements in the dose calibrator and those using a radiation survey meter were found to agree within 10%. It was determined that the dose calibrator method was superior to the survey meter method because the former allowed better defined measurement geometry and traceability of the activity standard back to the manufacturer. Part of the preparation of resin 90 Y microspheres for patient delivery is to draw out a predetermined activity from a shipping vial and place it into a V-vial for delivery to the patient. If the drawn activity was placed in a glass V-vial, the activity measured in the dose calibrator with a glass V-vial was 4% higher than the drawn activity from the shipping vial standard. If the drawn activity was placed in a polycarbonate V-vial, the activity measured in the dose calibrator with a polycarbonate V-vial activity was 20% higher than the drawn activity from the shipping vial standard. Careful characterization of the local activity measurement standard is recommended instead of simply accepting the calibration value of the dose calibrator manufacturer

  15. A data acquisition system for indentification of 90Sr/ 90Y in environmental samples

    International Nuclear Information System (INIS)

    Medin, G.; Brajnik, D.; Starcic, M.; Stanovnik, A.

    1996-01-01

    Often, in the stage of research and development of new techniques for detection of ionizing radiation, elaborate electronic systems are required. In this paper, we describe the relatively complex detector and electronic system used for a relatively simple but nevertheless demanding measurement of the beta emitting radionuclides 90 Sr/ 90 Y in environmental samples. The detection limit of 1 Bq in a thin, disc-shaped sample, was obtained by careful elimination of background. Contribution of other radionuclides in the sample, were eliminated or at least considerably reduced by using a silica aerogel as Cherenkov radiator and thin multiwire chamber in coincidence. Cosmic ray signals were reduced by large scintillation counters in anticoincidence. Finally, persisting RF pick-up signals were eliminated by using the signal from a wire antenna and identical MWPC preamplifier and discriminator for a veto to the master coincidence. For each accepted event, both timing and pulse height information was recorded with a personal computer

  16. Characterization of an extrapolation chamber in a 90Sr/90Y beta radiation field

    International Nuclear Information System (INIS)

    Oramas Polo, I.; Tamayo Garcia, J. A.

    2015-01-01

    The extrapolation chamber is a parallel plate chamber and variable volume based on the Bragg-Gray theory. It determines in absolute mode, with high accuracy the dose absorbed by the extrapolation of the ionization current measured for a null distance between the electrodes. This camera is used for dosimetry of external beta rays for radiation protection. This paper presents the characterization of an extrapolation chamber in a 90 Sr/ 90 Y beta radiation field. The absorbed dose rate to tissue at a depth of 0.07 mm was calculated and is (0.13206±0.0028) μGy. The extrapolation chamber null depth was determined and its value is 60 μm. The influence of temperature, pressure and humidity on the value of the corrected current was also evaluated. Temperature is the parameter that has more influence on this value and the influence of pressure and the humidity is not very significant. Extrapolation curves were obtained. (Author)

  17. Radioactive impurities in radiopharmaceuticals with Y-90. Consequences for waste disposal; Radioaktive Verunreinigungen in Radiopharmazeutika mit Y-90. Konsequenzen fuer die Entsorgung von Reststoffen

    Energy Technology Data Exchange (ETDEWEB)

    Wanke, C.; Solle, A.; Geworski, L. [Medizinische Hochschule Hannover (Germany). Stabsstelle Strahlenschutz und Abt. Medizinische Physik

    2016-07-01

    Y-90 plays an important role in nuclear medicine and is of particular interest in radiation synovectomy (RSO) and in Selective internal radiation therapy (SIRT). Longer-lived impurities were investigated in a pharmaceutical used in RSO and in glass microspheres applied for SIRT. For this, measurements were carried out to identify gamma-emitting impurities. Especially in the late measurements, after decay of Y-90, impurities such as Y-88 and Y-91, Zn-65, Eu-152, Gd-153, Tb-160 und Yb-169 were identified, which accounted for less than 0,01 % of the total radioactivity at the calibration date, so that all pharmaceutical requirements were met. The impurities, however, have to be taken into account in waste management and clearance. Assuming typical masses, waste from RSO can undergo unrestricted clearance based on the clearance values tabulated in the German Radiation Protection Ordinance, provided sufficient decay storage. For waste from SIRT with glass microspheres, however, other clearance or disposal options have to be found.

  18. PET optimization for improved assessment and accurate quantification of {sup 90}Y-microsphere biodistribution after radioembolization

    Energy Technology Data Exchange (ETDEWEB)

    Martí-Climent, Josep M., E-mail: jmmartic@unav.es; Prieto, Elena; Elosúa, César; Rodríguez-Fraile, Macarena; Domínguez-Prado, Inés; Vigil, Carmen; García-Velloso, María J.; Arbizu, Javier; Peñuelas, Iván; Richter, José A. [Nuclear Medicine Department, Clínica Universidad de Navarra, 36, Pío XII Avenue, 31008 Pamplona (Spain)

    2014-09-15

    Purpose: {sup 90}Y-microspheres are widely used for the radioembolization of metastatic liver cancer or hepatocellular carcinoma and there is a growing interest for imaging {sup 90}Y-microspheres with PET. The aim of this study is to evaluate the performance of a current generation PET/CT scanner for {sup 90}Y imaging and to optimize the PET protocol to improve the assessment and the quantification of {sup 90}Y-microsphere biodistribution after radioembolization. Methods: Data were acquired on a Biograph mCT-TrueV scanner with time of flight (TOF) and point spread function (PSF) modeling. Spatial resolution was measured with a{sup 90}Y point source. Sensitivity was evaluated using the NEMA 70 cm line source filled with {sup 90}Y. To evaluate the count rate performance, {sup 90}Y vials with activity ranging from 3.64 to 0.035 GBq were measured in the center of the field of view (CFOV). The energy spectrum was evaluated. Image quality with different reconstructions was studied using the Jaszczak phantom containing six hollow spheres (diameters: 31.3, 28.1, 21.8, 16.1, 13.3, and 10.5 mm), filled with a 207 kBq/ml {sup 90}Y concentration and a 5:1 sphere-to-background ratio. Acquisition time was adjusted to simulate the quality of a realistic clinical PET acquisition of a patient treated with SIR-Spheres{sup ®}. The developed methodology was applied to ten patients after SIR-Spheres{sup ®} treatment acquiring a 10 min per bed PET. Results: The energy spectrum showed the{sup 90}Y bremsstrahlung radiation. The {sup 90}Y transverse resolution, with filtered backprojection reconstruction, was 4.5 mm in the CFOV and degraded to 5.0 mm at 10 cm off-axis. {sup 90}Y absolute sensitivity was 0.40 kcps/MBq in the center of the field of view. Tendency of true and random rates as a function of the {sup 90}Y activity could be accurately described using linear and quadratic models, respectively. Phantom studies demonstrated that, due to low count statistics in {sup 90}Y PET

  19. Country report: India. Development of Radiopharmaceuticals Based on {sup 188}Re and {sup 90}Y for Radionuclide Therapy

    Energy Technology Data Exchange (ETDEWEB)

    Venkatesh, M.; Pandey, U.; Dhami, P. S.; Chakravarty, R.; Kameswaran, M.; Subramanian, S.; Dash, A.; Samuel, G. [Bhabha Atomic Research Centre, Trombay, Mumbai 400 085 (India)

    2010-07-01

    During the past decade, our group has focused attention on the development of therapeutic radiopharmaceuticals incorporating radioisotopes such as {sup 90}Y, {sup 188}Re etc. As the primary source of the radioisotopes {sup 90}Y and {sup 188}Re are the {sup 90}Sr/{sup 90}Y generators and {sup 188}W/{sup 188}Re generators respectively, the local availability of these generator systems is very important for the successful development of radiopharmaceuticals incorporating these radioisotopes. In this context, {sup 90}Sr/{sup 90}Y generators based on Supported Liquid Membrane (SLM) [1-3] and electrochemical techniques [4] could be designed and deployed in our laboratories for the elution of {sup 90}Y to be used for preparation of {sup 90}Y labeled products. This work formed a part of the IAEA co-ordinated CRP on “Development of Generator Technologies for Therapeutic Radionuclides: {sup 90}Y and {sup 188}Re”. In this report, work on the development of {sup 90}Y radiopharmaceuticals for treatment of liver cancer and non-Hodgkin’s lymphoma (NHL) is reported. In addition, comparison of the Extraction Paper Chromatography technique (EPC) developed for determination of {sup 90}Sr contamination in {sup 90}Y samples with the US Pharmacopeia recommended method as well as the validation of the EPC technique is presented.

  20. Two-stage supported liquid membrane method for the separation of carrier-free {sup 90}Y from {sup 90}Sr using KSM-17 and CMPO as carriers

    Energy Technology Data Exchange (ETDEWEB)

    Dhami, P S; Naik, P W; Dudwadkar, N L; Kannan, R; Achuthan, P V; Dakshinamoorthy, A; Jambunathan, U; Munshi, S K; Dey, P K [Fuel Reprocessing Division, Bhabha Atomic Research Centre, Mumbai (India); Pandey, Usha; Venkatesh, Meera [Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai (India)

    2007-07-01

    A two stage supported liquid membrane system is developed for the separation of carrier free {sup 90}Y from {sup 90}Sr for therapeutic applications. The feed containing {sup 90}Sr-{sup 90}Y in nitric acid solution at pH 2 is placed in the feed compartment and transported across a polytetrafluoroethylene membrane containing 2-ethyhexyl2ethylhexyl phosphonic acid to a 4M HNO{sub 3} receiver phase. This is then transported across another polytetrafluoroethylene membrane containing octyl phenyl N,N-diisobutylcarbamoyl methylphosphene oxide to another receiving phase, 1 M acetic acid. This has been implemented on simultaneous and sequential modes with very good yield. The second stage will act as a barrier for {sup 90}Sr, and will improve the product purity. (author)

  1. Role of diluent on the separation of {sup 90}Y from {sup 90}Sr by solvent extraction and supported liquid membrane using T2EHDGA as the extractant

    Energy Technology Data Exchange (ETDEWEB)

    Dutta, S. [Planning and Coordination Division, Bhabha Atomic Research Centre, Trombay, Mumbai - 400 085 (India); Raut, D.R. [Radiochemistry Division, Bhabha Atomic Research Centre, Trombay, Mumbai - 400 085 (India); Mohapatra, P.K., E-mail: mpatra@barc.gov.in [Radiochemistry Division, Bhabha Atomic Research Centre, Trombay, Mumbai - 400 085 (India)

    2012-04-15

    The separation behaviour of {sup 90}Y from {sup 90}Sr was investigated by diluent variation using solvent extraction and supported liquid membrane techniques employing N,N,N Prime ,N Prime -tetra-2-ethylhexyldiglycolamide (T2EHDGA) as the extractant. Both D{sub Y} (distribution ratio of Y(III)) and S.F. (separation factor) were found to be high in the solvent extraction studies when chloroform was used as the diluent. Subsequent supported liquid membrane (SLM) studies using PTFE flat sheet membranes containing 0.2 M T2EHDGA in various diluents indicated the trend of Y transport as xylene>hexone>chloroform>carbon tetrachloride>n-dodecane+30% iso-decanol mixture. However, the Sr(II) transport rates were also high with xylene, hexone, and carbon tetrachloride as the diluents which led us to carry out subsequent studies using chloroform and n-dodecane+30% iso-decanol mixture. Acid variation studies in chloroform system indicated an interesting phenomena of increasing Y(III) transport and decreasing Sr(II) transport with increasing acid concentration. Separation of {sup 90}Y from a mixture of {sup 90}Sr and {sup 90}Y was also attempted. - Highlights: Black-Right-Pointing-Pointer SLM studies using PTFE flat sheet membranes containing T2EHDGA as carrier was carried out for Y-90 separation from Sr-90. Black-Right-Pointing-Pointer The trend of Y transport as xylene>hexone>chloroform>carbon tetrachloride>n-dodecane+30% iso-decanol mixture. Black-Right-Pointing-Pointer Acid variation studies in chloroform system indicated an interesting phenomena of increasing Y(III) transport and decreasing Sr(II) transport with increasing acid concentration. Black-Right-Pointing-Pointer The present studies suggested that T2EHDGA-SLM show limited promise if coupled to another separation method such as extraction chromatography.

  2. Therapy with 90Y microspheres: radiation protection in new medical therapies

    International Nuclear Information System (INIS)

    Rojo, Ana; Puerta, Nancy

    2013-01-01

    Primary liver cancer is one of the most frequent in the world and with a low cure rate. Radioembolization using 90y spheres is a promising treatment of this pathology and involves the percutaneous vascular application of radioisotope-labeled the order of Micron size particles. The advantages of this technique include the permit administered high doses of radiation to small volumes with low relative toxicity, offer the possibility of treating all the liver including microscopic tumors, and finally, the feasibility of combined with other therapies. Radiation protection in new medical therapies requires justification and optimization, as requirements for their implementation. The application of the principle of optimization in the context of the protection of the patient must be the minimum that it can be reasonably reached compatible with the required doses of treatment dose to healthy tissue. With 90 Y microspheres therapy this optimization applies to the activity of 90y which is administered to the patient, and estimation methods are postulated. in this work are analyzed comparatively these methods, described the early physicists, equations and the limitations of each. Finally, it is concluded that the optimal method to be implemented for the evaluation of the activity of 90 Y manage must be based in a voxel dosimetric model specific for each patient, however, the partitional method may be a good alternative if you don't have the tools to apply the method

  3. Method for rapid screening analysis of Sr-90 in edible plant samples collected near Fukushima, Japan

    International Nuclear Information System (INIS)

    Amano, Hikaru; Sakamoto, Hideaki; Shiga, Norikatsu; Suzuki, Kaori

    2016-01-01

    A screening method for measuring 90 Sr in edible plant samples by focusing on 90 Y in equilibrium with 90 Sr is reported. 90 Y was extracted from samples with acid, co-precipitated with iron hydroxide, and precipitated with oxalic acid. The dissolved oxalate precipitate was loaded on an extraction chromatography resin, and the 90 Y-enriched eluate was analyzed by Cherenkov counting with a TDCR liquid scintillation counter. 90 Sr ( 90 Y) concentration was determined in plant samples collected near the damaged Fukushima Daiichi Nuclear Power Plants with this method. - Highlights: • A screening method for measuring 90 Sr in edible plant samples by focusing on 90 Y in equilibrium with 90 Sr is reported. • 90 Y was extracted from samples with acid, co-precipitated with iron hydroxide, and precipitated with oxalic acid. • The dissolved oxalate precipitate was loaded on an extraction chromatography resin. • 90 Y-enriched eluate was analyzed by Cherenkov counting with a TDCR liquid scintillation counter. • 90 Sr ( 90 Y) concentration was determined in edible plant samples collected near the damaged Fukushima Daiichi NPPs with this method.

  4. Pilot trial of Y-90 glass microspheres in the treatment of primary hepatocellular carcinoma

    International Nuclear Information System (INIS)

    Houle, S.; Yip, T.C.K.; Shepherd, F.A.; Rotstein, L.E.; Theis, B.; Cawthorn, R.; Barnes, K.

    1987-01-01

    A pilot trial is currently under way at our institution to determine the potential of new Y-90 glass microspheres (Theraspheres, Theragenics Corp., Atlanta) for the treatment of primary hepatocellular carcinoma. The Y-90 microspheres are injected through a percutaneous hepatic artery catheter positioned angiographically. The injection is facilitated by a new delivery system. Prior to the injection of the Y-90 microspheres, the presence of shunting is assessed by injecting Tc-99m human albumin microspheres (HAM) via the hepatic artery catheter. Bremsstrahlung scans done after injection demonstrate the distribution the Y-90 microspheres within the liver and the lack of extrahepatic activity. In the first group of patients treated, no significant toxicity was demonstrated for absorbed doses between 5,000 and 10,000 rad to the liver, and up to 20,000 rad to the tumor itself

  5. Application of microcomputer in the radiation treatment of cystic craniopharyngeomas with colloidal 90Y silicate

    International Nuclear Information System (INIS)

    Julow, Jenoe; Drasny, Gabor; Lanyi, Ferenc; Simkovics, Miklos; Hajda, Marta; Szeifert, Gyoergy; Toth, Szabolcs; Pasztor, Emil

    1987-01-01

    A computer program has been created and applied with success in the treatment of craniopharyngeomas. The program calculates first the volume of the cyst (from the data of cystography and puncture) then the volume of colloidal 90 Yttrium silicate which has to be injected. As the calculations need only about 5 min, the treatment can be carried out in one single session instead of two separate sessions, required previously. (L.E.) 5 refs.; 4 figs

  6. Labeling an anti-CD20 monoclonal antibody with 90Y

    International Nuclear Information System (INIS)

    Perera Pintado, Alejandro; Leyva Montaña, René; Prats Capote, Anaís; Góngora Bravo, Magdiel; Alberti Ramírez, Alejandro; León, Mariela; Hernández González, Ignacio; Dorvignit, Denise

    2016-01-01

    Lymphomas are among the 10 leading causes of death, both in Cuba and in the world, with an increasing incidence in recent years. Follicular lymphoma low-grade (indolent) is one of the most common in the Western world, representing 1/3 of all non-Hodgkin lymphomas (NHL). More than 90% of patients present with disseminated disease at diagnosis and generally have a slow evolution and good response to conventional treatment; but radically changed its forecast to relapse, resistance to therapeutic and histologic transformation can occur. The monoclonal antibody therapy has been a promising therapeutic. In this respect CD20 antigen it has been considered one of the most attractive targets in the therapy of follicular B cell lymphoma This is expressed in more than 90% of cases, while not present in stem cells and lines progenitors. Despite the success of immunotherapy, the relapse rate is still considerable. In order to increase the cytotoxic potential of immunotherapy, marked with beta emitting radionuclides alpha particles or monoclonal antibodies are used today. Despite encouraging results in patients with non-Hodgkin lymphomas refractory to other treatments, the extremely high costs of these commercial radiopharmaceuticals have greatly limited its application, even in the first world. A sustainable alternative is the marking of other anti-CD20 monoclonal antibodies, so researchers from several countries have concentrated their efforts on rituximaby other similar antibodies labeled with therapeutic radionuclides, as a possible cost-effectively to more problem. Today in Cuba it has an electrolytic generator 90 Sr- 90 Y Isotope Center, which ensures the availability of the radionuclide. In addition, the chimeric MAb rituximab is applied as part of the therapy of NHL in its health system and, recently, the Center for Molecular Immunology has obtained a chimeric monoclonal anti-CD20 antibody biosimilar rituximab, which is in phase clinical trial; which opens prospects for

  7. Evaluation of a pyrex glass shield for the dose reduction in extremities to manipulate a 90 Sr- 90 Y generator

    International Nuclear Information System (INIS)

    Ayra P, F.E.; Xiques C, A.; Torres B, M.B.

    2006-01-01

    The production of Y-90 of high activity it specifies (free of payee) for their use in radioimmunotherapy uses the Strontium 90 as isotope source. Depending on the method employee for the separation of both isotopes several types of generators are described in different bibliographies. The column generator used in the facilities of the Center of Isotopes requires of a frequent manipulation causing significant dose in the skin of the extremities due to the exhibition to the radiation beta of high energy. The properties of the shieldings for this radiation type have been well studied Y they consist in several publications. To be in correspondence with requirements of radiological protection in the Cuban legislation, the column was covered with a tube of glass pyrex of 5 mm of thickness and it was monitored the exposure with an ionization chamber. At the own time, the shielding using the Monte Carlo method was evaluated. It was used the MCNP 4C code to simulate the absorption of the beta particles generated in the process of disintegration of the Sr-90 and Y-90 in the glass shielding. The column generator and the fluence of beta particles were modeled in different points inside the shielding to determine if the experimentally measured values correspond to electrons that were not absorbed or to the weak stopping radiation generated in the glass due to the deceleration of these particles. A cylinder of 4 mm of diameter simulates the source (it dilutes) and a tube of walls of 6 mm of thickness simulates the shielding more the wall of the column around the generator. This it was divided in cells of 1 mm of thickness and the energy deposited in them was evaluated. The results show that all the electrons generated in the source are absorbed in the shielding and the exposure rates decrease in more of 78 times using the 5 mm of pyrex glass. The doses in extremities to the operators of the generator don't surpass the 70 mSv by year that is the dose restriction imposed in the

  8. Determination of strontium 90 in milk Ash; Dosage du strontium 90 dans les cendres de lait

    Energy Technology Data Exchange (ETDEWEB)

    Ballada, J; Jeanmaire, L [Commissariat a l' Energie Atomique, Fontenay-Aux-Roses (France). Centre d' Etudes Nucleaires

    1968-07-01

    This report describes a method of determination of {sup 90}Sr in milk ashes by extraction of {sup 90}Y in TBP. The tests which led to the choice of the operating process are presented together with tire result of an intercomparison. (author) [French] Le document decrit une methode de dosage du {sup 90}Sr dans les cendres de lait par extraction de {sup 90}Y dans le TBP. De plus, les auteurs rapportent les essais qui ont conduit au choix du mode operatoire presente, ainsi que les resultats d'une intercomparaison. (auteur)

  9. Dosimetry in radionuclide therapies with 90Y-conjugates. The IEO experience

    International Nuclear Information System (INIS)

    Cremonesi, M.; Ferrari, M.; Chinol, M.; Bartolomei, M.; Sacco, E.; Fiorenza, M.; Tosi, G.; Paganelli, G.; Stabin, M. G.

    2000-01-01

    The basis for successful radionuclide therapy is a high and stable uptake of the radiopharmaceutical in the target tissue along with low activity concentration in other normal organs. The contribution of dosimetry in radionuclide therapy is to predict before the treatment the absorbed doses in tumor and normal organs, to identify the critical organs, to minimize any possible toxicity and to evaluate the maximum tolerated dose. In this article is reported the experience concerning pharmacokinetics and dosimetry of two 90 Y-therapeutic protocols: 3-step pretargeting radioimmunotherapy (RIT) according to the biotin-avidin system and receptor mediated radionuclide therapy with the somatostatin analogue (DOTA-D-Phe 1 -Tyr 3 ) octreotide named DOTATOC. For the dosimetric analysis, analogous approaches for the two radiolabeled compounds due to the similar pharmacokinetic characteristics were adopted; the MIRD formalism was applied, taking into account both the physical and the biological characteristics of the radio conjugate and patients' metabolism. In order to determine biological clearance, serial blood samples and complete urine collection were obtained up to 48 hours after injection; to evaluate biodistribution, several whole body scans were acquired. Both therapies showed the advantageous characteristics of a fast blood clearance and a predominantly renal excretion of the radiopharmaceuticals thus lowering the irradiation of the total body. Although pharmacokinetic characteristics were similar, different critical organs were found for the two therapies: in particular, some considerations regarding red marrow, spleen and kidneys were required. The results of the studies indicate that high activities of 90 Y-biotin (3-step RIT) and 90 Y-DOTATOC can be administered with acceptable radiation doses to normal organs

  10. Analyses and quantitative determination of the strontium radioisotopes 89 and 90 in milk powder; Recherche et dosage des isotopes radioactifs 89 et 90 du strontium dans le lait en poudre

    Energy Technology Data Exchange (ETDEWEB)

    Jeanmaire, L; Michon, G [Commissariat a l' Energie Atomique, Saclay (France).Centre d' Etudes Nucleaires

    1959-07-01

    The authors describe a procedure for the determination of the strontium radioisotopes 89 and 90. The concentration of strontium is made possible by the insolubility of its nitrate salt in strong nitric acid which allows the removal of greatest part of calcium. The purification is performed on a cation exchange column. The amount of radioisotope 90 is determined by means of its daughter product yttrium 90 necessary calibrations and computations are treated in special paragraphs. With regard to the reproducibility of the measurements, the fluctuations are less than 20 per cent. This seems satisfaction for such a technique which have great sensibility while being long and necessitative great carefulness. (author) [French] Les auteurs decrivent une technique de dosage des isotopes 89 et 90 du strontium. La concentration du strontium est assuree grace a l'insolubilite de son nitrate dans l'acide nitrique concentre, ce qui permet d'eliminer la plus grande partie du Ca. La purification se fait sur une colonne echangeuse de cations. L'isotope 90 est dose grace a son descendant l'yttrium 90. Les etalonnages et calculs necessaires font l'objet de paragraphes detailles. En ce qui concerne la reproductibilite des mesures, les fluctuations sont inferieures a 20 pour cent, ce qui semble satisfaisant devant la grande sensibilite de la methode qui reste cependant longue et delicate. (auteur)

  11. Preoperative Y-90 microsphere selective internal radiation treatment for tumor downsizing and future liver remnant recruitment: a novel approach to improving the safety of major hepatic resections.

    Science.gov (United States)

    Gulec, Seza A; Pennington, Kenneth; Hall, Michael; Fong, Yuman

    2009-01-08

    Extended liver resections are being performed more liberally than ever. The extent of resection of liver metastases, however, is restricted by the volume of the future liver remnant (FLR). An intervention that would both accomplish tumor control and induce compensatory hypertrophy, with good patient tolerability, could improve clinical outcomes. A 53-year-old woman with a history of cervical cancer presented with a large liver mass. Subsequent biopsy indicated poorly differentiated carcinoma with necrosis suggestive of squamous cell origin. A decision was made to proceed with pre-operative chemotherapy and Y-90 microsphere SIRT with the intent to obtain systemic control over the disease, downsize the hepatic lesion, and improve the FLR. A surgical exploration was performed six months after the first SIRT (three months after the second). There was no extrahepatic disease. The tumor was found to be significantly decreased in size with central and peripheral scarring. The left lobe was satisfactorily hypertrophied. A formal right hepatic lobectomy was performed with macroscopic negative margins. Selective internal radiation treatment (SIRT) with yttrium-90 (Y-90) microspheres has emerged as an effective liver-directed therapy with a favorable therapeutic ratio. We present this case report to suggest that the portal vein radiation dose can be substantially increased with the intent of inducing portal/periportal fibrosis. Such a therapeutic manipulation in lobar Y-90 microsphere treatment could accomplish the end points of PVE with avoidance of the concern regarding tumor progression.

  12. Optimization of 90Sr/89Sr measurements

    Directory of Open Access Journals (Sweden)

    Legarda F.

    2012-04-01

    Full Text Available One of the key points in the double measurement method for the measurement of both, 89Sr and 90Sr, by using a proportional counter is the choice of the times at which the measurements should be done. In this paper, the formulae to calculate the 89Sr and 90Sr detection limits in conditions of radioactive equilibrium between 90Y and 90Sr are derived, and an analysis of them as a function of the time between the two measurements is done. The choice for the time of the second measurement is going to depend on the desired quality of the results to be obtained.

  13. Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: a phase I single-dose escalation trial.

    Science.gov (United States)

    Gulec, Seza A; Cohen, Steven J; Pennington, Kenneth L; Zuckier, Lionel S; Hauke, Ralph J; Horne, Heather; Wegener, William A; Teoh, Nick; Gold, David V; Sharkey, Robert M; Goldenberg, David M

    2011-06-15

    Humanized antibody hPAM4 specifically binds a mucin glycoprotein expressed in pancreatic adenocarcinomas. This phase I study evaluated a single dose of (90)Y-clivatuzumab tetraxetan ((90)Y-labeled hPAM4) in patients with advanced pancreatic cancer. Twenty-one patients (4 stage III; 17 stage IV) received (111)In-hPAM4 for imaging and serum sampling before (90)Y-hPAM4. Study procedures evaluated adverse events, safety laboratories, computed tomography (CT) scans, biomarkers, pharmacokinetics, radiation dosimetry, and immunogenicity (HAHA). (111)In-hPAM4 showed normal biodistribution with radiation dose estimates to red marrow and solid organs acceptable for radioimmunotherapy and with tumor targeting in 12 patients. One patient withdrew before (90)Y-hPAM4; otherwise, 20 patients received (90)Y doses of 15 (n = 7), 20 (n = 9), and 25 mCi/m(2) (n = 4). Treatment was well tolerated; the only significant drug-related toxicities were (NCI CTC v.3) grade 3 to 4 neutropenia and thrombocytopenia increasing with (90)Y dose. There were no bleeding events or serious infections, and most cytopenias recovered to grade 1 within 12 weeks. Three patients at 25 mCi/m(2) encountered dose-limiting toxicity with grade 4 cytopenias more than 7 days, establishing 20 mCi/m(2) as the maximal tolerated (90)Y dose. Two patients developed HAHA of uncertain clinical significance. Most patients progressed rapidly and with CA19-9 levels increasing within 1 month of therapy, but 7 remained progression-free by CT for 1.5 to 5.6 months, including 3 achieving transient partial responses (32%-52% tumor diameter shrinkage). (90)Y-Clivatuzumab tetraxetan was well tolerated with manageable hematologic toxicity at the maximal tolerated (90)Y dose, and is a potential new therapeutic for advanced pancreatic cancer. ©2011 AACR.

  14. Attempts at treating rheumatoid arthritis with radioactive yttrium

    International Nuclear Information System (INIS)

    Scott, J.T.

    1979-01-01

    Two years' observations on 33 knee joints in 33 patients with rheumatoid arthritis did not prove a therapeutic effect of Y 90 , which was tested in a randomized study against non-radioactive yttrium. It was noticable that 9 knee joints of the isotope group but only one of the control group became unstable. Independent of the yttrium treatment, significant improvement was noticed in patients where fibrin clots had been washed out of the joints in the course of arthroscopies. (orig.) [de

  15. Country report: Cuba. Local Production of 90Y And 188Re Radionuclides and Development of Radiopharmaceuticals for Therapy

    International Nuclear Information System (INIS)

    Xiques, Abmel; Hernández, Ignacio; Leyva, René; Pérez, Marylaine; Alonso, Luis Michel; Zamora, Minelys

    2010-01-01

    During the first period of this CRP we could test an efficient and reliable generator system based on ion-chromatography to obtain 90 Y from its parent radionuclide 90 Sr. This production scheme for 90 Y was outlined in the previous CRP related with the development of generator technologies. Quality parameters such as trace metals that can potentially interfere in the labeling of biomoléculas, 90 Y recovery, 90 Sr/ 90 Y ratio and radiation dose to bed matrix were evaluated. The results showed that high recovery and radionuclidic purity could be obtained for 90 Y during its repeated separation from the 90 Sr cow. No replacement or treatment of the cow were necessary and low waste generation and 90 Sr losses less that 0.1% after each run were also observed during the present study. A Fab’ fragment was enzimatically produced and purified from the monoclonal antibody h-R3 (Nimotuzumab®). The fragment and the parent antibody were successfully conjugated with DOTA and labeled with 90 Y. The radioinmunoconjugate thus obtained also exhibited a good 24 h in-vitro stability in an excess of DTPA. A 90 Y radiocoloid was prepared in a cromic phosphate particle for radiosynoviorthesis with promising results in animal models. Two alumina based 188 W/ 188 Re generators were prepared and their eluates were used in the labeling of hR3-DOTA conjugates. Quality control and in vivo evaluation in comparison with 99m Tc-hR3 showed very good results and similar pattern of distribution and pharmacokinetic and will be used in clinical trials for cancer patients. (author)

  16. Spin-flip isovector giant resonances from the 90Zr (n,p) 90Y reaction at 200 MeV

    International Nuclear Information System (INIS)

    Raywood, K.J.; Spicer, B.M.

    1989-01-01

    Doubly differential cross sections of the reaction 90 Zr(n,p) 90 Y have been measured at 200 MeV for excitations up to 38 MeV in the residual nucleus. An overall resolution of 1.3 MeV was achieved. The spectra show qualitative agreement in shape and magnitude with recent RPA calculations; however all of the calculations underestimate the high excitation region of the spectra. A multipole decomposition of the data has been performed using differential cross sections calculated in the DWIA. An estimate of the Gamow-Teller strength in the reaction is given. The isovector spin-flip dipole giant resonance has been identified and there is also an indication of isovector monopole strength. 39 refs., 16 figs., 1 tab

  17. Evaluation of a pyrex glass shield for the dose reduction in extremities to manipulate a {sup 90} Sr- {sup 90} Y generator; Evaluacion de un blindaje de vidrio pyrex para la reduccion de las dosis en extremidades al manipular un generador de {sup 90} Sr- {sup 90} Y

    Energy Technology Data Exchange (ETDEWEB)

    Ayra P, F.E.; Xiques C, A.; Torres B, M.B. [Centro de Isotopos, Carretera La Rada, Km 3 1/2, Guanabacoa, La Habana (Cuba)]. e-mail: feayra@centis.edu.cu

    2006-07-01

    The production of Y-90 of high activity it specifies (free of payee) for their use in radioimmunotherapy uses the Strontium 90 as isotope source. Depending on the method employee for the separation of both isotopes several types of generators are described in different bibliographies. The column generator used in the facilities of the Center of Isotopes requires of a frequent manipulation causing significant dose in the skin of the extremities due to the exhibition to the radiation beta of high energy. The properties of the shieldings for this radiation type have been well studied Y they consist in several publications. To be in correspondence with requirements of radiological protection in the Cuban legislation, the column was covered with a tube of glass pyrex of 5 mm of thickness and it was monitored the exposure with an ionization chamber. At the own time, the shielding using the Monte Carlo method was evaluated. It was used the MCNP 4C code to simulate the absorption of the beta particles generated in the process of disintegration of the Sr-90 and Y-90 in the glass shielding. The column generator and the fluence of beta particles were modeled in different points inside the shielding to determine if the experimentally measured values correspond to electrons that were not absorbed or to the weak stopping radiation generated in the glass due to the deceleration of these particles. A cylinder of 4 mm of diameter simulates the source (it dilutes) and a tube of walls of 6 mm of thickness simulates the shielding more the wall of the column around the generator. This it was divided in cells of 1 mm of thickness and the energy deposited in them was evaluated. The results show that all the electrons generated in the source are absorbed in the shielding and the exposure rates decrease in more of 78 times using the 5 mm of pyrex glass. The doses in extremities to the operators of the generator don't surpass the 70 mSv by year that is the dose restriction imposed in

  18. Toxicity of 90Y in a relatively insoluble form inhaled by Beagle dogs. XIV

    International Nuclear Information System (INIS)

    Hahn, F.F.; Hobbs, C.H.; Kusewitt, D.F.; McClellan, R.O.; Mauderly, J.L.; Pickrell, J.A.

    1982-01-01

    The metabolism, dosimetry and biological effects of inhaled 90 Y in fused aluminosilicate particles in Beagle dogs are being studied. Eighty-nine dogs with initial lung burdens ranging from 80 to 5200 μCi 90 Y/kg body weight and 12 control dogs are being maintained for life span observations. The lung burdens achieved, short physical half-life and relative insolubility of the 90 Y in this vector resulted in a relatively high, rapidly decreasing radiation dose rate to the lung. To date, 69 exposed dogs have died; 38 from radiation pneumonitis, seven with pulmonary neoplasms and 24 from other causes. Four control dogs have died. Twenty-nine surviving exposed and eight control dogs are being studied for their life spans

  19. Determination of strontium-90 in soil samples

    Energy Technology Data Exchange (ETDEWEB)

    Chang, C C

    1976-06-01

    The determination of /sup 90/Sr in soil by tri-n-butyl phosphate (TBP) is often interfered with iron which is always present in soil sample. Based on the method given by the U.S. Environmental Protection Agency, HClO/sub 4/ is added to remove iron ions while the soil sample is analyzed with TBP. The effect of different concentrations of HClO/sub 4/ on extraction yield of iron and chemical yield of yttrium is investigated. The experimental results show that 2N HClO/sub 4/ is the optimum concentration. The chemical yield of yttrium can reach about 60 percent, and all iron ions can be removed. This method has successfully been applied to analyze the soil samples taken from the site of the nuclear power plant in North Taiwan.

  20. The prognostic value of functional and anatomical parameters for the selection of patients receiving yttrium-90 microspheres for the treatment of liver cancer

    Science.gov (United States)

    Mesoloras, Geraldine

    Yttrium-90 (90Y) microsphere therapy is being utilized as a treatment option for patients with primary and metastatic liver cancer due to its ability to target tumors within the liver. The success of this treatment is dependent on many factors, including the extent and type of disease and the nature of prior treatments received. Metabolic activity, as determined by PET imaging, may correlate with the number of viable cancer cells and reflect changes in viable cancer cell volume. However, contouring of PET images by hand is labor intensive and introduces an element of irreproducibility into the determination of functional target/tumor volume (FTV). A computer-assisted method to aid in the automatic contouring of FTV has the potential to substantially improve treatment individualization and outcome assessment. Commercial software to determine FTV in FDG-avid primary and metastatic liver tumors has been evaluated and optimized. Volumes determined using the automated technique were compared to those from manually drawn contours identified using the same cutoff in the standard uptake value (SUV). The reproducibility of FTV is improved through the introduction of an optimal threshold value determined from phantom experiments. Application of the optimal threshold value from the phantom experiments to patient scans was in good agreement with hand-drawn determinations of the FTV. It is concluded that computer-assisted contouring of the FTV for primary and metastatic liver tumors improves reproducibility and increases accuracy, especially when combined with the selection of an optimal SUV threshold determined from phantom experiments. A method to link the pre-treatment assessment of functional (PET based) and anatomical (CT based) parameters to post-treatment survival and time to progression was evaluated in 22 patients with colorectal cancer liver metastases treated using 90Y microspheres and chemotherapy. The values for pre-treatment parameters that were the best

  1. Safety of {sup 90}Y Radioembolization in Patients Who Have Undergone Previous External Beam Radiation Therapy

    Energy Technology Data Exchange (ETDEWEB)

    Lam, Marnix G.E.H. [Division of Interventional Radiology, Stanford University School of Medicine, Stanford, California (United States); Department of Radiology and Nuclear Medicine, University Medical Center Utrecht (Netherlands); Abdelmaksoud, Mohamed H.K. [Division of Interventional Radiology, Stanford University School of Medicine, Stanford, California (United States); Chang, Daniel T.; Eclov, Neville C.; Chung, Melody P.; Koong, Albert C. [Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California (United States); Louie, John D. [Division of Interventional Radiology, Stanford University School of Medicine, Stanford, California (United States); Sze, Daniel Y., E-mail: dansze@stanford.edu [Division of Interventional Radiology, Stanford University School of Medicine, Stanford, California (United States)

    2013-10-01

    Purpose: Previous external beam radiation therapy (EBRT) is theoretically contraindicated for yttrium-90 ({sup 90}Y) radioembolization (RE) because the liver has a lifetime tolerance to radiation before becoming vulnerable to radiation-induced liver disease. We analyzed the safety of RE as salvage treatment in patients who had previously undergone EBRT. Methods and Materials: Between June 2004 and December 2010, a total of 31 patients who had previously undergone EBRT were treated with RE. Three-dimensional treatment planning with dose–volume histogram (DVH) analysis of the liver was used to calculate the EBRT liver dose. Liver-related toxicities including RE-induced liver disease (REILD) were reviewed and classified according to Common Terminology Criteria for Adverse Events version 4.02. Results: The mean EBRT and RE liver doses were 4.40 Gy (range, 0-23.13 Gy) and 57.9 Gy (range, 27.0-125.9 Gy), respectively. Patients who experienced hepatotoxicity (≥grade2; n=12) had higher EBRT mean liver doses (7.96 ± 8.55 Gy vs 1.62 ± 3.39 Gy; P=.037), the only independent predictor in multivariate analysis. DVH analysis showed that the fraction of liver exposed to ≥30 Gy (V30) was the strongest predictor of hepatotoxicity (10.14% ± 12.75% vs 0.84% ± 3.24%; P=.006). All patients with V30 >13% experienced hepatotoxicity. Fatal REILD (n=2) occurred at the 2 highest EBRT mean liver doses (20.9 Gy and 23.1 Gy) but also at the highest cumulative liver doses (91.8 Gy and 149 Gy). Conclusions: Prior exposure of the liver to EBRT may lead to increased liver toxicity after RE treatment, depending on fractional liver exposure and dose level. The V30 was the strongest predictor of toxicity. RE appears to be safe for the treatment of hepatic malignancies only in patients who have had limited hepatic exposure to prior EBRT.

  2. A method for energy window optimization for quantitative tasks that includes the effects of model-mismatch on bias: application to Y-90 bremsstrahlung SPECT imaging

    International Nuclear Information System (INIS)

    Rong Xing; Du Yong; Frey, Eric C

    2012-01-01

    Quantitative Yttrium-90 ( 90 Y) bremsstrahlung single photon emission computed tomography (SPECT) imaging has shown great potential to provide reliable estimates of 90 Y activity distribution for targeted radionuclide therapy dosimetry applications. One factor that potentially affects the reliability of the activity estimates is the choice of the acquisition energy window. In contrast to imaging conventional gamma photon emitters where the acquisition energy windows are usually placed around photopeaks, there has been great variation in the choice of the acquisition energy window for 90 Y imaging due to the continuous and broad energy distribution of the bremsstrahlung photons. In quantitative imaging of conventional gamma photon emitters, previous methods for optimizing the acquisition energy window assumed unbiased estimators and used the variance in the estimates as a figure of merit (FOM). However, for situations, such as 90 Y imaging, where there are errors in the modeling of the image formation process used in the reconstruction there will be bias in the activity estimates. In 90 Y bremsstrahlung imaging this will be especially important due to the high levels of scatter, multiple scatter, and collimator septal penetration and scatter. Thus variance will not be a complete measure of reliability of the estimates and thus is not a complete FOM. To address this, we first aimed to develop a new method to optimize the energy window that accounts for both the bias due to model-mismatch and the variance of the activity estimates. We applied this method to optimize the acquisition energy window for quantitative 90 Y bremsstrahlung SPECT imaging in microsphere brachytherapy. Since absorbed dose is defined as the absorbed energy from the radiation per unit mass of tissues in this new method we proposed a mass-weighted root mean squared error of the volume of interest (VOI) activity estimates as the FOM. To calculate this FOM, two analytical expressions were derived for

  3. A method for energy window optimization for quantitative tasks that includes the effects of model-mismatch on bias: application to Y-90 bremsstrahlung SPECT imaging.

    Science.gov (United States)

    Rong, Xing; Du, Yong; Frey, Eric C

    2012-06-21

    Quantitative Yttrium-90 ((90)Y) bremsstrahlung single photon emission computed tomography (SPECT) imaging has shown great potential to provide reliable estimates of (90)Y activity distribution for targeted radionuclide therapy dosimetry applications. One factor that potentially affects the reliability of the activity estimates is the choice of the acquisition energy window. In contrast to imaging conventional gamma photon emitters where the acquisition energy windows are usually placed around photopeaks, there has been great variation in the choice of the acquisition energy window for (90)Y imaging due to the continuous and broad energy distribution of the bremsstrahlung photons. In quantitative imaging of conventional gamma photon emitters, previous methods for optimizing the acquisition energy window assumed unbiased estimators and used the variance in the estimates as a figure of merit (FOM). However, for situations, such as (90)Y imaging, where there are errors in the modeling of the image formation process used in the reconstruction there will be bias in the activity estimates. In (90)Y bremsstrahlung imaging this will be especially important due to the high levels of scatter, multiple scatter, and collimator septal penetration and scatter. Thus variance will not be a complete measure of reliability of the estimates and thus is not a complete FOM. To address this, we first aimed to develop a new method to optimize the energy window that accounts for both the bias due to model-mismatch and the variance of the activity estimates. We applied this method to optimize the acquisition energy window for quantitative (90)Y bremsstrahlung SPECT imaging in microsphere brachytherapy. Since absorbed dose is defined as the absorbed energy from the radiation per unit mass of tissues in this new method we proposed a mass-weighted root mean squared error of the volume of interest (VOI) activity estimates as the FOM. To calculate this FOM, two analytical expressions were

  4. The role of (18)F-FDG positron emission tomography in the follow-up of liver tumors treated with (90)Yttrium radioembolization.

    Science.gov (United States)

    Bagni, Oreste; Filippi, Luca; Schillaci, Orazio

    2015-01-01

    In the last years, radioembolization (RE) has emerged as a novel technique for the treatment of malignant hepatic lesions using (90)Y embedded in spheres, which are infused directly into the hepatic arterial circulation. (90)Y-spheres, once implanted in liver, can release a significant radiation burden to neoplastic cells with a relative low dose to normal parenchyma. (90)Y RE results as a combination of embolization and radiation therapy, thus the standard radiologic follow up modalities may be not sufficiently accurate to assess tumor response to treatment. (18)Fluoro-deoxyglucose Positron Emission Tomography ((18)F-FDG PET) detects glucose uptake and metabolic activity in tumor cells. (18)F-FDG PET has become a well established diagnostic tool in many oncological scenarios. Furthermore, PET response criteria (PERCIST) have been recently introduced to categorize the metabolic response to therapy of cancer patients. Several semiquantitative parameters, such as SUVmax and its changes, the Functional Tumor Volume and the Total Lesion Glycolysis can be useful to accurately assess tumor changes after therapy. The purpose of this article is to present the literature on the role of (18)F-FDG PET in the evaluation of patients with primary and secondary liver tumors treated with (90)Y RE.

  5. Uncertainty and Detection Limit in Determination of 89,90Sr by Cherenkov Counting

    International Nuclear Information System (INIS)

    Grahek, Z.; Karanovic, G.; Nodilo, M.

    2013-01-01

    The methodology for the rapid determination of 89,90Sr in normal and emergency situations is given. Methodology is based on simultaneous separation of strontium and yttrium from samples and quantitative 89,90Sr determination by Cherenkov counting within three days. Methodology for quantitative determination by Cherenkov counting based on following changes of sample activity during the time is described and discussed. It has been shown that 89,90Sr can be determined with acceptable accuracy when 89Sr/90Sr ratio is over 10:1. Obtained results show that by using low level liquid scintillation counter it can be possible to determine 89Sr and 90Sr in broad range of concentration activities (1 - 1000 Bq (kgL) -1 ) with uncertainties below 10% within 2-3 days. Results also show that accuracy of determination of 89Sr (and 90Sr) depends on determination of difference between separation and counting time when activity ratio of 89Sr/90Sr is high. Analysis of combined uncertainty shows that it mainly depends on uncertainty of efficiency and recovery determination, uncertainty of activities determination for both isotopes and level of background radiation. Portion of each in combined uncertainty depend on level of activity of each isotope and its activity ratio.(author)

  6. Calibration and validation of a quality assurance system for {sup 90}Sr/{sup 90}Y radiation source trains

    Energy Technology Data Exchange (ETDEWEB)

    Rosenthal, P [Department of Radiation Therapy and Oncology, Freie Universitaet Berlin, Benjamin Franklin University Medical Centre, Hindenburgdamm 30, D-12200 Berlin (Germany); Weber, W [Novoste GmbH, Huettenallee 237 c, D-47800 Krefeld (Germany); Foerster, A [Department of Radiation Therapy and Oncology, Freie Universitaet Berlin, Benjamin Franklin University Medical Centre, Hindenburgdamm 30, D-12200 Berlin (Germany); Orth, O [Department of Radiation Therapy and Oncology, Freie Universitaet Berlin, Benjamin Franklin University Medical Centre, Hindenburgdamm 30, D-12200 Berlin (Germany); Koehler, B [Department of Radiation Therapy and Oncology, Freie Universitaet Berlin, Benjamin Franklin University Medical Centre, Hindenburgdamm 30, D-12200 Berlin (Germany); Seiler, F [Department of Radiation Therapy and Oncology, Freie Universitaet Berlin, Benjamin Franklin University Medical Centre, Hindenburgdamm 30, D-12200 Berlin (Germany)

    2003-03-07

    A quality assurance system (OPTIDOS, PTW-Freiburg) developed for dose rate verification of {sup 90}Sr/{sup 90}Y radiation source trains (RSTs) was calibrated and validated. These source trains are used in the 5-F-BetaCath{sup TM} system (Novoste Corp.) for the treatment of endovascular diseases. The calibration factor of the OPTIDOS system was obtained empirically and is valid for {sup 90}Sr/{sup 90}Y dose rate measurements at the specification point which is located at 2 mm distance from the source axis. A total of 187 OPTIDOS dose rate verifications of the 5-F-BetaCath{sup TM} system were performed in different hospitals. The histogram of the deviation between the manufacturer's dose rate specification and the dose rate measured using the OPTIDOS dosimetry system is Gaussian shaped with {+-}3% relative width and a mean shift of about +2% with respect to the corresponding dose rate specification. Additionally, 128 OPTIDOS dose rate verifications of the new jacketed RST (3.5-F-BetaCath{sup TM}, Novoste Corp.) were performed using the same calibration factor as derived for the 5-F-BetaCath{sup TM} system. Distribution of the deviation between the certified and the measured dose rate is nearly identical in comparison to the histogram of the 5-F-BetaCath{sup TM} system. The mean value of the deviations is shifted by -1.5% with respect to the certified dose rate. In order to compare the results of the calibrated OPTIDOS dosimetry system with a standard measuring method, separate dose rate measurements were performed using electron accelerator calibrated radiochromic films in which calibration is traceable to PTB (Physikalisch Technische Bundesanstalt, Germany). Deviation between both the methods is less than 3.1%. These results confirm that the calibrated OPTIDOS dosimetry system can be considered suitable for quality assurance of both types of RST used in the BetaCath{sup TM} systems.

  7. Use of yttrium-90 microspheres (TheraSphere) in a patient with unresectable hepatocellular carcinoma leading to liver transplantation: a case report.

    Science.gov (United States)

    Kulik, Laura M; Mulcahy, Mary F; Hunter, Russell D; Nemcek, Albert A; Abecassis, Michael M; Salem, Riad

    2005-09-01

    Prior to therapy, model for end stage liver disease (MELD) scoring, diagnostic imaging and tumor staging were performed in a patient with T3 HCC. The patient received an orthotopic liver transplant (OLT) 42 days after treatment. The explant specimen showed complete necrosis of the target tumor. Follow-up of this patient has demonstrated no evidence of recurrence. There was no life threatening or fatal adverse experiences related to treatment. This case report documents the natural course, history and outcome of a patient treated with yttrium-90 for unresectable HCC. The patient was downstaged from T3 to T2 and was subsequently transplanted.

  8. Yttrium-90 Needles in Interstitial Beta-Ray Therapy; Les Aiguilles d'Yttrium-90 en Endo-Electron-Therapie (Betatherapie Interstitielle); ИГЛЫ ИЗ ИТТРИЯ-90 ДЛЯ ЭНДОЭЛЕКТРОННОЙ ТЕРАПИИ ВНУТРИТКАНЕВОЙ БЕТА-ТЕРАГИ; Agujas de Itrio-90 en la Endo-Electronterapia (Betaterapia Intersticial)

    Energy Technology Data Exchange (ETDEWEB)

    Pierquin, B.; Mortreuil, M.; Beyer, H.; Dutreix, J.; Chassagne, D.; Galle, P.; Jammes, R. [Centre d' Etudes Nucleaires, Saclay (France)

    1963-03-15

    The Technical Unit for Interstitial Irradiation Therapy by Radioisotopes, of the Gustave Roussy Institute is at present studying, in collaboration with the Saclay Nuclear Centre, some therapeutic applications of interstitial beta-therapy using yttrium-90. Equipment: The needles consist of a stainless-steel tube, 1-mm diam., 0.1-mm wall thickness and 30 or 40 mm in length, closed at one end by a sharp point and at the other by a projecting head for attaching a pull-out wire. The yttrium oxide cylinders or seeds (5 mm x 0.6 mm) are irradiated for one week at a flux of 2.7 x 10{sup 12} n/cm{sup 2}s and are loaded three or five in each needle. Dosimetry: These yttrium-90 needles are supplied by the Saclay Centre with a standard activity of 1-1.5 me/cm (radioactive length). The activity is monitored both by a 4-{pi} counter and by a film densitometer. The reference dose is calculated by standard method at 2 mm from the tube wall assuming, with a certain approximation, a dose-rate of 10 rad/min for an activity of 1 me/cm. Therapeutic applications: Yttrium-90 needle radiobiology is still an almost unexplored field. The rapid fall-off in the dose beyond 3 mm from the needle wall causes difficulty in obtaining uniform distribution of irradiation in the treated tissues. In principle, the positioning of needles at 5 - 6 mm distance one from another is a possibility, but requires an implanting device capable of extremely delicate control, as an error of 1 or 2mm may cause too many hot or cold points. For that reason the authors decided to use the needles, at a first stage, in benign vascular tumours, with no biological attempt to obtain uniform irradiation of the tissue, the aim being confined to creating sclerotic areas in bands centred around the needles and separated by areas of tissue having received little or no irradiation. In this way it was-hoped to obtain an adequate sclerogenous effect in a certain number of tuberous angiomas while at the same time giving the

  9. A collimator optimization method for quantitative imaging: application to Y-90 bremsstrahlung SPECT.

    Science.gov (United States)

    Rong, Xing; Frey, Eric C

    2013-08-01

    Post-therapy quantitative 90Y bremsstrahlung single photon emission computed tomography (SPECT) has shown great potential to provide reliable activity estimates, which are essential for dose verification. Typically 90Y imaging is performed with high- or medium-energy collimators. However, the energy spectrum of 90Y bremsstrahlung photons is substantially different than typical for these collimators. In addition, dosimetry requires quantitative images, and collimators are not typically optimized for such tasks. Optimizing a collimator for 90Y imaging is both novel and potentially important. Conventional optimization methods are not appropriate for 90Y bremsstrahlung photons, which have a continuous and broad energy distribution. In this work, the authors developed a parallel-hole collimator optimization method for quantitative tasks that is particularly applicable to radionuclides with complex emission energy spectra. The authors applied the proposed method to develop an optimal collimator for quantitative 90Y bremsstrahlung SPECT in the context of microsphere radioembolization. To account for the effects of the collimator on both the bias and the variance of the activity estimates, the authors used the root mean squared error (RMSE) of the volume of interest activity estimates as the figure of merit (FOM). In the FOM, the bias due to the null space of the image formation process was taken in account. The RMSE was weighted by the inverse mass to reflect the application to dosimetry; for a different application, more relevant weighting could easily be adopted. The authors proposed a parameterization for the collimator that facilitates the incorporation of the important factors (geometric sensitivity, geometric resolution, and septal penetration fraction) determining collimator performance, while keeping the number of free parameters describing the collimator small (i.e., two parameters). To make the optimization results for quantitative 90Y bremsstrahlung SPECT more

  10. Intra-arterial treatment with 90Y microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University Hospital

    International Nuclear Information System (INIS)

    Lambert, Bieke; Mertens, Jeroen; Oltenfreiter, Ruth; Sturm, Emiel; Defreyne, Luc; Smeets, Peter; Troisi, Roberto; Vlierberghe, Hans van

    2011-01-01

    We report on our experience in terms of eligibility, safety, response and survival for treatment of hepatocellular carcinoma (HCC) with 90 Y microspheres. Secondly, we investigated the urinary excretion of 90 Y following treatment. We retrospectively reviewed all HCC patients referred to our department for 90 Y microsphere treatment. We recorded reasons for not proceeding to actual treatment. In case treatment was performed, we assessed the tolerance (Common Terminology Criteria for Adverse Events v3.0, CTCAE v3.0), the response [modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria] and long-term survival (Kaplan-Meier). The urinary excretion was estimated by 12-h urine collections post-injection for analysis in a gamma counter. Forty-three HCC patients were referred for radioembolization. Fourteen patients were excluded, mainly due to unfavourable 99m Tc-macroaggregated albumin (MAA) distribution. Twenty-nine patients were treated with 90 Y microspheres (TheraSphere, mean activity 2.17 GBq). In four patients severe clinical adverse events were encountered, however only in one case clearly related to the therapy. Twenty patients were assessable by mRECIST: complete response in 15%, partial response in 35%, stable disease in 30% and progression in 20% were observed. A median survival of 12.3 months (95% confidence interval 9.4-15.2) was estimated. Concerning the substudy on urinary excretion, only 0.0025% of the administered activity was excreted in the urine within the first 12 h following TheraSphere. Following a strict workup before admitting patients to radioembolization with TheraSphere, we found good clinical tolerance in the vast majority of patients. Radiological response assessment yielded an overall response rate of 50%, when evaluated early following treatment. Urine analysis showed consistently only low activities of 90 Y excreted in the urine. (orig.)

  11. Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours

    International Nuclear Information System (INIS)

    Romer, A.; Seiler, D.; Brunner, P.; Ng, Q.K.T.; Mueller-Brand, J.; Marincek, N.; Walter, M.A.; Koller, M.T.; Maecke, H.R.; Rochlitz, C.; Briel, M.; Schindler, C.

    2014-01-01

    Somatostatin-based radiopeptide treatment is generally performed using the β-emitting radionuclides 90 Y or 177 Lu. The present study aimed at comparing benefits and harms of both therapeutic approaches. In a comparative cohort study, patients with advanced neuroendocrine tumours underwent repeated cycles of [ 90 Y-DOTA]-TOC or [ 177 Lu-DOTA]-TOC until progression of disease or permanent adverse events. Multivariable Cox regression and competing risks regression were employed to examine predictors of survival and adverse events for both treatment groups. Overall, 910 patients underwent 1,804 cycles of [ 90 Y-DOTA]-TOC and 141 patients underwent 259 cycles of [ 177 Lu-DOTA]-TOC. The median survival after [ 177 Lu-DOTA]-TOC and after [ 90 Y-DOTA]-TOC was comparable (45.5 months versus 35.9 months, hazard ratio 0.91, 95 % confidence interval 0.63-1.30, p = 0.49). Subgroup analyses revealed a significantly longer survival for [ 177 Lu-DOTA]-TOC over [ 90 Y-DOTA]-TOC in patients with low tumour uptake, solitary lesions and extra-hepatic lesions. The rate of severe transient haematotoxicities was lower after [ 177 Lu-DOTA]-TOC treatment (1.4 vs 10.1 %, p = 0.001), while the rate of severe permanent renal toxicities was similar in both treatment groups (9.2 vs 7.8 %, p = 0.32). The present results revealed no difference in median overall survival after [ 177 Lu-DOTA]-TOC and [ 90 Y-DOTA]-TOC. Furthermore, [ 177 Lu-DOTA]-TOC was less haematotoxic than [ 90 Y-DOTA]-TOC. (orig.)

  12. Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours.

    Science.gov (United States)

    Romer, A; Seiler, D; Marincek, N; Brunner, P; Koller, M T; Ng, Q K T; Maecke, H R; Müller-Brand, J; Rochlitz, C; Briel, M; Schindler, C; Walter, M A

    2014-02-01

    Somatostatin-based radiopeptide treatment is generally performed using the β-emitting radionuclides (90)Y or (177)Lu. The present study aimed at comparing benefits and harms of both therapeutic approaches. In a comparative cohort study, patients with advanced neuroendocrine tumours underwent repeated cycles of [(90)Y-DOTA]-TOC or [(177)Lu-DOTA]-TOC until progression of disease or permanent adverse events. Multivariable Cox regression and competing risks regression were employed to examine predictors of survival and adverse events for both treatment groups. Overall, 910 patients underwent 1,804 cycles of [(90)Y-DOTA]-TOC and 141 patients underwent 259 cycles of [(177)Lu-DOTA]-TOC. The median survival after [(177)Lu-DOTA]-TOC and after [(90)Y-DOTA]-TOC was comparable (45.5 months versus 35.9 months, hazard ratio 0.91, 95% confidence interval 0.63-1.30, p = 0.49). Subgroup analyses revealed a significantly longer survival for [(177)Lu-DOTA]-TOC over [(90)Y-DOTA]-TOC in patients with low tumour uptake, solitary lesions and extra-hepatic lesions. The rate of severe transient haematotoxicities was lower after [(177)Lu-DOTA]-TOC treatment (1.4 vs 10.1%, p = 0.001), while the rate of severe permanent renal toxicities was similar in both treatment groups (9.2 vs 7.8%, p = 0.32). The present results revealed no difference in median overall survival after [(177)Lu-DOTA]-TOC and [(90)Y-DOTA]-TOC. Furthermore, [(177)Lu-DOTA]-TOC was less haematotoxic than [(90)Y-DOTA]-TOC.

  13. Does 99mTc MAA study accurately predict the Hepatopulmonary shunt fraction of 90Y theraspheres?

    International Nuclear Information System (INIS)

    Jha, Ashish; Zade, A.; Monteiro, P.; Shah, S.; Purandare, N.C.; Rangarajan, V.; Kulkarni, S.; Kulkarni, A.; Shetty, Nitin

    2010-01-01

    localization. IMAGE PROCESSING and DATA ANALYSIS: Both the sets pre and post therapeutic images were analyzed on dedicated workstation (Xeleris 1.1, GE Medical Systems). Hepatopulmonary shunt was calculated by self customized software developed on Xeleris workstation. Results: 13 patients undergoing - 90 Y Theraspheres therapy for radioembolisation of hepatic neoplasm were evaluated. The HPS fraction calculated from pre therapeutic 99m Tc MAA study and post therapeutic - 90 Y Bremsstrahlung images were 4.09% and 4.28% respectively. There is good correlation in the HPS fraction values by both methods (coefficient of correlation=0.973) CONCLUSION: The accuracy of Pre therapeutic 99m Tc MAA study is high in predicting the HPS of 90 Y-Theraspheres

  14. Migration and distribution of 90Sr in soil

    International Nuclear Information System (INIS)

    Yang Juncheng; Zhu Yongyi; Chen Jingjian

    1993-01-01

    The migration and distribution of radionuclide 90 Sr were conducted by the analysis of 97 soil longitudinal sections under natural conditions and by pot experiments with fallout and 90 Sr solution, respectively. Spring wheat and rice were employed in the pot experiments. The result showed that the radionuclide 90 Sr was mainly accumulated in the topsoil 0-10 cm under both of the natural and laboratory conditions. The vertical distribution of 90 Sr in soil agreed with the power function, which obtained was Y = 75.78 X -0.527 ; r = -0.986; n = 97. The existing forms of 90 Sr from fallout in soil, only 0.02-0.03% was in a soluble form and 0.06-0.07% in non-replaceable form

  15. Efficiency calibration of a liquid scintillation counter for 90Y Cherenkov counting

    International Nuclear Information System (INIS)

    Vaca, F.; Garcia-Leon, M.

    1998-01-01

    In this paper a complete and self-consistent method for 90 Sr determination in environmental samples is presented. It is based on the Cherenkov counting of 90 Y with a conventional liquid scintillation counter. The effects of color quenching on the counting efficiency and background are carefully studied. A working curve is presented which allows to quantify the correction in the counting efficiency depending on the color quenching strength. (orig.)

  16. Production of Strontium-90 Thermal Power Sources; Fabrication de sources d'energie thermique au strontium-90; Proizvodstvo istochnikov ''teplovoj ehnergii iz Sr''9''0; Preparacion de fuentes de energia termica con estroncio-90

    Energy Technology Data Exchange (ETDEWEB)

    Cochran, J. S.; Bloom, J. L.; Schneider, A. [Martin Company, Nuclear Division, Baltimore 3, MD (United States)

    1963-11-15

    debido a su abundancia, a sus propiedades nucleares y a la relativa facilidad con que permite construir generadores compactos de calor. Se emplean ya generadores a base de estroncio-90 para suministrar energia a centrales meteorologicas automaticas y aparatos auxiliares para la navegacion, y se esta estudiando la posibilidad de emplear este isotopo como fuente de energia para vehiculos espaciales. Se estudiaron diversos compuestos de estroncio que podian servir para este fin y se eligio el titanato porque reune las propiedades mas adecuadas. El estronico-90 se separa del resto d e los productos brutos de fision y se purifica hasta el grado requerido en las instalaciones de Hanford de la Comision de Energia Atomica de los Estados Unidos. Seguidamente se introduce en forma de carbonato en la ''celda caliente'' de la Martin Company, donde se transforma en pastilla, de titanato. Se sigue e l mismo proceso que en las tecnicas quimicas y ceramicas, pero adaptado para la manipulacion a distancia. Seguidamente las pastillas se encapsulan en recipientes de ''Hastelloy C'' para emplearlas en los generadores de energia termoelectrica. Estos procesos presentan problemas poco corrientes debido a que las grandes cantidades de estroncio-90 que se manejan (que podrian alcanzar millones de curies por ano) pueden originar gravisimos riegos radiologicos y de contaminacion. La memoria describe la instalacion, el equipo, el proceso y los criterios de seguridad. Describe tambien la experiencia adquirida recientemente al elaborar el combustilble para el generador SNAP-7 con los primeros 250 000 s de estroncio-90. Proporciona algunos detalles sobre los procedimientos de encapsulado, calorimetros, de descontaminacion y de evacuacion de desechos. (author) [Russian] Odnoj iz naibolee interesnykh oblastej primeneniya ogromnogo kolichestva radioaktivnykh otkhodov yavlyaetsya ispol'zovanie ikh v ustanovkakh s neposredstvennym preobrazovaniem ehnergii, prednaznachennykh dlya raboty v otdalennykh

  17. Gold nanorod-mediated hyperthermia enhances the efficacy of HPMA copolymer-90Y conjugates in treatment of prostate tumors

    International Nuclear Information System (INIS)

    Buckway, Brandon; Frazier, Nick; Gormley, Adam J.; Ray, Abhijit; Ghandehari, Hamidreza

    2014-01-01

    Introduction: The treatment of prostate cancer using a radiotherapeutic 90 Y labeled N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer can be enhanced with localized tumor hyperthermia. An 111 In labeled HPMA copolymer system for single photon emission computerized tomography (SPECT) was developed to observe the biodistribution changes associated with hyperthermia. Efficacy studies were conducted in prostate tumor bearing mice using the 90 Y HPMA copolymer with hyperthermia. Methods: HPMA copolymers containing 1, 4, 7, 10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) were synthesized by reversible addition-fragmentation transfer (RAFT) copolymerization and subsequently labeled with either 111 In for imaging or 90 Y for efficacy studies. Radiolabel stability was characterized in vitro with mouse serum. Imaging and efficacy studies were conducted in DU145 prostate tumor bearing mice. Imaging was performed using single photon emission computerized tomography (SPECT). Localized mild tumor hyperthermia was achieved by plasmonic photothermal therapy using gold nanorods. Results: HPMA copolymer-DOTA conjugates demonstrated efficient labeling and stability for both radionuclides. Imaging analysis showed a marked increase of radiolabeled copolymer within the hyperthermia treated prostate tumors, with no significant accumulation in non-targeted tissues. The greatest reduction in tumor growth was observed in the hyperthermia treated tumors with 90 Y HPMA copolymer conjugates. Histological analysis confirmed treatment efficacy and safety. Conclusion: HPMA copolymer-DOTA conjugates radiolabeled with both the imaging and treatment radioisotopes, when combined with hyperthermia can serve as an image guided approach for efficacious treatment of prostate tumors

  18. Investigation of pharmaceuticals and medical devices containing 90Y extracted from high radioactive liquid waste in spent-fuel reprocessing

    International Nuclear Information System (INIS)

    Hosoma, Takashi

    2012-07-01

    Pharmaceuticals and medical devices containing radioactive 90 Y are realized, approved and placed on the international market where three products are available in Europe and the United States, and one product in Japan. These products are used not for diagnosis but for treatment by internal irradiation. It was estimated from the deliberative report of the approval in Japan that 90 Y was extracted in Europe from high radioactive liquid waste (HALW) yielded in spent-fuel reprocessing. In this report, products placed on the market and physical properties were reviewed, reasons of the realization and conditions to realize succeeding products were estimated, extraction method was compared with other methods, technical subjects, and relevant regulations were investigated. Although a medical device containing radioactive 90 Y has been studied in Japan and one pharmaceutical product was approved, a breakthrough would be necessary to put 90 Y utilization beyond alternative treatments. The breakthrough would become be promising; for example, if conventional treatments could be supported by technical development to deliver 90 Y more sharply to the target with shorter serum half-life. Extraction of 90 Y nuclide from HALW has advantages over thermal neutron irradiation of natural nuclide, a system is envisioned where 90 Sr as a parent nuclide is separated in the reprocessing then transported to and stored in a factory of radiopharmaceuticals followed by 90 Y extraction on demand. (author)

  19. Structural and dielectric properties of yttrium substituted nickel ferrites

    International Nuclear Information System (INIS)

    Ognjanovic, Stevan M.; Tokic, Ivan; Cvejic, Zeljka; Rakic, Srdjan; Srdic, Vladimir V.

    2014-01-01

    Graphical abstract: - Highlights: • Dense NiFe 2−x Y x O 4 ceramics (with 0 ≤ x ≤ 0.3) were prepared. • Pure spinels were obtained for x ≤ 0.07 while for x ≥ 0.15 samples had secondary phases. • With addition of yttrium, ac conductivity slightly increased. • We suggest several effects that can explain the observed changes in ac conduction. • With addition of yttrium, dielectric constant increased while the tg δ decreased. - Abstract: The influence of Y 3+ ions on structural and dielectric properties of nickel ferrites (NiFe 2−x Y x O 4 , where 0 ≤ x ≤ 0.3) has been studied. The as-synthesized samples, prepared by the co-precipitation method, were analyzed by XRD and FTIR which suggested that Y 3+ ions were incorporated into the crystal lattice for all the samples. However, the XRD analysis of the sintered samples showed that secondary phases appear in the samples with x > 0.07. The samples have densities greater than 90% TD and the SEM images showed that the grain size decreases with the addition of yttrium. Dielectric properties measured from 150 to 25 °C in the frequency range of 100 Hz–1 MHz showed that the addition of yttrium slightly increases the ac conductivity and decreases the tg δ therefore making the materials better suited for the use in microwave devices

  20. Peptide Receptor Radionuclide Therapy with ''9''0Y DOTA TATE - First Results

    International Nuclear Information System (INIS)

    Artiko, V.; Sobic-Saranovic, D.; Petrovic, N.; Damjanovic, S.; Obradovic, V.

    2009-01-01

    Aim: The aim of this work is presentation of the preliminary results of the therapy of NETs with 90 Y DOTA TATE. Patients and methods: We investigated 15 patients with various neuroendocrine tumors. In all of them, together with other laboratory analyses and imaging methods, scintigraphy with somatostatin analogues was performed (in 3 with 111 In Octreoscan and in the other 4 with 99m Tc Tektrotyd) and high tumor uptake observed. The therapy was performed with 2-4,5 GBq 90 Y DOTA TATE per patient per one cycle, in the slow infusion in the physiological liquid (150 ml/15 min).Between the cycles, there was a time delay of 6-8 weeks. 30 minutes before the therapy, patients began receiving the infusion of amino acids (arginine and lysine) which lasted 4h. Before that, all therapies with somatostatin analogues were withdrawn. 24h-96h after the therapy, ''bremsstrahlung'' whole body imaging, SPECT and particular planar images were performed with gamma camera. Results: Analysis of the ''bremsstrahlung'' images showed uptake of the radiopharmaceutical in the liver, but the most of the activity was observed in the regions of the ''hot spots'' registered with previous 99m Tc Tektrotyd and 111 In Octreoscan images. According to our results, after the therapy, in two patients occurred progressive disease (PD), in seven stable disease (SD), and in six partial remission (PR). Up to now, there were no major clinical side effects hepatic function. Transient pancytopenia occurred in two patients, and impairment of kidney function in one. Conclusion: In spite of insufficient data, beneficial effects on clinical symptoms, hormone production and tumor proliferation were found, without major clinical side effects. Thus, according to preliminary results, treatment with 90 Y DOTA TATE is feasible method and might be useful for the management of patients with inoperable or disseminated neuroendocrine tumors. (author)

  1. Radiolabeling optimization and reduced staff radiation exposure for high-dose 90Y-ibritumomab tiuxetan (HD-Zevalin)

    International Nuclear Information System (INIS)

    Papi, Stefano; Martano, Luigi; Garaboldi, Lucia; Rossi, Annalisa; Cremonesi, Marta; Grana, Chiara Maria; Paolucci, Daniele; Sansovini, Maddalena; Paganelli, Giovanni; Chinol, Marco

    2010-01-01

    Introduction: 90 Y-Zevalin labeling may cause severe finger radiation exposure, especially in high-dose protocols (HD-Zevalin), where up to 7.4 GBq could be injected. In this work, we optimized the labeling of HD-Zevalin with special regard to simplicity, speed, safety and radiation protection. Methods: Factors influencing labeling outcome (activity, specific activity, time, final volume, stability) were studied separately. The critical steps of a standard radiolabeling procedure were optimized to reduce finger exposure, developing an alternative labeling procedure and including a different 90 Y supplier. Finger doses were monitored by thermoluminescent dosimeters at each fingertip under anti-X gloves, considering both absolute values and values after normalization to 1.48 GBq. Results: Labeling of 90 Y-Zevalin was safe and reproducible up to 7.4 GBq with a simple and single-step procedure offering good stability for several hours. Radiolabeling specific activity was found critical, being kept at 740 MBq.mg -1 . Radiochemical purity values ≥98% were routinely achieved. The alternative procedure allowed a sensible reduction of finger dose, due to both the different 90 Y vial and the handling. Finger exposure was reduced from 6.6±4.3 to 3.1±0.8 mSv/1.48 GBq in the case of the original 90 Y vial and from 1.5±0.9 to 0.3±0.1 mSv/1.48 GBq using a shielded 90 Y vial. Conclusions: HD-Zevalin can be prepared in a safe and reproducible way, giving high radiochemical purity values, good stability and low finger exposure. This study may improve the safety of nuclear medicine professionals involved in the preparation of Zevalin.

  2. Study on the source of optical activity: Pt. 6. ESR spectroscopy on the asymmetrical radical yields in 90Sr-90Y β irradiated D-and L-alanine

    International Nuclear Information System (INIS)

    Wang Wenqing; Zhao Jian; Ding Xiang

    1993-01-01

    Free radical formation in 90 Sr- 90 Y β irradiated D- and L-alanine is studied by ESR spectroscopy. To calibrate the probable differences in the size of ESR tubes, the different densities of alanine and the incidental different impurities, samples are firstly irradiated with 60 Co γ rays. Then the D- and L- alanine samples are irradiated with 90 Sr- 90 Y source at 77 K. Soon after irradiation, ESR measurement is performed on each sample. The average ratio H β+γ /H γ of D- alanine is 0.147 higher than that of L- alanine, indicating that more free radicals are induced in D- alanine by β irradiation. Irradiation at 77 K is capable of diminishing the effect of thermal movement on the polarization of β electrons and freezing the free radical formation. The experiments show the stereoselective interaction of β electrons with D- and L- amino acids, and so supports the Vester-ulbricht hypothesis

  3. Intra-arterial treatment with {sup 90}Y microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University Hospital

    Energy Technology Data Exchange (ETDEWEB)

    Lambert, Bieke; Mertens, Jeroen; Oltenfreiter, Ruth [Ghent University Hospital, Department of Nuclear Medicine, Ghent (Belgium); Sturm, Emiel; Defreyne, Luc [Ghent University Hospital, Department of Vascular and Interventional Radiology, Ghent (Belgium); Smeets, Peter [Ghent University Hospital, Department of Radiology, Ghent (Belgium); Troisi, Roberto [Ghent University Hospital, Department of Hepatobiliary Surgery and Liver Transplantation, Ghent (Belgium); Vlierberghe, Hans van [Ghent University Hospital, Department of Gastroenterology and Hepatology, Ghent (Belgium)

    2011-12-15

    We report on our experience in terms of eligibility, safety, response and survival for treatment of hepatocellular carcinoma (HCC) with {sup 90}Y microspheres. Secondly, we investigated the urinary excretion of {sup 90}Y following treatment. We retrospectively reviewed all HCC patients referred to our department for {sup 90}Y microsphere treatment. We recorded reasons for not proceeding to actual treatment. In case treatment was performed, we assessed the tolerance (Common Terminology Criteria for Adverse Events v3.0, CTCAE v3.0), the response [modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria] and long-term survival (Kaplan-Meier). The urinary excretion was estimated by 12-h urine collections post-injection for analysis in a gamma counter. Forty-three HCC patients were referred for radioembolization. Fourteen patients were excluded, mainly due to unfavourable {sup 99m}Tc-macroaggregated albumin (MAA) distribution. Twenty-nine patients were treated with {sup 90}Y microspheres (TheraSphere, mean activity 2.17 GBq). In four patients severe clinical adverse events were encountered, however only in one case clearly related to the therapy. Twenty patients were assessable by mRECIST: complete response in 15%, partial response in 35%, stable disease in 30% and progression in 20% were observed. A median survival of 12.3 months (95% confidence interval 9.4-15.2) was estimated. Concerning the substudy on urinary excretion, only 0.0025% of the administered activity was excreted in the urine within the first 12 h following TheraSphere. Following a strict workup before admitting patients to radioembolization with TheraSphere, we found good clinical tolerance in the vast majority of patients. Radiological response assessment yielded an overall response rate of 50%, when evaluated early following treatment. Urine analysis showed consistently only low activities of {sup 90}Y excreted in the urine. (orig.)

  4. Anti-CD45 radioimmunotherapy with 90Y but not 177Lu is effective treatment in a syngeneic murine leukemia model.

    Directory of Open Access Journals (Sweden)

    Johnnie J Orozco

    Full Text Available Radioimmunotherapy (RIT for treatment of hematologic malignancies has primarily employed monoclonal antibodies (Ab labeled with 131I or 90Y which have limitations, and alternative radionuclides are needed to facilitate wider adoption of RIT. We therefore compared the relative therapeutic efficacy and toxicity of anti-CD45 RIT employing 90Y and 177Lu in a syngeneic, disseminated murine myeloid leukemia (B6SJLF1/J model. Biodistribution studies showed that both 90Y- and 177Lu-anti-murine CD45 Ab conjugates (DOTA-30F11 targeted hematologic tissues, as at 24 hours 48.8 ± 21.2 and 156 ± 14.6% injected dose per gram of tissue (% ID/g of 90Y-DOTA-30F11 and 54.2 ± 9.5 and 199 ± 11.7% ID/g of 177Lu-DOTA-30F11 accumulated in bone marrow (BM and spleen, respectively. However, 90Y-DOTA-30F11 RIT demonstrated a dose-dependent survival benefit: 60% of mice treated with 300 µCi 90Y-DOTA-30F11 lived over 180 days after therapy, and mice treated with 100 µCi 90Y-DOTA-30F11 had a median survival 66 days. 90Y-anti-CD45 RIT was associated with transient, mild myelotoxicity without hepatic or renal toxicity. Conversely, 177Lu- anti-CD45 RIT yielded no long-term survivors. Thus, 90Y was more effective than 177Lu for anti-CD45 RIT of AML in this murine leukemia model.

  5. Determination of Sr-90 in rain water samples

    International Nuclear Information System (INIS)

    Lima, M.F.; Cunha, I.I.L.

    1988-01-01

    A work that aim is to establish radiochemical method for the determination of Sr-90 in rain water samples has been studied, as a step in an environmental monitoring program of radioactive elements. The analysis includes the preconcentration of strontium diluted in a large volume sample by precipitation of strontium as carbonate, separation of strontium from interfering elements (calcium, barium and rare earths), separation of strontium from ytrium, precipitation of purified strontium and ytrium respectively as carbonate and oxalate, and counting of Sr-90 and Y-90 activities in a low background anticoincidence beta counter. (author) [pt

  6. Determination of 90Sr in low-level radioactive wastes using extraction chromatography and LSC

    International Nuclear Information System (INIS)

    Temba, Eliane S.C.; Reis Junior, Aluisio S.; Mingote, Raquel M.; Monteiro, Roberto P.G.

    2009-01-01

    A procedure for the determination of 90 Sr in low-level radioactive wastes is presented in this work. It is a part of a methodology developed for the sequential radiochemical separation of radionuclides in low-level radioactive wastes. These radionuclides comprises the actinides and 55 Fe, 63 Ni and 90 Sr, classified as difficult-to-measure (DTM) radionuclides in the radioactive waste characterization, because they cannot be measured by direct measurements, like gamma spectrometry. A variety of methods have been reported in the literature, based on precipitation, liquid-liquid extraction and ion exchange. In this work, the separation was carried out using precipitation and extraction chromatography using the Sr Resin (Eichrom). This resin is strontium-selective, the extractant is a crown ether-derivative immobilized on an inert polymeric support. The 90 Sr eluted from column was measured by LSC. The counting was carried out within 5 hours of the start of yttrium ingrowth to minimize interferences from 90 Y. The counting efficiency was calculated by using a 90 Sr standard solution purified by the specific resin. The chemical yield of the procedure was determined gravimetrically by the addition of a stable Sr carrier. Optimum conditions for the pretreatment, separation and LSC setting were determined using simulated samples. This procedure showed to be rapid and achieved a good chemical recovery, with an average of 84 %, and a detection limit of 0.6 Bq L -1 . (author)

  7. Utility of Quantitative 99mTc-MAA SPECT/CT for 90yttrium-Labelled Microsphere Treatment Planning: Calculating Vascularized Hepatic Volume and Dosimetric Approach

    Science.gov (United States)

    Garin, Etienne; Rolland, Yan; Lenoir, Laurence; Pracht, Marc; Mesbah, Habiba; Porée, Philippe; Laffont, Sophie; Clement, Bruno; Raoul, Jean-Luc; Boucher, Eveline

    2011-01-01

    Objectives. The aim of this study was to assess the effectiveness of SPECT/CT for volume measurements and to report a case illustrating the major impact of SPECT/CT in calculating the vascularized liver volume and dosimetry prior to injecting radiolabelled yttrium-90 microspheres (Therasphere). Materials and Methods. This was a phantom study, involving volume measurements carried out by two operators using SPECT and SPECT/CT images. The percentage of error for each method was calculated, and interobserver reproducibility was evaluated. A treatment using Therasphere was planned in a patient with three hepatic arteries, and the quantitative analysis of SPECT/CT for this patient is provided. Results. SPECT/CT volume measurements proved to be accurate (mean error Therasphere used. Conclusions. MAA SPECT/CT is accurate for vascularized liver volume measurements, providing a valuable contribution to the therapeutic planning of patients with complex hepatic vascularization. PMID:21822489

  8. Country report: Cuba. Local Production of {sup 90}Y And {sup 188}Re Radionuclides and Development of Radiopharmaceuticals for Therapy

    Energy Technology Data Exchange (ETDEWEB)

    Xiques, Abmel; Hernández, Ignacio; Leyva, René; Pérez, Marylaine; Alonso, Luis Michel; Zamora, Minelys [Centro de Isotopos (CENTIS) (Cuba)

    2010-07-01

    During the first period of this CRP we could test an efficient and reliable generator system based on ion-chromatography to obtain {sup 90}Y from its parent radionuclide {sup 90}Sr. This production scheme for {sup 90}Y was outlined in the previous CRP related with the development of generator technologies. Quality parameters such as trace metals that can potentially interfere in the labeling of biomoléculas, {sup 90}Y recovery, {sup 90}Sr/{sup 90}Y ratio and radiation dose to bed matrix were evaluated. The results showed that high recovery and radionuclidic purity could be obtained for {sup 90}Y during its repeated separation from the {sup 90}Sr cow. No replacement or treatment of the cow were necessary and low waste generation and {sup 90}Sr losses less that 0.1% after each run were also observed during the present study. A Fab’ fragment was enzimatically produced and purified from the monoclonal antibody h-R3 (Nimotuzumab®). The fragment and the parent antibody were successfully conjugated with DOTA and labeled with {sup 90}Y. The radioinmunoconjugate thus obtained also exhibited a good 24 h in-vitro stability in an excess of DTPA. A {sup 90}Y radiocoloid was prepared in a cromic phosphate particle for radiosynoviorthesis with promising results in animal models. Two alumina based {sup 188}W/{sup 188}Re generators were prepared and their eluates were used in the labeling of hR3-DOTA conjugates. Quality control and in vivo evaluation in comparison with {sup 99m}Tc-hR3 showed very good results and similar pattern of distribution and pharmacokinetic and will be used in clinical trials for cancer patients. (author)

  9. A method for determination of 90Sr in vegetation

    International Nuclear Information System (INIS)

    Nygren, U.

    1998-12-01

    This report describes a method for determination of 90 Sr in vegetation. The method consists of wet-ashing the samples and separating Sr from the sample matrix by oxalate precipitation and extraction chromatography. 90 Y ingrowth is awaited after which Y is separated from Sr and 90 Y measured in a proportional counter. The method has been applied on two reference materials and the 90 Sr results agree well with the recommended values. The method has also been used on 20 samples of blueberry twigs and the mean recovery of Sr was 74%

  10. Novel approaches for 90Sr analyses in contaminated environmental samples

    International Nuclear Information System (INIS)

    Kavasi, N.; Sahoot, S.K.; Area, H.; Aono, T.

    2016-01-01

    Radioactive strontium isotopes are generated with high cumulative fission yield (5-6 %) during thermal neutron fission in a nuclear reactor. The physical half-life of 89 Sr (50.52 d) is short but that of 90 Sr (28.8 y) is long enough to generate radioecological repercussions. 90 Sr has a long-lasting biological half-life (∼18 y) in the human body, due to its chemical similarity to calcium the importance of 90 Sr analysis is emphasized in case of a nuclear disaster. The world-wide spread of 90 Sr, as a background, is derived from the global atmospheric fallout contributed by large-scale atmospheric nuclear weapons tests conducted from 1945. In case of local contamination, nuclear accidents are not the only source of 90 Sr isotope, misconducted underground nuclear weapon tests; improper handling of by-products of nuclear weapon production or normal operation of nuclear facilities (e.g. reprocessing plants) can be taken into account

  11. The 90 90 90 strategy to end the HIV Pandemic by 2030: Can the supply chain handle it?

    Science.gov (United States)

    Jamieson, David

    2016-01-01

    Introduction UNAIDS “90-90-90” strategy calls for 90% of HIV-infected individuals to be diagnosed by 2020, 90% of whom will be on anti-retroviral therapy (ART) and 90% of whom will achieve sustained virologic suppression. Reaching these targets by 2020 will reduce the HIV epidemic to a low-level endemic disease by 2030. However, moving the global response towards this universal test and treat model will pose huge challenges to public health systems in resource-limited settings, including global and local supply chain systems. These challenges are especially acute in Africa, which accounts for over 70% of the persons affected by HIV. Discussion From a supply chain perspective, each of the “90's” has possible complications and roadblocks towards realizing the promise envisioned by 90-90-90. For instance, ensuring that 90% of HIV-infected persons know their status will require a large increase in access to HIV tests compared with what is currently available. To ensure that there are enough anti-retrovirals available to treat the nearly 25 million people that will require them by 2020 represents a near doubling of the ARV supplied to treat the 13 million currently on treatment. Similarly, to monitor those on treatment means an unprecedented scale-up of viral load testing throughout Africa. Conclusions Larger issues include whether the capacity exists at the local level to handle these commodities when they arrive in the most severely affected countries, including considerations of the human resources and costs needed to make this strategy effective. We believe that such “real world” analysis of proposed strategies and policies is essential to ensure their most effective implementation. PMID:27370169

  12. The 90 90 90 strategy to end the HIV Pandemic by 2030: Can the supply chain handle it?

    Science.gov (United States)

    Jamieson, David; Kellerman, Scott E

    2016-01-01

    UNAIDS "90-90-90" strategy calls for 90% of HIV-infected individuals to be diagnosed by 2020, 90% of whom will be on anti-retroviral therapy (ART) and 90% of whom will achieve sustained virologic suppression. Reaching these targets by 2020 will reduce the HIV epidemic to a low-level endemic disease by 2030. However, moving the global response towards this universal test and treat model will pose huge challenges to public health systems in resource-limited settings, including global and local supply chain systems. These challenges are especially acute in Africa, which accounts for over 70% of the persons affected by HIV. From a supply chain perspective, each of the "90's" has possible complications and roadblocks towards realizing the promise envisioned by 90-90-90. For instance, ensuring that 90% of HIV-infected persons know their status will require a large increase in access to HIV tests compared with what is currently available. To ensure that there are enough anti-retrovirals available to treat the nearly 25 million people that will require them by 2020 represents a near doubling of the ARV supplied to treat the 13 million currently on treatment. Similarly, to monitor those on treatment means an unprecedented scale-up of viral load testing throughout Africa. Larger issues include whether the capacity exists at the local level to handle these commodities when they arrive in the most severely affected countries, including considerations of the human resources and costs needed to make this strategy effective. We believe that such "real world" analysis of proposed strategies and policies is essential to ensure their most effective implementation.

  13. Human Internal Contamination with Strontium-90 Titanate; Contamination Interne du Corps Humain par le Titanate de Strontium 90; 0412 041d 0414 ; Contaminacion Interna del Cuerpo Humano con Titanato de Estroncio-90

    Energy Technology Data Exchange (ETDEWEB)

    Bradley, F. J.; Wald, N.; Wechsler, R. L. [Graduate School of Public Health and School of Medicine, University of Pittsburgh, Pittsburgh, PA (United States)

    1964-11-15

    Strontium-90 has been used in multikilocurie quantities recently as a heat source for thermoelectric generators. The titanate was carefully selected for this purpose as the chemical form which best met requirements including inertness to corrosive attack in the event of accidental release to the environment. An industrial accidental exposure of one worker on 26 June 1963 to strontium-90 titanate powder, originally in the form of particles of about 120 {mu}m and less, provided an opportunity to attempt the assessment of the human body burden of this supposedly highly insoluble compound. Because of the physical and biological behaviour of the particles, it was assumed that the actual particle size which was dispersed and ingested and/or inhaled by the exposed person was in the range of 1 to 30 {mu}m. Three techniques were used to estimate the body burden. Whole-body radiation counting carried out by Dr. Charles H. Miller at Argonne National Laboratory, which only gave an upper limit because of the non-specific Bremsstrahlung spectrum from strontium-90, yttrium-90 indicated an initial total-body burden of 4.8 {mu}c. The second method, total urinary and faecal output collection, totalled 5.0 for the first 20 d. Combining that amount with an estimate of the amount retained in the body, an initial total-body burden of 5.2 {mu}c was obtained. The third technique, blood radioactivity determination, indicated an initial total-body burden of 6 {mu}c. The ratio of faecal to urinary output in the first 20 d was 15 to 1, and 94% of the total strontium-90 excretion was via the gastro-intestinal tract. It is of interest, however, that a significant fraction was evidently soluble. By the 20th post-incident day, it was estimated that the retained body burden was only 5% of the total intake. Methods used in that period to enhance faecal excretion by MgSO{sub 4} and urinary excretion by a combination of Ca-gluconate and NH{sub 4}CI are described. Subsequent excretion patterns and the

  14. Sr-90 determination in aqueous and soils samples

    International Nuclear Information System (INIS)

    Gonzalez Sintas, Maria F.; Cerchietti, Maria L.; Arguelles, Maria G.

    2009-01-01

    The main objective of this paper is to evaluate the method for Sr-90 determination in aqueous sample and soils. Area and Personal Dosimetry laboratory (DPA) determines the presence of Sr-90 by Liquid Scintillation (LSC) by applying method of the double window and corresponding adjustments. Calibration is performed by standard solutions of 90 Sr/ 90 Y, where spectral 90 Sr and 90 Y zones are optimized. The initial treatment of the liquid samples includes the concentration for evaporation, while the solid ones dissolve for microwave and acidic digestion. The separation of the analyte involves a selective chromatographic extraction. An average efficiency for 90 Sr of 77 ± 1 % was obtained; the factor a/b was 0,85 ± 0,01 and recovery of 82 ± 8 %. The resultant MAD was 0,10 Bq/L in aqueous samples and 0,10 Bq/g in solid samples. (author)

  15. Investigation on the influence of metal ion impurities on the complexation behavior of generator produced {sup 90}Y with bifunctional chelators

    Energy Technology Data Exchange (ETDEWEB)

    Pandey, Usha; Gamre, Naresh; Dash, Ashutosh [Isotope Applications and Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai (India)

    2014-05-01

    The {sup 90}Sr/ {sup 90}Y generator is the exclusive source of 'no carrier added' {sup 90}Y for targeted therapy. However, the concomitant presence of trace metals diminishes the complexation of {sup 90}Y with bifunctional chelators (BFCs). A systematic investigation was performed to evaluate the influence of trace metals on the complexation of {sup 90}Y (from an electrochemical generator) with BFCs such as p-SCN-Bn-PCTA, p-SCN-Bn-DTPA and p-SCN-Bn-DOTA. Our study indicates that while p-SCN-Bn-DTPA was least affected by most of the trace metals studied, p-SCN-Bn-PCTA was most sensitive to their presence and hence could be the ligand of choice for assessing the chemical purity of generator derived {sup 90}Y. (author)

  16. Improved quantitative 90 Y bremsstrahlung SPECT/CT reconstruction with Monte Carlo scatter modeling.

    Science.gov (United States)

    Dewaraja, Yuni K; Chun, Se Young; Srinivasa, Ravi N; Kaza, Ravi K; Cuneo, Kyle C; Majdalany, Bill S; Novelli, Paula M; Ljungberg, Michael; Fessler, Jeffrey A

    2017-12-01

    In 90 Y microsphere radioembolization (RE), accurate post-therapy imaging-based dosimetry is important for establishing absorbed dose versus outcome relationships for developing future treatment planning strategies. Additionally, accurately assessing microsphere distributions is important because of concerns for unexpected activity deposition outside the liver. Quantitative 90 Y imaging by either SPECT or PET is challenging. In 90 Y SPECT model based methods are necessary for scatter correction because energy window-based methods are not feasible with the continuous bremsstrahlung energy spectrum. The objective of this work was to implement and evaluate a scatter estimation method for accurate 90 Y bremsstrahlung SPECT/CT imaging. Since a fully Monte Carlo (MC) approach to 90 Y SPECT reconstruction is computationally very demanding, in the present study the scatter estimate generated by a MC simulator was combined with an analytical projector in the 3D OS-EM reconstruction model. A single window (105 to 195-keV) was used for both the acquisition and the projector modeling. A liver/lung torso phantom with intrahepatic lesions and low-uptake extrahepatic objects was imaged to evaluate SPECT/CT reconstruction without and with scatter correction. Clinical application was demonstrated by applying the reconstruction approach to five patients treated with RE to determine lesion and normal liver activity concentrations using a (liver) relative calibration. There was convergence of the scatter estimate after just two updates, greatly reducing computational requirements. In the phantom study, compared with reconstruction without scatter correction, with MC scatter modeling there was substantial improvement in activity recovery in intrahepatic lesions (from > 55% to > 86%), normal liver (from 113% to 104%), and lungs (from 227% to 104%) with only a small degradation in noise (13% vs. 17%). Similarly, with scatter modeling contrast improved substantially both visually and in

  17. Determination of 90Sr in waters of discharge of nuclear power plants

    International Nuclear Information System (INIS)

    Campos, J.M.; Equillor, H.E.

    2010-01-01

    The determination of 90 Sr has some problems because it is a pure beta emitter, and despite the specificity of radiochemical techniques used, their full identification is not always easy, especially when detected low activities. In addition, samples water discharge presents a matrix consisting of a series of fission or activation products, beta / gamma emitters, several of which may interfere with the determination of 90 Sr. This paper describes a simple method for the determination of 90 Sr in water of discharge of nuclear power plants, which is based on the purification of 90 Y, which is used in the ARN since 2009 and has yielded good results to the present, as no interferences were detected in the analysis of the decay of 90 Y. (authors) [es

  18. Treatment of hepatocellular carcinoma (HCC) with intra-arterial Yttrium-90 microspheres for down-staging patients to transplantation

    International Nuclear Information System (INIS)

    De Man, K.; Defreyne, L.; Delanghe, E.; Smeets, P.; Verhelst, X.; Geerts, A.; Van Vlierberghe, H.; Rogiers, X.; Troisi, R.; Lambert, B.

    2015-01-01

    Full text of publication follows. Introduction and aim: in our hospital, patients are referred for intra-arterial treatment with Yttrium-90 microspheres if they present with an HCC confined to the liver, but are ineligible for curative treatment options such as liver transplantation, partial hepatectomy or radio-frequent ablation. Additional eligibility criteria for radio-embolisation consist of Child-P ugh score Yttrium-90 microspheres in our hospital since 2008 and who presented at an age <70 and with a disease load exceeding the Milan criteria (single tumour ≤5 cm or ≤ 3 lesions ≤ 3 cm). We recorded whether the patient was down staged to a tumour load complying with the Milan criteria, and if so, whether transplantation was carried out. Results: 40 patients aged <70 years and with a tumour load exceeding the Milan criteria (all treated with TheraSphere, Nordion except 1 with SIR-Spheres, Sirtex) were evaluable. 35 had Barcelona Clinic Liver Cancer (BCLC) B stage disease and 5 had BCLC C. Overall median survival was 12.9 months. 16 out of 40 patients were down staged to the Milan criteria (40%, all BCLC B), of whom 8 were actually transplanted so far. Two patients are on the waiting list, 1 patient refuses to be listed and 1 patient suffers co-morbidity that excludes him from abdominal surgery. Unfortunately 4 patients died before or during work-out for transplantation: 1 unexplained sudden death, 1 lung embolism and 2 due to liver failure. The overall median survival was 30,4 months in the down staged patients. 24 out 40 patients (60%) did not have a tumour load within the Milan criteria at any point of their follow up and had a significant worse

  19. Investigation on the influence of metal ion impurities on the complexation behavior of generator produced {sup 90}Y with different bifunctional chelators

    Energy Technology Data Exchange (ETDEWEB)

    Pandey, Usha; Gamre, Naresh; Chakravarty, Rubel; Pillai, Maroor Raghavan Ambikalmajan; Dash, Ashutosh [Bhabha Atomic Research Centre, Trombay, Mumbai (India). Radiopharmaceuticals Div.

    2014-07-01

    While the {sup 90}Sr/{sup 90}Y generator is the exclusive source of obtaining 'no carrier added' {sup 90}Y for targeted therapy, the presence of trace metals in the radiolabeling solutions poses a serious challenge owing to their ability to diminish the {sup 90}Y complexation yields with bifunctional chelators (BFCs). p-SCN-Bn-PCTA is a novel ligand having faster complexation kinetics with a number of radiometals. In this work, a systematic investigation was performed to evaluate the chelating ability of p-SCN-Bn-PCTA for {sup 90}Y and the influence of trace metal ions on it's complexation with {sup 90}Y in comparison to p-SCN-Bn-DTPA and p-SCN-Bn-DOTA using {sup 90}YCl{sub 3} obtained from an electrochemical generator. Results from our study indicate that while p-SCN-Bn-PCTA gave very good radiolabeling yields with {sup 90}Y when the reaction was carried out by heating for few minutes, it was most sensitive to the presence of trace metals, especially Fe(III). An independent and useful observation is that p-SCN-Bn-PCTA could be considered as the ligand of choice for assessing the chemical purity of generator derived {sup 90}Y.

  20. Peptide receptor radionuclide therapy with {sup 90}Y-DOTATOC in recurrent meningioma

    Energy Technology Data Exchange (ETDEWEB)

    Bartolomei, Mirco; Bodei, Lisa; De Cicco, Concetta; Grana, Chiara Maria; Baio, Silvia Melania; Arico, Demetrio; Paganelli, Giovanni [European Institute of Oncology, Division of Nuclear Medicine, Milan (Italy); Cremonesi, Marta [European Institute of Oncology, Division of Medical Physics, Milan (Italy); Botteri, Edoardo [European Institute of Oncology, Division of Epidemiology and Biostatistics, Milan (Italy); Sansovini, Maddalena [Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Radiometabolic Medicine Division, Meldola (Italy)

    2009-09-15

    Meningiomas are generally benign and in most cases surgery is curative. However, for high-grade histotypes or partially resected tumours, recurrence is fairly common. External beam radiation therapy (EBRT) is usually given in such cases but is not always effective. We assessed peptide receptor radionuclide therapy (PRRT) using {sup 90}Y-DOTATOC in a group of patients with meningioma recurring after standard treatments in all of whom somatostatin receptors were strongly expressed on meningioma cell surfaces. Twenty-nine patients with scintigraphically proven somatostatin subtype 2 receptor-positive meningiomas were enrolled: 14 had benign (grade I), 9 had atypical (grade II) and 6 had malignant (grade III) disease. Patients received intravenous {sup 90}Y-DOTATOC for 2-6 cycles for a cumulative dose in the range of 5-15 GBq. Clinical and neuroradiological evaluations were performed at baseline, during and after PRRT. The treatment was well tolerated in all patients. MRI 3 months after treatment completion showed disease stabilization in 19 of 29 patients (66%) and progressive disease in the remaining 10 (34%). Better results were obtained in patients with grade I meningioma than in those with grade II-III, with median time to progression (from beginning PRRT) of 61 months in the low-grade group and 13 months in the high-grade group. PRRT with {sup 90}Y-DOTATOC can interfere with the growth of meningiomas. The adjuvant role of this treatment, soon after surgery, especially in atypical and malignant histotypes, deserves further investigation. (orig.)

  1. Test for the determination of 90Sr in soil

    International Nuclear Information System (INIS)

    1980-01-01

    The standardized method is based on the chemical separation (extraction, precipitation, etc.) of 90 Sr from other fission products. After long-term storage for 90 Sr- 90 Y equilibrium the activity of the sample precipitated in the form of Y(COO) 2 is measured. The Sr yield coefficient is determined by 85 Sr tracer or by gravimetry. The test is applicable for the determination of 90 Sr contamination originating from fallout or from other sources in soil, when the concentration of 90 Sr is higher than 0.2-0.4 Bqg -1 (5-10 pCig -1 ). The error of the method is less than +-2% of the amount of the 90 Sr present. (Sz.J.)

  2. A dosing method in the same time of the radiocesium and the radiostrontium in natural waters; Dosage simultane du cesium 137 et des strontium 89 et 90 dans les eaux naturelles

    Energy Technology Data Exchange (ETDEWEB)

    Scheidhauer, J; Messainguiral, L [Commissariat a l' Energie Atomique, Marcoule (France).Centre d' Etudes Nucleaires

    1960-07-01

    Prior a concentration and an unselective elution are effected by the way of an exchange resin. The cesium is absorbed on ammonium molybdophosphate precipitated with hydrofluoric acid after radium elimination. The strontium is stripped in concentrated nitric acid, precipitated in the form of strontium carbonate and then counted near the radioactive balance. At last the yttrium is separated by the thenoyltrifluoroacetone and counted on a counting device. From the outset of this paper, an analysis of the method is explained. (author) [French] On opere d'abord une concentration sur resine et une elution non selective. Le cesium est absorbe sur un precipite de phosphomolybdate d'ammonium en presence d'acide fluorhydrique, apres separation du radium. Le strontium est traite a l'acide nitrique concentre, precipite sous forme de carbonate et compte au voisinage de l'equilibre radioactif ({sup 90}Sr {sup 9O}y ). L'yttrium 90 est ensuite separe a la thenoyltrifluoracetone et compte. Une etude de la methode est presentee au debut de ce memoire. (auteur)

  3. Somatostatin-based radiopeptide therapy with [{sup 177}Lu-DOTA]-TOC versus [{sup 90}Y-DOTA]-TOC in neuroendocrine tumours

    Energy Technology Data Exchange (ETDEWEB)

    Romer, A.; Seiler, D.; Brunner, P.; Ng, Q.K.T.; Mueller-Brand, J. [University Hospital Basel, Institute of Nuclear Medicine, Basel (Switzerland); Marincek, N.; Walter, M.A. [University Hospital Basel, Institute of Nuclear Medicine, Basel (Switzerland); University Hospital Bern, Institute of Nuclear Medicine, Bern (Switzerland); Koller, M.T. [University Hospital Basel, Basel Institute for Clinical Epidemiology and Biostatistics, Basel (Switzerland); Maecke, H.R. [University Hospital Basel, Division of Radiochemistry, Basel (Switzerland); Rochlitz, C. [University Hospital Basel, Department of Oncology, Basel (Switzerland); Briel, M. [University Hospital Bern, Institute of Nuclear Medicine, Bern (Switzerland); University Hospital Basel, Basel Institute for Clinical Epidemiology and Biostatistics, Basel (Switzerland); McMaster University, Department of Clinical Epidemiology and Biostatistics, Hamilton (Canada); Schindler, C. [University of Basel, Swiss Tropical and Public Health Institute, Basel (Switzerland)

    2014-02-15

    Somatostatin-based radiopeptide treatment is generally performed using the β-emitting radionuclides {sup 90}Y or {sup 177}Lu. The present study aimed at comparing benefits and harms of both therapeutic approaches. In a comparative cohort study, patients with advanced neuroendocrine tumours underwent repeated cycles of [{sup 90}Y-DOTA]-TOC or [{sup 177}Lu-DOTA]-TOC until progression of disease or permanent adverse events. Multivariable Cox regression and competing risks regression were employed to examine predictors of survival and adverse events for both treatment groups. Overall, 910 patients underwent 1,804 cycles of [{sup 90}Y-DOTA]-TOC and 141 patients underwent 259 cycles of [{sup 177}Lu-DOTA]-TOC. The median survival after [{sup 177}Lu-DOTA]-TOC and after [{sup 90}Y-DOTA]-TOC was comparable (45.5 months versus 35.9 months, hazard ratio 0.91, 95 % confidence interval 0.63-1.30, p = 0.49). Subgroup analyses revealed a significantly longer survival for [{sup 177}Lu-DOTA]-TOC over [{sup 90}Y-DOTA]-TOC in patients with low tumour uptake, solitary lesions and extra-hepatic lesions. The rate of severe transient haematotoxicities was lower after [{sup 177}Lu-DOTA]-TOC treatment (1.4 vs 10.1 %, p = 0.001), while the rate of severe permanent renal toxicities was similar in both treatment groups (9.2 vs 7.8 %, p = 0.32). The present results revealed no difference in median overall survival after [{sup 177}Lu-DOTA]-TOC and [{sup 90}Y-DOTA]-TOC. Furthermore, [{sup 177}Lu-DOTA]-TOC was less haematotoxic than [{sup 90}Y-DOTA]-TOC. (orig.)

  4. Analyses and quantitative determination of the strontium radioisotopes 89 and 90 in milk powder

    International Nuclear Information System (INIS)

    Jeanmaire, L.; Michon, G.

    1959-01-01

    The authors describe a procedure for the determination of the strontium radioisotopes 89 and 90. The concentration of strontium is made possible by the insolubility of its nitrate salt in strong nitric acid which allows the removal of greatest part of calcium. The purification is performed on a cation exchange column. The amount of radioisotope 90 is determined by means of its daughter product yttrium 90 necessary calibrations and computations are treated in special paragraphs. With regard to the reproducibility of the measurements, the fluctuations are less than 20 per cent. This seems satisfaction for such a technique which have great sensibility while being long and necessitative great carefulness. (author) [fr

  5. Country report: Brazil. Development of Radiopharmaceuticals Based on {sup 188}Re and {sup 90}Y for Radionuclide Therapy at IPEN-CNEN/SP

    Energy Technology Data Exchange (ETDEWEB)

    Osso, Jr., J. A.; Barrio, G.; Dias, C. R.B.R.; Brambilla, T. P.; Dantas, D. M.; Suzuki, K. N.; Barboza, M. F.S.; Bortoleti, E.; Fukumori, N. T.; Mengatti, J. [Radiopharmacy Center – Institute of Energetic and Nuclear Research – IPE N-CNEN/SP, São Paulo – Brazil (Brazil)

    2010-07-01

    The overall objective of this CRP is to develop radiopharmaceuticals for targeted therapy using {sup 188}Re and {sup 90}Y and to study the performance of generators with long lived parent radionuclides as well as to validate the QC control procedures for estimating the purity of generator eluents. The CRP is expected to enhance the capability in production of {sup 90}Y and {sup 188}Re radiopharmaceuticals to meet the increasing demand of therapeutic products for clinical applications, in particular in Brazil. In this period efforts were made towards the assembling of {sup 90}Sr-{sup 90}Y generators, quality control of {sup 90}Y, the labelling of DMSA(V) and anti-CD20 with {sup 188}Re and the labelling of Hydroxiapatite(HA) with {sup 90}Y. (author)

  6. Activity measurements of {sup 18}F and {sup 90}Y with commercial radionuclide calibrators for nuclear medicine in Switzerland

    Energy Technology Data Exchange (ETDEWEB)

    Caffari, Yvan, E-mail: Yvan.Caffari@chuv.c [Institut de Radiophysique Appliquee, Grand-Pre 1, 1007 Lausanne (Switzerland); Spring, Philippe; Bailat, Claude; Nedjadi, Youcef; Bochud, Francois [Institut de Radiophysique Appliquee, Grand-Pre 1, 1007 Lausanne (Switzerland)

    2010-07-15

    The activity of radiopharmaceuticals in nuclear medicine is measured before patient injection with radionuclide calibrators. In Switzerland, the general requirements for quality controls are defined in a federal ordinance and a directive of the Federal Office of Metrology (METAS) which require each instrument to be verified. A set of three gamma sources (Co-57, Cs-137 and Co-60) is used to verify the response of radionuclide calibrators in the gamma energy range of their use. A beta source, a mixture of {sup 90}Sr and {sup 90}Y in secular equilibrium, is used as well. Manufacturers are responsible for the calibration factors. The main goal of the study was to monitor the validity of the calibration factors by using two sources: a {sup 90}Sr/{sup 90}Y source and a {sup 18}F source. The three types of commercial radionuclide calibrators tested do not have a calibration factor for the mixture but only for {sup 90}Y. Activity measurements of a {sup 90}Sr/{sup 90}Y source with the {sup 90}Y calibration factor are performed in order to correct for the extra-contribution of {sup 90}Sr. The value of the correction factor was found to be 1.113 whereas Monte Carlo simulations of the radionuclide calibrators estimate the correction factor to be 1.117. Measurements with {sup 18}F sources in a specific geometry are also performed. Since this radionuclide is widely used in Swiss hospitals equipped with PET and PET-CT, the metrology of the {sup 18}F is very important. The {sup 18}F response normalized to the {sup 137}Cs response shows that the difference with a reference value does not exceed 3% for the three types of radionuclide calibrators.

  7. Development of radioconjugate90Y-DOTATATE for therapy of neuroendocrine tumors positive to hSSTR2

    International Nuclear Information System (INIS)

    Gongora, M.; Alonso, L. M.; Rodriguez, A. M.; Leyva, R.; Solana, A.; Pino, M.; Alberti, A.

    2015-01-01

    Peptide receptor radionuclide therapy of patients with neuroendocrine tumors has expanded due to radiolabeling of DOTA-peptides, such as somatostatin analogue DOTA 0 -Tyr 3 -octreotate (DOTATATE) radiolabeled with Β-emitters radionuclides. The present work describes the labeling of DOTATATE with yttrium-90 from a novel electrochemical generator. All factors that could have influence in kinetic reaction of radiolabeled DOTA-peptide were also studied. The formulation with the highest radiochemical yield was assayed for serum stability, sera protein binding, stability in saline, in vitro stability in an excess of 50 mM EDTA and trans metallation studies in solutions of metal competitors (Fe 3+ , Ca 2+ , Mg 2+ and Za 2+ ). Our findings showed a formulation with high radiochemical purity and stability that allows further steps in the drug development process of this radiopharmaceutical. (Author) Peptide receptor radionuclide therapy of patients with neuroendocrine tumors has expanded due to radiolabeling of DOTA-peptides, such as somatostatin analogue DOTA 0 -Tyr 3 -octreotate (DOTATATE) radiolabeled with Β-emitters radionuclides. The present work describes the labeling of DOTATATE with yttrium-90 from a novel electrochemical generator. All factors that could have influence in kinetic reaction of radiolabeled DOTA-peptide were also studied. The formulation with the highest radiochemical yield was assayed for serum stability, sera protein binding, stability in saline, in vitro stability in an excess of 50 mM EDTA and trans metallation studies in solutions of metal competitors (Fe 3+ , Ca 2+ , Mg 2+ and Za 2+ ). Our findings showed a formulation with high radiochemical purity and stability that allows further steps in the drug development process of this radiopharmaceutical. (Author)

  8. The behaviour of selected yttrium containing bioactive glass microspheres in simulated body environments.

    Science.gov (United States)

    Cacaina, D; Ylänen, H; Simon, S; Hupa, M

    2008-03-01

    The study aims at the manufacture and investigation of biodegradable glass microspheres incorporated with yttrium potentially useful for radionuclide therapy of cancer. The glass microspheres in the SiO2-Na2O-P2O5-CaO-K2O-MgO system containing yttrium were prepared by conventional melting and flame spheroidization. The behaviour of the yttrium silicate glass microspheres was investigated under in vitro conditions using simulated body fluid (SBF) and Tris buffer solution (TBS), for different periods of time, according to half-life time of the Y-90. The local structure of the glasses and the effect of yttrium on the biodegradability process were evaluated by Fourier Transform Infrared (FT-IR) spectroscopy and Back Scattered Electron Imaging of Scanning Electron Microscopy (BEI-SEM) equipped with Energy Dispersive X-ray (EDX) analysis. UV-VIS spectrometry and Inductively Coupled Plasma Mass Spectrometry (ICP-MS) was used for analyzing the release behaviour of silica and yttrium in the two used solutions. The results indicate that the addition of yttrium to a bioactive glass increases its structural stability which therefore, induced a different behaviour of the glasses in simulated body environments.

  9. Biokinetics and dosimetry in patients administered with 111In-DOTA-Tyr3-octreotide: implications for internal radiotherapy with 90Y-DOTATOC

    International Nuclear Information System (INIS)

    Cremonesi, M.; Ferrari, M.; Maecke, H.R.; Tosi, G.; Zoboli, S.; Chinol, M.; Fiorenza, M.; Paganelli, G.; Stabin, M.G.; Orsi, F.O.; Jermann, E.; Robertson, C.

    1999-01-01

    Recent advances in receptor-mediated tumour imaging have resulted in the development of a new somatostatin analogue, DOTA-dPhe 1 -Tyr 3 -octreotide. This new compound, named DOTATOC, has shown high affinity for somatostatin receptors, ease of labelling and stability with yttrium-90 and favourable biodistribution in animal models. The aim of this work was to evaluate the biodistribution and dosimetry of DOTATOC radiolabelled with indium-111, in anticipation of therapy trials with 90 Y-DOTATOC in patients. Eighteen patients were injected with DOTATOC (10 μg), labelled with 150-185 MBq of 111 In. Blood and urine samples were collected throughout the duration of the study (0-2 days). Planar and single-photon emission tomography images were acquired at 0.5, 3-4, 24 and 48 h and time-activity curves were obtained for organs and tumours. A compartmental model was used to determine the kinetic parameters for each organ. Dose calculations were performed according to the MIRD formalism. Specific activities of >37 GBq/ μmol were routinely achieved. Patients showed no acute or delayed adverse reactions. The residence time for 111 In-DOTATOC in blood was 0.9±0.4 h. The injected activity excreted in the urine in the first 24 h was 73%±11%. The agent localized primarily in spleen, kidneys and liver. The residence times in source organs were: 2.2±1.8 h in spleen, 1.7±1.2 h in kidneys, 2.4±1.9 h in liver, 1.5±0.3 h in urinary bladder and 9.4±5.5 h in the remainder of the body; the mean residence time in tumour was 0.47 h (range: 0.03-6.50 h). Based on our findings, the predicted absorbed doses for 90 Y-DOTATOC would be 7.6±6.3 (spleen), 3.3±2.2 (kidneys), 0.7±0.6 (liver), 2.2±0.3 (bladder), 0.03±0.01 (red marrow) and 10.1 (range: 1.4-31.0) (tumour) mGy/MBq. These results indicate that high activities of 90 Y-DOTATOC can be administered with low risk of myelotoxicity, although with potentially high radiation doses to the spleen and kidneys. Tumour doses were high

  10. Solid phase extraction for determination of 90Sr in water sample

    International Nuclear Information System (INIS)

    Ometakova, J.

    2009-01-01

    We studied the use of an extraction chromatography for determination of 90 Sr in samples of contaminated water. The aim of the thesis was to compare selected products from the point of view of the strontium yields and time needed. Three commercial products: 3M Empore Strontium Rad Disk, AnaLig, Sr-Resin and two classical methods: liquid-liquid extraction with tributylphosphate and carbonate co-precipitation (to eliminate interferers) were used for separation of 90 Sr. The water sample was used in radiochemical analysis for determination volume activity of 90 Sr. A radiochemical strontium yield was traced by using radionuclide 85 Sr. Samples were counted over a two week period to monitor the ingrowth of 90 Y on TRI CARB LSC counter. Samples were measured using an HPGe detector to find out 85 Sr recoveries at 514 keV line and they were counted directly by Cherenkov counting after the growth of 90 Y using TriCarb LSC counter after a two- week period (author)

  11. Country report: Pakistan. Second Research Co-ordination Meeting on Development of Radiopharmaceuticals Based on 188Re and 90Y for Radionuclide Therapy, 22-26 March 2010, Vienna

    International Nuclear Information System (INIS)

    Mansur, M.S.; Mushtaq, A.

    2010-01-01

    Various experiments were carried out for the separation of 90 Y from 90 Sr using colloid formation behavior of 90 Y in basic pH range. When the acidic solution of 90 Sr/ 90 Y was treated with NaOH and passed through a small glass wool column, more than 95% 90 Y was retained on glass wool, which was further washed with 0.1 M NaOH. The 90 Y was extracted in 1 M HCl. Radionuclidic purity was determined by half life measurement. The contamination of parent was less than 0.0001%. Similarly when the colloid was passed through membrane filter more than 95% 90 Y was retained which was recovered by 1 M HCl. The contamination of 90 Sr was less than 0.0001%. The stock solution of 90 Sr/ 90 Y in NH 4 OH/NaOH was again passed through Millipore filter paper or glass wool after one week. The retention of 90Y was insignificant. The equilibrium mixture of 90 Sr/ 90 Y was acidified with HCl and again precipitated with addition of NH 4 OH or NaOH. The basic solution was passed through the Millipore filter or glass wool. More than 90% activity of 90 Y was retained, which was finally extracted in 1 M HCl It was concluded that for recovery of 90 Y from 90 Sr by colloid formation, the acidic solution of 90 Sr/ 90 Y shall be freshly precipitated by NH 4 OH or NaOH. It was also observed that the adsorption of 90 Y was quite high when the 90 Sr solution was left in a glass vial for the growth of 90 Y. However it can be easily extracted after keeping it in boiling water bath for few minutes. The separated 90 Y via colloid formation was used for the labeling of EDTMP. Labeling efficiency of 90 Y-EDTMP was more than 98%

  12. Molecular response assessed by {sup 68}Ga-DOTANOC and survival after {sup 90}Y microsphere therapy in patients with liver metastases from neuroendocrine tumours

    Energy Technology Data Exchange (ETDEWEB)

    Filippi, Luca; Salvatori, Rita; Bagni, Oreste [Santa Maria Goretti Hospital, Department of Nuclear Medicine, Latina (Italy); Scopinaro, Francesco [Sant' Andrea Hospital, Department of Nuclear Medicine, Rome (Italy); Pelle, Giuseppe; Cianni, Roberto [Santa Maria Goretti Hospital, Department of Interventional Radiology, Latina (Italy); Schillaci, Orazio [University Tor Vergata, Department of Biomedicine and Prevention, Rome (Italy)

    2016-03-15

    We investigated the prognostic role of {sup 68}Ga-DOTANOC in patients affected by hepatic metastases from neuroendocrine tumours (NET) undergoing {sup 90}Y radioembolization ({sup 90}Y-RE). A group of 15 consecutive patients with unresectable NET liver metastases underwent {sup 68}Ga-DOTANOC PET at baseline and 6 weeks after {sup 90}Y-RE. Molecular response was defined as a reduction of >50 % in the tumour-to-spleen ratio (ΔT/S). The patients were divided into two groups (responders with ΔT/S >50 % and nonresponders with ΔT/S <50 %) Patients were followed up by imaging and laboratory tests every 3 months until death or for at least 36 months following {sup 90}Y-RE. Statistical analysis was performed to identify factors predicting overall survival (OS) and progression-free survival (PFS). A decrease in T/S ratio was seen in all patients on {sup 68}Ga-DOTANOC PET scans performed after {sup 90}Y-RE. Nine patients were classified as responders and six as nonresponders. The mean OS in all patients was 31.0 months. Responders had a significantly (p < 0.001) longer OS (mean 36.0 ± 2.5 months) and PFS (mean 29.7 ± 3.4 months) than nonresponders. In a multivariate analysis, none of the other examined variables including age, unilobar vs. bilobar locations, bilirubin levels, radiological response or the presence of extrahepatic disease significantly predicted patient outcome. Molecular response assessed with {sup 68}Ga-DOTANOC PET might be a useful predictor of survival in patients affected by NET liver metastases treated with {sup 90}Y-RE. (orig.)

  13. Chemical Separation Technique of Strontium-90 in the Soil Water as theStandard Methods for Environmental Radioactivity Analysis

    International Nuclear Information System (INIS)

    Ngasifudin-Hamdani; Suratman; Djoko-Sardjono, Ign; Winduanto-Wahyu SP

    2000-01-01

    Research about separation technique of strontium-90 from its materialmatrix using chemical precipitation method has been done. That technique wasapplied on the detection of radionuclide strontium-90 containing in the soilwater of near nuclear reactor facility P3TM BATAN in three location. The twoimportant parameters used in this technique were growth time of Y-90 andstirring time. The result shown that activity of strontium-90 in the pos-01was between 1.801x10 -19 - 9.616x10 -17 μCi/cm 3 , pos-02 was8.448x10 -19 - 1.003x X 10 -16 μCi/cm 3 and pos-03 was 6.719x10 -19 - 11.644x10 -16 μCi/cm 3 . From those data shown that activity of Sr-90in the soil water of near nuclear reactor facility P3TM BATAN was still belowthe limit value of maximum concentration permitted i.e. 4.0x10 -7 -3.5x10 -6 μCi/cm 3 . The statistic test using analysis of varian twofactorial with random block design shown that the activity of Sr-90 in thesoil water was influenced by the interaction which take place between growthlong time of Y-90 and stirring long time. (author)

  14. Development and biological evaluation of {sup 90}Y-BPAMD as a novel bone seeking therapeutic agent

    Energy Technology Data Exchange (ETDEWEB)

    Rabiei, Ali; Shamsaei, Mojtaba [Amir Kabir University of Technology, Tehran (Iran, Islamic Republic of). Energy Engineering and Physics Dept.; Yousefnia, Hassan; Zolghadri, Samaneh; Jalilian, Amir Reza [Nuclear Science and Technology Research Institute (NSTRI), Tehran (Iran, Islamic Republic of); Enayati, Razieh [Islamic Azad Univ. (IAU), Tehran (Iran, Islamic Republic of). Faculty of Engineering

    2016-07-01

    Nowadays, the bone-seeking radiopharmaceuticals play an important role in the treatment of the bone-related pathologies. Whereas various phosphonate ligands have already been identified, a DOTA-based bisphosphonate, 4-{[(bis(phosphonomethyl))carbamoyl]methyl}-7,10-bis(carboxymethyl) -1,4,7,10-tetraazacyclododec-1-yl (BPAMD) with better characteristics has recently been synthesized. In this study, {sup 90}Y-BPAMD was developed with radiochemical purity >98% and the specific activity of 3.52 TBq/mmol in the optimized conditions as a new bone-seeking therapeutic agent. The complex demonstrated significant stability at room temperature and in human serum even after 48 h. At even low amount of hydroxyapatite (5 mg), more than 90% binding to hydroxyapatite was observed. Biodistribution studies after injection of the complex into the Syrian rats showed major accumulation of the labelled compound in the bone tissue and an insignificant uptake in the other organs all the times after injection. Generally, {sup 90}Y-BPAMD demonstrated interesting characteristics compared to the other {sup 90}Y bone-seeking agents and even {sup 166}Ho-BPAMD, and can be considered as a new bone-seeking candidate for therapeutic applications.

  15. Dosimetry of a 90Y-hydroxide liquid brachytherapy treatment approach to canine osteosarcoma using PET/CT

    International Nuclear Information System (INIS)

    Zhou, Jien Jie; Gonzalez, Arnulfo; Lenox, Mark W.; Fossum, Theresa W.; Frank, R. Keith; Simon, Jaime; Stearns, Stan; Ruoff, Catherine M.; Wendt, Richard E.; Akabani, Gamal

    2015-01-01

    A new treatment strategy based on direct injections of 90 Y-hydroxide into the tumor bed in dogs with osteosarcoma was studied. Direct injections of the radiopharmaceutical into the tumor bed were made according to a pretreatment plan established using 18 F-FDG images. Using a special drill, cannulas were inserted going through tissue, tumor and bone. Using these cannulas, direct injections of the radiopharmaceutical were made. The in vivo biodistribution of 90 Y-hydroxide and the anatomical tumor bed were imaged using a time-of-flight (TOF) PET/CT scanner. The material properties of the tissues were estimated from corresponding CT numbers using an electron-density calibration. Radiation absorbed dose estimates were calculated using Monte Carlo methods where the biodistribution of the pharmaceutical from PET images was sampled using a collapsing 3-D rejection technique. Dose distributions in the tumor bed and surrounding tissues were calculated, showing significant heterogeneity with multiple hot spots at injection sites. Dose volume histograms showed that approximately 33.9% of bone and tumor and 70.2% of bone marrow and trabecular bone received an absorbed dose over 200 Gy; approximately 3.2% of bone and tumor and 31.0% of bone marrow and trabecular bone received a total dose of over 1000 Gy. - Graphical abstract: Treatment of canine osteosarcoma using 90 Y-hydroxide using localized liquid brachytherapy. A 3-D co-registered PET/CT image showing the distribution of 90 Y in the left tibia of a dog with osteosarcoma. Multiple high activity hotspots are shown within bone marrow and isolated hotspots within the tumor bed, corresponding to the sites of administration. Absorbed doses were estimated to be as high as 2000 Gy to tumor. - Highlights: • A liquid brachytherapy treatment of canine osteosarcoma using 90 Y hydroxyapatite is presented. • Dosimetry of 90 Y hydroxyapatite liquid brachytherapy was carried out using PET-CT. • Activity distribution correlated

  16. ANÁLISIS COMPARATIVO DE LOS EFECTOS AGUDOS DE SESIONES DE ENTRENAMIENTO DE FUERZA CON CARGAS DEL 90 Y 30% 1 RM.

    Directory of Open Access Journals (Sweden)

    Jorge Dopico Calvo

    2010-10-01

    Full Text Available En una medición inicial (Pretest se obtuvo la 1RM de 23 sujetos masculinos en el ejercicio press banca, así como la potencia y fuerza media aplicada al 90 y 30% de 1RM (PMED90, FMED90, PMED30, FMED 30. Posteriormente 11 sujetos (Gr90 llevaron a cabo 2 sesiones de entrenamiento con cargas del 90%, mientras los 12 sujetos restantes (Gr30 lo hacían con cargas del 30%. Inmediatamente finalizada cada una de las sesiones se valoraba nuevamente PMED90, FMED90, PMED30, FMED30. Una semana después de la finalización de los entrenamientos se efectuó un Postest. Los resultados mostraron una mejora estadísticamente significativa del rendimiento de Gr30 al final de cada una de las sesiones de entrenamiento, respecto a Pretest y Postest, con el 90% de 1RM, mientras que Gr90 obtuvo mejoras significativas con el 30% respecto a Pretest, pero no respecto a Postest.
    PALABRAS CLAVE: fuerza, potencia, medición, efecto agudo.

  17. Equilibrium Studies on the Extraction of Yttrium from Chloride Medium by Mono (2-Ethylhexyl) 2-Ethylhexyl Phosphonic Acid (Ion quest 801)

    International Nuclear Information System (INIS)

    Zaki, E.E.; Ismail, Z.H.; Aly, H.F.; Sabet, S.A.

    2008-01-01

    Since 90 Y is one of the useful radioisotopes in nuclear medicine, liquid-liquid extraction of yttrium from chloride medium has been studied under various conditions using neutralized and un-neutralized mono (2-ethylhexyl) 2-ethylhexyl phosphonic acid (EHEHPA) as an extractant. Effect of reagent concentration, ph of the aqueous medium, metal ion concentration and nature of the diluent on the extraction process has been carried out. Effect of temperature was studied and thermodynamic parameters were evaluated. Yttrium extracted in organic phase was stripped with various reagents. The stoichiometry of the extracted species of yttrium was determined on the basis of slope analysis of experimental results. Equilibrium equations of the extraction process have been estimated and verified

  18. Determination of 90Sr in grass and soil

    International Nuclear Information System (INIS)

    Bajo, S.; Keil, R.

    1994-10-01

    A radiochemical method for the determination of 90 Sr in non-contaminated grass and soil is presented. The method is based on the leaching of 90 Sr from the mineralized samples followed by liquid-liquid extraction of 90 Y, its short lived daughter, by tributylphosphate and precipitation of Y-oxalate, which is counted in a low-level proportional counter. Based on dried samples of 30 g of soil and 100 g of grass the limit of detection is about 0.1 Bq/kg for both materials. (author) figs., tabs., 43 refs

  19. Inflammation-induced synergetic enhancement of nanoparticle treatments with DOXIL{sup ®} and {sup 90}Y-Lactosome for orthotopic mammary tumor

    Energy Technology Data Exchange (ETDEWEB)

    Kurihara, Kensuke; Ueda, Motoki [Graduate School of Medicine, Kyoto University, Department of Diagnostic Imaging and Nuclear Medicine (Japan); Hara, Isao [Shimadzu Corporation, Technology Research Laboratory (Japan); Hara, Eri [Kyoto University Hospital, Department of Experimental Therapeutics, Institute for Advancement of Clinical and Translational Science (Japan); Sano, Kohei [Graduate School of Medicine, Kyoto University, Department of Diagnostic Imaging and Nuclear Medicine (Japan); Makino, Akira [University of Fukui, Division of Molecular Imaging, Biomedical Imaging Research Center (Japan); Ozeki, Eiichi [Shimadzu Corporation, Technology Research Laboratory (Japan); Yamamoto, Fumihiko [Tohoku Pharmaceutical University, Department of Radiopharmacy (Japan); Saji, Hideo [Kyoto University, Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences (Japan); Togashi, Kaori [Graduate School of Medicine, Kyoto University, Department of Diagnostic Imaging and Nuclear Medicine (Japan); Kimura, Shunsaku, E-mail: shun@scl.kyoto-u.ac.jp [Kyoto University, Department of Material Chemistry, Graduate School of Engineering (Japan)

    2016-05-15

    Polymeric micelles (Lactosome) in the size of 20–30 nm were labeled with radionuclides of {sup 111}In ({sup 111}In-DOTA-Lactosome) for SPECT imaging and {sup 90}Y ({sup 90}Y-DOTA-Lactosome) for β-ray irradiation for mammary tumor in mice. The tumor site at the femoral right leg grafted with 4T1 cells was clearly imaged at 24 h after the intravenous injection. Biodistribution revealed that the half-life time of {sup 111}In-DOTA-Lactosome was 11 h, which enabled the nanoparticle selectively accumulated in tumor site due to the enhanced permeability and retention (EPR) effect. The anti-tumor therapeutic effect of {sup 90}Y-DOTA-Lactosome was observed depending on the dose frequency and amount. Under the condition of the percutaneous ethanol injection treatment, the therapeutic effect of {sup 90}Y-DOTA-Lactosome was enhanced due to the super EPR effect. Owing to the super EPR effect, co-administration of {sup 90}Y-DOTA-Lactosome and DOXIL{sup ®} inhibited the tumor growth during 15 days with their administrations.

  20. Innovation in metrology: fast automated radiochemical separation and measurement for strontium 89 and 90

    Energy Technology Data Exchange (ETDEWEB)

    Augeray, C.; Galliez, K.; Mouton, M.; Tarlette, L.; Loyen, J.; Fayolle, C.; Gleizes, M. [Institut de Radioprotection et de Surete Nucleaire - IRSN (France)

    2014-07-01

    Measuring radioactivity in the food and for radiological monitoring of the environment around Nuclear Facilities or mining sites requires the quantification of the radioactive isotopes present in the different compartments (liquids or solids), especially of the beta emitters. Strontium 89 and 90, both pure beta emitters are radioactive isotopes of interest. Because of their toxicity and the similarity of their chemical and physical behavior with calcium, these elements may be found through the food chain. After the Fukushima accident, the necessity of quantifying quickly radioactive isotopes such as strontium 89 and 90 appeared. The technique we are going to present concerns the determination of the activity concentration of strontium 89 and 90 in water, according to the {sup 89}Sr/{sup 90}Sr ratio. It consists of two stages: the chemical separation by ionic chromatography and the measurement of the activity concentration of strontium 89 and 90 by Cerenkov Effect. The automated separation has been developed and allows isolating the isotopes of strontium in particular the radioactive ones: strontium 89 and 90. The separation can be done within one hour. It was realized from the adaptation of existing analytical chemistry equipments with on-line couplings. The protocol of separation is based on the use of ions exchange columns of Ionic chromatography not as a separation and measurement technique of the cation but only as a separation technique. At the release time of the ion to be quantified, a fraction collector allows its recovery. The test portion is then analyzed with a liquid scintillation counter (LSC). The activity concentration is measured by Cerenkov Effect on a quenched sample. The quenching is realized by applying a thin colored film on the sample vial. This color quench is used to make strontium 90 counts disappear on the LS spectrum. This way, only yttrium 90 ingrowth and strontium 89 decay are measured (E{sup 90}Sr < E{sup 89}Sr < E{sup 90}Y

  1. Level of 90Sr in the urine of a small group of Finnish people

    International Nuclear Information System (INIS)

    Puhakainen, M.; Suomela, M.; Rahola, T.

    1999-01-01

    The aim of the study was to test the feasibility of the applied analysis method for 90 Sr and if possible to estimate the current level of the 90 Sr concentration in the urine. Urine samples were collected from seven Finnish volunteers in connection with studies of 137 Cs body burdens. The activity measurements of urine samples were performed 14 - 18 days after chemical separation of 90 Sr to allow ingrowing of 90 Y. The 90 Sr and 90 Y activities were measured simultaneously using a Quantulus liquid scintillation spectrometer. The detection limit for 90 Sr was 0.0033 Bq per sample, or 0.0007-0.0015 Bq 1 -1 . The 90 Sr activities in urine varied between 0.006 and 0.046 Bq 1 1 . The daily urinary excretion was found to be 0.007-0.018 Bq for the five volunteers that collected three-day urine samples. Assuming that the daily 90 Sr intake was constant and that 18% of the ingested activity was excreted in urine, the mean intake in the investigated group would vary between 0.039 and 0.1 Bq d -1 . Based on these estimated intake values the respective annual effective internal doses from 90 Sr and 90 Y varied from 0.4 to 1 Sv during the sampling period. (au)

  2. Country report: Germany. Preclinical evaluation of Y-90 labelled Rituximab and ERIC-1, two antibodies for tumor therapy

    Energy Technology Data Exchange (ETDEWEB)

    Schomäcker, Klaus; Fischer, Thomas [Department of Nuclear Medicine, University of Cologne, Cologne (Germany)

    2010-07-01

    This project focuses on harnessing the great potential of radionuclide therapy, using various different vehicles to transport radionuclides into tumor tissues. A central aim of the project will be to manufacture specific vehicle molecules whose tumor affinity and suitability for radioactive coupling have already been proven through laboratory trials on animals and cell cultures at the Department of Nuclear Medicine, University of Cologne and to label it with Y- 90. The vectors to be used to transport radionuclides into tumor tissue for treatment are antibodies against lymphomas and neuroblastomas. The technology applied for coupling Y-90 to various antibodies has been developed to a high level in Cologne and is now ready to be transferred and adapted to GMP (Good Manufacturing Practice) conditions. The antibody against NHL can be acquired commercially and must then be modified for binding to the therapeutically active nuclide Y-90. Similarly, the antibody against neuroblastoma must also be modified to bind to Y-90 but is produced in Cologne. To improve the therapeutic value of antibodies we tried to introduce the pretargeting method.

  3. Country report: Germany. Preclinical evaluation of Y-90 labelled Rituximab and ERIC-1, two antibodies for tumor therapy

    International Nuclear Information System (INIS)

    Schomäcker, Klaus; Fischer, Thomas

    2010-01-01

    This project focuses on harnessing the great potential of radionuclide therapy, using various different vehicles to transport radionuclides into tumor tissues. A central aim of the project will be to manufacture specific vehicle molecules whose tumor affinity and suitability for radioactive coupling have already been proven through laboratory trials on animals and cell cultures at the Department of Nuclear Medicine, University of Cologne and to label it with Y- 90. The vectors to be used to transport radionuclides into tumor tissue for treatment are antibodies against lymphomas and neuroblastomas. The technology applied for coupling Y-90 to various antibodies has been developed to a high level in Cologne and is now ready to be transferred and adapted to GMP (Good Manufacturing Practice) conditions. The antibody against NHL can be acquired commercially and must then be modified for binding to the therapeutically active nuclide Y-90. Similarly, the antibody against neuroblastoma must also be modified to bind to Y-90 but is produced in Cologne. To improve the therapeutic value of antibodies we tried to introduce the pretargeting method

  4. Beta radiation exposure of staff during and after therapies with 90Y-labelled substances

    International Nuclear Information System (INIS)

    Rimpler, A.; Barth, I.; Baum, R. B.; Senftleben, S.; Geworski, L.

    2008-01-01

    Radio-immuno-therapies (RITs) and peptide receptor radio-therapies (PRRTs) with 90 Y-labelled compounds offer promising prospects for tumor treatment in nuclear medicine. However, when preparing and performing these therapies, which require manipulations of high activities of 90 Y (>1 GBq), technicians and physicians may receive high exposures, mainly to the skin of the hands. Even non-occupationally exposed persons, such as caregivers and family members, receive external exposures in the initial period after therapy, arising from the 90 Y in the patient. The local skin doses of the individual staff members, measured during RITs and PRRTs with thermoluminescence detectors fixed with tapes to the fingers, vary considerably. The exposure of staff can exceed the annual permissible dose limit of 500 mSv if radiation protection standards are low. Thus, adequate safety measures are needed. Measurements of the dose rate around patients, made using survey meters with sufficient response to beta particles, indicate that the exposure of caregivers and family members is considerably higher than previously assumed, and was dominated by primary beta radiation instead of Bremsstrahlung. Nevertheless, under normal circumstances, the annual dose limits for the public (effective dose: 1 mSv, skin dose: 50 mSv) will be complied with. (authors)

  5. Preparation and biological evaluation of 111In-, 177Lu- and 90Y-labeled DOTA analogues conjugated to B72.3

    International Nuclear Information System (INIS)

    Mohsin, Huma; Fitzsimmons, Jonathan; Shelton, Tiffani; Hoffman, Timothy J.; Cutler, Cathy S.; Lewis, Michael R.; Athey, Phillip S.; Gulyas, Gyongyi; Kiefer, Garry E.; Frank, R. Keith; Simon, Jaime; Lever, Susan Z.; Jurisson, Silvia S.

    2007-01-01

    Three 1,4,7,10-tetraazacyclododecane-N,N',N '' ,N '' '-tetraacetic acid (DOTA) analogues were evaluated for relative in vivo stability when radiolabeled with 111 In, 90 Y and 177 Lu and conjugated to the monoclonal antibody B72.3. The DOTA analogues evaluated were 'NHS-DOTA' [N-hydroxysuccinimdyl (NHS) group activating one carboxylate], 'Arm-DOTA' (also known as MeO-DOTA; with a p-NCS, o-MeO-benzyl moiety on the methylene group of one acetic acid arm) and 'Back-DOTA' (with a p-NCS-benzyl moiety on a backbone methylene group of the macrocycle). The B72.3 was conjugated to the DOTA analogues to increase the retention time of the radioloabeled conjugates in vivo in mice. The serum stability of the various radiometalated DOTA conjugates showed them to have good stability out to 168 h (all >95% except 111 In-NHS-DOTA-B72.3, which was 91% stable). Hydroxyapatite stability for the 111 In and 177 Lu DOTA-conjugates was >95% at 168 h, while the 90 Y DOTA-conjugates were somewhat less stable (between 90% and 95% at 168 h). The biodistribution studies of the radiometalated DOTA-conjugates showed that no significant differences were observed for the 111 In and 177 Lu analogues; however, the 90 Y analogues showed lower stabilities, as evidenced by their increased bone uptake relative to the other two [2-20% injected dose per gram (% ID/g) for 90 Y and 2-8% ID/g for 111 In and 177 Lu]. The lower stability of the 90 Y analogues could be due to the higher beta energy of 90 Y and/or to the larger ionic radius of Y 3+ . Based on the bone uptake observed, the 177 Lu-NHS-DOTA-B72.3 had slightly lower stability than the 177 Lu-Arm-DOTA-B72.3 and 177 Lu-Back-DOTA-B72.3, but not significantly at all time points. For 90 Y, the analogue showing the lowest stability based on bone uptake was 90 Y-Arm-DOTA-B72.3, perhaps because of the metal's larger ionic radius and potential steric interactions minimizing effective complexation. The 111 In analogues all showed similar biological

  6. Determination of {sup 90}Sr in uranium fission products

    Energy Technology Data Exchange (ETDEWEB)

    Bajo, S; Tobler, L [Paul Scherrer Inst. (PSI), Villigen (Switzerland)

    1996-02-01

    A previously published radiochemical procedure for the determination of {sup 90}Sr in grass and soil has been successfully employed - with minor modifications - for the determination of this nuclide in a solution of uranium fission products. It is suitable for the determination of {sup 90}Sr in environmental materials following a nuclear accident. The procedure is based on tributylphosphate extraction of {sup 90}Y, precipitation of Y-oxalate, and counting in a proportional counter. (author) figs., tabs., 10 refs.

  7. Somatostatin-based Radiopeptide Therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in Neuroendocrine Tumors

    OpenAIRE

    Romer A Seiler D Marincek N Brunner P Koller MT Ng QK Maecke HR Muller-Brand J Rochlitz C B

    2014-01-01

    PURPOSE: Somatostatin based radiopeptide treatment is generally performed using the ß emitting radionuclides (90)Y or (177)Lu. The present study aimed at comparing benefits and harms of both therapeutic approaches. METHODS: In a comparative cohort study patients with advanced neuroendocrine tumours underwent repeated cycles of [(90)Y DOTA] TOC or [(177)Lu DOTA] TOC until progression of disease or permanent adverse events. Multivariable Cox regression and competing risks regression were emplo...

  8. Method of grass samples preparation for strontium-90 and cesium-137 analysis with the exception of ashing

    International Nuclear Information System (INIS)

    Antonova, V.A.; Prokof'ev, O.N.; Khazina, M.A.; Bajkovskaya, L.V.

    1978-01-01

    A method is proposed for the preparation of grass samples in the analysis for 90 Sr and 137 Cs, in which radionuclides are removed into solution as a result of the thermal treatment of samples in 0.01N solution of hydrochloric acid. A grass sample 0.8 kg in weight is covered with 8-10 l of 0.01 N solution of hydrochloric acid and boiled for 30 min, while being constantly stirred. The solution is filtered through cheese cloth, carriers for 90 Y and 137 Cs are introduced, and then oxalates are precipitated at pH=4. After the oxalates have been separated from the filtrate the 137 Cs content is determined using the antimonium-iodide technique. The oxalate precipitate is calcined, dissolved in 2N hydrochloric acid, while boiling, and precipitated by ammonia. The precipitate of hydrooxides is filtered. The solution is acidified by 2N hydrochloric acid up to pH 2-3, and the carrier for 90 Y is introduced. The 90 Sr content is determined by a conventional technique. The percentage of the transition of radionuclides from the grass samples into solution ammounts to: 88+-6% for 90 Sr, and 81+-7% for 137 Cs

  9. Ecological Dose Modeling of Aquatic and Riparian Receptors to Strontium-90 with an Emphasis on Radiosensitive Organs

    Energy Technology Data Exchange (ETDEWEB)

    Poston, Ted M.; Traub, Richard J.; Antonio, Ernest J.

    2011-07-20

    The 100-NR-2 site is the location of elevated releases of strontium-90 to the Columbia River via contaminated groundwater. The resulting dose to aquatic and riparian receptors was evaluated in 2005 (DOE 2009) and compared to U.S. Department of Energy (DOE) dose guidance values. We have conducted additional dose assessments for a broader spectrum of aquatic and riparian organisms using RESRAD Biota and specific exposure scenarios. Because strontium-90 accumulates in bone, we have also modeled the dose to the anterior kidney, a blood-forming and immune system organ that lies close to the spinal column of fish. The resulting dose is primarily attributable to the yttrium-90 progeny of strontium-90 and very little of the dose is associated with the beta emission from strontium-90. All dose modeling results were calculated with an assumption of secular equilibrium between strontium-90 and yttrum-90.

  10. Efficacy of Radiation Synovectomy with Y-90 in chronic knee joint synovitis

    International Nuclear Information System (INIS)

    Roiz, C.; Raigoso, P.; Suarez, J.P.; Llana, B.; Zeidan, N.; Dominguez, M.L.; Bernardo, L.; Fernandez, J.A.; Nunez, R.

    2002-01-01

    Aim: To evaluate the efficiency of Radiation Synovectomy (RSO) with Y-90 in knee joints of patients with chronic synovitis (CS) resistant to classical conventional therapy, and assess its long-term prognosis. Material and Methods: 22 patients (7 males,15 females, mean age 50, range 12-81) with CS of the knees, of a duration ranging from 2 to 48 years, were included in the study. All patients had suffered from CS for more than 6 months, and were resistant to anti-inflammatory drugs, immunosuppressants and intraarticular (IA) steroid therapy. The cases included:10 patients with rheumatoid arthritis (RA), 5 psoriatic arthritis (PA), 3 pigmented villonodular synovitis, 2 seronegative oligo-polyarthritis and 2 chronic mono arthritis. We used an IA dose of 3 to 5 mCi (37-185 MBq)of Y-90. The effect of the therapy with Y-90 on 22 knees was evaluated from 3 to 12 months after the RSO. Patients' response was assess and classified according to the results of plain radiology and following conventional rheumatological criteria as: A) Excellent (E) with a visual improvement (VI) of 80-100mm, no pain in motion, little or no palpable swelling, no inflammation; B) Good (G) VI of 60-90mm, minimal pain in motion, little palpable swelling; C) Mild (M) VI of 20-59mm, moderate reduction of pain, obvious swelling; D) Bad (B) VI of only 0-19 mm, no changes or an increase of pain in the swollen joints. Results: The response observed was classified as: E in 5 patients (23%); G in 10 patients (45%); M in 3 patients (14%); and B in 4(18%). The 4 patients with a response B, had all of them joint erosion on plain radiology. Furthermore, one of the patients was a failure from prior surgical synovectomy (SS). The other 3 patients subsequently had SS. In contrast, all the responses E and G were obtained exclusively in patients with RA or PA. No short or long-term adverse side effects were noted. Conclusion: RSO is an effective treatment for patients with persistent CS, specially in RA and PA. The

  11. Development of radioinmunoconjugate 90Y-DOTA-nimotuzumab-Fab for therapy of EGFR over expressing tumors

    International Nuclear Information System (INIS)

    Rodriguez, A. M.; Alonso, L. M.; Gongora, M.; Leyva, R.; Solana, A.

    2015-01-01

    Many monoclonal antibodies conjugated with 1,4,7,10-tetraaza cyclododecane-N, N', N'', N'''-tetraacetic acid (DOTA) and radiolabeled with 90 Y, have been used for radioimmunotherapy. As know IgG molecules are heavy proteins with a molecular weight of approximately 150 kDa. Accordingly, intact IgG antibodies may have significant slow kinetics biodistribution and severely limited properties of tissue penetration. Antibody fragments labeled with radio metals could be promising radiopharmaceuticals for imaging and non-invasive therapy due to its high affinity to the tumor, the lack of effector function and rapid pharmacokinetic. In this work, the nimotuzumab Fab fragment was obtained by cleavage with papain in molar excess. After separating the reaction mixture in three steps using affinity, size exclusion and ion exchange chromatography; the Fab fragment showed high values of purity, integrity and identity. The Fab fragment was derivatized with DOTA and labeled with 90 Y. The radioimmunoconjugate with high radiochemical yield was assessed by in vitro stability with an excess of 50mM DTPA. The development of 90 Y-DOTA-Nimotuzumab-Fab radioimmunoconjugate allows to count on as a potential agent for radioimmunotherapy. (Author)

  12. Procedure to carry out leakage test in beta radiation sealed sources emitters of 90Sr/90Y

    International Nuclear Information System (INIS)

    Alvarez R, J. T.

    2010-09-01

    In the alpha-beta room of the Secondary Laboratory of Dosimetric Calibration of the Metrology Department of Ionizing Radiations ophthalmic applicators are calibrated in absorbed dose terms in water D w ; these applicators, basically are emitter sealed sources of pure beta radiation of 90 Sr / 90 Y. Concretely, the laboratory quality system indicates to use the established procedure for the calibration of these sources, which establishes the requirement of to carry out a leakage test, before to calibrate the source. However, in the Laboratory leakage test certificates sent by specialized companies in radiological protection services have been received, in which are used gamma spectrometry equipment s for beta radiation leakage tests, since it is not reliable to detect pure beta radiation with a scintillating detector with NaI crystal, (because it could detect the braking radiation produced in the detector). Therefore the Laboratory has had to verify the results of the tests with a correct technique, with the purpose of determining the presence of sources with their altered integrity and radioactive material leakage. The objective of this work is to describe a technique for beta activity measurement - of the standard ISO 7503, part 1 (1988) - and its application with a detector Gm plane (type pankage) in the realization of leakage tests in emitter sources of pure beta radiation, inside the mark of quality assurance indicated by the report ICRU 76. (Author)

  13. Personnel dose reduction in 90Y microspheres liver-directed radioembolization: from interventional radiology suite to patient ward.

    Science.gov (United States)

    Law, Martin; Wong, K K; Tso, W K; Lee, Victor; Luk, M Y; Tong, C C; Chu, Ferdinand

    2017-03-01

    To describe a method to reduce the external radiation exposure emitted from the patient after liver-directed radioembolization using 90 Y glass microspheres, to quantitatively estimate the occupational dose of medical personnel providing patient care to the patient radioembolized with the use of the method and to discuss radiation exposure to patients who are adjacent if the patient radioembolized needs hospitalization. A lead-lined blanket of lead equivalence of 0.5 mm was used to cover the patient abdomen immediately after the 90 Y radioembolization procedure, in order to reduce the radiation emitted from the patient. The interventional radiologist used a rod-type puncture site compressor for haemostasis to avoid direct contact with possible residual radioactivity at the puncture site. Dose rates were measured at the interventional radiologist chest and hand positions during puncture site pressing for haemostasis with and without the use of the blanket. The measurement results were applied to estimate the occupational dose of colleagues performing patient care to the patient radioembolized. The exposure to patients adjacent in the ward was estimated if the patient radioembolized was hospitalized. The radiation exposures measured at the radiologist chest and hand positions have been significantly reduced with the lead-lined blanket in place. The radiologist, performing puncture site pressing at the end of radioembolization procedure, would receive an average hand dose of 1.95 μSv and body dose under his own lead apron of 0.30 μSv for an average 90 Y microsphere radioactivity of 2.54 GBq. Other medical personnel, nurses and porters, would receive occupational doses corresponding to an hour of background radiation. If the patient radioembolized using 90 Y needs hospitalization in a common ward, using the lead-lined blanket to cover the abdomen of the patient and keeping a distance of 2 m from the patient who is adjacent would reduce the exposure by 0

  14. Therapy of neuroendocrine carcinoma with Y-90 DOTA- preliminary results

    International Nuclear Information System (INIS)

    Artiko, V.; Obradovic, V.; Nadezda, N.; Djokic, D.; Jankovic, D.; Popovic, B.; Damjanovic, S.; Mikolajczak, R.; Pawlak, D.

    2007-01-01

    Full text: Aim: Cell membrane-specific somatostatin receptors are usually expressed by neuroendocrine tumors. Radiolabelled receptor-binding somatostatin analogues target tissues expressing these receptors and can be used for visualization and treatment. After the localization of tumors bearing somatostatin receptors with 111In or 99mTc labeled somatostatin analogues, in the case of high tumor uptake related to non target tissues, different radioisotopes have been used for their treatment. Thus, application of high doses of 111In- DTPA-octreotide had an impact on improvement of the clinical symptoms, without significant reduction of the tumor mass. However, 90Y somatostatin analogues (DOTA TOC, lanreotide) may be more effective for reduction of the tissue of the larger tumors while 177Lu labeled ones may be applied in smaller tumors. Combination of both of them seems to be the most effective therapy, particularly in tumors bearing both small and large lesions. The aim of this work is presentation of the preliminary results of the therapy of NETs with another octreotide analogue, 90Y DOTA TATE, which so far has been proved to have high therapeutic potential when labeled with 177Lu. Patients and methods: We investigated 7 patients with neuroendocrine tumors (two patients had neuroendocrine pancreatic carcinomas with liver metastases (one of them had metastases in peritoneal lymph nodes), one patient with operated (resected) bronchial carcinoid and liver metastases, three patients with neuroendocrine carcinomas of unknown origin and hepatic metastases (one with skeletal metastases) and one with pancreatic gastrinoma without metastases (surgery was impossible to perform). In all of them, together with other laboratory analyses and imaging methods, scintigraphy with somatostatin analogues was performed (in 3 with 111In Octreoscan and in the other 4 with 99mTc HYNIC TOC) and high tumor uptake was observed. The therapy was performed with 2- 4,5 GBq 90Y DOTA TATE per

  15. 真蛸热休克蛋白90基因(HSP90)的克隆及表达%Molecular cloning and feature analysis of heat shock protein 90 ( HSP90 ) from Octopus vulgaris

    Institute of Scientific and Technical Information of China (English)

    孙田田; 苏永全; 洪婧妮; 邬阳; 张曼; 毛勇

    2012-01-01

    为深入了解真蛸热应激响应机制,实验以真蛸的应激蛋白为研究对象,借助同源扩增和cDNA末端快速扩增(rapid amplification of cDNA ends,RACE)技术获得真蛸热休克蛋白90( HSP90)的cDNA全序列(2 709 bp),它包含119 bp的5′非编码区(untranslated regions,UTR)、454 bp的3′UTR和2 136 bp的开放阅读框(opening reading frame,ORF),ORF共编码71 1个氨基酸,推算其分子量为81.5 ku,理论等电点为5.09.同源分析显示,所推导的氨基酸序列高度保守,并且含有HSP90家族特有的5个保守信号序列区域.实时荧光定量PCR分析表明,该基因在所有选取的组织中均有表达,肝组织中表达量最高.%Octopus vulgaris,which owns a number of unique stress protection mechanisms is considered to be the most intelligent species of all invertebrates. A 2 709 bp full-length cDNA sequence of heat shock protein 90 ( HSP90 ) gene from O. vulgaris was obtained by homologous amplification and rapid amplification of cDNA ends (RACE). It consisted of a 119 bp 5'untranslated region (UTR) ,a2 136 bp open reading frame(ORF)and a 454 bp 3'UTR. The inferred amino acids sequence was composed of 711 amino acids, whose molecular weight and isoelectric point were 81. 5 ku and 5. 09, respectively. Homologous analysis showed the inferred amino acids sequence was highly conserved and contained five classical HSP90 signature sequences. Real-time quantitative PCR ( RT-PCR) results displayed HSP90 expressed in every tissues chosen, with the most in liver. This study which was the first time to obtain HSP90 gene from Cephalopod played an important role in studying stress mechanisms on the most intelligent invertebrate.

  16. Simplified method for the determination of strontium-90 in large amounts of bone-ash; Methode simplifiee de dosage du strontium 90 sur des quantites importantes de cendres d'os

    Energy Technology Data Exchange (ETDEWEB)

    Patti, F; Jeanmaire, L [Commissariat a l' Energie Atomique, Fontenay-aux-roses (France). Centre d' Etudes Nucleaires

    1966-06-01

    The principle of the determination is based on a 3-step process: 1) concentrating the strontium by attacking the ash with nitric acid; 2) elimination of residual phosphoric ions by a double precipitation of strontium oxalate; and 3) extraction of yttrium 90, counted in the oxalate form. The advantages of the method: -) using simple techniques it makes it possible to process 50 g of ash; -) the initial concentration of strontium considerably reduces the volume of the solutions as well as the size of precipitates handled. Fuming nitric acid is used in a specially designed burette. (authors) [French] Le principe du dosage repos sur un procede en 3 etapes: 1) Concentration du strontium par une attaque nitrique des cendres; 2) Elimination des ions phosphoriques restants par une double precipitation de l'oxalate de strontium. 3) Extraction de l'yttrium 90, compte sous forme d'oxalate. Interet de la methode: dans des conditions techniques simples, elle permet le traitement de 50 g de cendres d'os; la concentration initiale du strontium reduit notablement le volume des solutions ainsi que l'importance des precipites manipules. L'acide nitrique fumant est utilise par l'intermediaire d'une burette specialement concue a cet effet.

  17. Epidemiological impact of achieving UNAIDS 90-90-90 targets for HIV care in India: a modelling study.

    Science.gov (United States)

    Maddali, Manoj V; Gupta, Amita; Shah, Maunank

    2016-07-07

    Recent UNAIDS '90-90-90' targets propose that to end the HIV epidemic by 2030, 90% of persons living with HIV (PLWH) worldwide should know their diagnosis, 90% of diagnosed PLWH should be on antiretroviral therapy (ART) and 90% of PLWH on ART should be virally suppressed by 2020. We sought to quantify the epidemiological impact of achieving these targets in India. We constructed a dynamic-transmission model of the Indian HIV epidemic to project HIV infections and AIDS-related deaths that would occur in India over 15 years. We considered several scenarios: continuation of current care engagement (with early ART initiation), achieving 90-90-90 targets on time and delaying achievement by 5 or 10 years. In the base case, assuming continuation of current care engagement, we project 794 000 (95% uncertainty range (UR) 571 000-1 104 000) HIV infections and 689 000 (95% UR 468 000-976 000) AIDS-related deaths in India over 15 years. In this scenario, nearly half of PLWH diagnosed would fail to achieve viral suppression by 2030. With achievement of 90-90-90 targets, India could avert 392 000 (95% UR 248 000-559 000) transmissions (48% reduction) and 414 000 (95% UR 260 000-598 000) AIDS-related deaths (59% reduction) compared to the base-case scenario. Furthermore, fewer than 20 000 (95% UR 12 000-30 000) HIV infections would occur in 2030. Delaying achievement of targets resulted in a similar reduction in HIV incidence by 2030 but at the cost of excess overall infections and mortality. India can halve the epidemiological burden of HIV over 15 years with achievement of the UNAIDS 90-90-90 targets. Reaching the targets on time will require comprehensive healthcare strengthening, especially in early diagnosis and treatment, expanded access to second-line and third-line ART and long-term retention in care. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

  18. ANSI/ASHRAE/IESNA Standard 90.1-2007 Final Determination Quantitative Analysis

    Energy Technology Data Exchange (ETDEWEB)

    Halverson, Mark A.; Liu, Bing; Richman, Eric E.; Winiarski, David W.

    2011-05-01

    The United States (U.S.) Department of Energy (DOE) conducted a final quantitative analysis to assess whether buildings constructed according to the requirements of the American National Standards Institute (ANSI)/American Society of Heating, Refrigerating and Air-Conditioning Engineers (ASHRAE)/Illuminating Engineering Society of North America (IESNA) Standard 90.1-2007 would result in energy savings compared with buildings constructed to ANSI/ASHRAE/IESNA Standard 90.1-2004. The final analysis considered each of the 44 addenda to ANSI/ASHRAE/IESNA Standard 90.1-2004 that were included in ANSI/ASHRAE/IESNA Standard 90.1-2007. All 44 addenda processed by ASHRAE in the creation of Standard 90.1-2007 from Standard 90.1-2004 were reviewed by DOE, and their combined impact on a suite of 15 building prototype models in 15 ASHRAE climate zones was considered. Most addenda were deemed to have little quantifiable impact on building efficiency for the purpose of DOE’s final determination. However, out of the 44 addenda, 9 were preliminarily determined to have measureable and quantifiable impact.

  19. New modalities (setting, fractionation) of radioimmunotherapy by 90Y-ibritumomab tiuxetan (90Y zevalin) in first line treatment of follicular type non Hodgkin malignant lymphomas: efficiency, toxicity and personalized dosimetry approach

    International Nuclear Information System (INIS)

    Morschhauser, F.

    2008-12-01

    Rationale: radioimmunotherapy (R.I.T.) with 90 Y-ibritumomab tiuxetan ([ 90 Y] Zevalin ) is a new treatment option for patients with relapsed/refractory non Hodgkin follicular lymphoma (F.L.). Efficacy increases when Zevalin is used earlier in the disease course. Currently, Zevalin dosage is based on weight and not dosimetry. This most likely results in a wide range of absorbed dose to critical organs and tumor, which in turn translates in unpredictable efficacy and toxicity. Optimizing R.I.T. with [ 90 Y] Zevalin will require its use as part of first-line therapy and implementation of patient-specific dosimetry methods in clinical trials. Objectives and methods: we have consecutively studied 2 new modalities of using Zevalin in first line therapy of F.L.. First, we conducted an international, randomized, phase 3 trial to evaluate the efficacy and safety of consolidation with Zevalin(15 MBq/Kg) in patients with advanced-stage F.L. achieving at least a partial response after induction immuno chemotherapy. A second approach consisted of evaluating a fractionated schedule with 2 doses of Zevalin (11.1 MBq/kg each), 9 to 13 weeks apart, as front line therapy in F.L. patients with high tumor burden. As part of this second approach, we designed a refined imaging-based (planar and 3-dimensional) dosimetry protocol to improve prediction of dose efficacy and toxicity after each dose of zevalin. Data acquisition was performed in 3 centers (Lille, Nantes and Manchester) while data treatment and specific dose calculations for major organ, tumor masses and bone marrow were centralized. Conclusion: Consolidation of first remission with 90 Y-ibritumomab tiuxetan in advanced-stage follicular lymphoma is highly effective with no unexpected toxicities, prolonging P.F.S. by 2 years and resulting in high P.R.-to-C.R. conversion rates regardless of type of first-line induction treatment. Preliminary data show the feasibility of front line fractionated R.I.T. with Zevalin in patient

  20. Radiopharmaceutical development based on human blood albumin microspheres and 90Y

    International Nuclear Information System (INIS)

    Petriev, V M; Vlasova, O P; Postnov, A A; Epstein, N B

    2017-01-01

    New radiopharmaceutial (RP) based on human serum albumin microspheres (MSA) and 90 Y was developed for treatment of liver cancer. The optimized synthesis using chelation resulted in approximately 80% yield with high specific activity. The RP developed was tested in mice with inoculated sarcoma-37. In two weeks the tumor size reduced by 43% after the treatment with the dose of 500 μCi injected into the tumor site. (paper)

  1. Tumor-targeting properties of 90Y- and 177Lu-labeled α-melanocyte stimulating hormone peptide analogues in a murine melanoma model

    International Nuclear Information System (INIS)

    Miao Yubin; Hoffman, Timothy J.; Quinn, Thomas P.

    2005-01-01

    The purpose of this study was to compare the tumor-targeting properties of 90 Y-DOTA-Re(Arg 11 )CCMSH and 177 Lu-DOTA-Re(Arg 11 )CCMSH in a murine melanoma mouse model. Methods: The in vitro properties of cellular internalization and retention of 90 Y-DOTA-Re(Arg 11 )CCMSH and 177 Lu-DOTA-Re(Arg 11 )CCMSH were studied in B16/F1 murine melanoma cells. The pharmacokinetics of 90 Y-DOTA-Re(Arg 11 )CCMSH and 177 Lu-DOTA-Re(Arg 11 )CCMSH were determined in B16/F1 melanoma-bearing C57 mice. Results: 90 Y-DOTA-Re(Arg 11 )CCMSH and 177 Lu-DOTA-Re(Arg 11 )CCMSH exhibited fast cellular internalization and extended cellular retention in B16/F1 cells. High receptor-mediated tumor uptake and retention coupled with fast whole-body clearance of 90 Y-DOTA-Re(Arg 11 )CCMSH and 177 Lu-DOTA-Re(Arg 11 )CCMSH were demonstrated in B16/F1 tumor-bearing C57 mice. The tumor uptakes of 90 Y-DOTA-Re(Arg 11 )CCMSH and 177 Lu-DOTA-Re(Arg 11 )CCMSH were 25.70±4.64 and 14.48±0.85 %ID/g at 2 h, and 14.09±2.73 and 17.68±3.32 %ID/g at 4 h postinjection. There was little activity accumulated in normal organs except for kidney. Conclusions: High tumor-targeting properties of 90 Y-DOTA-Re(Arg 11 )CCMSH and 177 Lu-DOTA-Re(Arg 11 )CCMSH highlighted their potential as radiopharmaceuticals for targeted radionuclide therapy of melanoma in further investigations

  2. Study on the coextraction of scandium-yttrium-lumogallion complex

    International Nuclear Information System (INIS)

    Okada, T.; Shimoishi, Y.; Miyata, H.; Toei, K.

    1977-01-01

    The coextraction of scandium-yttrium-lumogallion [LMG;4-chloro-6-(2,4-dihydroxyphenylazo)-1-hydroxybenzene-2-sulfonic acid] into diethyl ether has been studied. The acid dissociation constants of LMG, pKsub(a2) and pKsub(a3), were estimated to be 6.24 and 8.05 respectively. The composition of the complex extracted was determined by using the radioisotopes 46 Sc and 90 Y and by spectrophotometry of LMG and the ratio of the components was Sc:Y:LMG = 1:1:3. The coextraction scheme was discussed briefly. (author)

  3. Country report: Pakistan. Second Research Co-ordination Meeting on Development of Radiopharmaceuticals Based on {sup 188}Re and {sup 90}Y for Radionuclide Therapy, 22-26 March 2010, Vienna

    Energy Technology Data Exchange (ETDEWEB)

    Mansur, M. S.; Mushtaq, A. [Isotope Production Division, Pakistan Institute of Nuclear Science and Technology, P.O. Nilore, Islamabad (Pakistan)

    2010-07-01

    Various experiments were carried out for the separation of {sup 90}Y from {sup 90}Sr using colloid formation behavior of {sup 90}Y in basic pH range. When the acidic solution of {sup 90}Sr/{sup 90}Y was treated with NaOH and passed through a small glass wool column, more than 95% {sup 90}Y was retained on glass wool, which was further washed with 0.1 M NaOH. The {sup 90}Y was extracted in 1 M HCl. Radionuclidic purity was determined by half life measurement. The contamination of parent was less than 0.0001%. Similarly when the colloid was passed through membrane filter more than 95% {sup 90}Y was retained which was recovered by 1 M HCl. The contamination of {sup 90}Sr was less than 0.0001%. The stock solution of {sup 90}Sr/{sup 90}Y in NH{sub 4}OH/NaOH was again passed through Millipore filter paper or glass wool after one week. The retention of 90Y was insignificant. The equilibrium mixture of {sup 90}Sr/{sup 90}Y was acidified with HCl and again precipitated with addition of NH{sub 4}OH or NaOH. The basic solution was passed through the Millipore filter or glass wool. More than 90% activity of {sup 90}Y was retained, which was finally extracted in 1 M HCl It was concluded that for recovery of {sup 90}Y from {sup 90}Sr by colloid formation, the acidic solution of {sup 90}Sr/{sup 90}Y shall be freshly precipitated by NH{sub 4}OH or NaOH. It was also observed that the adsorption of {sup 90}Y was quite high when the {sup 90}Sr solution was left in a glass vial for the growth of {sup 90}Y. However it can be easily extracted after keeping it in boiling water bath for few minutes. The separated {sup 90}Y via colloid formation was used for the labeling of EDTMP. Labeling efficiency of {sup 90}Y-EDTMP was more than 98%.

  4. Heat Shock Protein 90 (HSP90 and Her2 in Adenocarcinomas of the Esophagus

    Directory of Open Access Journals (Sweden)

    Julia Slotta-Huspenina

    2014-06-01

    Full Text Available Her2 overexpression and amplification can be found in a significant subset of esophageal adenocarcinomas. The activity of Her2 has been shown to be modulated by molecular chaperones such as HSP90. We analyzed expression/amplification data for HSP90 and Her2 on 127 primary resected esophageal adenocarcinomas in order to evaluate a possible relationship between these two molecules. HSP90 expression determined by immunohistochemistry was observed in various levels. Thirty nine (39 tumors (30.7% were classified as Her2-positive according to their immunoreactivity and amplification status. There was a significant correlation between HSP90 expression and Her2-status (p = 0.008. This could also be demonstrated by quantitative protein expression analysis with reverse phase protein arrays (r = 0.9; p < 0.001. Her2-status was associated withpT-category (p = 0.041, lymph node metastases (p = 0.049 and tumor differentiation (p = 0.036 with a higher percentage of cases with negative Her2 status in lower tumor stagesA negative Her2-status was also associated with better survival in univariate and multivariate analysis (p = 0.001 and p = 0.014. For HSP90, no associations between clinical and pathological parameters were found. The observed association between HSP90 expression and Her2 suggests a co-regulation of these molecules in at least a subset of esophageal adenocarcinomas. Anti-HSP90 drugs, which recently have been introduced in cancer treatment, may also be an option for these tumors by targeting HSP90 alone or in combination with Her2.

  5. Heat Shock Protein 90 (HSP90) and Her2 in Adenocarcinomas of the Esophagus

    Energy Technology Data Exchange (ETDEWEB)

    Slotta-Huspenina, Julia; Becker, Karl-Friedrich [Institute of Pathology, Technische Universität München, München 81765 (Germany); Feith, Marcus [Department of Surgery, Klinikum Rechts der Isar der Technischen Universität München, München 81622 (Germany); Walch, Axel [Institute of Pathology, Helmholtz Zentrum München, Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), Neuherberg 85764 (Germany); Langer, Rupert, E-mail: rupert.langer@pathology.unibe.ch [Institute of Pathology, University of Bern, Bern 3010 (Switzerland)

    2014-06-27

    Her2 overexpression and amplification can be found in a significant subset of esophageal adenocarcinomas. The activity of Her2 has been shown to be modulated by molecular chaperones such as HSP90. We analyzed expression/amplification data for HSP90 and Her2 on 127 primary resected esophageal adenocarcinomas in order to evaluate a possible relationship between these two molecules. HSP90 expression determined by immunohistochemistry was observed in various levels. Thirty nine (39) tumors (30.7%) were classified as Her2-positive according to their immunoreactivity and amplification status. There was a significant correlation between HSP90 expression and Her2-status (p = 0.008). This could also be demonstrated by quantitative protein expression analysis with reverse phase protein arrays (r = 0.9; p < 0.001). Her2-status was associated withpT-category (p = 0.041), lymph node metastases (p = 0.049) and tumor differentiation (p = 0.036) with a higher percentage of cases with negative Her2 status in lower tumor stagesA negative Her2-status was also associated with better survival in univariate and multivariate analysis (p = 0.001 and p = 0.014). For HSP90, no associations between clinical and pathological parameters were found. The observed association between HSP90 expression and Her2 suggests a co-regulation of these molecules in at least a subset of esophageal adenocarcinomas. Anti-HSP90 drugs, which recently have been introduced in cancer treatment, may also be an option for these tumors by targeting HSP90 alone or in combination with Her2.

  6. Elements of a thermic method of preparing beta-sources with fused carriers, including strontium-90; Elements d'une methode thermique de preparation de sources beta avec des entraineurs fondus, y compris le strontium-90; Osnovy termicheskogo metoda prigotovleniya beta-istochnikov s plavlennymi nositelyami, vklyuchayushchimi strontsij-90; Bases de un metodo termico de preparacion de fuentes beta con portadores fundidos, incluido el estroncio-90

    Energy Technology Data Exchange (ETDEWEB)

    Bogdanov, N I; Zakharova, K P; Zimakov, P V; Kulichenko, V V

    1962-01-15

    comprises entre 100 et 1000{sup o}C, et expliquent le choix des parametres de base du procede employe. Ils precisent les fondements de la methode qui consiste a monter une preparation vitreuse contenant la quantite necessaire de {sup 90}Sr, sur des supports de forme et dimensions diverses en acier, ceramique et autres matieres. Enfin, les auteurs examinent les parametres de base qui permettent l'exploitation sure et sans danger des differents types de sources, et ils donnent des renseignements sur les sources de {sup 90}Sr preparees par la methode thermique. (author) [Spanish] Las fuentes de radiaciones ionizantes basadas en el radioisotopo {sup 90}Sr se utilizan ampliamente en la industria para los dispositivos y sistemas de control y regulacion automaticos. La preparacion de las fuentes consiste en la deshidratacion de una mezcla formada por una solucion radiactiva de nitrato de estroncio, y compuestos tales como el anhidrido borico, silice, alumina, etc. Por calentamiento de la mezcla deshidratada a temperaturas elevadas, se obtiene una masa fundida muy fluida que, una vez fria, da una masa vitrea que contiene la cantidad requerida de {sup 90}Sr. Los autores presentan datos y examinan los resultados obtenidos al estudiar la deshidratacion del sistema SrO - B{sub 2}O{sub 3}- SiO{sub 2} a temperaturas comprendidas entre 100 y 1000{sup o} C; tambien explican su eleccion de los parametros basicos del proceso tecnologico. Exponen en lineas generales un metodo que consiste en montar sobre acero, materiales ceramicos u otras sustancias, de distintas formas y dimensiones, una masa vitrea que contenga la cantidad requerida de {sup 90}Sr. La memoria estudia los parametros fundamentales para lograr una explotacion regular y segura de los distintos tipos de fuente, y presenta datos relativos y fuentes de {sup 90}Sr preparadas por el metodo termico. (author) [Russian] Istochniki ioniziruyushchikh izluchenij na osnove radioizotopa Sr''9''0 shiroko primenyayutsya v priborakh i skhemakh

  7. Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study.

    Science.gov (United States)

    Marincek, Nicolas; Jörg, Ann-Catherine; Brunner, Philippe; Schindler, Christian; Koller, Michael T; Rochlitz, Christoph; Müller-Brand, Jan; Maecke, Helmut R; Briel, Matthias; Walter, Martin A

    2013-01-15

    We describe the long-term outcome after clinical introduction and dose escalation of somatostatin receptor targeted therapy with [90Y-DOTA]-TOC in patients with metastasized neuroendocrine tumors. In a clinical phase I dose escalation study we treated patients with increasing [90Y-DOTA]-TOC activities. Multivariable Cox regression and competing risk regression were used to compare efficacy and toxicities of the different dosage protocols. Overall, 359 patients were recruited; 60 patients were enrolled for low dose (median: 2.4 GBq/cycle, range 0.9-7.8 GBq/cycle), 77 patients were enrolled for intermediate dose (median: 3.3 GBq/cycle, range: 2.0-7.4 GBq/cycle) and 222 patients were enrolled for high dose (median: 6.7 GBq/cycle, range: 3.7-8.1 GBq/cycle) [90Y-DOTA]-TOC treatment. The incidences of hematotoxicities grade 1-4 were 65.0%, 64.9% and 74.8%; the incidences of grade 4/5 kidney toxicities were 8.4%, 6.5% and 14.0%, and the median survival was 39 (range: 1-158) months, 34 (range: 1-118) months and 29 (range: 1-113) months. The high dose protocol was associated with an increased risk of kidney toxicity (Hazard Ratio: 3.12 (1.13-8.59) vs. intermediate dose, p = 0.03) and a shorter overall survival (Hazard Ratio: 2.50 (1.08-5.79) vs. low dose, p = 0.03). Increasing [90Y-DOTA]-TOC activities may be associated with increasing hematological toxicities. The dose related hematotoxicity profile of [90Y-DOTA]-TOC could facilitate tailoring [90Y-DOTA]-TOC in patients with preexisting hematotoxicities. The results of the long-term outcome suggest that fractionated [90Y-DOTA]-TOC treatment might allow to reduce renal toxicity and to improve overall survival. (ClinicalTrials.gov number NCT00978211).

  8. Status and methodology of publicly available national HIV care continua and 90-90-90 targets: A systematic review.

    Directory of Open Access Journals (Sweden)

    Reuben Granich

    2017-04-01

    Full Text Available In 2014, the Joint United Nations Program on HIV/AIDS (UNAIDS issued treatment goals for human immunodeficiency virus (HIV. The 90-90-90 target specifies that by 2020, 90% of individuals living with HIV will know their HIV status, 90% of people with diagnosed HIV infection will receive antiretroviral treatment (ART, and 90% of those taking ART will be virally suppressed. Consistent methods and routine reporting in the public domain will be necessary for tracking progress towards the 90-90-90 target.For the period 2010-2016, we searched PubMed, UNAIDS country progress reports, World Health Organization (WHO, UNAIDS reports, national surveillance and program reports, United States President's Emergency Plan for AIDS Relief (PEPFAR Country Operational Plans, and conference presentations and/or abstracts for the latest available national HIV care continuum in the public domain. Continua of care included the number and proportion of people living with HIV (PLHIV who are diagnosed, on ART, and virally suppressed out of the estimated number of PLHIV. We ranked the described methods for indicators to derive high-, medium-, and low-quality continuum. For 2010-2016, we identified 53 national care continua with viral suppression estimates representing 19.7 million (54% of the 2015 global estimate of PLHIV. Of the 53, 6 (with 2% of global burden were high quality, using standard surveillance methods to derive an overall denominator and program data from national cohorts for estimating steps in the continuum. Only nine countries in sub-Saharan Africa had care continua with viral suppression estimates. Of the 53 countries, the average proportion of the aggregate of PLHIV from all countries on ART was 48%, and the proportion of PLHIV who were virally suppressed was 40%. Seven countries (Sweden, Cambodia, United Kingdom, Switzerland, Denmark, Rwanda, and Namibia were within 12% and 10% of achieving the 90-90-90 target for "on ART" and for "viral suppression

  9. Strontium-90 and cesium-137 in total diet

    International Nuclear Information System (INIS)

    1979-01-01

    Under the commission of Science and Technology Agency, prefectural public health laboratories and institutes and Japan Chemical Analysis Center have collected total diet samples, and determined the contents of 90 Sr and 137 Cs in these samples. Thirty-two prefectural public health laboratories and institutes have collected 2 times a year all the daily regular diet consumed for five persons, namely three meals and other eating between them. These samples were collected at Japan Chemical Analysis Center after carbonization without smoke rising. At Japan Chemical Analysis Center, these samples were ashed in an electric muffle furnace. And the ash to which both some carriers were added were destroyed with hydrochloric acid and nitric acid. The nuclides were dissolved into hydrochloric acid and filtrated, after it was added with nitric acid. The nuclides were dissolved into hydrochloric acid and filtrated, after it was added with nitric acid. The samples solution including radionuclides was extracted with hydrochloric acid and water, and 90 Y which reached radioactive equivallence to 90 Sr, and 137 Cs were chemically separated from it. And the radioactivity was measured with low back ground beta-ray spectrometer. (author)

  10. Procedure to carry out leakage test in beta radiation sealed sources emitters of {sup 90}Sr/{sup 90}Y; Procedimiento para realizar prueba de fuga en fuentes selladas de radiacion beta emisoras de {sup 90}Sr/{sup 90}Y

    Energy Technology Data Exchange (ETDEWEB)

    Alvarez R, J. T., E-mail: trinidad.alvarez@inin.gob.m [ININ, Departamento de Metrologia de Radiaciones Ionizantes, Laboratorio Secundario de Calibracion Dosimetrica, Carretera Mexico-Toluca s/n, 52750 Ocoyoacac, Estado de Mexico (Mexico)

    2010-09-15

    In the alpha-beta room of the Secondary Laboratory of Dosimetric Calibration of the Metrology Department of Ionizing Radiations ophthalmic applicators are calibrated in absorbed dose terms in water D{sub w}; these applicators, basically are emitter sealed sources of pure beta radiation of {sup 90}Sr / {sup 90}Y. Concretely, the laboratory quality system indicates to use the established procedure for the calibration of these sources, which establishes the requirement of to carry out a leakage test, before to calibrate the source. However, in the Laboratory leakage test certificates sent by specialized companies in radiological protection services have been received, in which are used gamma spectrometry equipment s for beta radiation leakage tests, since it is not reliable to detect pure beta radiation with a scintillating detector with NaI crystal, (because it could detect the braking radiation produced in the detector). Therefore the Laboratory has had to verify the results of the tests with a correct technique, with the purpose of determining the presence of sources with their altered integrity and radioactive material leakage. The objective of this work is to describe a technique for beta activity measurement - of the standard ISO 7503, part 1 (1988) - and its application with a detector Gm plane (type pankage) in the realization of leakage tests in emitter sources of pure beta radiation, inside the mark of quality assurance indicated by the report ICRU 76. (Author)

  11. Measurement of strontium-89 and strontium-90 in environmental waters. A tentative reference method

    International Nuclear Information System (INIS)

    1976-03-01

    A tentative reference method for the measurement of 89 Sr and 90 Sr in environmental waters is described. Samples of environmental water sources are collected, preserved with acid-strontium carrier, and analyzed for 89 Sr and/or 90 Sr. The isotopes are separated from the sample water by precipitating with stable strontium carrier as carbonate. The strontium carbonate is dissolved, 90 Sr separated, the strontium reprecipitated as carbonate, filtered, and counted for the combined 89 Sr and 90 Sr activity. The 90 y is allowed to grow in from the 90 y activity; the strontium carbonate is redissolved; the 90 y is separated, precipitated, and counted for the 90 Sr determination. The 89 Sr activity is then determined by difference of the total 89 Sr and 90 y and the separate 90 Sr activities. Recoveries are determined from the added and found (recovered) strontium carrier. Counting efficiencies are determined with prepared standard reference samples. Results are reported in pCi/liter

  12. Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy.

    Science.gov (United States)

    Seregni, E; Maccauro, M; Chiesa, C; Mariani, L; Pascali, C; Mazzaferro, V; De Braud, F; Buzzoni, R; Milione, M; Lorenzoni, A; Bogni, A; Coliva, A; Lo Vullo, S; Bombardieri, E

    2014-02-01

    Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin analogues has been demonstrated to be an effective therapeutic option in patients with disseminated neuroendocrine tumours (NET). Treatment with tandem [(90)Y]DOTA-TATE and [(177)Lu]DOTA-TATE may improve the efficacy of PRRT without increasing the toxicity. In a phase II study we evaluated the feasibility of combined PPRT with a high-energy beta emitter ((90)Y) and a medium-energy beta/gamma emitter ([(177)Lu) in patients with metastatic NET refractory to conventional therapy. A group of 26 patients with metastatic NET were treated with four therapeutic cycles of alternating [[(177)Lu]DOTA-TATE (5.55 GBq) and [(90)Y]DOTA-TATE (2.6 GBq). A dosimetric evaluation was carried out after administration of [[(177)Lu]DOTA-TATE to calculate the absorbed doses in healthy organs. The acute and long-term toxicities of repeated treatment were analysed. PRRT efficacy was evaluated according to RECIST. Administration of tandem [(90)Y]DOTA-TATE and [[(177)Lu]DOTA-TATE induced objective responses in 42.3 % of patients with metastatic NET with a median progression-free survival longer than 24 months. Of patients with pretreatment carcinoid syndrome, 90 % showed a symptomatic response or a reduction in tumour-associated pain. The cumulative biologically effective doses (BED) were below the toxicity limit in the majority of patients, in the absence of renal function impairment. The results of our study indicates that combined [(90)Y]DOTA-TATE and [(177)Lu]DOTA-TATE therapy is a feasible and effective therapeutic option in NET refractory to conventional therapy. Furthermore, the absence of kidney damage and the evaluated cumulative BEDs suggest that increasing the number of tandem administrations is an interesting approach.

  13. Cerenkov Counter for In-Situ Groundwater Monitoring of 90Sr

    Directory of Open Access Journals (Sweden)

    Lindsay C. Todd

    2005-02-01

    Full Text Available Groundwater contamination from 90Sr is an environmental challenge posed topresent and former nuclear weapons related sites. Traditional methods of extractinggroundwater samples and performing laboratory analyses are expensive, time-consumingand induce significant disposal challenges. The authors present here a prototype countercapable of measuring 90Sr groundwater concentrations in-situ at or below the drinking waterlimit of 8 pCi/liter. The 90Y daughter of 90Sr produces high-energy electrons, which cancreate Cerenkov light. Photomultiplier tubes convert the Cerenkov light into an electronicpulse, which then undergoes signal processing with standard electronics. Strontium-90concentrations near the drinking water limit can be measured in a matter of hours if it is insecular equilibrium with the 90Y daughter. The prototype counter is compact, can bedeployed in an American Standard 6-inch, well while operated by a single person, andtransmits the results to a central monitoring location.

  14. Dosimetric comparison of {sup 90}Y, {sup 32}P, and {sup 186}Re radiocolloids in craniopharyngioma treatments

    Energy Technology Data Exchange (ETDEWEB)

    Sadeghi, Mahdi; Karimi, Elham; Hosseini, S. Hamed [Agricultural, Medical and Industrial Research School, Nuclear Science and Technology Research Institute, P.O. Box 31485/498, Karaj (Iran, Islamic Republic of); Faculty of Engineering, Research and Science Campus, Islamic Azad University, P.O. Box 14155/4933, Tehran (Iran, Islamic Republic of)

    2009-11-15

    Purpose: In the radionuclide treatment of some forms of brain tumors such as craniopharyngiomas, the selection of the appropriate radionuclide for therapy is a key element in treatment planning. The aim was to study the influence by considering the beta-emitter radionuclide dose rate in an intracranial cyst. Methods: Dosimetry was performed using the MCNP4C radiation transport code. Analytical dosimetry was additionally performed using the Loevinger and the Berger formulas in the MATLAB software. Each result was compared under identical conditions. The advantages and disadvantages of using {sup 90}Y versus {sup 32}P and {sup 186}Re were investigated. Results: The dose rate at the inner surface of the cyst wall was estimated to be 400 mGy/h for a 1 MBq/ml concentration of {sup 90}Y. Under identical conditions of treatment, the corresponding dose rates were 300 mGy/h for {sup 32}P and 160 mGy/h for {sup 186}Re. For a well-defined cyst radius and identical wall thickness, higher dose rates resulted for {sup 90}Y. Conclusions: To achieve the same radiological burden, the required amount of physical activity of injectable solution is lower for {sup 32}P. This is found to be a consequence of both the radionuclide physical half-life and the pattern of energy deposition from the emitted radiation. According to the half-life and dose-rate results, {sup 90}Y would be a good substitute for {sup 32}P.

  15. Evaluation of Efficacy of Radioimmunotherapy with 90Y-Labeled Fully Human Anti-Transferrin Receptor Monoclonal Antibody in Pancreatic Cancer Mouse Models.

    Directory of Open Access Journals (Sweden)

    Aya Sugyo

    Full Text Available Pancreatic cancer is an aggressive tumor and the prognosis remains poor. Therefore, development of more effective therapy is needed. We previously reported that 89Zr-labeled TSP-A01, an antibody against transferrin receptor (TfR, is highly accumulated in a pancreatic cancer xenograft, but not in major normal organs. In the present study, we evaluated the efficacy of radioimmunotherapy (RIT with 90Y-TSP-A01 in pancreatic cancer mouse models.TfR expression in pancreatic cancer cell lines (AsPC-1, BxPC-3, MIAPaCa-2 was evaluated by immunofluorescence staining. 111In-labeled anti-TfR antibodies (TSP-A01, TSP-A02 were evaluated in vitro by cell binding assay with the three cell lines and by competitive inhibition assay with MIAPaCa-2. In vivo biodistribution was evaluated in mice bearing BxPC-3 and MIAPaCa-2 xenografts. Tumor volumes of BxPC-3 and MIAPaCa-2 were sequentially measured after 90Y-TSP-A01 injection and histological analysis of tumors was conducted.MIAPaCa-2 cells showed the highest TfR expression, followed by AsPC-1 and BxPC-3 cells. 111In-TSP-A01 and 111In-TSP-A02 bound specifically to the three cell lines according to TfR expression. The dissociation constants for TSP-A01, DOTA-TSP-A01, TSP-A02, and DOTA-TSP-A02 were 0.22, 0.28, 0.17, and 0.22 nM, respectively. 111In-TSP-A01 was highly accumulated in tumors, especially in MIAPaCa-2, but this was not true of 111In-TSP-A02. The absorbed dose for 90Y-TSP-A01 was estimated to be 8.3 Gy/MBq to BxPC-3 and 12.4 Gy/MBq to MIAPaCa-2. MIAPaCa-2 tumors treated with 3.7 MBq of 90Y-TSP-A01 had almost completely disappeared around 3 weeks after injection and regrowth was not observed. Growth of BxPC-3 tumors was inhibited by 3.7 MBq of 90Y-TSP-A01, but the tumor size was not reduced.90Y-TSP-A01 treatment achieved an almost complete response in MIAPaCa-2 tumors, whereas it merely inhibited the growth of BxPC-3 tumors. 90Y-TSP-A01 is a promising RIT agent for pancreatic cancer, although further

  16. ANSI/ASHRAE/IES Standard 90.1-2013 Preliminary Determination: Qualitative Analysis

    Energy Technology Data Exchange (ETDEWEB)

    Halverson, Mark A.; Hart, Reid; Athalye, Rahul A.; Rosenberg, Michael I.; Richman, Eric E.; Winiarski, David W.

    2014-03-01

    Section 304(b) of the Energy Conservation and Production Act (ECPA), as amended, requires the Secretary of Energy to make a determination each time a revised version of ASHRAE Standard 90.1 is published with respect to whether the revised standard would improve energy efficiency in commercial buildings. When the U.S. Department of Energy (DOE) issues an affirmative determination on Standard 90.1, states are statutorily required to certify within two years that they have reviewed and updated the commercial provisions of their building energy code, with respect to energy efficiency, to meet or exceed the revised standard. This report provides a preliminary qualitative analysis of all addenda to ANSI/ASHRAE/IES Standard 90.1-2010 (referred to as Standard 90.1-2010 or 2010 edition) that were included in ANSI/ASHRAE/IES Standard 90.1-2013 (referred to as Standard 90.1-2013 or 2013 edition).

  17. Biokinetics and dosimetry in patients administered with {sup 111}In-DOTA-Tyr{sup 3}-octreotide: implications for internal radiotherapy with {sup 90}Y-DOTATOC

    Energy Technology Data Exchange (ETDEWEB)

    Cremonesi, M.; Ferrari, M.; Maecke, H.R.; Tosi, G. [Department of Health Physics, European Institute of Oncology, Milan (Italy); Zoboli, S.; Chinol, M.; Fiorenza, M.; Paganelli, G. [Division of Nuclear Medicine, European Institute of Oncology, via Ripamonti, 435, I-20141-Milan (Italy); Stabin, M.G. [Nuclear Energy Department, Recife, Pernambuco (Brazil); Orsi, F.O. [Department of Radiology, European Institute of Oncology, Milan (Italy); Jermann, E. [Nuclear Medicine Department, University of Basel (Switzerland); Robertson, C. [Department of Epidemiology and Biostatistics, European Institute of Oncology, Milan (Italy)

    1999-08-01

    Recent advances in receptor-mediated tumour imaging have resulted in the development of a new somatostatin analogue, DOTA-dPhe{sup 1}-Tyr{sup 3}-octreotide. This new compound, named DOTATOC, has shown high affinity for somatostatin receptors, ease of labelling and stability with yttrium-90 and favourable biodistribution in animal models. The aim of this work was to evaluate the biodistribution and dosimetry of DOTATOC radiolabelled with indium-111, in anticipation of therapy trials with {sup 90}Y-DOTATOC in patients. Eighteen patients were injected with DOTATOC (10 {mu}g), labelled with 150-185 MBq of {sup 111}In. Blood and urine samples were collected throughout the duration of the study (0-2 days). Planar and single-photon emission tomography images were acquired at 0.5, 3-4, 24 and 48 h and time-activity curves were obtained for organs and tumours. A compartmental model was used to determine the kinetic parameters for each organ. Dose calculations were performed according to the MIRD formalism. Specific activities of >37 GBq/ {mu}mol were routinely achieved. Patients showed no acute or delayed adverse reactions. The residence time for {sup 111}In-DOTATOC in blood was 0.9{+-}0.4 h. The injected activity excreted in the urine in the first 24 h was 73%{+-}11%. The agent localized primarily in spleen, kidneys and liver. The residence times in source organs were: 2.2{+-}1.8 h in spleen, 1.7{+-}1.2 h in kidneys, 2.4{+-}1.9 h in liver, 1.5{+-}0.3 h in urinary bladder and 9.4{+-}5.5 h in the remainder of the body; the mean residence time in tumour was 0.47 h (range: 0.03-6.50 h). Based on our findings, the predicted absorbed doses for {sup 90}Y-DOTATOC would be 7.6{+-}6.3 (spleen), 3.3{+-}2.2 (kidneys), 0.7{+-}0.6 (liver), 2.2{+-}0.3 (bladder), 0.03{+-}0.01 (red marrow) and 10.1 (range: 1.4-31.0) (tumour) mGy/MBq. These results indicate that high activities of {sup 90}Y-DOTATOC can be administered with low risk of myelotoxicity, although with potentially high radiation

  18. Biokinetics and dosimetry in patients administered with [sup 111]In-DOTA-Tyr[sup 3]-octreotide: implications for internal radiotherapy with [sup 90]Y-DOTATOC

    Energy Technology Data Exchange (ETDEWEB)

    Cremonesi, M.; Ferrari, M.; Maecke, H.R.; Tosi, G. (Department of Health Physics, European Institute of Oncology, Milan (Italy)); Zoboli, S.; Chinol, M.; Fiorenza, M.; Paganelli, G. (Division of Nuclear Medicine, European Institute of Oncology, via Ripamonti, 435, I-20141-Milan (Italy)); Stabin, M.G. (Nuclear Energy Department, Recife, Pernambuco (Brazil)); Orsi, F.O. (Department of Radiology, European Institute of Oncology, Milan (Italy)); Jermann, E. (Nuclear Medicine Department, University of Basel (Switzerland)); Robertson, C. (Department of Epidemiology and Biostatistics, European Institute of Oncology, Milan (Italy))

    1999-08-01

    Recent advances in receptor-mediated tumour imaging have resulted in the development of a new somatostatin analogue, DOTA-dPhe[sup 1]-Tyr[sup 3]-octreotide. This new compound, named DOTATOC, has shown high affinity for somatostatin receptors, ease of labelling and stability with yttrium-90 and favourable biodistribution in animal models. The aim of this work was to evaluate the biodistribution and dosimetry of DOTATOC radiolabelled with indium-111, in anticipation of therapy trials with [sup 90]Y-DOTATOC in patients. Eighteen patients were injected with DOTATOC (10 [mu]g), labelled with 150-185 MBq of [sup 111]In. Blood and urine samples were collected throughout the duration of the study (0-2 days). Planar and single-photon emission tomography images were acquired at 0.5, 3-4, 24 and 48 h and time-activity curves were obtained for organs and tumours. A compartmental model was used to determine the kinetic parameters for each organ. Dose calculations were performed according to the MIRD formalism. Specific activities of >37 GBq/ [mu]mol were routinely achieved. Patients showed no acute or delayed adverse reactions. The residence time for [sup 111]In-DOTATOC in blood was 0.9[+-]0.4 h. The injected activity excreted in the urine in the first 24 h was 73%[+-]11%. The agent localized primarily in spleen, kidneys and liver. The residence times in source organs were: 2.2[+-]1.8 h in spleen, 1.7[+-]1.2 h in kidneys, 2.4[+-]1.9 h in liver, 1.5[+-]0.3 h in urinary bladder and 9.4[+-]5.5 h in the remainder of the body; the mean residence time in tumour was 0.47 h (range: 0.03-6.50 h). Based on our findings, the predicted absorbed doses for [sup 90]Y-DOTATOC would be 7.6[+-]6.3 (spleen), 3.3[+-]2.2 (kidneys), 0.7[+-]0.6 (liver), 2.2[+-]0.3 (bladder), 0.03[+-]0.01 (red marrow) and 10.1 (range: 1.4-31.0) (tumour) mGy/MBq. These results indicate that high activities of [sup 90]Y-DOTATOC can be administered with low risk of myelotoxicity, although with potentially high radiation

  19. Gastric injury from 90Y to left hepatic lobe tumors adjacent to the stomach: fact or fiction?

    International Nuclear Information System (INIS)

    Gates, Vanessa L.; Hickey, Ryan; Marshall, Karen; Williams, Melissa; Salzig, Krystina; Lewandowski, Robert J.; Salem, Riad

    2015-01-01

    Radioembolization with 90 Y microspheres is a locoregional radiation therapy for unresectable hepatic neoplasm. Non-target delivery of 90 Y microspheres resulting in gastrointestinal (GI) symptoms is a recognized complication; there is minimal knowledge regarding the radiation effect to the gastric wall from left hepatic lobe 90 Y treatments. Our aim was to study the incidence of GI complications when the target tissue (hepatic parenchyma ± tumor) is in close proximity to the gastric wall. We hypothesized that liver (tumor) to stomach proximity does not correlate with increased toxicity. Between November 2011 and September 2013, we studied all patients who underwent left lobe radioembolization with 90 Y glass microspheres. With Institutional Review Board (IRB) approval, we retrospectively reviewed MRI/CT images of these patients, identifying a subset of patients with the left hepatic lobe <1 cm from the gastric wall. Patients were seen in clinic 1 month posttreatment and subsequently at 3-month intervals. Short- and long-term gastric adverse events were tabulated. Ninety-seven patients successfully underwent left hepatic lobe 90 Y microsphere radioembolization in which the average distance from the liver to the stomach wall was 1.0 ± 2.8 mm. The average dose for patients who received radioembolization to the left hepatic lobe was 109 ± 57 Gy. Fifty patients had tumor within 1 cm of the gastric wall. The average dose for patients who received radioembolization to the left hepatic lobe with tumor within 1 cm of the gastric wall was 121 ± 41 Gy. There were no reportable or recordable medical events. Of the patients, 34 % reported abdominal pain that was grade 1-2; 65 % of the patients reported no abdominal pain. None of the 97 patients developed a clinically evident GI ulcer. Patients with left lobe tumors adjacent to or abutting the stomach do not exhibit acute or chronic radiation effects following radioembolization with glass microspheres. (orig.)

  20. Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma

    Directory of Open Access Journals (Sweden)

    Mostafa Mohamed, MD

    2016-01-01

    Conclusion: All bridge therapies demonstrated good pathological response and DFS after LT. SBRT and Y90 demonstrated significantly less grade ≥3 acute toxicity. Choice of optimal modality depends on tumor size, pretreatment bilirubin level, Child-Pugh status, and patient preference. Such a decision is best made at a multidisciplinary tumor board as is done at our institution.

  1. Occupational radiation exposure of medical staff performing 90Y-loaded microsphere radioembolization

    International Nuclear Information System (INIS)

    Laffont, Sophie; Ardisson, Valerie; Lenoir, Laurence; Rolland, Yan; Rohou, Tanguy; Edeline, Julien; Pracht, Marc; Sourd, Samuel Le; Lepareur, Nicolas; Garin, Etienne

    2016-01-01

    Radioembolization of liver cancer with 90 Y-loaded microspheres is increasingly used but data regarding hospital staff exposure are scarce. We evaluated the radiation exposure of medical staff while preparing and injecting 90 Y-loaded glass and resin microspheres especially in view of the increasing use of these products. Exposure of the chest and finger of the radiopharmacist, nuclear medicine physician and interventional radiologist during preparation and injection of 78 glass microsphere preparations and 16 resin microsphere preparations was monitored. Electronic dosimeters were used to measure chest exposure and ring dosimeters were used to measure finger exposure. Chest exposure was very low for both products used (<10 μSv from preparation and injection). In our experience, finger exposure was significantly lower than the annual limit of 500 mSv for both products. With glass microspheres, the mean finger exposure was 13.7 ± 5.2 μSv/GBq for the radiopharmacist, and initially 17.9 ± 5.4 μSv/GBq for the nuclear medicine physician reducing to 13.97 ± 7.9 μSv/GBq with increasing experience. With resin microspheres, finger exposure was more significant: mean finger exposure for the radiopharmacist was 295.1 ± 271.9 μSv/GBq but with a reduction with increasing experience to 97.5 ± 35.2 μSv/GBq for the six most recent dose preparations. For administration of resin microspheres, the greatest mean finger exposure for the nuclear medicine physician (the most exposed operator) was 235.5 ± 156 μSv/GBq. Medical staff performing 90 Y-loaded microsphere radioembolization procedures are exposed to safe levels of radiation. Exposure is lower than that from treatments using 131 I-lipiodol. The lowest finger exposure is from glass microspheres. With resin microspheres finger exposure is acceptable but could be optimized in accordance with the ALARA principle, and especially in view of the increasing use of radioembolization. (orig.)

  2. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study

    International Nuclear Information System (INIS)

    Bodei, Lisa; Zoboli, Stefania; Grana, Chiara; Bartolomei, Mirco; Rocca, Paola; Caracciolo, Maurizio; Chinol, Marco; Paganelli, Giovanni; Cremonesi, Marta; Maecke, Helmut R.

    2003-01-01

    The aim of this study was to determine the maximum tolerated dose of 90 Y-DOTATOC per cycle administered in association with amino acid solution as kidney protection in patients with somatostatin receptor-positive tumours. Forty patients in eight groups received two cycles of 90 Y-DOTATOC, with activity increased by 0.37 GBq per group, starting at 2.96 and terminating at 5.55 GBq. All patients received lysine ± arginine infusion immediately before and after therapy. Forty-eight percent developed acute grade I-II gastrointestinal toxicity (nausea and vomiting) after amino acid infusion whereas no acute adverse reactions occurred after 90 Y-DOTATOC injection up to 5.55 GBq/cycle. Grade III haematological toxicity occurred in three of seven (43%) patients receiving 5.18 GBq, which was defined as the maximum tolerable activity per cycle. Objective therapeutic responses occurred. Five GBq per cycle is the recommended dosage of 90 Y-DOTATOC when amino acids are given to protect the kidneys. Although no patients developed acute kidney toxicity, delayed kidney toxicity remains a major concern, limiting the cumulative dose to 25 Gy. The way forward with this treatment would seem to be to identify more effective renal protective agents, in order to be able to increase the cumulative injectable activity and hence tumour dose. (orig.)

  3. ANSI/ASHRAE/IES Standard 90.1-2013 Preliminary Determination: Quantitative Analysis

    Energy Technology Data Exchange (ETDEWEB)

    Halverson, Mark A.; Rosenberg, Michael I.; Wang, Weimin; Zhang, Jian; Mendon, Vrushali V.; Athalye, Rahul A.; Xie, YuLong; Hart, Reid; Goel, Supriya

    2014-03-01

    This report provides a preliminary quantitative analysis to assess whether buildings constructed according to the requirements of ANSI/ASHRAE/IES Standard 90.1-2013 would result in energy savings compared with buildings constructed to ANSI/ASHRAE/IES Standard 90.1-2010.

  4. Critical experiments analysis by ABBN-90 constant system

    Energy Technology Data Exchange (ETDEWEB)

    Tsiboulia, A.; Nikolaev, M.N.; Golubev, V. [Institute of Physics and Power Engineering, Obninsk (Russian Federation)] [and others

    1997-06-01

    The ABBN-90 is a new version of the well-known Russian group-constant system ABBN. Included constants were calculated based on files of evaluated nuclear data from the BROND-2, ENDF/B-VI, and JENDL-3 libraries. The ABBN-90 is intended for the calculation of different types of nuclear reactors and radiation shielding. Calculations of criticality safety and reactivity accidents are also provided by using this constant set. Validation of the ABBN-90 set was made by using a computerized bank of evaluated critical experiments. This bank includes the results of experiments conducted in Russia and abroad of compact spherical assemblies with different reflectors, fast critical assemblies, and fuel/water-solution criticalities. This report presents the results of the calculational analysis of the whole collection of critical experiments. All calculations were produced with the ABBN-90 group-constant system. Revealed discrepancies between experimental and calculational results and their possible reasons are discussed. The codes and archives INDECS system is also described. This system includes three computerized banks: LEMEX, which consists of evaluated experiments and their calculational results; LSENS, which consists of sensitivity coefficients; and LUND, which consists of group-constant covariance matrices. The INDECS system permits us to estimate the accuracy of neutronics calculations. A discussion of the reliability of such estimations is finally presented. 16 figs.

  5. Moneda ibérica y gens mariana (107-90 a.C.

    Directory of Open Access Journals (Sweden)

    López Sánchez, Fernando

    2010-12-01

    Full Text Available The division between domi/rider reverses with a palm and armed militiae/rider in (Celtiberian currency leads us to establish a link between certain mints and military camps. An example of this can be found in the Ikale (n sken denarii, which must be related to the troops sent in the direction of Córdoba by Kese, in support of Sertorius (97-93 B.C.. The Sekobirikes denarii, on the other hand, were the coins used by the troops of Sekaisa while in the territory of the Arevaci with T. Didius and V. Flaccus (98-92 B.C., and all of the bronze Catalan series corresponds with the start of the Bellum Sociale (90 B.C.. During the second century B.C., Rome waged war in Hispania on the invitation of cities such as Osca, Turiasu or Segeda-Sekaisa, which were threatened by powerful enemies. In the period of Marius the (Celtiberian armies adopted a Roman approach to warfare. All of the (Celtiberian currency was minted between the years 107 and 90 B.C., and as such it reflects not the Roman conquest of Hispania, but the formation of a Hispanic branch of the Roman army.La división entre reversos domi/jinete con palma y militiae/jinete armado en la moneda (celtibérica permite afi rmar que algunas cecas hispanas se corresponden con campamentos militares. Así, los denarios Ikale(nsken deben ponerse en relación con las tropas enviadas por Kese hacia Córdoba en apoyo de Sertorio (97-93 a.C.. Los denarios Sekobirikes, por su parte, son las monedas de las tropas de Sekaisa en territorio arévaco con T. Didio y V. Flaco (98-92 a.C.. Las series catalanas en bronce se corresponden todas con el inicio del Bellum Sociale (90 a.C.. Roma luchó en Hispania durante el siglo II a.C. por invitación de ciudades como Segeda-Sekaisa, amenazadas por enemigos demasiado poderosos. Los ejércitos (celtibéricos combatían a la romana en tiempos de Mario. La moneda (celtibérica clásica fue toda ella acuñada entre los años 107 y 90 a.C. Refleja, no la conquista romana de

  6. Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study

    Directory of Open Access Journals (Sweden)

    Marincek Nicolas

    2013-01-01

    Full Text Available Abstract Background We describe the long-term outcome after clinical introduction and dose escalation of somatostatin receptor targeted therapy with [90Y-DOTA]-TOC in patients with metastasized neuroendocrine tumors. Methods In a clinical phase I dose escalation study we treated patients with increasing [90Y-DOTA]-TOC activities. Multivariable Cox regression and competing risk regression were used to compare efficacy and toxicities of the different dosage protocols. Results Overall, 359 patients were recruited; 60 patients were enrolled for low dose (median: 2.4 GBq/cycle, range 0.9-7.8 GBq/cycle, 77 patients were enrolled for intermediate dose (median: 3.3 GBq/cycle, range: 2.0-7.4 GBq/cycle and 222 patients were enrolled for high dose (median: 6.7 GBq/cycle, range: 3.7-8.1 GBq/cycle [90Y-DOTA]-TOC treatment. The incidences of hematotoxicities grade 1–4 were 65.0%, 64.9% and 74.8%; the incidences of grade 4/5 kidney toxicities were 8.4%, 6.5% and 14.0%, and the median survival was 39 (range: 1–158 months, 34 (range: 1–118 months and 29 (range: 1–113 months. The high dose protocol was associated with an increased risk of kidney toxicity (Hazard Ratio: 3.12 (1.13-8.59 vs. intermediate dose, p = 0.03 and a shorter overall survival (Hazard Ratio: 2.50 (1.08-5.79 vs. low dose, p = 0.03. Conclusions Increasing [90Y-DOTA]-TOC activities may be associated with increasing hematological toxicities. The dose related hematotoxicity profile of [90Y-DOTA]-TOC could facilitate tailoring [90Y-DOTA]-TOC in patients with preexisting hematotoxicities. The results of the long-term outcome suggest that fractionated [90Y-DOTA]-TOC treatment might allow to reduce renal toxicity and to improve overall survival. (ClinicalTrials.gov number NCT00978211.

  7. Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study

    Science.gov (United States)

    2013-01-01

    Background We describe the long-term outcome after clinical introduction and dose escalation of somatostatin receptor targeted therapy with [90Y-DOTA]-TOC in patients with metastasized neuroendocrine tumors. Methods In a clinical phase I dose escalation study we treated patients with increasing [90Y-DOTA]-TOC activities. Multivariable Cox regression and competing risk regression were used to compare efficacy and toxicities of the different dosage protocols. Results Overall, 359 patients were recruited; 60 patients were enrolled for low dose (median: 2.4 GBq/cycle, range 0.9-7.8 GBq/cycle), 77 patients were enrolled for intermediate dose (median: 3.3 GBq/cycle, range: 2.0-7.4 GBq/cycle) and 222 patients were enrolled for high dose (median: 6.7 GBq/cycle, range: 3.7-8.1 GBq/cycle) [90Y-DOTA]-TOC treatment. The incidences of hematotoxicities grade 1–4 were 65.0%, 64.9% and 74.8%; the incidences of grade 4/5 kidney toxicities were 8.4%, 6.5% and 14.0%, and the median survival was 39 (range: 1–158) months, 34 (range: 1–118) months and 29 (range: 1–113) months. The high dose protocol was associated with an increased risk of kidney toxicity (Hazard Ratio: 3.12 (1.13-8.59) vs. intermediate dose, p = 0.03) and a shorter overall survival (Hazard Ratio: 2.50 (1.08-5.79) vs. low dose, p = 0.03). Conclusions Increasing [90Y-DOTA]-TOC activities may be associated with increasing hematological toxicities. The dose related hematotoxicity profile of [90Y-DOTA]-TOC could facilitate tailoring [90Y-DOTA]-TOC in patients with preexisting hematotoxicities. The results of the long-term outcome suggest that fractionated [90Y-DOTA]-TOC treatment might allow to reduce renal toxicity and to improve overall survival. Trial registration ClinicalTrials.gov number:NCT00978211 PMID:23320604

  8. S values at voxels level for 188Re and 90Y calculated with the MCNP-4C code

    International Nuclear Information System (INIS)

    Coca, M.A.; Torres, L.A.; Cornejo, N.; Martin, G.

    2008-01-01

    Full text: MIRD formalism at voxel level has been suggested as an optional methodology to perform internal radiation dosimetry calculation during internal radiation therapy in Nuclear Medicine. Voxel S values for Y 90 , 131 I, 32 P, 99m Tc and 89 Sr have been published to different sizes. Currently, 188 Re has been proposed as a promising radionuclide for therapy due to its physical features and availability from generators. The main objective of this work was to estimate the voxel S values for 188 Re at cubical geometry using the MCNP-4C code for the simulations of radiation transport and energy deposition. Mean absorbed dose to target voxels per radioactive decay in a source voxel were estimated and reported for 188 Re and Y 90 . A comparison of voxel S values computed with the MCNP code and the data reported in MIRD Pamphlet 17 for 90 Y was performed in order to evaluate our results. (author)

  9. Assessing Intra-arterial Complications of Planning and Treatment Angiograms for Y-90 Radioembolization

    Energy Technology Data Exchange (ETDEWEB)

    Ahmed, Osman, E-mail: osman1423@gmail.com [Rush University Medical Center, Section of Interventional Radiology, Department of Radiology (United States); Patel, Mikin V. [University of Chicago, Department of Radiology (United States); Masrani, Abdulrahman; Chong, Bradford; Osman, Mohammed; Tasse, Jordan; Soni, Jayesh; Turba, Ulku Cenk; Arslan, Bulent [Rush University Medical Center, Section of Interventional Radiology, Department of Radiology (United States)

    2017-05-15

    PurposeTo report hepatic arterial-related complications encountered during planning and treatment angiograms for radioembolization and understand any potential-associated risk factors.Materials and Methods518 mapping or treatment angiograms for 180 patients with primary or metastatic disease to the liver treated by Yttrium-90 radioembolization between 2/2010 and 12/2015 were retrospectively reviewed. Intra-procedural complications were recorded per SIR guidelines. Patient demographics, indication for treatment, prior exposure to chemotherapeutic agents, operator experience, and disease burden were reviewed. Technical variables including type of radioembolic (glass vs. resin microspheres), indication for angiography (mapping vs. treatment), variant anatomy, and attempts at coil embolization were also assessed.ResultsThirteen (13/518, 2.5%) arterial-related complications occurred in 13 patients. All but two complications resulted during transcatheter coil embolization to prevent non-target embolization. Complications included coil migration (n = 6), arterial dissection (n = 2), focal vessel perforation (n = 2), arterial thrombus (n = 2), and vasospasm prohibiting further arterial sub-selection (n = 1). Transarterial coiling was identified as a significant risk factor of complications on both univariate and multivariate regression analysis (odds ratio 7.8, P = 0.004). Usage of resin microspheres was also a significant risk factor (odds ratio 9.5, P = 0.042). No other technical parameters or pre-procedural variables were significant after adjusting for confounding on multivariate analysis (P > 0.05).ConclusionIntra-procedural hepatic arterial complications encountered during radioembolization were infrequent but occurred mainly during coil embolization to prevent non-target delivery to extra-hepatic arteries.

  10. Radioimmunotherapy of small cell lung cancer xenograft mice with a 90Y anti-ROBO1 monoclonal antibody: Pathological study of effects on tumor and normal organs

    International Nuclear Information System (INIS)

    Fujiwara, K.; Koyama, K.; Kitada, T.; Takahashi, M.; Momose, T.; Suga, K.

    2015-01-01

    Full text of publication follows. ROBO1 is a membrane protein that is concerned about axon guidance. It is reported that ROBO1 contributes to tumor metastasis and angio genesis. ROBO1 is specifically expressed at high levels in small cell lung cancer (SCLC). In this study, we performed radioimmunotherapy (RIT) to SCLC models, and analyzed pathological alteration of tumor and organs. Methods: For the biodistribution study, 111 In-DOTA anti-ROBO1 IgG (about 370 kBq, 111 In anti-ROBO1) was injected into NCI-H69 xenograft mice via tail vein. To evaluate antitumor effect, RIT study was performed. 90 Y-DOTA anti-ROBO1 IgG (about 7.4 MBq, 90 Y anti-ROBO1) was injected. The experiments measured tumor volume, mouse weights and blood cell counts periodically. The tumors and organs (liver, kidney, intestine, spleen, femoral and sternum) of mice were obtained, and histopathologic analysis were carried out. Results: as a result of biodistribution study, the specific accumulation in the tumor of 111 In anti-ROBO1 was observed. Liver, kidney, spleen and lung showed comparatively high accumulation of 111 In anti-ROBO1. In the RIT study, 90 Y anti-ROBO1 significantly reduced tumor volume compared with original volume and increased median survival time to 58 days (p<0.01, versus saline, 28 days), while 90 Y anti-ROBO1 induced transient pancytopenia. Histopathologic analysis of tumors and organs further validated the therapeutic efficacy and the systemic toxicity of 90 Y anti-ROBO1. In day 7 when tumor volume reduced to 60% compared with original volume, irreversible nuclear denaturation and fibrosis were observed. The percentage of TUNEL-positive cells increased to 11.4%±5.1 in the day 7 (p<0.01, versus control, 4.14%±1.4), which showed increase of DNA fragmentation and apoptosis in the tumor tissues. Normal organs excluding spleen and sternum showed no significant injury. In day 7 post injection, spleen showed transient reduction of hematopoietic cells. Hematopoietic cells in

  11. S values at voxels level for 188Re and 90Y calculated with the MCNP-4C code

    International Nuclear Information System (INIS)

    Coca Perez, Marco Antonio; Torres Aroche, Leonel Alberto; Cornejo, Nestor; Martin Hernandez, Guido

    2003-01-01

    The main objective of this work was estimate the voxels S values for 188 Re at cubical geometry using the MCNP-4C code for the simulation of radiation transport and energy deposition. Mean absorbed dose to target voxels per radioactive decay in a source voxels were estimated and reported for 188 Re and Y 90 . A comparison of voxels S values computed with the MCNP code the data reported in MIRD pamphlet 17 for 90 Y was performed in order to evaluate our results

  12. Determination of 90Sr by liquid scintillation counting

    International Nuclear Information System (INIS)

    Cerchetti, Maria L.; Aghazarian, V.P.

    2006-01-01

    99m Tc, the result of the radioactive decay of 99 Mo, is one of the most applied radioisotopes in nuclear medicine and is used in nuclear medicine as a radiopharmaceutical product. It is important to ensure 99 Mo quality in order to fit the 99m Tc quality specifications. The main objective was to obtain a technique for 90 Sr determination in 99 Mo and environmental samples. The purification of 90 Sr is performed by extraction chromatography where crown-ether resin (Sr-Spec, Eichrom) was used. The measurement of the 90 Sr activity is performed by Liquid Scintillation Counting (LSC) using the double windows method. This method permits the 90 Sr determination without waiting until radiochemical equilibrium 90 Sr / 90 Y has been reached. The recovery factor was determined by gamma spectrometry with 85 Sr, and by gravimetry with stable strontium carrier solution. The minimum detectable activity was 0,05 Bq. The recovery factor was the major contribution in the total uncertainty. (author)

  13. ANSI/ASHRAE/IES Standard 90.1-2013 Determination of Energy Savings: Qualitative Analysis

    Energy Technology Data Exchange (ETDEWEB)

    Halverson, Mark A.; Rosenberg, Michael I.; Hart, Philip R.; Richman, Eric E.; Athalye, Rahul A.; Winiarski, David W.

    2014-09-04

    This report provides a final qualitative analysis of all addenda to ANSI/ASHRAE/IES Standard 90.1-2010 (referred to as Standard 90.1-2010 or 2010 edition) that were included in ANSI/ASHRAE/IES Standard 90.1-2013 (referred to as Standard 90.1-2013 or 2013 edition). All addenda in creating Standard 90.1-2013 were evaluated for their projected impact on energy efficiency. Each addendum was characterized as having a positive, neutral, or negative impact on overall building energy efficiency.

  14. Computed tomography hepatic arteriography has a hepatic falciform artery detection rate that is much higher than that of digital subtraction angiography and 99mTc-MAA SPECT/CT: Implications for planning 90Y radioembolization?

    Energy Technology Data Exchange (ETDEWEB)

    Burgmans, M.C., E-mail: mburgmans@hotmail.com [Department of Diagnostic Radiology, Singapore General Hospital, Outram Road, Singapore 169608 (Singapore); Too, C.W., E-mail: too.chow.wei@singhealth.com.sg [Department of Diagnostic Radiology, Singapore General Hospital, Outram Road, Singapore 169608 (Singapore); Kao, Y.H., E-mail: yung.h.kao@gmail.com [Department of Nuclear Medicine and PET, Singapore General Hospital, Outram Road, Singapore 169608 (Singapore); Goh, A.S.W., E-mail: anthony.goh.s.w@sgh.com.sg [Department of Nuclear Medicine and PET, Singapore General Hospital, Outram Road, Singapore 169608 (Singapore); Chow, P.K.H., E-mail: gsupc@singnet.com.sg [Department of General Surgery, Singapore General Hospital, Outram Road, Singapore 169608 (Singapore); Office of Clinical Sciences, Duke-NUS Graduate Medical School Singapore, 8 College Road, Singapore 169857 (Singapore); Department of Surgical Oncology, National Cancer Center Singapore, 11 Hospital Drive, Singapore 169610 (Singapore); Tan, B.S., E-mail: tan.bien.soo@sgh.com.sg [Department of Diagnostic Radiology, Singapore General Hospital, Outram Road, Singapore 169608 (Singapore); Tay, K.H., E-mail: tay.kiang.hiong@sgh.com.sg [Department of Diagnostic Radiology, Singapore General Hospital, Outram Road, Singapore 169608 (Singapore); Lo, R.H.G., E-mail: richard.lo.h.g@sgh.com.sg [Department of Diagnostic Radiology, Singapore General Hospital, Outram Road, Singapore 169608 (Singapore)

    2012-12-15

    Purpose: To compare the hepatic falciform artery (HFA) detection rates of digital subtraction angiography (DSA), computed tomography hepatic arteriography (CTHA) and 99mTc-macroaggregated albumin (99mTc-MAA) single photon emission computed tomography with integrated CT (SPECT/CT) and to correlate HFA patency with complication rates of yttrium-90 (90Y) radioembolization. Material and methods: From August 2008 to November 2010, 79 patients (range 23–83 years, mean 62.3 years; 67 male) underwent pre-treatment DSA, CTHA and 99mTc-MAA scintigraphy (planar/SPECT/CT) to assess suitability for radioembolization with 90Y resin microspheres. Thirty-seven patients were excluded from the study, because CTHA was performed with a catheter position that did not result in opacification of the liver parenchyma adjacent to the falciform ligament. DSA, CTHA and 99mTc-MAA SPECT/CT images and medical records were retrospectively reviewed. Results: A patent HFA was detected in 22 of 42 patients (52.3%). The HFA detection rates of DSA, CTHA and 99mTc-MAA SPECT/CT were 11.9%, 52.3% and 13.3%, respectively (p < 0.0001). An origin from the segment 4 artery was seen in 51.7% of HFAs. Prophylactic HFA coil-embolization prior to 90Y microspheres infusion was performed in 2 patients. Of the patients who underwent radioembolization with a patent HFA, none developed supra-umbilical radiation dermatitis. One patient experienced epigastric pain attributed to post-embolization syndrome and was managed conservatively. Conclusion: The HFA detection rate of CTHA is superior to that of DSA and 99mTc-MAA SPECT/CT. Complications related to non-target radiation of the HFA vascular territory rarely occur, even in patients undergoing radioembolization with a patent HFA.

  15. Computed tomography hepatic arteriography has a hepatic falciform artery detection rate that is much higher than that of digital subtraction angiography and 99mTc-MAA SPECT/CT: Implications for planning 90Y radioembolization?

    International Nuclear Information System (INIS)

    Burgmans, M.C.; Too, C.W.; Kao, Y.H.; Goh, A.S.W.; Chow, P.K.H.; Tan, B.S.; Tay, K.H.; Lo, R.H.G.

    2012-01-01

    Purpose: To compare the hepatic falciform artery (HFA) detection rates of digital subtraction angiography (DSA), computed tomography hepatic arteriography (CTHA) and 99mTc-macroaggregated albumin (99mTc-MAA) single photon emission computed tomography with integrated CT (SPECT/CT) and to correlate HFA patency with complication rates of yttrium-90 (90Y) radioembolization. Material and methods: From August 2008 to November 2010, 79 patients (range 23–83 years, mean 62.3 years; 67 male) underwent pre-treatment DSA, CTHA and 99mTc-MAA scintigraphy (planar/SPECT/CT) to assess suitability for radioembolization with 90Y resin microspheres. Thirty-seven patients were excluded from the study, because CTHA was performed with a catheter position that did not result in opacification of the liver parenchyma adjacent to the falciform ligament. DSA, CTHA and 99mTc-MAA SPECT/CT images and medical records were retrospectively reviewed. Results: A patent HFA was detected in 22 of 42 patients (52.3%). The HFA detection rates of DSA, CTHA and 99mTc-MAA SPECT/CT were 11.9%, 52.3% and 13.3%, respectively (p < 0.0001). An origin from the segment 4 artery was seen in 51.7% of HFAs. Prophylactic HFA coil-embolization prior to 90Y microspheres infusion was performed in 2 patients. Of the patients who underwent radioembolization with a patent HFA, none developed supra-umbilical radiation dermatitis. One patient experienced epigastric pain attributed to post-embolization syndrome and was managed conservatively. Conclusion: The HFA detection rate of CTHA is superior to that of DSA and 99mTc-MAA SPECT/CT. Complications related to non-target radiation of the HFA vascular territory rarely occur, even in patients undergoing radioembolization with a patent HFA.

  16. Long-term effect of 90Y pituitary implantation in acromegaly

    International Nuclear Information System (INIS)

    Jadresic, A.; Jimenez, L.E.; Joplin, G.F.

    1987-01-01

    This report examines the long-term trends in GH levels and pituitary function in a group of 38 acromegalic patients who were selected insofar as we were able to follow them up for more than 10 years after a single dose 90 Y interstitial pituitary irradiation as the sole treatment. Mean serum GH had fallen from 106 to 24 mIU/l within 3-6 months and then slowly declined to 4 mIU/l after 10 years. GH levels of ≤5 mIU/l during a 50 g oral glucose tolerance test were obtained in 8% of patients at 3-6 months and in 18% at 1 year, the cumulative percentage increasing to 53% at 10, and 76% at 14 years. The percentage of patients requiring hormone replacement therapy rose from nil pre-implant to 16% by 3-6 months, and then slowly increased to 39% by 14 years. Serial coned radiographs of the pituitary fossa were available for 32 patients. By 10 years, 16 showed thickening of the dorsum sellae and/or reduction of at least one diameter by 3 mm. Concerning symptoms, all 29 patients whose GH level fell to ≤5 mIU/l showed improvements, 22 becoming asymptomatic. Seven patients with lesser falls in GH levels (from a mean of 193 to a mean of 15 mIU/l) all improved, one becoming asymptomatic. Two showed no variation. These results show that 90 Y pituitary implants have a cumulative effect over the years in inducting remission and hypopituitarism in acromegalic patients, the early decline in GH levels being swifter than from other forms of irradiation. (author)

  17. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3[octreotide, a promising somatostatin analogue for radionuclide therapy

    International Nuclear Information System (INIS)

    Jong, M. de; Bakker, W.H.; Krenning, E.P.; Breeman, W.A.P.; Pluijm, M.E. van der; Bernard, B.F.; Visser, T.J.; Jermann, E.; Behe, M.; Powell, P.; Maecke, H.R.

    1997-01-01

    In vitro octreotide receptor binding of [ 111 In-DOTA 0 ,d-Phe 1 ,Tyr 3 [octreotide ( 111 In-DOTATOC) and the in vivo metabolism of 90 Y- or 111 In-labelled DOTATOC were investigated in rats in comparison with [ 111 In-DTPA 0 [octreotide [ 111 In-DTPAOC). 111 In-DOTATOC was found to have an affinity similar to octreotide itself for the octreotide receptor in rat cerebral cortex microsomes. Twenty-four hours after injection of 90 Y- or 111 In-labelled DOTATOC, uptake of radioactivity in the octreotide receptor-expressing tissues pancreas, pituitary, adrenals and tumour was a factor of 2-6 that after injection of 111 In-DTPAOC. Uptake of labelled DOTATOC in pituitary, pancreas, adrenals and tumour was almost completely blocked by pretreatment with 0.5 mg unlabelled octreotide, indicating specific binding to the octreotide receptors. These findings strongly indicate that 90 Y-DOTATOC is a promising radiopharmaceutical for radiotherapy and that 111 In-DOTATOC is of potential value for diagnosis of patients with octreotide receptor-positive lesions, such as most neuroendocrine tumours. (orig.). With 3 figs., 2 tabs

  18. Radioactive contamination of animal bones by 90Sr

    International Nuclear Information System (INIS)

    Franic, Z.; Maracic, M.

    1996-01-01

    90 Sr has been regarded as the fission product of great potential hazard to living things because of the unique combination of its 28-y long half-life, the very energetic beta particle of its 90 Y daughter, and its general resemblance to calcium in metabolic processes. Therefore, due to chemical and metabolic similarity to calcium, bone is the critical organ for radioactive isotopes of strontium. The Department of Radiation Protection of the Institute for Medical Research and Occupational Health, has carried out radioactivity measurements of the food chain as part of an extended monitoring programme, since 1963. This includes systematic, long-term measurements of 90 Sr in long bones of some domestic animals (cows and pigs) while data on lamb bones exist for the very beginning of the investigated period, and for the period after the Chernobyl nuclear accident

  19. (90)Y -PET imaging: Exploring limitations and accuracy under conditions of low counts and high random fraction.

    Science.gov (United States)

    Carlier, Thomas; Willowson, Kathy P; Fourkal, Eugene; Bailey, Dale L; Doss, Mohan; Conti, Maurizio

    2015-07-01

    (90)Y -positron emission tomography (PET) imaging is becoming a recognized modality for postinfusion quantitative assessment following radioembolization therapy. However, the extremely low counts and high random fraction associated with (90)Y -PET may significantly impair both qualitative and quantitative results. The aim of this work was to study image quality and noise level in relation to the quantification and bias performance of two types of Siemens PET scanners when imaging (90)Y and to compare experimental results with clinical data from two types of commercially available (90)Y microspheres. Data were acquired on both Siemens Biograph TruePoint [non-time-of-flight (TOF)] and Biograph microcomputed tomography (mCT) (TOF) PET/CT scanners. The study was conducted in three phases. The first aimed to assess quantification and bias for different reconstruction methods according to random fraction and number of true counts in the scan. The NEMA 1994 PET phantom was filled with water with one cylindrical insert left empty (air) and the other filled with a solution of (90)Y . The phantom was scanned for 60 min in the PET/CT scanner every one or two days. The second phase used the NEMA 2001 PET phantom to derive noise and image quality metrics. The spheres and the background were filled with a (90)Y solution in an 8:1 contrast ratio and four 30 min acquisitions were performed over a one week period. Finally, 32 patient data (8 treated with Therasphere(®) and 24 with SIR-Spheres(®)) were retrospectively reconstructed and activity in the whole field of view and the liver was compared to theoretical injected activity. The contribution of both bremsstrahlung and LSO trues was found to be negligible, allowing data to be decay corrected to obtain correct quantification. In general, the recovered activity for all reconstruction methods was stable over the range studied, with a small bias appearing at extremely high random fraction and low counts for iterative algorithms

  20. 90Y -PET imaging: Exploring limitations and accuracy under conditions of low counts and high random fraction

    International Nuclear Information System (INIS)

    Carlier, Thomas; Willowson, Kathy P.; Fourkal, Eugene; Bailey, Dale L.; Doss, Mohan; Conti, Maurizio

    2015-01-01

    Purpose: 90 Y -positron emission tomography (PET) imaging is becoming a recognized modality for postinfusion quantitative assessment following radioembolization therapy. However, the extremely low counts and high random fraction associated with 90 Y -PET may significantly impair both qualitative and quantitative results. The aim of this work was to study image quality and noise level in relation to the quantification and bias performance of two types of Siemens PET scanners when imaging 90 Y and to compare experimental results with clinical data from two types of commercially available 90 Y microspheres. Methods: Data were acquired on both Siemens Biograph TruePoint [non-time-of-flight (TOF)] and Biograph microcomputed tomography (mCT) (TOF) PET/CT scanners. The study was conducted in three phases. The first aimed to assess quantification and bias for different reconstruction methods according to random fraction and number of true counts in the scan. The NEMA 1994 PET phantom was filled with water with one cylindrical insert left empty (air) and the other filled with a solution of 90 Y . The phantom was scanned for 60 min in the PET/CT scanner every one or two days. The second phase used the NEMA 2001 PET phantom to derive noise and image quality metrics. The spheres and the background were filled with a 90 Y solution in an 8:1 contrast ratio and four 30 min acquisitions were performed over a one week period. Finally, 32 patient data (8 treated with Therasphere ® and 24 with SIR-Spheres ® ) were retrospectively reconstructed and activity in the whole field of view and the liver was compared to theoretical injected activity. Results: The contribution of both bremsstrahlung and LSO trues was found to be negligible, allowing data to be decay corrected to obtain correct quantification. In general, the recovered activity for all reconstruction methods was stable over the range studied, with a small bias appearing at extremely high random fraction and low counts for

  1. Preparation of silica coated and 90Y-radiolabeled β-NaYF4 upconverting nanophosphors for multimodal tracing

    Science.gov (United States)

    Najmr, Stan; Lu, Tianfeng; Keller, Austin W.; Zhang, Mingyue; Lee, Jennifer D.; Makvandi, Mehran; Pryma, Daniel A.; Kagan, Cherie R.; Murray, Christopher B.

    2018-06-01

    Rare-earth (RE) compounds have been actively pursued for therapeutic and diagnostic applications due to their ability to upconvert near infrared light into the UV–vis range. Through nanoengineering and bottom-up synthesis, additional functionality can be added to these upconverting systems. Herein, we report the synthesis of 90Y-doped β-NaYF4:Er, Yb upconverting nanophosphors (UCNPs) to enable β-particle emission and upconversion by the same UCNP. To homogenously incorporate the radionuclides, we employ a hydroxide metathesis method to produce the RE precursor required for the solvothermal synthesis of monodisperse UCNPs. Once incorporated, we find that the β-emitting 90Y dopants do not influence the energy pathways required for upconversion, enabling simultaneous radio- and optical-tracing. The resulting large (>100 nm in height and width), anisotropic, 90Y-radiolabeled β-NaYF4 UCNPs are then coated with silica using a modified, micelle-driven Stöber process to enable their dispersion in polar solvents. Doing so highlights the importance of surfactant (Igepal CO-520) and silica source (tetraethyl orthosilicate) interactions to the continuity of the silica shell and makes the vast library of silica surface chemistry and functionality accessible to upconverting radiotracers.

  2. Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation

    International Nuclear Information System (INIS)

    Koumarianou, Eftychia; Mikolajczak, Renata; Pawlak, Dariusz; Zikos, Xhristos; Bouziotis, Pinelopi; Garnuszek, Piotr; Karczmarczyk, Urszula; Maurin, Michal; Archimandritis, Spyridon C.

    2009-01-01

    Introduction: The aim of the study was to compare in vitro and in vivo a novel DOTA-chelated bombesin (BN) analog of the amino acid sequence, QRLGNQWAVGHLM-CONH 2 (BN[2-14]NH 2 ), labeled with 90 Y and 177 Lu, for its potential use in targeted radiotherapy of tumors expressing gastrin releasing peptide (GRP) receptors. The same amino acid sequence, but with different chelator, referred as BN1.1 (Gly-Gly-Cys-Aca-QRLGNQWAV